

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please call 800-835-4709 or 240-402-8010, extension 1. CBER Consumer Affairs Branch or send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6)
Subject: Data mining
Date: Tuesday, January 12, 2021 1:51:05 PM
Attachments: (b) (6) <[\(b\) \(6\)@CDC](#)>; [\(b\) \(6\) VAERS data mining_20200110_DRAFT.pptx](#)

Dear (b) (6)

Our core weekly data mining run (previously refreshing monthly) called “VAERS Signals Weekly US All” was just refreshed this afternoon (as of date 1/10/21) and there are no EB05’s >2 for any COVID vaccines. Attached are 3 slides providing contextual information including caveats and limitations that we can discuss at our weekly meeting on Thursday at 2pm.

Best,

(b) (6)

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported adverse event [AE] for a product relative to other products)
- Hypothesis generating
 - Statistical signal of disproportional reporting (SSDR) \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

(b) (6) Data Mining Methods



- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-AE pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
- Results adjusted by gender, year received and age
- Vaccine-AE pairs ranked by lower 5% bound of EBGM confidence interval (EB05)
- Standard threshold for alert: $EB05 \geq 2$

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.

Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe program, media reports)
- Potential statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding by indication and other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

From: (b) (6)
To: (b) (6) (CDC); (b) (6) (CDC)
Cc: (b) (6) (CDC); (b) (6)
Subject: RE: Data mining
Date: Tuesday, January 12, 2021 5:35:48 PM
Attachments: (b) (6) VAERS data mining_202001_DRAFT.pptx

Hi (b) (6)

In addition to the overall run (mentioned in earlier email below) which now refreshes weekly, we have our pre-existing (refreshing monthly) subset runs (and I've added a line to the second attached slide to describe them) which have an earlier 'as of date' of 1/6/21. For all of these subset runs for both EUA COVID vaccines, a total of 4 PTs had an EB05 of >2, all of which were in the age 45 - <65 year ("Adult2") subset and that output is as follows:

Drug	Event	Adult2 EB05 20210106	N
COVID19 (COVID19 (PFIZER-BIONTECH))	Dysgeusia	2.118	49
COVID19 (COVID19 (PFIZER-BIONTECH))	Flushing	2.408	118
COVID19 (COVID19 (PFIZER-BIONTECH))	Palpitations	2.004	104
COVID19 (COVID19 (PFIZER-BIONTECH))	Paraesthesia oral	2.184	88

Please feel free to share this hypothesis generating output along with the limitations reflected in the slides with your team/command chain, though these are not intended to be shared more broadly.

Best,
(b) (6)

PS: I'm planning to be on the 6pm call tonight and available to answer any questions

From: (b) (6)
Sent: Tuesday, January 12, 2021 1:51 PM
To: (b) (6) (CDC) (b) (6)@cdc.gov; (b) (6) (CDC) (b) (6)@cdc.gov
Cc: (b) (6) (CDC) (b) (6)@cdc.gov; (b) (6)@fda.hhs.gov; (b) (6)@fda.hhs.gov;
(b) (6)@fda.hhs.gov; (b) (6)@fda.hhs.gov;
(b) (6)@fda.hhs.gov
Subject: Data mining

Dear (b) (6)

Our core weekly data mining run (previously refreshing monthly) called "VAERS Signals Weekly US All" was just refreshed this afternoon (as of date 1/10/21) and there are no EB05's >2 for any COVID vaccines. Attached are 3 slides providing contextual information including caveats and limitations that we can discuss at our weekly meeting on Thursday at 2pm.

Best,
(b) (6)

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported adverse event [AE] for a product relative to other products)
- Hypothesis generating
 - Statistical signal of disproportional reporting (SSDR) \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

(b) (6) Data Mining Methods



- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-AE pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
- Results adjusted by gender, year received and age
- Vaccine-PT pairs ranked by lower 5% bound of EBGM confidence interval (EB05)
 - Subsets available monthly for age (0-1, 2-8, 9-18, 19-44, 45-64, ≥65, unknown), gender, and serious/fatal
- Standard threshold for alert: $EB05 \geq 2$

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.

Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe program, media reports)
- Potential statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding by indication and other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

From: (b) (6)
To: (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6)
Subject: Weekly data mining
Date: Tuesday, February 2, 2021 7:57:05 AM

Good morning (b) (6)

Our “VAERS Signals Weekly US All” run had no alerts (EB05>2) for any PT for either EUA COVID vaccine (as of 1/29/21).

Best,

(b) (6)

COVID vaccine (as of 1/29/21).

Best,

(b) (6)

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: Data mining
Date: Tuesday, February 23, 2021 6:48:00 AM

Hi (b) (6)

Our "VAERS Signals Weekly US All" run had no alerts (EB05>2) for any PT for any EUA COVID vaccine (as of 2/18/21).

Thanks,

(b) (6)

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, March 9, 2021 6:50:13 AM

Good morning (b) (6)

This "US Signals Summary Table" had no alerts (EB05>2) for any PT for any EUA COVID vaccine (as of 3/5/21).

Thanks,

(b) (6)

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: Weekly data mining
Date: Tuesday, March 16, 2021 7:13:14 AM
Attachments: [USST 20210311.xls](#)
(b) (6) <[\(b\) \(6\)@CDC](#)> <[VAERS data mining methods and limitations 2021_03_DRAFT.pptx](#)>

Hi (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our 'US Signals Summary Table' ('as of date' 3/11/21) along with 3 slides providing contextual information including caveats and limitations. Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210311	US Serious EB05 20210311	US Fatal EB05 20210311	US Infant EB05 20210311	US Child EB05 20210311	US Teen EB05 20210311	US Adult1 EB05 20210311	US Adult2 EB05 20210311	US Adult3 EB05 20210311	US Female EB05 20210311	US Male EB05 20210311	
COVID19 (COVID-19 (JANSSEN))	Chills	2.267				0.071		2.092		1.651	1.072	2.194	1.637

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported AE for product relative to other products) in large database
- Can be useful for screening and hypothesis generating only
 - Evaluate findings in clinical and epidemiological context (e.g., unexpected?)
 - Compelling hypotheses should be explored (e.g., via case series analyses)
 - Statistical signal of disproportionality \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

(b) (6) VAERS Data Mining Methods



- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-PT pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
 - adjusted by age, gender and year received
- Vaccine-PT pairs ranked by lower 5% bound of EBGM CI (EB05)
- Standard alert threshold: EB05 >2
- Weekly US summary table includes subset alerts for age (0-1, 2-8, 9-18, 19-44, 45-64, and ≥ 65 years), gender, and serious/fatal

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.

Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe, media reports)
- False alerts from statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding (e.g., by indication)
- Other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

From: (b) (6)
To: (b) (6) ; (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6)
Subject: RE: Weekly data mining
Date: Tuesday, March 23, 2021 2:00:03 PM
Attachments: [USST 2021_0319.xls](#)
(b) (6) [VAERS data mining methods and limitations 2021_03_DRAFT.pptx](#)

Hi (b) (6) ,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our 'US Signals Summary Table' ('as of date' 3/19/21) along with 3 slides providing contextual information including caveats and limitations. Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210319	US Serious EB05 20210319	US Fatal EB05 20210319	US Infant EB05 20210319	US Child EB05 20210319	US Teen EB05 20210319	US Adult1 EB05 20210319	US Adult2 EB05 20210319	US Adult3 EB05 20210319	US Female EB05 20210319	US Male EB05 20210319	Comment
COVID19 (COVID19 (JANSSEN))	Chills	2.26	0.935	0.892	1.012	2.074	2.085	1.965	2.363	1.742	0.938	1.742	
COVID19 (COVID19 (JANSSEN))	Feeling cold	2.47	0.873	2.822	0.567	2.04	1.257	1.048	2.595	1.048	2.595	0.938	
COVID19 (COVID19 (JANSSEN))	Hypertidrosis	1.898	0.928	0.892	0.567	2.04	1.369	0.554	1.615	0.554	1.615	1.687	
COVID19 (COVID19 (JANSSEN))	Pyrexia	2.041	0.683	0.892	0.971	1.95	1.845	1.559	2.098	1.559	2.098	1.651	
COVID19 (COVID19 (JANSSEN))	Tremor	2.074	0.683	0.892	0.971	1.825	1.553	0.997	1.942	0.997	1.942	1.276	

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported AE for product relative to other products) in large database
- Can be useful for screening and hypothesis generating only
 - Evaluate findings in clinical and epidemiological context (e.g., unexpected?)
 - Compelling hypotheses should be explored (e.g., via case series analyses)
 - Statistical signal of disproportionality \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

(b) (6)

VAERS Data Mining Methods



- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-PT pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
 - adjusted by age, gender and year received
- Vaccine-PT pairs ranked by lower 5% bound of EBGM CI (EB05)
- Standard alert threshold: EB05 >2
- Weekly US summary table includes subset alerts for age (0-1, 2-8, 9-18, 19-44, 45-64, and \geq 65 years), gender, and serious/fatal

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.

Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe, media reports)
- False alerts from statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding (e.g., by indication)
- Other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: RE: Weekly data mining
Date: Tuesday, March 30, 2021 7:02:29 AM
Attachments: (b) (6) <[VAERS data mining methods and limitations 2021_03_DRAFT.pptx](#)>
<[USST_20210326.xls](#)>

Hi (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our 'US Signals Summary Table' ('as of date' 3/26/21) along with 3 slides providing contextual information including caveats and limitations. Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported AE for product relative to other products) in large database
- Can be useful for screening and hypothesis generating only
 - Evaluate findings in clinical and epidemiological context (e.g., unexpected?)
 - Compelling hypotheses should be explored (e.g., via case series analyses)
 - Statistical signal of disproportionality \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

(b) (6) VAERS Data Mining Methods



- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-PT pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
 - adjusted by age, gender and year received
- Vaccine-PT pairs ranked by lower 5% bound of EBGM CI (EB05)
- Standard alert threshold: EB05 >2
- Weekly US summary table includes subset alerts for age (0-1, 2-8, 9-18, 19-44, 45-64, and ≥ 65 years), gender, and serious/fatal

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.

Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe, media reports)
- False alerts from statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding (e.g., by indication)
- Other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

Drug	Event	US EB05 20210326	US Serious EB05 20210326	US Fatal EB05 20210326	US Infant EB05 20210326	US Child EB05 20210326	US Teen EB05 20210326	US Adult1 EB05 20210326	US Adult2 EB05 20210326	US Adult3 EB05 20210326	US Female EB05 20210326	US Male EB05 20210326	Comment
COVID19 (COV D19 (JANSSEN))	Chills	1.969	0.951	0.693			1.022	1.862	1.626	2.223	2.068	1.546	
COVID19 (COV D19 (JANSSEN))	Fall	1.002	0.287				0.524	2.037	0.71	0.255	1.038	0.642	
COVID19 (COV D19 (JANSSEN))	Feeling cold	2.186						2.282	1.35	1.448	2.246	1.19	
COVID19 (COV D19 (JANSSEN))	Hypohidrosis	1.875	0.91				0.729	2.003	1.403	0.856	1.741	1.736	
COVID19 (COV D19 (JANSSEN))	Syncope	1.781	0.799					2.194	1.133	0.605	1.67	1.415	
COVID19 (COV D19 (JANSSEN))	Vital signs measurement	2.313						1.739	0.673	0.896	1.497	0.974	

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: RE: Weekly data mining
Date: Tuesday, April 13, 2021 6:12:45 AM
Attachments: [USST_20210408.xls](#)

Hi (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our 'US Signals Summary Table' ('as of date' 4/8/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210408	US Serious EB05 20210408	US Fatal EB05 20210408	US Infant EB05 20210408	US Child EB05 20210408	US Teen EB05 20210408	US Adult1 EB05 20210408	US Adult2 EB05 20210408	US Adult3 EB05 20210408	US Female EB05 20210408	US Male EB05 20210408	Comment
COVID19 (COVID19 (JANSSEN))	Fall	1.653	0.463	0.893			0.506	2.127	0.657	0.276	1.835	0.638	
COVID19 (COVID19 (JANSSEN))	Feeling cold	1.968	0.411	0.896				2.141	1.399	1.357	2.013	1.385	
COVID19 (COVID19 (JANSSEN))	Loss of consciousness	1.752	0.907				0.484	2.087	1.343	0.516	1.514	1.701	
COVID19 (COVID19 (JANSSEN))	Syncope	1.614	0.744	0.894			0.359	2.095	1.318	0.549	1.708	1.566	
COVID19 (COVID19 (JANSSEN))	Syringe issue	2.337					0.547	1.651	2.013	0.892	1.614	2.053	
COVID19 (COV D19 (JANSSEN))	Vital signs measurement	2.53	0.706					2.637	1.144	1.292	2.151	1.81	
COVID19 (COV D19 (PFIZER-BIONTECH))	Body temperature	1.839	1.008	0.896		0.536	0.565	1.958	2.095	1.761	1.799	1.653	

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: Weekly data mining
Date: Tuesday, April 20, 2021 6:16:38 AM
Attachments: [USST_20210416.xls](#)

Hi (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/16/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210416	US Serious EB05 20210416	US Fatal EB05 20210416	US Infant EB05 20210416	US Child EB05 20210416	US Teen EB05 20210416	US Adult1 EB05 20210416	US Adult2 EB05 20210416	US Adult3 EB05 20210416	US Female EB05 20210416	US Male EB05 20210416	Comment
COVID19 (COVID19 (JANSSEN))	Fall	1.498	0.751	0.887			0.652	2.409	1.007	0.447	1.446	1.318	
COVID19 (COVID19 (JANSSEN))	Loss of consciousness	1.975	0.958	0.89			0.751	2.29	1.569	0.582	1.862	1.857	
COVID19 (COVID19 (JANSSEN))	Syncope	1.979	0.783	0.884			0.843	2.224	1.588	0.58	1.88	1.846	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	2.368		0.904				0.539		0.558	0.992	0.692	
COVID19 (COVID19 (JANSSEN))	Thrombosis	1.252	2.317					0.671	1.094	1.005	1.268	0.903	
COVID19 (COVID19 (JANSSEN))	Vital signs measurement	2.308	0.662				0.525	2.247	1.491	1.497	2.245	1.803	
COVID19 (COVID19 (PFIZER-BIONTECH))	Body temperature	1.786	1.028	0.89		0.538	0.545	1.994	2.064	1.758	1.763	1.636	

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, April 27, 2021 8:41:55 AM
Attachments: [USST_20210423.xls](#)

Hi (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/23/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210423	US Serious EB05 20210423	US Fatal EB05 20210423	US Infant EB05 20210423	US Child EB05 20210423	US Teen EB05 20210423	US Adult1 EB05 20210423	US Adult2 EB05 20210423	US Adult3 EB05 20210423	US Female EB05 20210423	US Male EB05 20210423	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,026	0,67					0,596	0,428	0,631	1,353	1,077	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	1,354	2,103	0,878			0,541	0,755	1,05	0,847	1,249	0,767	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	1,541	2,601	0,88				1,124	1,001	0,918	1,478	0,854	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	1,838	2,871	0,887			0,541	1,466	1,156	0,639	1,694	0,771	
COVID19 (COVID19 (JANSSEN))	Heavy menstrual bleeding	2,36	0,798					2,399	1,5		2,344		
COVID19 (COVID19 (JANSSEN))	Interchange of vaccine products	1,636											
COVID19 (COVID19 (JANSSEN))	Menstruation irregular	2,122						0,586	1,058	1,29	2,222	1,554	1,328
COVID19 (COVID19 (JANSSEN))	Menstruation irregular	2,122							2,047	1,554	2,075	2,075	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,281	2,062	0,887	0,605		0,484	1,047	1,104	1,289	1,349	1,034	
COVID19 (COVID19 (JANSSEN))	Syncope	1,794	0,815	0,88				1,026	2,001	1,557	0,461	1,803	1,647
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,214	3,039	1,986	0,605		0,597	2,001	1,9	2,112	2,372	1,587	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	1,707	2,129	0,882				1,048	1,419	1,271	1,758	1,05	
COVID19 (COVID19 (MODERNA))	Injection site pruritus	1,985	0,958				0,462	2,026	2,03	1,721	1,975	1,948	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,102	1,508	0,883				0,565	1,758	1,733	1,637	2,031	1,638
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	2,075						0,64	1,247	1,632	2,074	1,962	1,79
COVID19 (COVID19 (PFIZER-BIONTECH))	Product use issue	2,086	0,942	0,878				1,94	1,698	1,507	2,031	1,377	
COVID19 (COVID19 (PFIZER-BIONTECH))	Vaccination site pain	2,01	0,778	0,872			0,508	2,165	2,082	1,614	1,905	2,032	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,042	0,983	0,88				1,3	1,527	1,781	1,89	1,455	

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, May 11, 2021 7:07:31 AM

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/7/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

From: (b) (6)
To: (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>
Cc: (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>
Subject: RE: Weekly data mining
Date: Tuesday, May 11, 2021 8:40:34 AM
Attachments: [USST_20210507.xls](#)

Apologies all for forgetting the attachment – please see attached.

Thanks,

(b) (6)

From: (b) (6)
Sent: Tuesday, May 11, 2021 7:07 AM
To: (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>
Cc: (b) (6) <(b) (6)@fda.hhs.gov>; (b) (6) <(b) (6)@fda.hhs.gov>; (b) (6) <(b) (6)@fda.hhs.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>
Subject: RE: Weekly data mining

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/7/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210507	US Serious EB05 20210507	US Fatal EB05 20210507	US Infant EB05 20210507	US Child EB05 20210507	US Teen EB05 20210507	US Adult1 EB05 20210507	US Adult2 EB05 20210507	US Adult3 EB05 20210507	US Female EB05 20210507	US Male EB05 20210507	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,113	0,991					0,697	0,304	0,734	1,716	1,223	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,338	2,721	0,88				1,415	1,415	3,837	2,955	1,245	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	1,818	2,288					1,071	1,598	1,406	1,873	1,259	
COVID19 (COVID19 (JANSSEN))	Anti-coagulant therapy	2,168	2,976	0,680	0,61			1,542	1,516	2,175	2,408	1,391	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,315	2,771	0,889			0,548	1,642	1,785	0,632	2,058	1,193	
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head abnormal	1,982	2,344	0,916	0,61		0,548	1,631	1,627	1,446	2,408	1,046	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,118	1,923	0,891				1,768	1,898	2,349	2,373	1,666	
COVID19 (COVID19 (JANSSEN))	Dysmenorrhea	1,396	0,707					2,074	0,941		1,929		
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,389	1,541	0,888			0,501	2,274	1,81	2,264	2,595	1,4	
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,152	0,887					2,075	1,565	0,702	2,295	1,025	
COVID19 (COVID19 (JANSSEN))	Heavy menstrual bleeding	2,365	0,769					2,498	1,552		2,353		
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	2,813	2,707	0,884				1,019	1,237	1,411	2,391	0,884	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1,519	2,201	0,882			0,547	1,233	0,791	0,644	1,483	0,607	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,692	2,063	0,879				1,613	1,392	1,327	1,769	1,243	
COVID19 (COVID19 (JANSSEN))	Menstruation irregular	2,174						2,182	1,528		2,143		
COVID19 (COVID19 (JANSSEN))	Platelet count	1,786	2,106	0,89	0,61		0,521	1,235	1,939	1,19	2,068	0,941	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,313	2,259	0,885				1,788	2,243	1,575	2,703	1,362	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,662	1,919	0,888	0,61			0,593	1,176	1,524	1,885	1,265	
COVID19 (COVID19 (JANSSEN))	Syncope	1,797	0,903	0,885	0,61		0,899	2,039	1,566	0,646	1,787	1,71	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,156						0,753	1,12	0,942	1,513	1,419	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,255	2,649	0,999	0,61		0,561	2,034	2,126	3,398	2,564	1,676	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	1,792	2,049	0,881				1,168	0,881	1,237	1,483	0,922	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,021	1,344	0,883			0,548	1,717	1,741	1,613	2,116	1,461	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,306	2,333	0,886				1,507	1,809	2,256	2,612	1,501	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	1,715	2,299	0,881			0,548	1,358	1,211	1,111	1,547	0,902	
COVID19 (COVID19 (JANSSEN))	Venogram normal	3,314	2,832	0,883				2,046	1,409	0,673	3,449	0,869	
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,113				0,521	0,562	0,768	0,834	0,878	1,059	0,917	
COVID19 (COVID19 (MODERNA))	Product temperature excursion issue	2,038						0,586	0,493	0,57	0,501	0,696	
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,134	1,625	0,891				2	2,211	2,087	1,948	1,925	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,212	1,712	0,888				1,862	1,953	2,076	2,136	1,876	
COVID19 (COVID19 (PFIZER-BIONTECH))	Off label use	1,76	1,064	0,882				2,011	1,67	1,687	1,791	1,378	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	2,035						0,698	1,29	1,569	2,145	1,89	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product use issue	2,117	0,969	0,881				0,512	1,954	1,713	1,619	1,458	
COVID19 (COVID19 (PFIZER-BIONTECH))	SARS-CoV-2 test	1,958	1,612	0,898				1,313	1,953	2,02	1,828	1,91	
COVID19 (COVID19 (PFIZER-BIONTECH))	Vaccination site pain	1,942	0,751	0,875			0,601	2,067	1,953	1,645	1,868	1,92	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,179	1,242	0,894				1,459	1,945	2,022	2,072	1,71	

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#);
Subject: RE: Weekly data mining
Date: Tuesday, May 18, 2021 7:08:31 AM
Attachments: [USST_20120514.xls](#)

Good morning (b) (6) ,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/14/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210514	US Serious EB05 20210514	US Fatal EB05 20210514	US Infant EB05 20210514	US Child EB05 20210514	US Teen EB05 20210514	US Adult1 EB05 20210514	US Adult2 EB05 20210514	US Adult3 EB05 20210514	US Female EB05 20210514	US Male EB05 20210514	Comment
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2 064	0 626					0 639	0 379	0 742	1 699	1 236	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2 55	2 605		0.884			1 118	1 468	4 639	2 474	1 301	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	1 983	2 164					1 175	1 735	1 46	2 023	1 36	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2 314	2 546			0.611		1 78	1 534	3 24	3 055	1 42	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	2 742	2 846					1 975	1 933	0 633	2 553	1 2	
COVID19 (COV D19 (JANSSEN))	Cerebral venous thrombosis	1 84	2 138		0.885			1 128	0 937	0 66	1 529	0 811	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2 142	2 261			0.611		1 813	1 705	1 651	2 81	1 171	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2 287	1 878					0 327	1 915	2 031	2 662	1 702	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2 502	1 532					0 509	1 97	3 319	2 711	1 611	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1 82	1 413					0 563	1 383	1 747	1 39	2 083	0 38
COVID19 (COV D19 (JANSSEN))	Gate palsy	2 239	0 9						2 145	1 642	2 449	1 063	
COVID19 (COV D19 (JANSSEN))	Heavy menstrual bleeding	2 251	0 714						2 376	1 554	2 249	0 54	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	3 732	2 839		0.887			1 128	1 357	2 058	3 867	0 963	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	1 669	2 279		0.866			1 373	0 82	0 644	1 632	0 812	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	1 877	2 065		0.883			0 563	1 669	1 502	1 608	1 339	
COVID19 (COV D19 (JANSSEN))	Menstruation irregular	2 102							2 05	1 619	2 072	0 565	
COVID19 (COV D19 (JANSSEN))	Peripneal embolism	2 168	1 387		0.885				0 525	0 879	1 965	0 825	
COVID19 (COV D19 (JANSSEN))	Platelet count	1 928	2 12		0.893			0 509	1 402	2 146	2 229	1 043	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2 477	2 178		0.889			0 474	1 885	2 464	1 639	3 028	1 431
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	2 391	2 133		0.886				1 103	1 042	0 676	1 52	0 738
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	1 831	1 868		0.891			0 603	1 315	1 67	2 299	2 076	1 399
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	2 889							0 875	1 605	5 402	1 928	1 831
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2 105	0 975		0.887				1 301	1 494	1 44	1 698	1 482
COVID19 (COV D19 (JANSSEN))	Thrombosis	2 293	2 535		1.881			0 575	2 017	3 301	3 465	2 653	1 709
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2 253	2 287		0.885				1 286	1 32	1 907	0 662	0 931
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2 052	1 285		0.887			0 55	1 87	1 804	1 689	2 302	1 362
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2 569	2 36		0.889				1 742	1 981	2 865	3 199	1 611
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1 909	1 15			0 6			1 344	2 019	2 012	1 899	1 641
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1 872	1 022						1 208	1 754	1 153	2 057	0 86
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	2 027	2 455					0 55	1 501	1 841	0 546	0 991	0 991
COVID19 (COV D19 (JANSSEN))	Venogram normal	4 137	3 081		0.887				2 96	1 662	0 676	4 439	0 956
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2 152				0.528			0 606	0 594	0 874	0 91	0 75
COVID19 (COV D19 (MODERNA))	Product temperature excursion issue	2 097							0 555	0 419	0 811	0 457	0 765
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2 108	1 634		0.895				0 779	1 973	2 162	1 821	1 914
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2 202	1 735		0.891				0 631	1 844	1 967	2 107	1 895
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	2 115							0 626	1 599	1 778	2 148	1 966
COVID19 (COV D19 (PFIZER-BIONTECH))	Product use issue	2 085	0 962		0.885				0 5	1 923	1 7	2 038	1 446
COVID19 (COV D19 (PFIZER-BIONTECH))	Vaccination site pain	1 871	0 718		0.879				0 628	2 007	1 854	1 582	1 895
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	2 16	1 199		0.868				0 631	1 476	1 822	2 017	1 718

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, May 25, 2021 6:35:48 AM
Attachments: [USST_20120521.xls](#)

Good morning (b) (6) ,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/21/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210521	US Serious EB05 20210521	US Fatal EB05 20210521	US Infant EB05 20210521	US Child EB05 20210521	US Teen EB05 20210521	US Adult EB05 20210521	US Adult2 EB05 20210521	US Adult3 EB05 20210521	US Female EB05 20210521	US Male EB05 20210521	Comment	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,125	0,772					0,752	0,352	0,734	1,761	1,229		
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,559	2,613	0,878			0,548	1,186	1,55	4,401	2,79	1,275		
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	1,965	2,118					1,185	1,868	1,435	2,122	1,37		
COVID19 (COVID19 (JANSSEN))	Arteriovenous malformation	2,206	2,372	0,887	0,611			1,687	1,601	2,405	2,772	1,386		
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,007	2,853	0,887			0,557	2,252	1,974	0,632	2,977	1,204		
COVID19 (COVID19 (JANSSEN))	Chills	1,377	0,93	0,888			2,314	1,4	1,229	0,94	1,434	1,149		
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head abnormal	2,256	2,336	0,901	0,611		0,548	1,939	1,868	1,637	2,944	1,314		
COVID19 (COVID19 (JANSSEN))	Computerized tomogram thorax abnormal	1,807	1,87	0,881			0,941	1,424	1,451	1,654	2,019	1,226		
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,34	1,886	0,887			0,531	1,963	2,116	2,801	2,782	1,782		
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,562	1,45	0,886			0,496	2,369	2,019	2,637	2,787	1,553		
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,826	1,378	0,886	0,604		0,56	1,362	1,811	1,337	2,163	0,981		
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,19	0,882					2,102	1,642	0,686	0,686	2,53		
COVID19 (COVID19 (JANSSEN))	Heavy menstrual bleeding	2,14	0,737					2,178	1,654	2,136	0,546	0,546		
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,286	2,863	0,881				1,298	1,440	2,582	4,576	1,063		
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1,93	2,321	0,879				1,682	0,83	0,648	1,944	0,62		
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,944	2,09	0,876			0,61	1,688	1,523	1,754	2,129	1,401		
COVID19 (COVID19 (JANSSEN))	Menstruation irregular	2,03	0,679					1,986	1,681	2,001	0,569	0,569		
COVID19 (COVID19 (JANSSEN))	Off label use	1,184					3,192	0,29	0,42	0,78	0,993	0,993		
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	2,612	1,508	0,879				0,531	0,894	2,346	1,75	0,836		
COVID19 (COVID19 (JANSSEN))	Platelet count	2,052	2,348	0,893	0,611		0,54	1,639	2,283	1,317	2,382	1,118		
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,507	2,217	0,882			0,467	1,85	2,503	1,908	3,216	1,415		
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	2,817	2,587	0,879				1,298	1,158	0,679	2,03	0,905		
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,793	1,788	0,887	0,611		0,62	1,305	1,636	2,265	2,094	1,336		
COVID19 (COVID19 (JANSSEN))	Pyrexia	1,418	0,904	0,888				2,326	1,446	1,233	0,942	1,476	1,188	
COVID19 (COVID19 (JANSSEN))	Scan with contrast abnormal	1,834	2,055					1,025	1,606	1,081	1,754	1,151		
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	3,049						1,012	2,607	5,96	2,462	2,19		
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,249	1,011	0,881			0,557	1,404	1,462	1,34	1,86	1,5		
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,308	2,513	1,971	0,611		0,592	2,094	2,359	3,628	2,707	1,697		
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,164	2,215	0,879				1,298	1,25	0,658	1,827	0,826		
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,028	1,162	0,88			0,549	1,787	1,781	1,685	2,351	1,309		
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,607	2,284	0,883				1,883	1,98	3,274	3,028	1,725		
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,914	1,232		0,602			1,315	2,072	2,043	1,88	1,685		
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,913	1,035					1,379	1,797	1,109	2,147	0,848		
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	2,503	2,646				0,557	1,83	1,41	0,539	2,559	1,003		
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,034	2,963	0,879				3,188	1,67	0,665	4,645	0,913		
COVID19 (COVID19 (JANSSEN))	Vital signs measurement	1,893	0,54					1,893	2,017	1,352	1,245	1,58		
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,188			0,528			0,531	0,486	0,546	0,831	0,79		
COVID19 (COVID19 (MODERNA))	Product temperature excursion issue	2,067						0,398	0,312	0,556	0,271	0,484		
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,07	1,622	0,894				1,936	2,107	2,055	1,884	1,677		
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,153	1,689	0,885				1,841	1,938	2,081	2,091	1,862		
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	2,079						1,44	1,625	1,769	2,119	1,979		
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,087	1,212	0,881				0,591	1,465	1,833	1,995	2,023	1,681	

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, June 1, 2021 9:02:22 AM
Attachments: [USST_20210528.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/28/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210528	US Serious EB05 20210528	US Fatal EB05 20210528	US Infant EB05 20210528	US Child EB05 20210528	US Teen EB05 20210528	US Adult1 EB05 20210528	US Adult2 EB05 20210528	US Adult3 EB05 20210528	US Female EB05 20210528	US Male EB05 20210528	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,074	0,747					0,755	0,396		0,721	1,726	1,297
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,763	2,706	0,881				1,252	1,655		4,6	3,47	1,002
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,004	2,114	0,877				1,245	1,889		1,423	2,04	1,489
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,006	2,125	0,894				1,552	1,61		1,961	2,462	1,281
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,865	2,763	0,888		0,611		2,022	2,056		0,607	2,962	1,151
COVID19 (COV D19 (JANSSEN))	Chills	1,383	0,919	0,891				1,419	1,228		0,925	1,437	1,162
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2,306	2,373	0,907		0,611		0,539	1,71		1,976	1,843	1,326
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	1,852	1,912	0,863				0,521	1,39		1,605	1,647	1,247
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,335	1,894	0,888				0,519	2,031		2,671	2,737	1,797
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,527	1,424	0,887				0,453	2,363		2,1	2,081	1,52
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,185	1,398	0,889		0,602		0,606	1,404		1,185	1,35	0,998
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1,823	0,941	0,88				0,542	1,522		1,612	0,741	2,003
COVID19 (COV D19 (JANSSEN))	Gaze palsy	2,258	0,877						2,18		1,667	0,764	1,017
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,437	2,96	0,885					1,359		1,673	1,595	4,185
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	2,665	2,041					0,556	1,273		0,96	0,569	0,932
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,011	2,381	0,881					1,828		0,914	1,922	0,7
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,553	2,095	0,88					0,606		1,556	1,872	1,161
COVID19 (COV D19 (JANSSEN))	Off label use	1,245							0,297		0,429	0,803	1,075
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3,031	1,594	0,88					0,535		0,905	2,123	1,889
COVID19 (COV D19 (JANSSEN))	Platelet count	2,055	2,32	0,894		0,611			1,807		2,328	1,285	2,363
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,383	2,082	0,886					1,797		2,421	1,791	2,997
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	3,498	2,676	0,881					1,359		1,183	0,681	0,919
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	1,797	1,785	0,893		0,611			0,603		1,26	1,729	2,171
COVID19 (COV D19 (JANSSEN))	Pyrexia	1,421	0,881	0,889					2,3		1,465	1,221	0,928
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	3,219							1,285		3,279	7,907	2,831
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2,228	1,043	0,882					1,43		1,432	1,342	1,733
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,292	2,512	1,597		0,611			0,674		2,07	2,392	3,464
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,195	2,21	0,88					1,426		1,189	0,656	1,914
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,03	1,15	0,882					0,549		1,717	1,909	2,357
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,669	2,317	0,887					2,075		2,034	3,54	3,112
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1,941	1,247			0,6			1,352		2,167	1,964	1,938
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	2,03	1,023						1,418		2,015	1,181	2,317
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	2,894	2,778						0,556		2,778	1,459	0,54
COVID19 (COV D19 (JANSSEN))	Venogram normal	4,155	2,971	0,881					3,414		1,673	0,668	0,911
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2,225							0,47		0,546	0,806	0,617
COVID19 (COV D19 (MODERNA))	Product temperature excursion issue	2,142				0,528			0,945		0,331	0,532	0,235
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2,059	1,64	0,896					0,723		1,881	2,055	1,864
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2,133	1,672	0,888					0,678		1,827	1,899	2,101
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	2,063							1,513		1,75	1,835	1,978
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	2,05	1,187	0,881					0,581		1,446	1,773	2,024

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, June 8, 2021 6:55:21 AM
Attachments: [USST_20210604.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/4/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210604	US Serious EB05 20210604	US Fatal EB05 20210604	US Infant EB05 20210604	US Child EB05 20210604	US Teen EB05 20210604	US Adult1 EB05 20210604	US Adult2 EB05 20210604	US Adult3 EB05 20210604	US Female EB05 20210604	US Male EB05 20210604	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,158	0,751					0,732	0,369		0,719	1,777	1,371
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,84	2,638	0,882			0,538	1,299	1,884		4,285	3,816	1,163
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,064	2,094	0,88			0,546	1,257	2,038		1,368	2,113	1,54
COVID19 (COVID19 (JANSSEN))	Anti-coagulant therapy	1,895	0,864			0,611		1,521	1,48		1,861	2,285	1,175
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,678	1,834	0,895			0,554	1,214	1,468		1,171	2,087	0,844
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,872	2,65	0,891			0,538	2,129	2,148		0,687	3,24	1,082
COVID19 (COVID19 (JANSSEN))	Chills	1,409	0,925	0,889			0,518	2,278	1,462		1,239	1,459	1,194
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,324	2,311	0,909		0,611		0,931	1,719		2,032	1,815	3,168
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,789	1,794	0,883			0,592	1,269	1,656		1,536	2,08	1,206
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,357	1,917	0,893			0,518	2,023	2,105		2,883	2,796	1,796
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,933	1,32	0,888			0,622	2,361	2,106		1,937	2,845	1,488
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,854	1,384	0,89		0,605		0,572	1,388		1,857	1,428	2,278
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,809	0,926	0,881			0,602	1,548	1,542		0,737	2,084	0,929
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,292	0,928	0,881				2,239	1,666		0,838	2,76	1,056
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	3,957	2,842	0,885				1,231	1,881		1,508	5,262	0,933
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	3,365	2,161				0,554	1,355	1,047		0,574	1,955	0,918
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,06	2,343	0,881				1,59	1,032		0,651	2,087	0,691
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,986	2,054	0,88			0,571	1,662	1,625		1,85	2,228	1,419
COVID19 (COV D19 (JANSSEN))	Off label use	1,3					3,741	0,31	0,428		0,824	1,145	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3,777	1,684	0,881				0,542	0,916		2,381	2,101	0,845
COVID19 (COV D19 (JANSSEN))	Platelet count	2,13	2,425	0,898		0,611		0,539	1,832		2,472	1,276	2,487
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,42	2,026	0,886			0,403	1,833	2,493		1,879	3,105	1,339
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	4,306	2,809	0,882				0,898	1,217		0,884	3,771	0,938
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0,179					0,498	2,211	1,505		0,577	1,599	1,746
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	1,807	1,757	0,895		0,611		0,689	1,289		2,099	2,083	1,38
COVID19 (COV D19 (JANSSEN))	Pyrexia	1,438	0,897	0,889			2,157	1,489	1,228		0,929	1,483	1,232
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	3,491						1,348	4,359		8,572	3,471	2,781
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2,247	1,087	0,883			0,554	1,292	1,685		1,255	1,736	1,681
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,288	2,548	1,975		0,611		2,032	2,41		3,378	2,675	1,714
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,077	1,216	0,884			0,539	1,768	1,899		1,629	2,481	1,278
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,599	2,207	0,889				1,985	2,127		2,855	2,955	1,836
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1,894	1,319			0,603		1,338	2,106		1,893	1,915	1,633
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	1,982	1,043	0,879				1,488	1,683		1,586	2,085	1,3
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1,962	0,985					1,382	1,979		1,138	2,247	0,888
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	2,993	2,886				0,547	2,467	1,474		0,54	3,364	1,017
COVID19 (COV D19 (JANSSEN))	Venogram normal	4,172	2,843	0,882				3,761	1,691		0,611	5,117	0,884
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2,286					0,528	0,516	0,431		0,792	0,787	0,57
COVID19 (COV D19 (MODERNA))	Product temperature excursion issue	2,133						0,358	0,258		0,511	0,232	0,456
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	1,964	1,683	0,897				0,823	1,988		2,034	1,779	1,773
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2,053	1,705	0,889				0,712	1,843		2,071	2,001	1,781
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	2,021						1,513	1,777		1,863	2,124	1,947
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	2,02	1,254	0,884				0,576	1,431		1,744	2,028	1,624

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: Weekly data mining
Date: Tuesday, June 15, 2021 8:28:58 AM
Attachments: [USST_20210611.xls](#)

Good morning (b) (6),

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/11/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210611	US Serious EB05 20210611	US Fatal EB05 20210611	US Infant EB05 20210611	US Child EB05 20210611	US Teen EB05 20210611	US Adult1 EB05 20210611	US Adult2 EB05 20210611	US Adult3 EB05 20210611	US Female EB05 20210611	US Male EB05 20210611	Comment
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2 294	0 610					0 716	0 556	0 722	1 637	1 414	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3 008	2 639	0 885			0 532	1 387	1 668	4 511	3 946	1 23	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2 128	2 061	0 879			0 54	1 295	2 097	1 414	2 074	1 655	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	1 914	1 859	0 897	0 611			1 656	1 569	1 949	2 418	1 204	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	1 796	2 018	0 885			0 547	0 994	1 269	0 574	1 901	0 732	
COVID19 (COV D19 (JANSSEN))	Body temperature	1 918	0 894				1 418	1 874	2 01	1 569	1 873	1 671	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	1 759	1 874	0 898			0 546	1 329	1 536	1 154	2 169	0 895	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3 176	2 689	0 893			0 546	2 052	2 797	0 69	3 991	1 167	
COVID19 (COV D19 (JANSSEN))	Chills	1 436	0 952	0 891			2 099	1 505	1 254	0 938	1 483	1 225	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2 326	2 221	0 904	0 611		0 526	1 801	2 028	1 784	3 153	1 331	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	1 636	1 754	0 894			0 674	1 334	1 721	1 917	2 093	1 295	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2 398	1 939	0 894			0 502	2 098	2 145	2 815	2 834	1 88	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2 502	1 252	0 899			0 512	2 366	2 093	1 793	2 842	1 461	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1 94	1 494	0 891	0 608		0 634	1 479	1 934	1 534	2 376	1 042	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1 795	0 941	0 882			0 504	1 596	1 551	0 741	2 023	0 957	
COVID19 (COV D19 (JANSSEN))	Gaze palsy	2 361	0 926	0 883			2 332	1 891	0 832	2 87	1 107	1 107	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	4 307	3 03	0 887			1 604	2 144	1 551	5 398	1 091	1 091	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	4 908	2 66			0 554	1 758	1 448	0 578	4 397	1 079	1 079	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1 822	1 242	0 886			1 308	1 677	0 876	2	1 011	1 011	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2 051	2 282	0 883			1 584	1 109	0 65	2 152	0 749	0 749	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2 018	1 989	0 882			0 556	1 712	1 677	1 631	2 276	1 425	
COVID19 (COV D19 (JANSSEN))	Off label use	1 425	0 189				3 971	0 321	0 544	0 901	0 901	1 353	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1 72	0 753				1 962	1 031		2 065			
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	4 011	1 716	0 883			0 547	0 926		2 13	2 181	0 851	
COVID19 (COV D19 (JANSSEN))	Platelet count	2 248	2 531	0 898	0 611		0 54	2 022	2 637	1 288	2 693	1 253	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2 533	2 142	0 898			0 365	1 921	2 681	2 075	3 199	1 435	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	4 719	2 854	0 883			1 699	1 255	0 686	4 456	0 955	0 955	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0 235					0 495	3 119	1 727	1 881	2 255	2 255	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	1 877	1 765	0 896	0 611		0 693	1 382	1 825	2 095	1 473	1 473	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	3 676					1 434	5 032	6 64	3 942	3 384	3 384	
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2 161	1 056	0 885			0 547	1 277	1 628	1 226	1 672	1 663	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2 33	2 555	1 959	0 611		0 646	2 028	2 457	3 401	1 806	1 806	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2 069	1 947	0 883			1 35	1 242	0 653	1 528	0 886	0 886	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2 148	1 26	0 886			0 533	1 889	1 95	1 688	1 282	1 282	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2 601	2 157	0 888			1 968	2 145	3 104	2 818	1 924	1 924	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2 182	1 712				2 041	1 384	1 136	1 396	2 096	1 396	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1 883	1 481		0 605		0 519	1 362	2 077	1 798	1 898	1 84	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	1 974	1 025	0 881			1 562	1 599	1 599	1 575	2 101	1 283	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1 962	0 965				1 962	1 433	1 953	1 947	2 122	1 049	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3 334	2 717				0 547	2 962	1 516	0 542	3 837	1 091	
COVID19 (COV D19 (JANSSEN))	Venogram normal	3 993	2 787	0 883			3 098	1 81	0 684	5 318	0 845	0 845	
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2 354				0 528	0 502	0 379	0 498	0 687	0 717	0 493	
COVID19 (COV D19 (MODERNA))	Product temperature excursion issue	2 155					0 26	0 223	0 351	0 131	0 369	0 369	
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	1 892	1 689	0 899			0 761	1 779	1 96	2 009	1 714	1 702	
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2 012	1 704	0 892			0 736	1 721	1 84	2 063	1 973	1 75	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	2 008					1 46	1 877	1 927	2 114	1 958	1 912	
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	1 983	1 252	0 885			0 617	1 498	1 724	2 012	1 95	1 628	

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#);
Subject: RE: Weekly data mining
Date: Tuesday, June 22, 2021 6:51:29 AM
Attachments: [USST_20210618.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/18/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210618	US Serious EB05 20210618	US Fatal EB05 20210618	US Infant EB05 20210618	US Child EB05 20210618	US Teen EB05 20210618	US Adult1 EB05 20210618	US Adult2 EB05 20210618	US Adult3 EB05 20210618	US Female EB05 20210618	US Male EB05 20210618	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,323	0,856	0,863				0,701	0,559	0,719	1,947	1,355	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,403	2,766	0,887				1,668	1,971	4,523	4,279	1,441	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,355	2,121	0,88				0,536	1,55	2,304	1,438	2,227	1,891
COVID19 (COVID19 (JANSSEN))	Arlicoglutin therapy	1,948	1,946	0,897				1,72	1,72	1,719	1,884	2,377	1,338
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,154	2,259	0,865	0.612			0,549	1,017	1,297	0,669	0,609	
COVID19 (COVID19 (JANSSEN))	Body temperature	1,963	0,887					1,367	1,958	2,026	1,535	1,927	1,704
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,866	1,882	0,9				0,541	1,389	1,734	1,129	2,461	0,898
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	1,906	1,61	0,895				0,948	0,815	1,199	0,855	0,741	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,586	2,787	0,893				0,548	2,335	3,5	0,766	3,948	1,257
COVID19 (COVID19 (JANSSEN))	Chills	1,453	0,948	0,89				2,042	1,525	1,268	0,945	1,499	1,243
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,49	2,25	0,905	0.612			0,506	2,032	2,236	1,802	3,387	1,442
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,965	1,798	0,884				0,557	1,351	1,899	1,64	2,203	1,388
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,439	1,936	0,884				0,485	2,121	2,177	2,881	1,903	1,903
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,474	1,253	0,889				0,488	2,33	2,138	1,794	2,865	1,463
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,011	1,453	0,891	0.608			0,483	1,657	2,031	1,466	2,392	1,164
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,819	0,982	0,883				0,493	1,521	1,716	0,813	2,069	0,96
COVID19 (COVID19 (JANSSEN))	Gate palsy	2,399	0,945	0,883				2,443	1,722	0,828	2,848	1,162	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,635	3,119	0,887				1,615	2,704	3,288	5,931	1,091	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,602	2,816					0,555	1,954	1,81	0,674	5,588	1,109
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,229	2,274	0,883				1,964	1,057	0,652	2,606	0,747	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,099	1,979	0,882				0,542	1,773	1,827	1,838	2,32	1,528
COVID19 (COVID19 (JANSSEN))	Off label use	1,487	0,305	3,778				0,372	0,551	0,369	0,911	1,438	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,61	0,753					2,254	1,012		2,016		
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	4,295	1,704	0,883				0,551	0,934	2,215	2,435	0,856	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,459	2,701	0,899	0.612			0,542	2,206	3,049	1,245	1,446	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,597	2,169	0,888				0,335	1,928	2,843	2,207	3,347	1,561
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,186	2,949	0,884				2,946	0,687	0,687	5,086	0,972	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,301		0,563				2,53	1,71	2,807	1,965	2,429	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,004	1,777	0,895	0.612			0,69	1,508	1,943	2,196	1,62	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,269		1,894				1,894	5,979	9,092	4,374	3,616	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,142	1,034	0,885				0,549	1,296	1,584	1,667	1,637	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,395	2,529	1,837	0.612			0,841	2,139	2,488	3,331	1,882	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,168	1,802	0,883				1,415	1,211	0,655	2,109	0,885	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,17	1,253	0,886				0,53	1,867	2,03	1,634	1,317	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,767	2,184	0,889				2,143	2,285	3,227	2,86	2,183	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,395	1,654	0,884				2,497	1,417	1,171	2,358	1,481	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,882	1,448	0,882	0.605			1,385	2,082	1,897	1,73	1,634	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	1,963	1,054	0,881				0,505	1,552	1,58	1,628	2,069	1,303
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,943	0,969					1,379	1,998	1,296	2,147	1,026	
COVID19 (COVID19 (JANSSEN))	Venogram	2,352	2,038					1,769	1,505	0,569	2,296	0,82	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,975	2,913					0,543	3,641	1,726	0,632	4,519	1,117
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,149	2,736	0,884				0,528	3,208	2,053	0,665	5,261	0,863
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,395		0,449				0,284	0,387	0,387	0,595	0,398	
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,088	0,904	0,883				0,132	0,222	0,222	0,732	2,058	2,116
COVID19 (COVID19 (MODERNA))	Product temperature excursion issue	2,204						0,157	0,195	0,328	0,087	0,327	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,98	1,725	0,892				0,724	1,69	1,833	2,059	1,942	1,736
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,969						1,403	1,887	1,924	2,095	1,927	1,885
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,939	1,261	0,886				0,651	1,47	1,712	2,009	1,922	1,6

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: RE: Weekly data mining
Date: Tuesday, June 29, 2021 8:39:14 AM
Attachments: [USST_20210625.xls](#)

Good morning (b) (6),

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/25/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210625	US Serious EB05 20210625	US Fatal EB05 20210625	US Infant EB05 20210625	US Child EB05 20210625	US Teen EB05 20210625	US Adult1 EB05 20210625	US Adult2 EB05 20210625	US Adult3 EB05 20210625	US Female EB05 20210625	US Male EB05 20210625	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,363	0,261	0,079				0,707	0,556	0,711	1,58	1,356	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,414	2,713	0,886			0,524	1,657	1,964	4,51	4,284	1,443	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,442	2,166	0,875			0,533	1,609	2,411	1,495	2,366	1,945	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,095	1,905	0,903				1,627	1,885	2,051	2,669	1,355	
COVID19 (COVID19 (JANSSEN))	Blood Nitrogen decreased	2,285	2,286	0,882	0,612		0,551	1,031	1,318	0,87	2,95	0,816	
COVID19 (COVID19 (JANSSEN))	Body temperature	1,986	0,904				1,379	2,025	2,059	1,555	1,948	1,736	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,957	1,923	0,899			0,543	1,483	1,779	1,175	2,584	0,981	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	1,976	1,636	0,882			0,55	0,821	1,172	0,856	2,205	0,746	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,632	2,758	0,89			0,55	2,363	3,739	0,763	4,075	1,261	
COVID19 (COVID19 (JANSSEN))	Chills	1,466	0,956	0,888			2,03	1,544	1,279	0,943	1,509	1,229	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,566	2,253	0,905	0,612		0,51	2,146	2,303	1,939	3,481	1,493	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,038	1,834	0,879			0,551	1,391	2,031	1,661	2,249	1,475	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,456	1,934	0,893			0,489	2,192	2,176	2,897	2,879	1,933	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,476	1,44	0,896			0,45	2,409	2,138	1,783	2,874	1,47	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,057	1,488	0,889	0,608		0,45	1,603	2,219	1,501	2,451	1,209	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,809	0,958	0,879			0,483	1,528	1,719	0,808	2	0,999	
COVID19 (COVID19 (JANSSEN))	Gate palsy	2,438	0,961	0,879				2,433	1,822	0,814	2,938	1,215	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,61	3,157	0,884				1,633	3,004	3,55	5,8	1,165	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,49	2,749		0,557			2,141	1,64	0,675	5,774	1,088	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,893	1,315	0,883				1,395	1,705	0,994	2,062	1,058	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,382	2,301	0,88				1,853	1,172	0,653	2,777	0,754	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,088	1,959	0,882			0,532	1,77	1,825	1,845	2,295	1,936	
COVID19 (COVID19 (JANSSEN))	Off label use	1,506	0,167				4,221	0,377	0,555	0,388	0,923	1,479	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,647	0,754					2,544	1,021			2,118	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	4,712	2,015	0,879				0,688	0,94	0,296	4,212	0,86	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,375	2,536	0,896		0,612		0,531	2,131	3,04	1,228	2,84	1,37
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,662	2,258	0,886			0,316	2,011	3,008	2,194	3,35	1,566	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,034	2,969	0,88				2,42	1,325	0,688	5,061	1,057	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,331						0,565	2,488	1,807	2,024	2,132	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,066	1,807	0,897	0,612		0,68	1,608	1,985	2,247	2,302	1,667	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,394		0,882				2,136	5,887	9,642	4,583	3,928	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,109	1,08	0,882			0,551	1,258	1,587	1,197	1,677	1,575	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,391	2,544	1,879	0,612		0,84	2,103	2,482	3,25	2,688	1,906	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,354	1,975	0,88				1,572	1,248	0,652	2,308	0,894	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,181	1,267	0,883			0,52	1,884	2,029	1,681	2,584	1,349	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,809	2,197	0,896	0,612			2,196	2,332	3,228	2,902	2,24	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,499	1,924	0,888				2,645	1,463	1,238	2,542	1,514	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	1,989	1,102	0,877			0,497	1,533	1,663	1,612	2,092	1,308	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,841	0,966					1,297	1,904	1,343	2,046	0,99	
COVID19 (COVID19 (JANSSEN))	Venogram	2,229	1,988					1,619	1,5	0,568	2,274	1,107	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	4,03	2,91				0,545	3,621	1,789	0,633	4,676	1,107	
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,195	2,626	0,88				3,475	1,992	0,662	5,372	0,861	
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,417				0,528	0,434	0,356	0,5	0,637	0,599	0,498	
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,193	0,877	0,879		0,725	2,237	0,126	0,214	0,736	2,15	2,221	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,969	1,736	0,889			0,776	1,694	1,822	2,053	1,933	1,73	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,944					1,376	1,88	1,907	2,084	1,907	1,863	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,929	1,299	0,884			0,646	1,495	1,698	2,016	1,909	1,628	

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, July 6, 2021 1:52:18 PM
Attachments: [USST_20210702.xls](#)

Hi (b) (6),

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/2/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210702	US Serious EB05 20210702	US Fatal EB05 20210702	US Infant EB05 20210702	US Child EB05 20210702	US Teen EB05 20210702	US Adult1 EB05 20210702	US Adult2 EB05 20210702	US Adult3 EB05 20210702	US Female EB05 20210702	US Male EB05 20210702	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,665	1,665	0,863	0,863	1,721	1,475	1,475	1,507	1,507	2,109	1,033	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,385	0,86	0,881	0,709	0,638	0,638	0,638	0,711	0,711	1,952	1,411	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,341	2,659	0,887	0,519	1,683	1,997	1,997	4,302	4,321	1,396	1,396	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,499	2,101	0,679	0,522	1,566	2,411	1,522	2,380	1,895	1,895	1,322	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,056	1,866	0,915	0,544	1,742	1,928	1,928	2,04	2,04	2,691	1,322	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,126	2,297	0,883	0,544	1,003	1,319	1,319	0,666	0,666	2,761	0,793	
COVID19 (COVID19 (JANSSEN))	Body temperature	1,961	0,907	0,807	1,397	2,008	2,013	2,013	1,506	1,922	1,73	1,73	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	1,977	2,037	0,88	0,544	1,207	1,775	1,775	0,906	0,906	1,218	1,794	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,92	1,865	0,901	0,544	1,425	1,8	1,137	1,137	2,456	0,97	0,97	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	1,948	1,809	0,883	0,55	0,822	1,171	1,171	0,849	0,849	2,214	0,742	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,489	2,722	0,891	0,544	2,288	3,627	3,627	4,021	4,021	1,211	1,211	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,561	2,234	0,905	0,501	2,118	2,324	2,324	1,841	3,397	1,531	1,531	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,031	1,837	0,884	0,543	1,396	2,021	2,021	1,705	2,333	1,421	1,421	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,454	1,928	0,897	0,495	2,183	2,189	2,189	2,843	2,92	1,913	1,913	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,455	1,476	0,887	0,443	2,392	2,084	2,084	1,901	2,839	1,48	1,48	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,009	1,462	0,889	0,412	1,611	2,188	2,188	1,494	1,204	1,204	1,204	
COVID19 (COVID19 (JANSSEN))	Gate palsy	2,406	0,95	0,88	0,412	2,406	1,801	1,801	0,813	2,929	1,195	1,195	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,651	3,112	0,885	0,412	1,641	3,093	3,093	3,508	5,657	1,189	1,189	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,621	2,865	0,884	0,557	3,245	1,645	1,645	0,676	5,948	1,088	1,088	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,84	1,272	0,884	0,412	1,345	1,652	1,652	0,928	2,047	1,019	1,019	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,315	2,27	0,881	0,412	1,887	1,15	0,653	2,965	0,754	1,499	1,499	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,071	1,946	0,883	0,412	1,76	1,842	1,841	1,841	2,328	1,461	1,461	
COVID19 (COVID19 (JANSSEN))	Off label use	1,542	0,156	0,368	0,368	0,649	0,649	0,649	0,965	0,965	1,461	1,461	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,598	0,755	0,881	0,412	1,19	1,006	1,006	1,949	1,949	1,461	1,461	
COVID19 (COVID19 (JANSSEN))	Peripherical embolism	4,711	2,021	0,881	0,412	0,669	0,84	0,84	2,279	4,218	0,86	0,86	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,434	2,567	0,903	0,526	2,166	3,062	3,062	1,448	2,899	1,515	1,515	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,611	2,23	0,887	0,412	2,003	2,943	2,943	2,154	3,277	1,55	1,55	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,169	3,046	0,881	0,412	3,016	1,522	0,689	4,815	1,245	1,245	1,245	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	3,367	0,562	0,881	0,412	2,802	1,812	1,812	2,209	2,209	2,209	2,209	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,047	1,798	0,9	0,412	1,569	1,983	2,245	2,3	1,644	1,644	1,644	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,419	1,112	0,883	0,551	3,236	6,033	6,033	10,959	4,8	3,887	3,887	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,117	2,117	0,883	0,412	1,227	1,133	1,133	1,725	1,567	1,567	1,567	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,399	2,526	1,908	0,62	2,145	2,496	2,496	3,245	2,722	1,909	1,909	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,271	1,934	0,881	0,412	1,579	1,217	1,217	0,653	0,881	1,725	1,567	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,158	1,25	0,884	0,516	1,863	1,968	1,968	2,514	1,371	1,371	1,371	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,795	2,226	0,889	0,412	2,102	2,355	2,355	3,139	2,943	2,211	2,211	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,484	1,963	0,883	0,412	2,713	1,477	1,477	2,609	1,469	1,469	1,469	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,81	1,449	0,879	0,412	1,329	2,006	2,006	1,654	1,839	1,564	1,564	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	1,904	1,157	0,876	0,493	1,517	1,771	1,771	1,627	2,108	1,368	1,368	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,838	1,021	0,881	0,412	1,284	1,938	1,938	1,442	2,06	1,021	1,021	
COVID19 (COVID19 (JANSSEN))	Venogram	2,233	1,887	0,881	0,412	1,722	1,5	0,565	2,247	0,851	0,851	0,851	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,758	2,844	0,881	0,54	3,156	1,794	1,794	0,634	4,603	1,953	1,953	
COVID19 (COVID19 (JANSSEN))	Venogram normal	3,978	2,589	0,881	0,412	3,257	2,002	2,002	0,663	5,291	0,838	0,838	
COVID19 (COVID19 (MODERNA))	Accidental exposure to product	2,023	0,833	0,883	0,501	0,386	0,545	0,46	0,753	0,683	0,804	0,804	
COVID19 (COVID19 (MODERNA))	No adverse event	1,597	0,528	0,882	0,716	2,022	0,862	1,005	0,904	1,26	1,353	1,353	
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,418	0,875	0,88	0,501	0,428	0,342	0,499	0,618	0,577	0,49	0,49	
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,247	1,95	0,88	0,716	2,294	0,123	0,215	0,738	2,205	2,271	2,271	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,95	1,727	0,89	0,412	0,861	1,701	1,814	2,031	1,912	1,727	1,727	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,92	1,375	0,885	0,412	1,871	1,895	1,895	2,069	1,884	1,84	1,84	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,924	1,31	0,885	0,412	0,644	1,512	1,682	2,015	1,905	1,629	1,629	

Drug	Event	US EB05 20210709	US Serious EB05 20210709	US Fatal EB05 20210709	US Infant EB05 20210709	US Child EB05 20210709	US Teen EB05 20210709	US Adult EB05 20210709	US Adult EB05 20210709	US Adult EB05 20210709	US Female EB05 20210709	US Male EB05 20210709	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,927	1,975	0,95				1,554	1,461	1,253	2,565	1,043	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,444	0,887	0,879				0,709	0,712	0,711	2,082	1,413	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,199	2,907	0,864				0,919	1,589	1,827	4,279	4,329	1,331
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,444	2,208	0,875				0,905	1,612	2,447	1,504	2,485	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,076	1,899	0,907		0,612		1,783	1,988	2,03	2,72	1,355	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,131	1,887	0,879				0,544	1,001	1,318	0,867	2,792	0,793
COVID19 (COVID19 (JANSSEN))	CSF protein increased	1,993	2,067	0,876				1,272	1,773	0,934	1,208	1,828	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,975	1,933	0,899				0,543	1,486	1,799	1,122	2,533	1,007
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,442	2,729	0,863				0,564	1,729	2,222	3,633	4,028	1,189
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,526	2,215	0,904		0,612		0,501	2,036	2,305	1,807	3,37	1,498
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,096	1,904	0,936				0,535	1,614	2,109	1,669	2,34	1,528
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,423	1,949	0,898				0,486	2,135	2,165	2,831	2,904	1,885
COVID19 (COVID19 (JANSSEN))	Feeling cold	1,804	0,714	0,876				1,296	2,002	1,542	1,121	1,904	1,45
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,396	1,483	0,864				0,438	2,341	2,062	1,969	2,787	1,465
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,989	1,531	0,886		0,608		0,384	1,637	1,508	1,508	2,331	1,241
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,372	0,942	0,876				0,972	2,357	1,779	0,812	2,864	1,185
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,657	0,881						1,642	3,508	2,238	5,588	1,273
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,623	2,872	0,881				0,556	3,276	1,643	0,676	5,396	1,087
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,825	1,28	0,881				1,344	1,681	0,921	2,032	1,011	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,2	2,284	0,877				1,715	1,149	0,654	2,57	0,74	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,029	1,921	0,979				0,504	1,715	1,815	1,818	2,286	1,473
COVID19 (COVID19 (JANSSEN))	Off label use	1,567	0,157	0,365				0,641	0,366	0,977	1,454		
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,6	0,755	0,877					2,207	1,026		1,861	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	4,29	2,115	0,646				0,529	1,047	1,421	2,238	4,21	0,927
COVID19 (COVID19 (JANSSEN))	Platelet count	2,386	2,554	0,9		0,612		0,529	2,1	3,009	1,421	2,801	1,51
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,665	2,296	0,933				0,3	1,977	2,36	2,23	3,261	1,95
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,176	3,057	0,877					3,048	1,52	0,689	4,832	1,244
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,382						0,687	2,096	1,904	3,324	2,368	2,368
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,049	1,827	0,9		0,612		0,87	1,604	2,01	2,22	2,311	1,645
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,434							3,301	6,034	10,893	4,827	3,894
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,116	1,116	0,879				0,55	1,225	1,699	1,13	1,726	1,564
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,363	2,52	1,867		0,612		0,621	2,103	2,465	3,236	2,683	1,899
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,272	1,933	0,877				1,196	1,216	0,663	2,328	0,881	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,133	1,256	0,882				0,511	1,815	2,011	1,631	2,468	1,389
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,843	2,282	0,889		0,612			2,337	3,375	2,963	2,229	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,435	1,928	0,879					1,433	1,263	2,535	1,469	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2,043	1,325	0,873				0,493	1,611	1,872	1,696	2,065	1,556
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,788	1,031						1,281	1,882	1,414	2,03	0,883
COVID19 (COVID19 (JANSSEN))	Varicella	2,256	2,01	1,724					1,478	0,566	1,201	0,851	
COVID19 (COVID19 (JANSSEN))	Varicella abnormal	3,776	2,901					0,539	2,908	1,793	0,719	4,779	1,042
COVID19 (COVID19 (JANSSEN))	Varicella normal	3,863	2,606						3,269	2,001	0,663	5,302	0,938
COVID19 (COVID19 (MODERNA))	Accidental exposure to product	2,016						0,388	0,626	0,481	0,754	0,806	
COVID19 (COVID19 (MODERNA))	No adverse event	1,562	0,833	0,88				0,501	0,074	1,01	0,902	1,227	1,352
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,456						0,528	0,339	0,481	0,597	0,596	0,482
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,28	0,875	0,876		0,716			0,123	0,215	0,739	2,298	2,298
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,946	1,736	0,938					1,713	1,809	2,032	1,906	1,731
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,891							1,411	1,881	1,902	1,864	1,82
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,916	1,321	0,883					1,615	1,676	2	1,894	1,63

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: RE: Weekly data mining
Date: Tuesday, July 20, 2021 7:02:23 AM
Attachments: [USST_20210716.xls](#)

Good morning (b) (6) ,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/16/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210716	US Serious EB05 20210716	US Fatal EB05 20210716	US Infant EB05 20210716	US Child EB05 20210716	US Teen EB05 20210716	US Adult EB05 20210716	US Adult2 EB05 20210716	US Adult3 EB05 20210716	US Female EB05 20210716	US Male EB05 20210716	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,922	1,92	0,923				1,425	1,425	1,425	2,924	1,924	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,457	0,885	0,882				0,775	0,775	0,718	0,71	2,094	1,408
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,18	2,803	0,889			0,214	1,58	1,58	1,895	4,278	3,363	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,413	2,186	0,88			0,495	1,598	1,598	1,68	2,377	1,936	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,03	1,851	0,906	0,612			1,691	1,691	1,952	1,999	2,623	1,349
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,983	2,272	0,953				0,989	0,989	1,31	0,963	2,972	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	1,97	2,019	0,88				1,188	1,809	0,989	1,133	1,9	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,937	1,885	0,901			0,543	1,478	1,783	1,783	1,196	2,486	0,968
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,258	2,925	0,891			0,538	2,122	3,236	0,756	3,784	1,181	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,475	2,17	0,909	0,612			0,492	2,023	2,28	1,801	3,204	1,506
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,032	1,852	0,895			0,52	1,483	2,074	1,616	2,264	1,5	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,358	1,9	0,899			0,477	2,067	2,088	2,833	2,845	1,824	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,345	1,495	0,887			0,431	2,279	2,025	1,87	2,685	1,464	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,933	1,472	0,889	0,608			0,362	1,987	1,983	1,6	2,295	1,203
COVID19 (COVID19 (JANSSEN))	Glaze palty	2,4	0,937	0,88				2,482	2,851	1,785	0,805	1,247	
COVID19 (COVID19 (JANSSEN))	Guttain-blare syndrome	1,628	1,647	0,878				1,137	2,031	0,965	1,382	1,55	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,611	3,125	0,885			1,463	3,365	2,144	2,545	1,265	1,265	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,457	2,83	0,855			0,555	3,227	1,622	0,871	5,524	1,045	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1,683	1,821	0,88			0,104	1,455	2,026	1,109	1,586	1,426	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,077	2,225	0,881				1,7	1,127	0,854	2,254	0,739	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,987	1,877	0,922			0,453	1,721	1,78	1,765	2,241	1,428	
COVID19 (COVID19 (JANSSEN))	Off label use	1,587	0,154	0,862			4,659	0,362	0,638	0,364	0,988	1,521	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,591	0,755					2,175	1,604	1,932			
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	4,315	2,102	0,881			0,649	1,644	1,644	2,144	4,096	0,904	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,336	2,481	0,92	0,612		0,52	1,983	2,926	1,387	1,489	1,489	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,624	2,272	0,928			0,296	2,094	2,969	2,117	3,216	1,977	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,255	3,136	0,881			2,996	1,792	0,69	5,046	1,286	1,286	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,394		0,901			0,567	3,009	1,956	4,162	2,388		
COVID19 (COVID19 (JANSSEN))	Pulsmonary embolism	2,015	1,796	0,901	0,612		0,659	1,608	1,949	2,215	1,625	1,625	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,478						3,253	5,987	11,262	4,911	3,906	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,127	1,107	0,883			0,55	1,221	1,742	1,112	1,76	1,549	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,318	2,448	0,607	0,612		0,607	2,047	2,404	3,171	2,617	1,88	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,326	1,994	0,881			1,78	1,192	1,192	0,664	2,437	0,878	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,111	1,237	0,885			0,593	1,798	1,992	1,606	2,428	1,394	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,717	2,222	0,891	0,612			2,071	2,242	3,38	2,879	2,161	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,401	1,666	0,881				2,668	1,426	1,426	1,424	1,424	
COVID19 (COVID19 (JANSSEN))	Venogram	2,114	1,928					1,589	1,535	0,567	2,159	0,826	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,719	2,837				0,539	3,043	1,701	0,718	4,629	1,103	
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,153	2,831	0,881				3,455	2,982	0,754	5,907	0,913	
COVID19 (COVID19 (MODERNA))	Accidental exposure to product	2,034						0,389	0,528	0,463	0,756	0,874	0,806
COVID19 (COVID19 (MODERNA))	No adverse event	1,524	0,819	0,882		0,458		2,18	0,976	0,8	1,281	1,265	
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,417				0,54		0,435	0,332	0,476	0,578	0,544	0,48
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,29		0,881		0,724		2,339	0,116	0,216	0,741	2,282	2,298
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,938		0,889				0,882	1,709	1,797	2,019	1,896	1,73
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,884						1,405	1,882	1,905	2,066	1,855	1,818
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,905	1,325	0,886				0,976	1,512	1,872	2	1,879	1,628

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, July 27, 2021 7:09:13 AM
Attachments: [USST_20210723.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/23/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210723	US Serious EB05 20210723	US Fatal EB05 20210723	US Infant EB05 20210723	US Child EB05 20210723	US Teen EB05 20210723	US Adult1 EB05 20210723	US Adult2 EB05 20210723	US Adult3 EB05 20210723	US Female EB05 20210723	US Male EB05 20210723	Comment
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2,506	0,969	0,876				0,776	0,776	0,776	2,148	1,466	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2,997	2,527	0,883			0,514	1,556	1,534	3,789	4,091	1,356	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,377	2,156	0,875			0,492	1,557	2,385	1,675	2,393	1,899	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2,008	1,825	0,911		0,612	0,405	1,725	1,916	1,916	2,534	1,329	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	2,38	2,416	0,877			0,544	1,068	1,426	0,663	3,264	0,863	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,077	2,102	0,873			0,873	1,249	1,953	0,979	1,295	1,532	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	1,937	1,893	0,898			0,543	1,992	1,703	1,214	2,513	0,961	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3,196	2,577	0,898			0,538	2,038	2,922	0,741	3,873	1,117	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2,406	2,108	0,908		0,612	0,492	2,023	2,217	1,746	3,122	1,494	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	1,982	1,809	0,878			0,521	1,473	2,014	1,591	2,222	1,461	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,373	1,893	0,902			0,477	2,081	2,115	2,853	2,866	1,843	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,354	1,518	0,881			0,419	2,304	2,06	1,88	2,689	1,491	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,919	1,447	0,885		0,609	0,349	1,56	2,065	1,622	2,275	1,212	
COVID19 (COV D19 (JANSSEN))	Gate palsy	2,379	1,952	0,873				2,546	1,726	0,798	2,935	1,257	
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	1,776	1,764	0,872				2,274	3,763	1,025	1,543	1,678	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,74	3,251	0,881				2,096	1,84	0,771	5,717	1,34	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,569	2,923	0,881			0,556	3,263	1,326	0,671	6,078	1,943	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	1,73	1,88	0,874			0,074	1,509	2,093	1,149	1,647	1,463	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,004	2,171	0,874				1,123	1,592	0,654	2,271	0,724	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1,654	1,614	0,874				0,812	2,014	0,696	1,044	1,554	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,947	1,823	0,875			0,486	1,741	1,735	1,71	2,16	1,452	
COVID19 (COV D19 (JANSSEN))	Off label use	1,62	0,148	0,358			4,741	0,358	0,635	0,36	1,016	1,545	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1,592	0,758	0,874				2,192	1,022	1,942	1,942	1,942	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	4,047	2,022	0,874				0,649	1,018	2,148	2,828	0,922	
COVID19 (COV D19 (JANSSEN))	Platelet count	2,332	2,462	0,894		0,612	0,516	2,107	2,984	1,356	2,77	1,461	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,377	2,271	0,892			0,296	1,58	2,955	2,051	3,195	1,564	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5,265	3,133	0,874				3,034	1,793	0,69	5,067	1,237	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0,411		0,62				2,315	1,938	4,224	2,349	2,138	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2,002	1,782	0,905		0,612	0,647	1,992	1,979	2,148	2,27	1,613	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	4,45						2,498	6,051	11,269	4,969	3,673	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	1,733	1,815	0,881			0,434	1,592	1,933	1,033	2,054	1,166	
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2,073	1,082	0,876			0,55	1,203	1,702	1,101	1,718	1,526	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,314	2,436	1,075		0,612	0,607	2,068	2,389	3,189	2,82	1,677	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,333	1,987	0,874				1,756	1,187	0,654	2,459	0,877	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,105	1,229	0,88			0,588	1,833	1,942	1,882	2,443	1,372	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,654	2,166	0,89				2,105	2,192	3,31	2,81	2,125	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2,275	1,743	0,877			0,471	1,476	1,873	1,741	2,016	1,558	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	2,013	1,29	0,87				1,945	1,936	1,989	2,007	1,126	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1,935	1,045	0,877				0,526	1,625	2,066	1,146	1,302	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	0,83	1,039	0,877				1,699	1,531	0,568	2,281	0,826	
COVID19 (COV D19 (JANSSEN))	Venogram	2,191	2,034	0,877			0,539	3,066	1,641	0,7	4,527	1,076	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3,516	2,723	0,874				3,472	2,088	0,753	5,321	0,912	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4,16											
COVID19 (COV D19 (MODERNA))	Accidental exposure to product	2,085						0,392	0,531	0,468	0,758	0,812	
COVID19 (COV D19 (MODERNA))	No adverse event	1,602	0,808	0,875			0,494	2,106	0,968	1,015	0,904	1,366	
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2,425						0,377	0,309	0,408	0,553	0,478	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2,325	0,878	0,874			0,741	2,379	0,111	0,214	0,718	2,337	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1,867						1,396	1,875	1,862	2,056	1,81	

From: (b) (6)
To: (b) (6) | (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: Weekly data mining
Date: Wednesday, August 4, 2021 4:26:16 PM
Attachments: [USST_2021_0730.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/30/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
(b) (6)

Drug	Event	US EB05 20210730	US Serious EB05 20210730	US Fatal EB05 20210730	US Infant EB05 20210730	US Child EB05 20210730	US Teen EB05 20210730	US Adult EB05 20210730	US Adult EB05 20210730	US Adult3 EB05 20210730	US Female EB05 20210730	US Male EB05 20210730	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1,175	1,727	0.852				1,403	1,705	1,124	2,432	1,551	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,522	0,907	0,887				0,763	0,772	0,698	2,146	1,474	
COVID19 (COVID19 (JANSSEN))	Adverse event	2,014	0,992	0,886				0,863	0,762	0,648	1,888	1,511	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,066	2,668	0,892			0,515	1,529	2,021	3,846	4,206	1,137	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,383	2,142	0,886				1,525	2,394	1,703	2,44	1,854	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,015	1,828	0,914		0,612		1,716	1,89	2,017	2,541	1,342	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,557	2,482	0,887			0,539	1,21	1,431	0,664	3,646	0,865	
COVID19 (COVID19 (JANSSEN))	ClF protein increased	2,11	2,135	0,884				1,283	2,013	0,976	1,384	1,917	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,989	1,852	0,905			0,537	1,096	1,793	1,262	1,927	1,026	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,208	2,607	0,895			0,539	2,381	2,851	0,741	3,812	1,225	
COVID19 (COVID19 (JANSSEN))	Computed tomogram head abnormal	2,435	2,137	0,914		0,612	0,49	2,082	2,281	1,756	3,143	1,531	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,979	1,802	0,889			0,511	1,505	2,022	1,568	2,255	1,439	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,369	1,884	0,906			0,474	2,114	2,112	2,812	2,881	1,839	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,352	1,965	0,89			0,42	2,335	2,028	1,797	2,878	1,51	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,92	1,468	0,893		0,61	0,34	1,561	1,652	1,652	2,256	1,247	
COVID19 (COVID19 (JANSSEN))	Glare palsy	2,346	0,944	0,884				1,754	2,508	0,797	2,448	1,246	
COVID19 (COVID19 (JANSSEN))	Guillain-Barre syndrome	1,801	1,81	0,884				1,111	2,346	1,056	1,575	1,696	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,811	3,353	0,891				2,125	3,813	4,121	5,748	1,343	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,589	2,91	0,887			0,557	3,332	1,942	0,672	6,107	1,944	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1,783	1,956	0,885			0,06	1,597	1,522	1,222	1,732	1,494	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,024	2,168	0,885				1,623	1,125	0,665	2,398	0,725	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1,749	1,817	0,884				0,814	2,05	0,839	1,133	1,634	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,963	1,862	0,886			0,478	1,774	1,742	1,742	2,202	1,455	
COVID19 (COVID19 (JANSSEN))	Off label use	1,627	0,147	0,891				0,352	0,621	0,363	1,02	1,02	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,6	0,757	0,885				2,232	1,003	1,003	1,962	1,455	
COVID19 (COVID19 (JANSSEN))	Plaque embolism	3,039	2,016	0,885			0,65	1,019	1,914	2,488	2,488	0,922	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,313	2,533	0,902		0,612	0,511	2,064	2,991	1,368	2,782	1,446	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,581	2,259	0,891			0,286	1,909	2,921	2,033	3,172	1,552	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	4,987	3,252	0,885				3,108	1,805	0,602	4,867	1,315	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,425						0,393	2,24	4,132	2,297	2,123	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,994		0,907		0,612	0,649	1,976	1,974	2,131	2,282	1,59	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,549						2,566	6,305	11,82	5,216	3,937	
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	1,811	0,889	0,889			0,432	1,674	1,949	1,125	2,108	1,253	
COVID19 (COVID19 (JANSSEN))	Thrombolytic superficial	2,135	1,143	0,887			0,651	1,26	1,688	1,201	1,817	1,529	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,298	2,406	0,895		0,612	0,605	2,079	2,369	3,114	2,6	1,879	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,235	1,951	0,885				1,189	1,638	0,664	2,208	0,877	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,129	1,263	0,889			0,59	1,889	1,899	1,69	2,484	1,383	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,647	2,17	0,897		0,612		2,055	2,18	3,318	2,77	2,145	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,773	1,708	0,882				1,922	1,344	1,305	2,386	1,406	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2,014	1,374	0,882			0,473	1,521	1,852	1,72	1,994	1,588	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,805	1,03	0,882				1,238	1,944	1,567	2	1,097	
COVID19 (COVID19 (JANSSEN))	Vaccination failure	0,956	1,24	0,956				1,978	3,041	1,209	1,501	1,501	
COVID19 (COVID19 (JANSSEN))	Venogram	2,282	2,059	0,889				1,675	1,665	0,965	2,326	0,891	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,056	2,635	0,885			0,53	2,967	1,683	0,17	4,086	1,062	
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,072	2,512	0,885				3,105	2,373	0,754	5,081	0,914	
COVID19 (COVID19 (MODERNA))	No adverse event	1,972	0,81	0,885			0,483	0,925	0,977	0,863	1,24	1,34	
COVID19 (COVID19 (MODERNA))	Accidental exposure to product	2,114						0,381	0,533	0,47	0,675	0,787	
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,456					0,544	0,329	0,278	0,383	0,547	0,444	
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,36	0,867	0,885				2,422	0,869	0,24	0,672	2,318	2,381
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,849						1,397	1,877	1,887	2,066	1,828	1,786

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, August 10, 2021 7:22:49 AM
Attachments: [USST_20210806.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 8/6/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210806	US Serious EB05 20210806	US Fatal EB05 20210806	US Infant EB05 20210806	US Child EB05 20210806	US Teen EB05 20210806	US Adult1 EB05 20210806	US Adult2 EB05 20210806	US Adult3 EB05 20210806	US Female EB05 20210806	US Male EB05 20210806	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,706	1,656	0,054				1,366	1,416	1,208	1,266	1,043	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1,759	1,736	0,088				1,45	1,792	1,225	1,063	1,189	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2,525	0,904	0,892				0,758	0,712	0,689	2,147	1,49	
COVID19 (COV D19 (JANSSEN))	Adverse event	2,043	0,980	0,692				0,949	0,762	0,699	1,48	1,574	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3,13	2,586	0,897			0,517	1,612	2,159	3,54	4,292	1,384	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,373	2,145	0,893			0,478	1,536	2,437	1,716	2,378	1,931	
COVID19 (COV D19 (JANSSEN))	Antibody test	1,894	0,82					0,661	1,832	2,373	1,723	1,492	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2,034	1,834	0,921	0,612			0,396	1,723	1,948	1,992	1,359	
COVID19 (COV D19 (JANSSEN))	Areflexia	1,758	2,077	0,89				0,817	1,73	1,026	1,347	1,342	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	2,655	2,509	0,893			0,536	1,21	1,595	0,659	3,866	0,859	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,196	2,205	0,89				1,427	2,095	0,961	1,659	1,842	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2,013	1,979	0,908			0,539	1,7	1,843	1,263	2,555	1,087	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3,175	2,582	0,899			0,541	2,33	2,853	0,74	3,829	1,207	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2,453	2,141	0,92	0,612			0,487	2,021	2,297	1,614	3,154	1,511
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	1,98	1,808	0,897			0,51	1,487	1,998	1,655	2,253	1,447	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,348	1,876	0,909			0,477	2,098	2,085	2,8	1,819	1,819	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,333	1,546	0,905			0,414	2,29	2,067	1,624	2,661	1,513	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,932	1,489	0,899	0,61		0,328	1,557	2,131	1,654	2,275	1,28	
COVID19 (COV D19 (JANSSEN))	Gasze palsy	2,268	0,959	0,891				2,372	1,72	0,792	2,721	1,209	
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	1,855	1,846	0,89			0,041	1,165	2,351	1,127	1,724	1,69	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,878	3,376	0,896				2,141	4,123	4,096	5,837	1,342	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,599	2,892	0,891			0,558	3,379	1,946	0,672	6,126	1,043	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	1,811	1,851	0,891				1,694	2,107	1,297	1,798	1,454	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,129	2,219	0,891				1,472	1,204	0,741	2,732	0,712	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1,811	1,894	0,907				0,907	2,031	0,911	1,276	1,608	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,996	1,851	0,893			0,471	1,736	1,816	1,765	2,265	1,448	
COVID19 (COV D19 (JANSSEN))	Off label use	1,652	0,243	0,89			4,86	0,348	0,61	0,346	1,057	1,558	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1,603	0,756	2,263				1,004	1,004	1,004	1,976	1,146	
COVID19 (COV D19 (JANSSEN))	Pain assessment	2,017	0,85				0,54	1,468	1,629	1,96	1,96	0,921	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3,937	1,996	0,891				0,651	1,02	1,911	2,503	1,021	
COVID19 (COV D19 (JANSSEN))	Platelet count	2,287	2,457	2,082	0,612			3,083	3,083	2,795	1,372	1,438	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,287	2,257	0,896			0,281	2,01	2,938	2,024	3,232	1,54	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5,165	3,191	0,891				3,155	1,809	0,691	4,903	1,241	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0,463	0,569	2,428	0,612			2,036	4,031	2,41	2,312	2,312	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	1,955	1,763	0,911			0,652	1,562	1,984	2,131	2,275	1,602	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	4,594						2,626	6,178	11,918	5,373	4,008	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	1,798	1,868	0,894			0,424	1,598	1,932	1,144	2,09	1,253	
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2,239	1,122	0,892			0,552	1,311	1,777	1,2	1,927	1,59	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,275	2,364	1,765	0,612		0,608	2,08	2,34	3,04	2,586	1,843	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,187	1,902	0,891				1,59	1,19	0,654	2,122	0,877	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,124	1,302	0,894			0,586	1,841	1,959	1,747	2,456	1,413	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,631	2,174	0,901	0,612			2,081	2,174	3,266	2,801	2,174	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2,207	1,664					2,462	1,391	1,257	2,352	1,354	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1,048	1,34	0,896			0,524	0,966	2,091	3,989	1,4	1,601	
COVID19 (COV D19 (JANSSEN))	Venogram	2,194	2,018					1,653	1,634	0,651	2,23	0,924	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3,251	2,596	0,891			0,532	2,586	1,793	0,699	4,223	1,047	
COVID19 (COV D19 (JANSSEN))	Venogram normal	3,896	2,411	0,891				2,762	2,377	0,747	4,842	0,897	
COVID19 (COV D19 (MODERNA))	Accidental exposure to product	2,128					0,385	0,519	0,471	0,738	0,678	0,77	
COVID19 (COV D19 (MODERNA))	No adverse event	1,568	0,81	0,891		0,47		0,923	0,969	0,891	1,343	1,343	
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2,477				0,545		0,258	0,374	0,565	0,443	0,377	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2,373	0,867	0,891		0,763		2,437	0,964	0,238	2,331	2,331	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1,828					1,368	1,873	1,854	2,059	1,803	1,772	

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: RE: Weekly data mining
Date: Tuesday, August 17, 2021 7:01:02 AM
Attachments: [USST_20210813.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 8/13/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210813	US Serious EB05 20210813	US Fatal EB05 20210813	US Infant EB05 20210813	US Child EB05 20210813	US Teen EB05 20210813	US Adult1 EB05 20210813	US Adult2 EB05 20210813	US Adult3 EB05 20210813	US Female EB05 20210813	US Male EB05 20210813	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,76	1,77	0,696			0,455	1,346	1,484	1,352	2,149	0,997	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1,804	1,7	0,678				1,455	1,753	1,287	2,024	1,235	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2,813	0,901	0,884				0,885	0,776	0,68	2,18	0,581	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2,97	2,40	0,69			0,514	1,609	2,04	1,366	3,596	4,161	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,307	2,108	0,665			0,479	1,553	2,424	1,721	2,458	1,863	
COVID19 (COV D19 (JANSSEN))	Antibody test	1,998	0,84					0,706	1,84	3,29	1,807	1,567	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2,031	1,792	0,912	0,612		0,472	1,725	1,901	2,013	2,667	1,361	
COVID19 (COV D19 (JANSSEN))	Arteritis	1,804	2,091	0,881				0,888	1,786	1,02	1,403	1,907	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	2,744	2,505	0,885				1,213	1,608	0,658	4,004	0,861	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,207	2,194	0,882				1,431	2,124	0,957	1,863	1,857	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2,045	1,974	0,902				1,768	1,882	1,269	2,695	1,064	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3,071	2,51	0,893				2,353	2,52	0,738	3,718	1,193	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2,447	2,109	0,914	0,612			1,966	2,292	1,849	3,127	1,565	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2,018	1,816	0,891				1,471	2,006	1,792	2,273	1,505	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,382	1,887	0,908				2,172	2,079	2,841	2,932	1,834	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,325	1,52	0,888				2,287	2,025	1,849	2,677	1,493	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,974	1,547	0,892	0,611			1,618	2,133	1,713	2,349	1,271	
COVID19 (COV D19 (JANSSEN))	Gaze palsy	2,253	0,94	0,883				2,39	1,685	0,793	2,74	1,188	
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	1,842	1,845	0,881				1,203	2,403	1,104	1,698	1,7	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,928	3,464	0,889				2,549	3,752	5,122	6,015	1,484	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,755	2,965				0,558	3,458	2,476	0,671	6,328	1,045	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	1,81	1,967	0,882			0,035	1,72	2,109	1,298	1,86	1,46	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,071	2,167	0,883				1,561	1,142	0,743	2,664	0,706	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1,817	1,881					0,952	2,001	0,908	1,318	1,588	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,01	1,878	0,885			0,473	1,78	1,812	1,841	2,267	1,508	
COVID19 (COV D19 (JANSSEN))	Off label use	1,757	0,25	0,881				5,022	0,351	0,614	1,142	1,62	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1,628	0,754					2,327	1,005	0,441	2,028		
COVID19 (COV D19 (JANSSEN))	Pain assessment	2,16	0,9				0,54	1,622	1,958	0,979	2,019	1,302	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	4,022	1,992	0,882				0,651	1,02	2,004	2,696	0,922	
COVID19 (COV D19 (JANSSEN))	Platelet count	2,361	2,489		0,612		0,5	2,06	3,18	1,36	2,927	1,457	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,581	2,244	0,889				2,005	2,959	2,029	3,265	1,422	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5,422	3,298	0,883				3,824	2,145	0,691	5,255	1,422	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0,484						2,591	2,009	4,169	2,608	2,312	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2,022	1,755	0,907	0,612		0,571	2,008	2,307	2,161	2,307	1,626	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	4,753						3,483	5,506	12,191	5,638	4,087	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	1,806	1,858	0,886			0,422	1,666	1,995	1,156	2,137	1,242	
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2,267	1,122	0,885				1,305	1,812	1,937	1,937	1,627	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,325	2,357	1,808	0,612		0,605	2,077	2,341	3,088	2,645	1,877	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,123	1,988	0,892				1,84	1,195	0,653	2,185	0,855	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,107	1,289	0,887				1,811	1,927	1,827	2,43	1,421	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,882	2,181	0,895	0,612		0,469	2,177	2,167	3,362	2,127	1,508	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2,224	1,687					2,387	1,468	1,31	2,37	1,386	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	0,922	1,476	0,892			0,524	1,059	2,031	3,944	1,392	1,521	
COVID19 (COV D19 (JANSSEN))	Venogram	2,291	2,025					1,783	1,683	0,559	2,343	0,977	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3,306	2,621				0,623	2,436	1,843	0,7	4,329	1,032	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4,01	2,407	0,883				2,815	2,015	0,749	5,086	0,898	
COVID19 (COV D19 (MODERNA))	Accidental exposure to product	2,084						0,519	0,47	0,73	0,65	0,759	
COVID19 (COV D19 (MODERNA))	No adverse event	1,531	0,801	0,883			0,459	2,141	0,914	0,96	0,809	1,214	
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2,429					0,547	0,29	0,249	0,385	0,416	0,376	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2,394	0,869	0,883			0,847	2,47	1,008	0,23	0,657	2,349	2,426
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	1,961	1,795	0,911				0,938	1,778	1,903	2,016	1,719	
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0,791	0,799	0,883	2,73			0,587	0,587	0,577	1,005	1,005	
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	1,946	1,735	0,895				0,895	1,685	1,772	2,04	1,901	1,754
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1,814	0,636	0,889				1,367	1,88	1,652	2,084	1,803	1,751
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	1,916	1,966					1,916	1,66	2,039	1,69	1,652	

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: RE: Weekly data mining
Date: Tuesday, August 24, 2021 5:23:45 PM
Attachments: [USST_20210820.xls](#)

Hi (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 8/20/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210820	US Serious EB05 20210820	US Fatal EB05 20210820	US Infant EB05 20210820	US Child EB05 20210820	US Teen EB05 20210820	US Adult1 EB05 20210820	US Adult2 EB05 20210820	US Adult3 EB05 20210820	US Female EB05 20210820	US Male EB05 20210820	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,760	1,679	0,266				0.43	1,268	1,525	1,401	2,169	0,977
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1,843	1,703	0,870					1,431	1,837	1,361	2,078	1,266
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,564	0,892	0,884					0,856	0,759	0,643	2,154	1,515
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,127	2,502	0,892				0,517	1,704	2,059	3,196	4,323	1,426
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,413	2,094	0,884				0,479	1,599	1,855	1,855	2,501	1,931
COVID19 (COVID19 (JANSSEN))	Antibody test	2,09	0,84	0,76				0,519	0,78	1,758	3,171	1,902	1,682
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,067	1,766	0,01		0,612		0,462	1,715	1,903	2,196	2,726	1,392
COVID19 (COVID19 (JANSSEN))	Arflexia	1,862	2,108	0,881				0,877	1,911	1,911	1,054	1,507	1,377
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,719	2,462	0,884				0,539	1,072	1,859	0,657	4,198	0,851
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,319	2,237	0,882				0,538	1,544	2,189	0,983	1,816	1,904
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,105	1,946	0,903				0,538	1,62	1,911	1,334	1,857	1,949
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	1,901	1,75	0,884				0,544	0,983	0,954	1,519	2,128	0,909
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,138	2,504	0,893		0,612		0,467	2,278	2,712	0,747	3,738	1,219
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,516	2,1	0,921				0,418	2,319	2,042	1,941	3,239	1,622
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,062	1,81	0,891				0,512	1,447	2,021	1,983	2,344	1,532
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,433	1,871	0,905				0,481	2,155	2,101	3,078	3,011	1,869
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,364	1,498	0,888				0,418	2,319	2,042	1,941	2,731	1,516
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,979	1,499	0,892		0,611		0,369	1,576	2,157	1,79	2,363	1,275
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,817	0,978	0,882				0,446	1,613	1,69	0,8	2,046	1,072
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,261	0,939	0,893				0,561	2,358	1,893	0,801	2,781	1,164
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	1,979	1,899	0,881				1,234	2,523	1,262	1,835	1,812	1,471
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,063	3,431	0,889				2,597	3,914	5,568	6,296	1,502	1,502
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,871	2,968	0,889				3,521	2,636	0,669	6,465	1,652	1,652
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1,834	1,95	0,882				0,027	1,705	2,165	1,353	1,897	1,471
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,183	2,208	0,883				1,574	1,165	1,165	0,747	3,148	0,707
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1,875	1,899	0,95				0,95	2,087	0,632	1,334	1,654	1,654
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,056	1,874	0,886				0,47	1,758	1,859	1,956	2,292	1,568
COVID19 (COVID19 (JANSSEN))	Off label use	1,803	0,25	0,881				0,029	0,351	0,603	0,432	1,178	1,657
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,679	0,756	0,886				2,385	1,012	2,121	2,121	1,326	1,326
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,339	0,899	0,889				0,543	1,61	2,082	1,084	2,211	0,905
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,874	1,884	0,882				0,053	0,999	0,999	3,378	3,141	1,508
COVID19 (COVID19 (JANSSEN))	Platelet count	2,495	2,489	0,9		0,612		2,062	3,216	1,414	3,141	1,508	1,508
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,633	2,216	0,889				0,274	2,016	3,01	2,173	3,33	1,567
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,709	3,385	0,883				4,225	2,234	0,689	5,671	1,433	1,433
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,528						0,576	2,574	2,072	4,767	3,127	2,505
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,062	1,727	0,905		0,612		0,738	1,587	2,014	2,282	2,362	1,653
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	1,873	1,738	0,886				1,446	1,349	2,009	1,721	1,557	1,557
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	2,208	1,32	0,889				0,561	1,6	1,83	0,543	1,936	2,046
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	5,199						0,56	3,083	5,618	13,351	6,288	4,475
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	1,861	1,83	0,886				0,418	1,664	1,909	1,239	2,22	1,274
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,3	1,165	0,885				0,555	1,351	1,796	1,263	1,916	1,701
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,439	1,78	0,886		0,612		0,604	2,12	2,369	3,303	2,79	1,943
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,172	1,951	0,882				0,585	1,657	1,205	0,651	2,247	0,859
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,172	1,305	0,887				0,473	1,823	1,987	1,944	2,48	1,495
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,728	2,153	0,898				0,473	2,196	2,16	3,539	3,038	2,142
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,256	1,688	0,889				0,472	2,39	1,453	1,427	2,419	1,42
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2,002	1,292	0,879				0,472	1,453	1,875	1,786	1,939	1,64
COVID19 (COVID19 (JANSSEN))	Vaccination failure	1,024	1,676	0,891				0,527	1,098	2,07	4,238	1,588	1,691
COVID19 (COVID19 (JANSSEN))	Venogram	2,304	1,999	0,886				0,472	1,766	1,642	0,549	2,351	0,978
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,36	2,85	0,885				0,625	2,61	1,828	0,7	4,318	1,039
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,006	2,413	0,883				0,625	2,774	3,009	0,754	4,89	0,968
COVID19 (COVID19 (MODERNA))	No adverse event	1,453	0,801	0,883			0,445	2,134	0,868	0,938	0,807	1,165	1,288
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,209						0,289	0,289	0,388	0,536	0,374	0,346
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,38	0,889	0,883			0,851	0,289	0,104	0,222	2,338	2,418	1,508
COVID19 (COVID19 (PFIZER-BIONTECH))	Body height	1,838	0,885	0,885				0,567	0,911	1,157	2,169	1,762	1,443
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,121	1,801	0,911				0,94	1,795	1,925	2,166	1,977	1,89
COVID19 (COVID19 (PFIZER-BIONTECH))	Exposure via breast milk	0,704	0,799	0,883		2,264		0,499	1,673	1,799	0,51	1,038	1,038
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,08	1,735	0,895				0,897	1,673	1,799	2,219	2,012	1,848
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,848	0,638	0,889				1,369	1,9	1,883	2,257	1,842	1,778
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,032	1,363	0,889				0,732	1,528	1,692	2,196	2,017	1,718

From: (b) (6)
To: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Cc: (b) (6) <[\(b\) \(6\)@CDC](#)>; (b) (6) <[\(b\) \(6\)@CDC](#)>
Subject: RE: Weekly data mining
Date: Tuesday, August 31, 2021 7:48:22 AM
Attachments: [USST_20210827.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 8/27/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210827	US Serious EB05 20210827	US Fatal EB05 20210827	US Infant EB05 20210827	US Child EB05 20210827	US Teen EB05 20210827	US Adult1 EB05 20210827	US Adult2 EB05 20210827	US Adult3 EB05 20210827	US Female EB05 20210827	US Male EB05 20210827	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,601	1,731	0	0	0	0	0.426	1,361	1,619	1,426	2,349	1,011
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1,903	1,693	0	0	0	0	0	1,47	1,846	1,487	2,097	1,344
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,515	0	0	0	0	0	0	0.848	0,707	0,63	2,159	1,513
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,063	2,431	0	0	0	0	0.507	1,638	2,055	4,095	4,165	1,434
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,414	0	0	0	0	0	0.469	0,883	1,617	2,424	1,855	1,904
COVID19 (COVID19 (JANSSEN))	Antibody test	2,287	0	0	0	0	0	0.597	0,753	1,867	2,985	2,086	1,856
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,095	1,74	0	0	0	0	0.459	1,776	1,884	2,221	2,76	1,417
COVID19 (COVID19 (JANSSEN))	Areflexia	1,968	2,162	0	0	0	0	0.612	0,882	1,962	1,165	1,508	1,498
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,429	1,174	0	0	0	0	0.309	0,845	2,081	1,056	1,55	1,03
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,591	2,375	0	0	0	0	0.54	1,06	1,914	0,655	3,785	0,857
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,984	2,23	0	0	0	0	0.81	1,544	2,208	1,975	1,839	1,948
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,178	0	0	0	0	0	0.538	1,618	1,987	1,365	2,995	1,128
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	1,954	1,688	0	0	0	0	0.612	0,987	0,939	1,58	2,236	0,916
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,27	2,517	0	0	0	0	0.539	2,407	2,836	0,753	3,89	1,224
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,582	2,066	0	0	0	0	0.569	1,983	2,44	1,968	3,32	1,671
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,091	1,795	0	0	0	0	0.507	1,477	2,022	2,049	2,361	1,569
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,489	1,872	0	0	0	0	0.479	2,151	2,136	3,166	3,096	1,915
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,44	1,204	0	0	0	0	0.415	0,91	2,023	1,174	1,589	0,984
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,419	1,566	0	0	0	0	0.415	2,327	2,118	1,971	2,745	1,605
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,032	1,515	0	0	0	0	0.369	1,609	2,205	1,898	2,419	1,337
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,847	0	0	0	0	0	0.45	1,616	1,74	0,806	2,09	1,078
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,261	0	0	0	0	0	0.45	2,351	1,679	0,809	2,753	1,207
COVID19 (COVID19 (JANSSEN))	Guillain-Barre syndrome	2,106	1,93	0	0	0	0	0.612	1,263	2,632	1,39	1,976	1,885
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,158	3,512	0	0	0	0	0.561	3,438	3,786	5,857	6,534	1,673
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6	2,975	0	0	0	0	0.025	3,632	2,86	0,668	6,628	1,059
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1,93	1,962	0	0	0	0	0.025	1,836	2,215	1,451	1,991	1,553
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,258	2,213	0	0	0	0	0.612	1,597	1,176	0,75	3,422	0,709
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1,909	1,869	0	0	0	0	0.534	0,956	2,063	1,019	1,382	1,665
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,087	1,853	0	0	0	0	0.307	1,788	1,861	2,015	2,322	1,601
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,44	1,08	0	0	0	0	0.307	0,995	2,058	0,516	1,695	0,85
COVID19 (COVID19 (JANSSEN))	Off label use	1,853	0	0	0	0	0	0.45	5,293	0,343	0,572	1,216	1,672
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,731	0	0	0	0	0	0.544	2,505	1,02	2,223	2,223	1,422
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,474	0	0	0	0	0	0.544	1,71	2,158	1,094	2,351	1,422
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,489	1,8	0	0	0	0	0.612	0,653	0,974	2,63	2,207	0,909
COVID19 (COVID19 (JANSSEN))	Platelet count	2,652	2,517	0	0	0	0	0.612	0,504	2,204	3,367	1,429	1,622
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,745	1,151	0	0	0	0	0.608	0,333	1,481	2,002	1,337	1,333
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,706	2,224	0	0	0	0	0.475	2,056	6,239	3,052	2,238	1,622
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,653	3,466	0	0	0	0	0.612	4,367	2,339	0,688	5,901	1,642
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,992	0	0	0	0	0	0.58	3,792	2,237	4,884	3,385	2,714
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1,626	1,369	0	0	0	0	0.744	0,305	1,255	1,199	2,044	1,116
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,104	1,717	0	0	0	0	0.612	0,643	1,912	2,04	2,34	2,428
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	1,932	1,724	0	0	0	0	0.612	1,494	1,334	2,129	1,789	1,586
COVID19 (COVID19 (JANSSEN))	Superior sagittal sinus thrombosis	1,44	1,177	0	0	0	0	0.561	0,98	0,843	0,65	2,008	0,602
COVID19 (COVID19 (JANSSEN))	Suspected COV D-19	2,463	1,821	0	0	0	0	0.556	1,663	2,074	0,567	2,094	2,426
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	5,709	0	0	0	0	0	0.655	3,209	5,361	14,615	6,957	4,918
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	1,956	1,864	0	0	0	0	0.42	1,682	2,043	1,271	2,347	1,335
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,344	1,154	0	0	0	0	0.556	1,327	1,876	1,289	1,955	1,732
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,861	2,332	0	0	0	0	0.603	2,178	2,431	3,438	2,929	2,042
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,317	2,045	0	0	0	0	0.612	1,892	1,201	0,65	2,471	0,863
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,204	1,295	0	0	0	0	0.588	1,78	2,005	2,072	2,51	1,532
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,765	2,098	0	0	0	0	0.558	2,244	2,193	3,159	3,159	2,127
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,279	1,685	0	0	0	0	0.475	2,378	1,462	1,923	2,398	1,476
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2,036	1,333	0	0	0	0	0.474	1,421	1,929	1,908	1,978	1,682
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,831	1,053	0	0	0	0	0.612	1,18	2,021	1,85	1,966	1,19
COVID19 (COVID19 (JANSSEN))	Vaccination failure	1,103	1,864	0	0	0	0	0.528	1,132	2,279	4,595	1,725	1,908
COVID19 (COVID19 (JANSSEN))	Venogram	2,365	2,034	0	0	0	0	0.621	1,71	1,75	0,544	2,4	1,033
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,37	2,845	0	0	0	0	0.621	2,689	1,821	4,357	3,357	1,039
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,217	2,512	0	0	0	0	0.621	3,196	3,265	0,757	5,112	1,059
COVID19 (COVID19 (MODERNA))	Exposure via breast milk	1,295	0	0	0	0	0	3.202	0,715	1,102	1,188	1,785	0,785
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,052	0	0	0	0	0	0.535	0,33	0,289	0,408	0,542	0,34
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,309	0	0	0	0	0	0.81	2,401	0,149	0,221	0,952	2,351
COVID19 (COVID19 (PFIZER-BIONTECH))	Body height	1,912	0	0	0	0	0	0.57	0,918	1,182	2,21	1,858	1,475
COVID19 (COVID19 (PFIZER-BIONTECH))	Disease recurrence	2,036	1,906	0	0	0	0	0.843	1,4	1,572	1,897	2,001	1,502
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,315	1,815	0	0	0	0	0.958	1,868	1,931	2,299	2,16	2,06
COVID19 (COVID19 (PFIZER-BIONTECH))	Exposure via breast milk	0,613	0	0	0	0	0	2.412	0,412	0,412	0,439	1,04	1,04
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,169	1,74	0	0	0	0	0.914	1,691	1,85	2,355	2,116	1,938
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,898	0,64	0	0	0	0	1.412	1,922	1,937	2,386	1,807	1,619
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,119	1,34	0	0	0	0	0.738	1,542	1,707	2,328	2,114	1,761

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, September 7, 2021 6:51:39 AM
Attachments: [USST_20210903.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 9/3/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210903	US Serious EB05 20210903	US Fatal EB05 20210903	US Infant EB05 20210903	US Child EB05 20210903	US Teen EB05 20210903	US Adult1 EB05 20210903	US Adult2 EB05 20210903	US Adult3 EB05 20210903	US Adult4 EB05 20210903	US Female EB05 20210903	US Male EB05 20210903	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1.527	1.775	0.552	1.336		0.421	1.336	1.646	1.575	2.479	1.556	2.479	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1.933	1.687	0.871	1.455			1.455	1.950	1.55	2.054	1.55	2.054	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2.803	0.929	0.878	0.835			0.835	0.755	0.696	2.296	1.496	1.496	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3.198	2.465	0.856	1.942		0.509	1.942	2.206	4.057	4.278	1.484	4.278	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2.089	2.089	0.88	0.47			0.47	1.698	2.029	1.98	2.029	1.98	
COVID19 (COVID19 (JANSSEN))	Anion gap decreased	1.609	1.472	0.879	0.424			0.424	1.107	2.012	0.774	1.167	1.167	
COVID19 (COVID19 (JANSSEN))	Antibody test	2.293	0.836	0.874	0.598			0.598	0.775	1.902	2.134	2.017	1.96	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2.157	1.755	0.946	0.455	0.612		0.455	1.804	1.936	2.311	1.474	2.311	
COVID19 (COVID19 (JANSSEN))	Areflexia	2.047	2.155	0.876	0.877			0.877	1.965	1.258	1.576	1.515	1.515	
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1.46	1.201	0.879	0.3	0.609		0.3	0.918	2.108	1.038	1.566	1.072	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2.459	0.876	0.873	0.641			0.641	1.153	1.962	0.974	1.962	0.974	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2.41	2.22	0.875	1.561			1.561	1.618	2.286	1.085	1.848	2.002	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2.185	1.918	0.905	0.539			0.539	2.005	1.361	2.972	1.119	2.972	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2.039	1.684	0.884	0.854			0.854	1.227	0.958	2.219	0.79	2.219	
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2.053	1.725	0.876	1.068			1.068	0.997	1.559	2.306	1.013	2.306	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3.244	2.509	0.888	0.935			0.935	2.353	2.897	0.751	3.843	1.218	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2.666	2.056	0.928	0.571	0.612		0.571	2.117	2.511	2.004	1.711	2.511	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2.189	1.823	0.898	0.51			0.51	1.546	2.078	2.241	2.462	1.662	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2.56	1.865	0.902	0.48			0.48	2.243	2.181	3.219	1.975	3.163	
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1.484	1.232	0.879	0.983			0.983	1.163	1.616	2.077	1.037	2.077	
COVID19 (COVID19 (JANSSEN))	Feeling cold	1.807	0.817	0.876	1.211			1.211	2.008	1.514	1.052	1.91	1.427	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2.404	1.5	0.884	0.415	0.611		0.415	2.317	2.117	1.9	2.722	1.589	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2.103	1.58	0.893	0.363			0.363	1.625	2.264	2.49	1.411	2.49	
COVID19 (COVID19 (JANSSEN))	Fibrin D trimer normal	1.889	0.969	0.875	1.667			1.667	1.753	0.806	1.115	1.115	1.115	
COVID19 (COVID19 (JANSSEN))	Gasze palsy	2.296	0.949	0.876	0.876			0.876	1.868	0.892	2.753	1.252	2.753	
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2.203	1.932	0.873	1.262			1.262	2.74	1.987	1.981	1.981	1.981	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.225	3.643	0.856	3.265			3.265	3.981	6.541	6.652	1.79	6.652	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.101	2.994	0.874	0.561			0.561	3.729	3.309	6.737	1.065	6.737	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1.987	1.98	0.871	1.847		0.026	1.847	2.277	1.468	2.046	1.572	2.046	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1.87	1.189	0.881	1.323			1.323	1.806	0.953	2.011	1.11	2.011	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2.328	2.229	0.876	1.621			1.621	1.182	3.61	0.712	3.61	0.712	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1.697	1.384	0.874	1.001			1.001	2.036	0.986	1.521	1.515	1.515	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1.977	1.908	0.873	0.963			0.963	2.197	1.027	1.39	1.757	1.39	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.135	1.85	0.881	1.78		0.533	1.78	1.93	2.048	2.411	1.597	2.411	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1.464	1.087	0.873	0.3			0.3	1.025	2.083	0.512	1.693	0.892	
COVID19 (COVID19 (JANSSEN))	Off label use	1.8	0.332	0.874	0.315			0.315	0.572	0.572	0.36	1.178	0.36	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1.783	0.757	0.873	2.621			2.621	1.024	1.2315	2.315	1.371	2.315	
COVID19 (COVID19 (JANSSEN))	Pain assessment	2.437	0.888	0.875	0.545			0.545	1.64	2.053	1.083	2.311	1.371	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3.651	1.798	0.875	0.653			0.653	0.977	2.696	0.977	0.913	0.913	
COVID19 (COVID19 (JANSSEN))	Platelet count	2.675	2.433	0.917	0.505	0.612		0.505	2.084	3.32	3.259	1.68	3.259	
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1.772	1.486	0.887	0.33	0.609		0.33	1.502	2.008	1.325	2.086	1.362	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2.748	2.207	0.885	0.427			0.427	2.104	3.077	2.26	3.077	1.626	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5.827	3.499	0.876	4.174			4.174	2.512	5.792	0.688	5.792	0.688	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0.782			0.579			0.579	2.981	2.241	5.017	3.72	2.817	
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1.652	1.365	0.876	0.302	0.744		0.302	1.263	2.016	1.22	2.066	1.147	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2.172	1.728	0.916	0.645	0.612		0.645	1.638	2.088	2.471	2.488	1.746	
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2.01	1.723	0.879	1.498			1.498	1.378	2.241	1.85	1.621	1.621	
COVID19 (COVID19 (JANSSEN))	Superior sagittal sinus thrombosis	1.448	1.184	0.874	0.561			0.561	0.943	2.064	0.65	0.603	0.603	
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	2.731	2.215	0.9	0.556			0.556	1.722	2.122	0.673	2.312	0.673	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	6.415			0.656			0.656	2.586	6.408	14.711	7.484	5.344	
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2.006	1.862	0.883	0.42			0.42	1.865	2.362	1.324	2.362	1.394	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2.354	1.164	0.878	0.551			0.551	1.957	1.898	1.282	1.971	1.749	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2.645	2.279	1.753	0.608	0.612		0.608	2.132	2.437	3.537	2.916	2.096	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2.579	2.057	0.875	1.933			1.933	1.208	0.65	2.558	0.866	0.866	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	1.292	0.988	0.88	0.585			0.585	1.772	2.038	2.122	2.598	1.574	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2.837	2.106	0.893	0.56	0.612		0.56	2.332	2.249	3.575	3.281	2.173	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2.352	1.796	0.882	0.477			0.477	2.473	1.539	2.485	1.534	1.534	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1.773	1.452	0.873	0.872	0.608		0.872	1.191	2.041	1.753	0.923	1.753	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2.051	1.335	0.871	0.467			0.467	1.421	1.886	1.886	1.984	1.702	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1.871	1.083	0.876	1.188			1.188	2.024	2.007	1.98	1.98	1.225	
COVID19 (COVID19 (JANSSEN))	Vaccination failure	1.351	2.145	0.908	0.995		0.598	0.995	2.134	4.463	1.831	2.002	2.002	
COVID19 (COVID19 (JANSSEN))	Venogram	2.346	2.02	0.876	1.662		0.617	1.662	2.662	1.863	0.704	2.407	1.024	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3.368	2.631	0.876	2.443			2.443	3.269	5.107	0.758	4.298	1.046	
COVID19 (COVID19 (JANSSEN))	Venogram normal	4.143	2.443	0.876	2.443			2.443	3.269	5.107	0.758	4.298	1.046	
COVID19 (COVID19 (MODERNA))	Exposure via breast milk	1.264	0.755		1.181	3.215	0.715	1.181	0.516	1.261	1.261	0.824	1.261	
COVID19 (COVID19 (MODERNA))	No adverse event	1.263	0.835	0.88	0.396		0.396	2.003	0.909	0.91	0.772	1.115	1.115	
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2.306	0.862	0.876	0.141		0.81	2.422	0.141	0.214	2.36	2.36	2.36	
COVID19 (COVID19 (PFIZER-BIONTECH))	Body height	1.958	0.981	0.878	0.57			0.57	1.903	1.235	2.282	1.912	1.501	
COVID19 (COVID19 (PFIZER-BIONTECH))	Disease recurrence	2.115	1.022	0.874	0.643			0.643	1.446	1.606	1.988	2.077	1.565	
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2.459	1.759	0.926	0.971			0.971	1.835	2.236	2.143	2.236	2.143	
COVID19 (COVID19 (PFIZER-BIONTECH))	Exposure via breast milk	0.575	0.819	0.878	0.78	2.72		0.78	0.363			0.382	1.021	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2.238	1.736	0.894	1.736		0.928	1.736	1.736	2.419	2.181	2.012	2.012	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1.92	0.643	0.873	1.412			1.412	1.939	1.978	1.899	1.837	1.837	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2.108	1.31	0.884	0.762			0.762	1.511	1.683	2.336	2.102	1.77	

From: (b) (6)
To: (b) (6) <[\(CDC\)\(CDC\)](#)>
Cc: (b) (6) <[\(CDC\)\(CDC\)](#)>
Subject: RE: Weekly data mining
Date: Tuesday, September 14, 2021 6:16:57 AM
Attachments: [USST_20210910.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 9/10/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210910	US Serious EB05 20210910	US Fatal EB05 20210910	US Infant EB05 20210910	US Child EB05 20210910	US Teen EB05 20210910	US Adult1 EB05 20210910	US Adult2 EB05 20210910	US Adult3 EB05 20210910	US Female EB05 20210910	US Male EB05 20210910	Comment	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1 971	1 178	0 075			0 425	1 447	1 642	1 671	2 444	1 131		
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1 595	1 167	0 186				1 555	1 894	1 526	2 101	1 433		
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2 905	0 923	0 887				0 832	0 759	0 609	2 397	1 492		
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1 712	1 174	0 874				1 176	1 282	1 074	2 031	0 923		
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3 249	2 446	0 877			0 511	1 997	2 095	4 007	4 351	1 489		
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2 574	2 071	0 872			0 47	1 737	2 549	2 121	2 857	2 006		
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	1 674	1 539	0 868			0 41	1 157	2 098	0 827	1 926	1 159		
COVID19 (COV D19 (JANSSEN))	Antibody test	2 291	0 929	0 862				0 595	0 762	1 923	2 027	1 946		
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2 193	1 743	0 861	0 612			1 847	1 953	2 36	2 87	1 509		
COVID19 (COV D19 (JANSSEN))	Areflexia	2 114	2 093	0 864				0 884	2 003	1 241	1 571	1 606		
COVID19 (COV D19 (JANSSEN))	Baclofen count decreased	1 595	1 284	0 871				1 015	2 122	1 101	1 241	1 101		
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3 136	2 499	0 869		0 609		1 587	2 032	1 075	2 03	0 937		
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1 642	1 463	0 872				1 096	1 962	1 122	2 03	1 007		
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2 548	2 271	0 862				1 587	2 032	1 075	2 03	0 937		
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2 258	1 845	0 911				1 715	2 028	1 409	3 184	1 127		
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2 358	1 941	0 882				1 049	1 233	0 958	2 704	0 872		
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2 004	1 624	0 864				1 037	0 988	1 553	2 244	0 993		
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3 298	2 5	0 879			0 537	2 442	2 866	0 752	3 832	1 212		
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2 726	2 103	0 933	0 612			0 574	2 261	2 522	2 066	3 56	1 733	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head normal	1 888	1 443	0 875				0 343	1 616	2	1 329	1 935	1 536	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2 228	1 815	0 897				0 514	1 551	2 14	2 255	2 546	1 664	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2 573	1 877	0 896				0 484	2 228	2 193	3 26	3 19	1 982	
COVID19 (COV D19 (JANSSEN))	Esatinight count decreased	1 599	1 358	0 871				1 08	2 258	1 223	1 772	1 091		
COVID19 (COV D19 (JANSSEN))	Feeling cold	1 815	0 801	0 863				1 177	2 021	1 532	1 033	1 92	1 431	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2 379	1 388	0 874				0 415	2 305	2 104	1 845	2 705	1 566	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	2 132	1 564	0 892				0 367	1 653	2 314	2 096	2 53	1 425	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1 922	1 006	0 863	0 611			0 452	1 638	1 903	0 803	2 126	1 177	
COVID19 (COV D19 (JANSSEN))	Gasze palsy	2 293	0 938	0 864				2 42	1 657	2 732	0 889	1 254		
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	2 264	1 921	0 891				1 283	2 806	1 425	2 022	2 039		
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	1 295	0 876	0 876				0 29	3 091	4 091	1 83	6 076	1 83	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6 303	3 111	0 864			0 563	4 371	3 687	6 982	1 071	1 071		
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2 005	1 976	0 865				0 024	1 804	2 32	1 481	2 116	1 585	
COVID19 (COV D19 (JANSSEN))	Intensive care	1 411	1 856	0 943				0 044	1 892	1 892	1 782	2 281	1 585	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1 956	1 291	0 871				1 382	1 9	2 064	0 954	1 195		
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2 405	2 229	0 864				1 66	1 187	0 752	3 795	0 715		
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1 792	1 441	0 861				1 125	2 107	1 081	1 646	1 554		
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1 989	1 883	0 967				0 967	2 23	1 395	1 02	1 766		
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2 179	1 854	0 869			0 539	1 874	1 93	2 088	2 489	1 814		
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head normal	1 501	1 101	0 859				0 298	1 059	2 090	0 959	1 793	0 888	
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1 378	1 215	0 935	0 609			0 055	1 744	1 654	2 067	0 882		
COVID19 (COV D19 (JANSSEN))	Off label use	1 733	0 309	0 862				5 316	0 295	0 55	0 346	1 13	1 556	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1 781	0 757	0 867				2 819	1 014	1 014	2 279	1 014		
COVID19 (COV D19 (JANSSEN))	Pain assessment	2 332	0 886	0 866				0 546	1 571	2 053	1 05	2 216		
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	4 01	1 982	0 864				0 655	1 076	3 418	2 43	3 014		
COVID19 (COV D19 (JANSSEN))	Platelet count	2 728	2 407	0 914	0 612			0 504	2 066	3 318	1 649	3 288	1 684	
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1 809	1 486	0 88				0 332	2 039	1 341	1 341	2 134	1 012	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2 75	2 155	0 876				0 424	2 122	3 057	2 281	3 487	1 63	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5 947	3 52	0 864					4 27	2 851	0 699	5 925	1 719	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0 835		0 867				0 647	3 208	2 349	5 288	3 004		
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1 73	1 421	0 868	0 744			0 3	1 37	2 082	1 258	1 201		
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2 207	1 716	0 824	0 612			0 639	1 644	2 113	2 563	1 773		
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2 055	1 714	0 868				1 613	1 406	1 931	2 22	1 655		
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1 496	1 204	0 969				0 563	0 883	0 651	1 145	0 817		
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	2 822	2 267	0 899				0 557	1 763	2 152	0 986	2 334	2 823	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	6 887		0 867				0 627	3 446	14 814	7 815	5 53		
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2 041	1 882	0 877				0 42	2 089	1 35	2 465	1 396		
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2 38	1 211	0 867				0 553	1 374	1 965	1 442	2 029	1 735	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2 658	2 076	0 791	0 612			0 91	2 108	2 435	3 038	2 922	2 122	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2 368	2 01	0 864				2 001	1 192	0 651	2 697	0 858		
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2 234	1 275	0 869				0 588	1 771	2 046	1 129	2 52	1 389	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2 79	2 026	0 995	0 612			0 568	2 298	2 215	3 474	3 246	2 137	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2 374	1 776	0 86				0 48	1 623	1 489	2 477	1 569		
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1 786	1 427	0 86	0 608			1 196	2 048	1 951	1 775	1 67		
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	2 001	1 387	0 858				0 471	1 371	1 973	2 014	1 946	1 74	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1 911	1 125	0 864				1 271	2 056	1 988	2 024	1 245		
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1 401	2 246	0 913				0 6	0 88	2 221	4 517	1 906	2 055	
COVID19 (COV D19 (JANSSEN))	Venogram	2 54	2 068	0 868				1 802	1 908	0 542	2 733	1 103		
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3 395	2 593	0 868				0 619	2 793	1 819	4 389	1 038		
COVID19 (COV D19 (JANSSEN))	Venogram normal	4 307	2 476	0 864				3 589	2 747	0 759	5 354	1 04		
COVID19 (COV D19 (MODERNA))	Exposure via breast milk	1 28	0 775	0 864		3 748	0 724	1 183	0 517	1 275	0 837			
COVID19 (COV D19 (MODERNA))	No adverse event	1 266	0 834	0 87				2 002	0 919	0 936	1 128	1 231		
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2 342	0 911	0 867			0 82	2 459	0 232	0 626	2 356	2 391		
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1 955	0 979	0 867				0 593	0 891	1 25	2 288	1 497		
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2 09	1 031	0 862				0 642	1 442	1 659	2 008	1 569		
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2 35	1 751	0 928				0 966	1 796	1 885	2 169	2 138	2 056	
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0 59	0 795	0 864		4 067		0 379	0 564	0 379	0 267	1 004		
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2 196	1 726	0 887				0 96	1 719	1 901	2 406	2 149	1 979	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product administered to patient of inappropriate age	0 299	0 317	0 857			2 175	0 3	0 208	0 118	0 361	0 275	0 322	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1 886	0 651	0 868				1 398	1 898	1 931	2 39	1 869	1 806	
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	2 082	1 302	0 874				0 784	1 527	1 693	2 31	1 766		

From: (b) (6)
To: (b) (6) <[\(CDC\)](#)>; (b) (6) <[\(CDC\)](#)>
Cc: (b) (6) <[\(CDC\)](#)>; (b) (6) <[\(CDC\)](#)>
Subject: RE: Weekly data mining
Date: Tuesday, September 21, 2021 6:42:16 AM
Attachments: [USST_20210917.xls](#)

Hi (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 9/17/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EB05 20210917	US Serious EB05 20210917	US Fatal EB05 20210917	US Infant EB05 20210917	US Child EB05 20210917	US Teen EB05 20210917	US Adult1 EB05 20210917	US Adult2 EB05 20210917	US Adult3 EB05 20210917	US Female EB05 20210917	US Male EB05 20210917	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1 553	1 739	0 870	0 411	1 436	1 729	1 578	2 352	1 149			
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1 952	1 659	0 857		1 496	1 912	1 598	2 159	1 409			
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2 958	0 92	0 865		0 881	0 758	0 608	2 398	1 53			
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3 037	0 876	0 876	0 51	2 014	1 892	1 432	4 239	1 432			
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2 052	1 663	0 861		1 682	1 642	1 031	1 431	1 431			
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2 512	2 021	0 872		0 462	1 706	2 491	2 071	1 942			
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	1 644	1 466	0 865		0 404	1 12	2 126	0 797	1 915			
COVID19 (COV D19 (JANSSEN))	Antibody test	2 223	0 854	0 86		0 59	0 795	1 796	1 885	1 842			
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2 186	1 713	1 722	0 613	0 46	1 814	1 964	2 368	2 869			
COVID19 (COV D19 (JANSSEN))	Arrhythmia	2 136	2 109	0 861		0 883	2 101	1 239	1 619	1 603			
COVID19 (COV D19 (JANSSEN))	Barisophyll count decreased	1 545	1 279	0 867		0 286	0 284	1 074	1 074	1 056			
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3 339	2 62	0 871	0 61	1 376	2 016	0 757	4 523	0 921			
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2 505	2 218	0 86		1 568	2 401	1 139	2 072	2 018			
COVID19 (COV D19 (JANSSEN))	Cerebral haemangioma	1 908	1 292	0 868		1 34	0 973	2 587	0 628				
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2 288	1 941	0 91	0 54	1 806	2 002	1 409	3 248	1 126			
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2 223	1 852	0 881	0 551	1 048	1 203	0 96	2 673	0 854			
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2 029	1 572	0 862		1 035	1 039	1 545	2 259	0 991			
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	2 485	2 069	0 878		0 536	2 443	2 834	0 751	1 209			
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2 684	2 069	0 931	0 613	0 565	2 286	2 452	2 073	3 564			
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2 166	1 76	0 868		0 496	1 544	2 097	2 134	2 463			
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2 56	1 857	0 894		0 482	2 213	2 196	3 18	3 182			
COVID19 (COV D19 (JANSSEN))	Eosinophili count decreased	1 576	1 324	0 866		1 051	2 294	1 177	1 785	1 06			
COVID19 (COV D19 (JANSSEN))	Feeling cold	1 803	0 786	0 861		1 166	2 009	1 525	1 023	1 91			
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2 353	1 364	0 872	0 611	0 394	2 281	2 113	1 851	2 654			
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	2 121	1 529	0 892	0 356	1 644	2 113	2 323	2 057	2 529			
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1 91	0 988	0 861	0 447	1 636	1 887	1 607	2 107	1 171			
COVID19 (COV D19 (JANSSEN))	Gaze palsy	2 262	0 931	0 862		2 418	1 638	1 638	0 888	2 69			
COVID19 (COV D19 (JANSSEN))	Guillain-Barre syndrome	2 254	1 92	0 858		1 247	2 841	2 05	1 515	2 05			
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5 432	3 537	0 874		3 378	4 391	6 735	6 749	2 211			
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6 285	0 285	0 862	0 561	0 660	3 959	6 069	3 959	1 069			
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	1 994	1 967	0 862	0 022	1 871	2 341	2 117	1 503	1 578			
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1 958	1 311	0 869		1 405	1 494	0 952	2 092	1 182			
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2 393	2 217	0 862		1 659	1 185	0 752	3 768	0 714			
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1 824	1 455	0 859		1 134	1 684	1 028	1 649	1 616			
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1 927	1 809	0 863		0 953	2 157	1 009	1 368	1 713			
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2 17	1 829	0 867	0 532	1 17	1 896	1 908	2 097	1 597			
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1 496	1 094	0 856	0 28	1 067	2 065	1 792	0 598	0 861			
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1 366	1 201	0 875	0 61	0 049	0 508	1 797	1 621	2 063			
COVID19 (COV D19 (JANSSEN))	Off label use	1 702	0 66	0 86		5 317	0 296	0 919	0 32	1 114			
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1 777	0 757	0 871		2 831	1 013	2 267					
COVID19 (COV D19 (JANSSEN))	Pain assessment	2 44	0 879	0 879	0 545	1 568	2 111	1 136	2 39	1 334			
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3 984	1 969	0 861	0 613	0 656	1 075	3 182	2 396	1 912			
COVID19 (COV D19 (JANSSEN))	Platelet count	2 692	2 397	0 913	0 613	0 503	3 287	1 633	3 234	1 661			
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1 912	1 473	0 881	0 609	0 323	1 578	2 021	1 353	2 162			
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2 757	2 159	0 874		0 418	2 119	3 066	2 333	3 495			
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5 939	3 504	0 862		4 263	2 601	0 688	5 928	1 713			
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0 958		0 785		3 86	2 918	6 069	4 438	3 519			
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1 723	1 416	0 868	0 744	0 283	1 351	2 148	1 235	2 154			
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2 184	1 689	0 929	0 613	0 619	1 647	2 093	2 496	2 504			
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2 029	1 66	0 868		1 585	1 383	2 1	1 885	1 628			
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1 493	1 197	0 863	0 561	0 968	0 863	0 65	2 134	0 616			
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	2 889	2 288	0 918		0 551	1 939	2 217	2 379	2 873			
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	6 677		0 656		3 446	6 544	14 741	7 838	5 502			
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2 041	1 864	0 874		0 416	1 711	1 367	2 47	1 403			
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2 396	1 202	0 865	0 551	1 417	1 846	1 433	2 024	1 728			
COVID19 (COV D19 (JANSSEN))	Thrombosis	2 66	2 254	1 738	0 613	0 609	2 075	2 409	3 545	2 903			
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2 268	1 958	0 862		1 907	1 19	0 65	2 469	0 857			
COV D19 (COV D19 (JANSSEN))	Ultrasound Doppler	2 255	1 278	0 867	0 67	1 776	2 587	2 087	2 133	1 626			
COV D19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2 791	2 015	0 883	0 613	0 563	2 281	2 247	3 435	2 13			
COV D19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2 38	1 781	0 859		0 475	2 443	1 677	1 52	2 414			
COV D19 (COV D19 (JANSSEN))	Ultrasound scan	1 787	1 37	0 857	0 609	1 194	1 979	2 003	1 739	1 935			
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	2 027	1 338	0 855		0 469	1 383	1 905	1 525	1 732			
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1 917	1 113	0 861		1 29	2 067	1 924	2 024	1 261			
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1 455	2 285	1 008	0 599	2 285	1 054	2 265	4 699	1 841			
COVID19 (COV D19 (JANSSEN))	Venogram	2 645	2 145	0 857	0 618	1 917	1 836	0 636	2 928	1 028			
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3 382	2 577	0 862		2 795	1 811	0 705	4 38	1 036			
COVID19 (COV D19 (JANSSEN))	Venogram normal	4 389	2 532	0 862		3 584	2 708	0 876	5 477	1 038			
COVID19 (COV D19 (MODERNA))	Exposure via breast milk	1 259	0 775		4 564		1 17	0 517	1 265	0 878			
COVID19 (COV D19 (MODERNA))	No adverse event	1 263	0 834	0 868	0 309	2 016	0 92	0 938	0 785	1 233			
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2 355	0 908	0 865	0 905	2 475	0 163	0 232	0 627	2 405			
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1 957	0 978	0 865		0 568	0 889	1 25	1 922	1 497			
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2 082	1 039	0 86		0 641	1 449	1 637	2 014	1 571			
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2 343	1 746	0 929		0 966	1 767	1 865	2 13	2 045			
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0 598	0 794	0 862	4 766		0 4	0 402	0 402	0 976			
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2 189	1 714	0 866		0 981	1 715	1 907	2 401	1 968			
COVID19 (COV D19 (PFIZER-BIONTECH))	Product administered to patient of inappropriate age	0 302	0 369	0 856	2 611	0 303	0 224	0 118	0 278	0 324			
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1 885	0 653	0 861		1 401	1 999	1 937	2 391	1 861			
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	2 063	1 299	0 872		0 783	1 511	1 694	2 292	1 763			

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, September 28, 2021 5:57:17 AM
Attachments: [USST_20210924.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 9/24/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20210924	US Serious EB05 20210924	US Fatal EB05 20210924	US Infant EB05 20210924	US Child EB05 20210924	US Teen EB05 20210924	US Adult1 EB05 20210924	US Adult2 EB05 20210924	US Adult3 EB05 20210924	US Female EB05 20210924	US Male EB05 20210924	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,257	1,734	0	0.66			0.414	1,326	1,775	1,543	2,366	1,171
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1,987	1,677	1,863				1,479	2,029	1,562	2,177	1,451	
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,717	1,212	0,915				0,489	1,175	1,519	1,499	2,017	1,223
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	3,036	0,811	0	0	0	0		0,768	0,768	0,768	2,460	1,511
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,726	1,188	0,881					1,245	1,222	1,222	2	0,874
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2,96	2,267	0	0	0	0	0,511	2,02	1,92	3,635	4,226	1,399
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2,071	1,662	0,886					1,739	1,657	1,02	1,971	1,419
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,502	0,879	0,679				0,463	1,668	2,471	2,128	2,809	1,904
COVID19 (COV D19 (JANSSEN))	Arion gap decreased	1,711	1,482	0	0	0	0		1,147	2,277	0,783	1,955	1,849
COVID19 (COV D19 (JANSSEN))	Antibody test	2,217	0,843	0,866				0,591	0,834	1,732	1,801	1,976	1,167
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	1,691	1,691	1,547	0,612			0,46	1,834	1,981	2,345	2,873	1,929
COVID19 (COV D19 (JANSSEN))	Arterflexia	2,164	2,128	0,867					0,883	2,098	1,337	1,679	1,593
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1,617	1,267	0,872	0,61			0,354	1,038	2,427	1,049	1,792	1,148
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1,487	1,358	0,876	0,61			0,293	1,157	2,08	1,004	1,725	1,106
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3,204	2,585	0,876				0,527	1,323	2,013	0,756	4,558	0,905
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,597	2,255	0,866					1,568	2,538	1,214	2,235	2,207
COVID19 (COV D19 (JANSSEN))	Cerebral haematoma	1,912	1,29	0,873					1,342	0,972		2,623	0,526
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2,231	1,892	0,909				0,54	1,783	1,957	1,39	3,188	1,107
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2,395	1,944	0,884				0,551	1,047	1,203	1,043	3,338	0,853
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2,203	1,486	0,867					1,023	1,032	1,51	2,254	0,984
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3,178	2,413	0,882					2,374	2,641	0,747	3,807	1,195
COVID19 (COV D19 (JANSSEN))	Computerized tomogram head abnormal	2,698	2,057	0,937	0,611			0,567	2,26	2,423	2,196	3,476	1,744
COVID19 (COV D19 (JANSSEN))	Computerized tomogram thorax abnormal	2,145	1,722	0,9				0,496	1,512	2,095	2,105	2,46	1,909
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,53	1,835	0,895				0,484	2,179	2,165	3,135	3,133	1,95
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	1,596	1,305	0,871					1,1	2,291	1,158	1,795	1,106
COVID19 (COV D19 (JANSSEN))	Feeling cold	1,795	0,788	0,867				1,169	2,004	1,518	1,005	1,806	1,411
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,325	1,357	0,876				0,397	2,239	2,082	1,849	2,59	1,575
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	2,121	1,51	0,894	0,612			0,357	1,619	2,345	2,064	2,512	1,444
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1,888	0,991	0,867				0,447	1,636	1,85	0,788	2,107	1,114
COVID19 (COV D19 (JANSSEN))	Flare rash	6,294	0,192	0,868				0,438	2,427	0,866	0,866	1,269	1,699
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	2,272	1,932	0,864				1,275	2,88	2,273	1,557	2,073	2,053
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,407	3,516	0,879				0,561	3,391	4,39	6,46	6,695	2,214
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,294	3,121	0,868				0,529	4,979	3,503	6,472	6,695	2,214
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2,047	1,995	0,868				0,021	1,905	2,432	2,155	1,538	1,637
COVID19 (COV D19 (JANSSEN))	International normalized ratio normal	1,57	1,333	0,874					1,388	1,937	0,95	2,07	1,217
COVID19 (COV D19 (JANSSEN))	Isular vein thrombosis	2,221	1,868	0,868					1,547	1,17	0,751	1,714	1,008
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1,817	1,448	0,865				1,117	2,131	1,649	1,649	1,608	1,608
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1,945	1,781	0,867					0,936	2,249	1,006	1,399	1,722
COVID19 (COV D19 (JANSSEN))	Lymphocyte percentage decreased	1,432	1,162	0,869				0,191	0,918	2,002	1,361	1,744	1,038
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,169	1,808	0,872				0,524	1,886	1,892	2,171	2,51	1,593
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1,54	1,099	0,862				0,372	1,113	2,1	0,587	1,634	0,883
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1,368	1,196	0,86	0,61			0,143	0,889	1,836	1,573	2,038	0,883
COVID19 (COV D19 (JANSSEN))	Off label use	1,681	0,25	0,866				0,594	0,375	0,599	0,343	1,082	1,535
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1,785	0,757	0,863					2,883	1,014		2,283	
COVID19 (COV D19 (JANSSEN))	Pain assessment	2,554	0,877	0,867				0,54	1,838	2,15	1,118	2,498	1,443
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3,884	1,924	0,867					0,656	1,075	2,316	2,234	1,011
COVID19 (COV D19 (JANSSEN))	Platelet count	2,721	2,483	0,914	0,612			0,504	2,023	3,18	1,686	3,24	1,687
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1,909	1,449	0,863	0,61			0,323	1,558	2,035	1,343	2,133	1,361
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,774	2,167	0,878				0,42	2,134	3,072	2,394	3,495	1,678
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5,958	3,523	0,868					4,273	2,585	0,688	5,981	1,716
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1		0				0,789	3,855	3,069	6,042	4,481	3,603
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1,743	1,428	0,873	0,745			0,284	1,981	2,179	1,229	2,157	2,335
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2,174	1,675	0,936	0,612			0,617	1,619	2,087	2,512	2,482	1,764
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2,004	1,603	0,873					1,573	1,372	2,002	1,878	1,598
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1,465	1,195	0,867				0,591	0,987	0,847	0,65	2,149	0,608
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	2,917	2,425	0,93				0,545	1,864	2,305	2,431	2,882	2,882
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	6,843	3,039	0,866				0,656	3,473	6,559	15,105	6,004	5,657
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2,104	1,889	0,878				0,418	1,726	2,184	1,384	2,535	1,466
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia superficial	2,281	1,135	0,87					1,407	1,778	1,365	1,972	1,672
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,641	2,227	1,749	0,612			0,599	2,034	2,388	3,502	2,84	2,144
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,196	1,896	0,867					1,637	3,177	0,65	2,244	0,856
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,266	1,29	0,871				0,672	1,814	2,063	2,14	2,544	1,636
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,794	2,015	0,886	0,612			0,564	2,286	2,256	3,477	3,31	2,121
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2,431	1,756	0,868				0,477	2,559	1,745	1,407	2,401	1,76
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	2,007	1,385	0,861					1,388	1,921	1,9	1,898	1,705
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1,928	1,157	0,87					1,319	2,1	1,783	2,041	1,262
COVID19 (COV D19 (JANSSEN))	Vasodilation failure	1,471	2,416	1,72				0,586	0,995	2,262	4,7	1,866	2,124
COVID19 (COV D19 (JANSSEN))	Venogram	2,693	2,108	0,866					1,924	1,909	0,633	3,01	1,027
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3,246	2,504	0,875				0,619	2,703	1,729	0,704	4,17	1,035
COVID19 (COV D19 (JANSSEN))	Venogram normal	4,45	2,611	0,875					3,643	3,58	5,472	1,108	
COVID19 (COV D19 (JANSSEN))	Exposure via breast milk	1,265	0,767	0,868					1,178	0,517	1,278	0,882	
COVID19 (COV D19 (MODERNA))	No adverse event	1,249	0,848	0,875	4,152	0,764		0,298	2,007	0,914	0,929	0,779	1,126
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2,375	0,908	0,87				0,979	2,505	0,151	0,216	2,395	2,425
COVID19 (COV D19 (MODERNA))	Product dose omission issue	1,885	1,922	0,866					2,002	1,845	1,484	1,784	1,983
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1,94	0,985	0,871				0,603	0,884	1,261	2,264	1,912	1,484
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2,072	1,036	0,866					0,64	1,664	2,001	2,04	1,507
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2,316	1,737	0,932				1,006	1,771	1,856	2,117	2,025	1,028
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0,634	0,817	0,87	6,504				0,87	0,398	0,399	1,08	
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2,177	1,707	0,89					1,721	1,812	2,393	1,957	1,867
COVID19 (COV D19 (PFIZER-BIONTECH))	Product administered to patient of inappropriate age	0,306	0,368	0,862			3,373	0,306	0,249	0,108	0,35	0,329	0,329
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1,863	0,659	0,869				1,39	1,893	1,924	1,845	1,786	1,864
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	2,065	1,287	0,877				0,823	1,518	1,692	2,299	2,052	1,772

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, October 5, 2021 6:02:15 AM
Attachments: [USST_20211001.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/1/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211001	US Serious EB05 20211001	US Fatal EB05 20211001	US Infant EB05 20211001	US Child EB05 20211001	US Teen EB05 20211001	US Adult1 EB05 20211001	US Adult2 EB05 20211001	US Adult3 EB05 20211001	US Female EB05 20211001	US Male EB05 20211001	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1.534	1.660	1.569	0.407			1.534	1.569	1.726	2.374	1.144	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	2.04	1.717	1.878				1.515	2.043	1.771	1.459	1.459	
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1.81	1.261	0.923	0.489			1.221	1.553	1.642	2.057	1.344	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	0.963	0.862	0.864				0.864	2.482	0.762	2.48	1.584	
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1.744	1.195	0.89				1.373	1.318	1.199	2.027	0.992	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3.014	2.278	0.889	0.511			1.937	1.948	3.949	4.31	1.414	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2.084	1.651	0.879				1.797	1.614	1.822	2.039	1.382	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2.511	1.967	0.865				1.691	2.497	2.152	2.981	1.932	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary normal	1.69	1.439	0.882				1.137	2.251	1.137	1.94	1.189	
COVID19 (COV D19 (JANSSEN))	Antibody test	2.171	0.819	0.878			0.612	0.591	0.829	1.778	1.947	1.797	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2.203	1.469	1.547				0.446	1.639	2.376	2.868	1.544	
COVID19 (COV D19 (JANSSEN))	Areflexia	2.142	2.09	0.879				0.883	2.046	1.339	1.668	1.58	
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1.623	1.298	0.882	0.609			0.346	1.022	2.422	1.118	1.821	1.132
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1.505	1.368	0.865	0.609			0.309	1.141	2.053	1.114	1.767	1.056
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1.66	1.303	0.879				1.262	2.001	1.381	1.851	1.311	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3.059	2.535	0.886				0.523	1.296	1.999	0.756	0.906	
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1.542	1.39	0.865				0.26	1.094	1.894	2.086	0.977	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2.581	2.226	0.878				1.542	2.54	2.208	2.221	2.058	
COVID19 (COV D19 (JANSSEN))	Cerebral haematoma	1.776	1.223	0.884				1.341	0.941	1.528	2.655	0.618	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2.26	1.888	0.911	0.54			1.784	1.528	1.346	3.346	1.09	
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2.411	1.932	0.893	0.551			1.047	1.203	1.042	3.369	0.654	
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2.049	1.549	0.879				1.005	1.09	1.499	2.341	1.016	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3.217	2.421	0.891	0.537			2.495	2.887	0.748	3.837	1.196	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2.76	2.075	0.932	0.611			0.649	2.281	2.446	3.569	1.781	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2.174	1.729	0.906				0.492	1.51	2.172	2.486	1.648	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2.542	1.84	0.904				0.481	2.167	2.195	3.107	1.807	
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	1.577	1.275	0.862				1.073	1.073	2.245	1.218	1.795	1.053
COVID19 (COV D19 (JANSSEN))	Feeling cold	1.804	0.79	0.879				1.161	1.536	1.008	1.915	1.421	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2.32	1.327	0.886				0.392	2.206	2.089	1.965	1.601	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	2.106	1.471	0.899	0.611			0.347	1.635	2.397	1.527	1.403	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1.871	0.985	0.879				0.442	1.613	0.785	2.104	1.12	
COVID19 (COV D19 (JANSSEN))	Galze palsy	2.253	0.93	0.88				0.439	2.324	1.653	0.882	1.244	
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	2.939	2.942	1.942				0.877	1.342	1.657	2.112	2.12	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.36	3.473	0.889				3.398	4.402	6	6.89	1.982	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.307	3.114	0.88				0.561	4.365	3.443	6.976	1.069	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2.028	1.969	0.919				0.019	2.651	1.916	2.097	1.647	
COVID19 (COV D19 (JANSSEN))	Intensive care	1.68	1.396	0.959	0.745			0.003	1.317	1.859	2.044	1.298	
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1.74	1.284	0.874				0.421	1.58	1.777	1.249	2.063	1.222
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1.94	1.276	0.865				0.421	1.276	1.923	0.934	1.192	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2.161	2.058	1.5				1.17	0.746	2.727	1.674	1.61	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1.83	1.446	0.877				1.194	2.09	1.081	1.674	1.161	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1.963	1.784	0.866				0.926	2.23	1.091	1.445	1.711	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.192	1.808	0.882	0.522			1.877	1.897	2.299	2.549	1.6	
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1.553	1.108	0.875				0.364	1.098	2.143	0.629	0.892	
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1.4	1.221	0.889	0.609			0.22	0.877	1.872	1.677	2.125	0.881
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1.376	1.133	0.878				0.112	1.128	1.541	1.028	2.065	0.663
COVID19 (COV D19 (JANSSEN))	Off label use	1.608	0.237	0.878				5.549	0.383	0.873	1.022	1.434	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1.769	0.757	0.878				2.892	1.014	0.376	2.295	1.434	
COVID19 (COV D19 (JANSSEN))	Pain assessment	2.515	0.875	0.54				1.839	2.139	1.095	2.539	1.395	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3.723	1.906	0.879				0.656	1.075	2.447	2.25	0.996	
COVID19 (COV D19 (JANSSEN))	Platelet count	2.729	2.468	0.929	0.612			0.504	1.97	3.141	1.693	1.714	
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1.802	1.432	0.862	0.609			0.31	1.558	2.041	1.339	2.133	1.352
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2.772	2.16	0.89				0.416	2.112	2.553	3.484	1.692	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	6	3.558	0.88				4.279	3.638	0.689	5.969	2.084	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1.008	1.008	0.856				3.865	3.968	5.988	4.388	3.636	
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1.761	1.432	0.884	0.744			0.273	1.368	1.271	2.211	1.235	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2.264	1.683	0.945	0.612			0.804	1.642	2.129	2.54	1.802	
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2.01	1.59	0.884				1.591	1.402	1.007	1.189	1.595	
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	1.772	1.245	0.876	0.609			0.374	1.123	1.928	1.405	2.012	1.143
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2.213	1.089	0.882				0.552	1.377	1.735	1.354	1.894	1.66
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	3.017	2.964	1.572				0.546	1.985	2.309	0.773	2.963	2.979
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	6.876	0.613	0.656				3.471	6.58	15.272	6.03	5.677	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2.169	1.938	0.891				0.412	1.756	2.233	1.413	2.625	1.5
COVID19 (COV D19 (JANSSEN))	Thrombosis	2.634	2.217	1.751	0.612			0.699	2.028	3.322	2.927	2.169	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2.153	1.847	0.88				1.768	1.778	0.652	2.171	0.857	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2.264	1.275	0.883				0.667	1.796	2.065	2.13	2.542	1.635
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2.827	2.056	0.894	0.612			0.551	2.353	2.299	3.511	3.31	2.185
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2.44	1.765	0.884				0.473	1.735	1.466	2.411	1.78	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1.927	1.137	0.882				1.345	2.081	1.731	2.033	1.274	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1.527	2.841	2.128				0.652	2.281	4.426	2.006	2.183	
COVID19 (COV D19 (JANSSEN))	Venogram	2.61	2.059	0.877				0.577	2.059	1.77	2.878	1.016	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3.21	2.469	0.879				0.619	2.71	1.692	4.101	1.036	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4.295	2.522	0.88				3.57	2.517	0.875	5.292	1.093	
COVID19 (COV D19 (MODERNA))	Exposure via breast milk	1.268	0.766	0.88	3.624	0.778		1.179	0.517	1.281	0.868	0.868	
COVID19 (COV D19 (MODERNA))	Headache	0.954	0.955	0.879	2.343			0.303	0.941	1.011	0.952	1.022	
COVID19 (COV D19 (MODERNA))	No adverse event	1.246	0.84	0.884				0.292	0.915	0.926	1.024	1.216	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2.393	0.909	0.862	1.203			2.528	0.173	0.206	0.598	2.438	
COVID19 (COV D19 (MODERNA))	Product dose omission issue	1.915	1.939	0.879				2.084	1.941	1.87	1.507	1.808	2.02
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1.935	0.964	0.882				0.603	0.88	1.286	2.238	1.473	
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2.053	1.052	0.878				0.64	1.47	1.967	1.967	1.596	
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2.293	1.704	0.935				1.006	1.751	1.82	2.075	1.988	
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0.66	0.846	0.882	7.751			0.384	0.384	0.384			

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, October 12, 2021 6:30:24 AM
Attachments: [USST_20211008.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/8/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211009	US Serious EB05 20211008	US Fatal EB05 20211008	US Infant EB05 20211009	US Child EB05 20211008	US Teen EB05 20211008	US Adult1 EB05 20211008	US Adult2 EB05 20211008	US Adult3 EB05 20211008	US Female EB05 20211009	US Male EB05 20211008	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,013	0,65				0,406	1,568	2,013	1,568	1,571	1,571	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,017	1,661	0,88				1,516	2,046	1,649	1,649	1,432	
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,802	1,241	0,92			0,488	1,272	1,81	1,571	2,08	1,345	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	3,072	0,885					0,871	0,741	2,455	1,507	1,507	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,017	2,254	0,891			0,51	1,937	2,013	4,336	3,749	3,366	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,065	1,601	0,882				1,729	1,616	1,242	1,384	1,384	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,558	2	0,892			0,455	1,691	2,565	2,223	2,94	1,986	
COVID19 (COVID19 (JANSSEN))	Action gap decreased	1,703	1,428	0,897				1,115	1,638	0,796	1,217	1,217	
COVID19 (COVID19 (JANSSEN))	Antibody test	2,207	0,811	0,882				0,825	1,653	1,884	1,985	1,831	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,22	1,884	1	0,612		0,446	1,86	2,009	2,406	2,871	1,576	
COVID19 (COVID19 (JANSSEN))	Asthenia	2,089	2,009	0,883				0,884	1,929	1,917	1,938	1,938	
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,689	1,347	0,886	0,61			0,344	1,122	2,382	1,181	1,201	
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,531	1,354	0,886	0,61			0,308	1,178	2,097	1,076	1,101	
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,714	1,333	0,883				0,415	1,319	2,069	1,409	1,338	
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1,73	1,29	0,887				0,472	1,279	2,03	1,347	2,046	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3,6	2,726	0,891			0,522	1,677	2,202	0,756	4,862	0,976	
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,684	1,448	0,888			0,257	1,13	1,977	1,217	2,207	0,957	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,602	2,198	0,882				1,586	2,538	1,189	2,175	2,123	
COVID19 (COVID19 (JANSSEN))	Cerebral haematoma	1,784	1,22	0,867				1,339	0,841	2,699	0,618	0,618	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,274	1,881	0,914			0,539	1,853	1,524	1,469	1,121	1,121	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,504	1,966	0,901			0,549	1,046	1,299	1,024	3,429	0,916	
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,052	1,528	0,883				1,006	1,094	1,478	2,351	1,014	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,356	2,5	0,896			0,535	2,26	2,521	3,992	0,743	1,244	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,739	2,04	0,938	0,611			2,291	2,454	2,555	2,255	1,761	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head normal	1,91	1,403	0,888			0,419	1,605	2,002	1,453	2,063	1,453	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,113	1,656	0,905			0,489	1,485	2,122	1,99	2,432	1,602	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,587	1,862	0,917			0,479	2,183	2,209	3,249	3,135	2,013	
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,606	1,285	0,885				1,152	2,208	1,776	1,204	1,129	
COVID19 (COVID19 (JANSSEN))	Feeling cold	1,783	0,787	0,862			1,163	2,004	1,521	1,018	1,807	1,411	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,907	1,529	0,89			0,391	2,188	2,663	2,118	2,663	1,586	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,096	1,452	0,905	0,611			0,344	2,374	2,532	1,934	1,395	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,916	0,993	0,882			0,439	1,676	1,883	0,785	2,174	1,146	
COVID19 (COVID19 (JANSSEN))	Genze entry	2,028	0,952	0,885				0,432	2,334	1,665	2,464	1,331	
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2,334	1,902	0,881				1,339	2,847	1,691	2,126	2,101	
COVID19 (COVID19 (JANSSEN))	Haemolysis decreased	1,671	1,289	0,89	0,607		0,446	1,236	1,943	1,531	2,018	1,219	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	2,113	3,421	0,891				3,421	4,374	1,84	1,84	1,84	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,627	3,345	0,883			0,56	4,748	5,142	6,669	6,669	1,069	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,046	1,957	0,883			0,019	1,816	2,492	1,248	2,123	1,864	
COVID19 (COVID19 (JANSSEN))	Intensive care	1,702	1,389	0,889				1,004	1,894	1,826	1,336	1,336	
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,709	1,234	0,878	0,746		0,419	1,565	1,768	2,059	1,511	1,196	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,947	1,283	0,887				1,353	1,977	0,92	2,089	1,207	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,112	2,083	0,883				2,495	1,153	2,745	2,704	2,704	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,827	1,45	0,881				1,209	2,093	1,067	1,651	1,638	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1,956	1,746					0,916	2,21	1,417	1,083	1,734	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,166	1,177	0,885	0,52			1,825	1,899	2,543	2,543	1,567	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	1,875	1,337	0,88	0,611			1,349	1,967	1,253	2,1	1,105	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,587	1,128	0,88				1,17	2,161	0,641	1,873	0,946	
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,473	1,268	0,895	0,61			0,22	0,957	1,843	1,731	0,932	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,428	1,117	0,884				1,109	1,581	1,066	2,104	0,711	
COVID19 (COVID19 (JANSSEN))	Off label use	1,565	0,288	0,883				5,691	0,37	0,549	0,441	1,399	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,789	0,758	0,886				2,899	1,017	2,315	2,315	2,315	
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,501	0,86	0,88			0,539	1,735	2,253	2,469	1,084	1,427	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,756	1,895	0,883				0,656	1,077	2,545	1,077	0,996	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,881	2,449	0,929	0,612		0,488	1,919	3,134	3,109	1,734	1,74	
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,82	1,439	0,899	0,61			0,307	1,543	2,042	1,45	1,384	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,787	2,138	0,892			0,413	2,125	3,092	2,451	1,694	1,694	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,023	3,54	0,883				4,296	3,171	0,888	6,007	2,09	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1,941					0,86	3,913	2,978	5,887	4,478	3,67	
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1,785	1,438	0,889	0,745			1,438	2,159	2,284	1,289	1,249	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,21	1,676	0,952	0,612		0,601	1,662	2,132	2,521	2,529	1,797	
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	1,966	1,559	0,889				1,521	1,367	2,149	1,918	1,548	
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1,742	1,298	0,886	0,609		0,561	1,347	2,013	1,419	1,409	1,409	
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	1,795	1,263	0,879	0,61		0,371	1,233	1,843	1,396	1,103	1,115	
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2,204	1,105	0,885				0,55	1,397	1,76	1,297	1,711	
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	3,074	2,663	1,788				2,012	2,392	2,654	3,019	2,654	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	6,927	0,61				0,655	3,498	6,553	15,574	8,083	5,763	
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2,2	1,862	0,899			0,408	1,822	2,197	1,511	2,614	1,56	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,638	2,205	1,825	0,612			2,028	2,377	3,557	2,132	2,132	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,287	1,934	0,883				1,768	1,288	0,652	2,4	0,857	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,295	1,292	0,888			0,656	1,842	2,084	2,197	2,682	1,653	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,782	2	0,895	0,612			2,287	2,275	3,335	2,342	2,137	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,448	0,89	0,88			0,473	2,686	1,769	1,472	2,411	1,739	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,744	1,3	0,88	0,609			1,195	1,934	2,044	1,648	1,648	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,976	1,159	0,885				1,364	2,178	1,787	2,101	1,294	
COVID19 (COVID19 (JANSSEN))	Vaccination failure	1,406	2,696	2,173			0,577	1,061	2,343	1,982	4,743	2,16	
COVID19 (COVID19 (JANSSEN))	Venogram	2,765	2,105	0,886				2,207	1,751	0,723	3,167	1,015	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,266	2,473	0,885			0,619	1,963	1,894	1,529	1,832	2,045	
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,291	2,479	0,883				3,58	2,438	0,863	5,28	1,092	
COVID19 (COVID19 (MODERNA))	Exposure via breast milk	1,274	0,767	0,886	5,651	0,797		1,187	0,515	1,283	0,835	0,835	
COVID19 (COVID19 (MODERNA))	Headache	0,967	0,656	0,88	4,09			0,944	0,896	0,953	1,026	1,026	
COVID19 (COVID19 (MODERNA))	No adverse event	1,227	0,842	0,888			0,294	0,9	0,906	1,102	0,766	1,211	
COVID19 (COVID19 (MODERNA))	Product administration to patient of inappropriate age	2,384	0,928	0,885			1,316	2,56	0,172	0,107	0,591	2,437	
COVID19 (COVID19 (MODERNA))	Product dose omission issue	1,847	1,953	0,882				2,119	1,963	1,894	1,529	1,529	
COVID19 (COVID19 (PFIZER-BIONTECH))	Body height	1,93	1,002	0,886				0,879	1,288	2,218	1,909	1,476	
COVID19 (COVID19 (PFIZER-BIONTECH))	Disease recurrence	2,056	1,051	0,882				1,509	1,671	1,961	2,023	1,587	
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,292	1,798	0,884				0,996	2,765	2,069	1,616	1,616	
COVID19 (COVID19 (PFIZER-BIONTECH))	Exposure via breast milk	0,695	0,847	0,885	9,271			0,384	0,384	0,406	1,108	0,406	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,158	1,701	0,9				1,012	1,725	1,918	2,127	1,936	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product administered to patient of inappropriate age	0,307	0,340	0,878		4,258		0,307	0,339	0,339	0,339	0,339	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,84	0,753	0,883				1,381	1,886	2,312	1,773	1,773	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,035	1,295	0,89				0,846	1,513	1,704	2,219	2,02	1,762

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, October 19, 2021 6:14:00 AM
Attachments: [USST_20211015.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/15/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211015	US Serious EB05 20211015	US Fatal EB05 20211015	US Infant EB05 20211015	US Child EB05 20211015	US Teen EB05 20211015	US Adult1 EB05 20211015	US Adult2 EB05 20211015	US Adult3 EB05 20211015	US Female EB05 20211015	US Male EB05 20211015	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,036	1,613	1,036			0.405	1,036	1,036	1,036	1,036	1,036	1,036
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1,392	1,613	1,392				1,452	2,119	1,654	1,654	2,373	1,38
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1,337	1,253	1,253			0.486	1,227	1,694	1,605	2,146	1,362	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	1,607	1,087	1,087				1,086	2,444	1,785	2,444	1,585	
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1,756	1,202	1,202				1,324	1,344	1,279	2,015	1,034	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2,997	2,232	2,232			0.507	1,875	2,074	3,606	4,256	1,378	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2,088	1,585	1,585				1,737	1,682	1,104	2,142	1,353	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,57	2,008	2,008			0.453	1,172	2,598	2,197	2,98	1,991	
COVID19 (COV D19 (JANSSEN))	Arion gap decreased	1,784	1,529	1,529			0.379	1,193	2,404	0.771	2,079	1,248	
COVID19 (COV D19 (JANSSEN))	Antibody test	2,249	0,812	0,867			0.584	0,82	1,658	2,002	2,017	1,83	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2,224	1,681	1,005	0.612		0.445	1,875	2,01	1,875	2,42	1,963	
COVID19 (COV D19 (JANSSEN))	Arteriogram carotid abnormal	1,823	1,172	0,868			0.911	1,172	2,401	1,172	2,217	0,937	
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1,731	1,375	0,87	0.61		0.342	1,144	2,408	1,211	1,968	1,209	
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1,587	1,404	0,869	0.608		0.302	1,217	2,188	1,109	1,828	1,158	
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1,759	1,366	0,869			0.413	1,324	2,154	1,444	2,006	1,37	
COVID19 (COV D19 (JANSSEN))	Blood chloride increased	1,829	1,381	0,878			0.471	1,283	2,179	1,495	2,134	1,259	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3,376	2,947	0,879			0.519	1,524	2,484	0.743	4,453	1,019	
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1,717	1,443	0,879			0.264	1,114	1,998	1,285	2,275	0,992	
COVID19 (COV D19 (JANSSEN))	Blood urea decreased	1,672	1,549	0,865			0.194	1,296	2,068	1,211	1,972	0,876	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,626	2,203	0,867				1,571	2,602	1,718	2,255	2,128	
COVID19 (COV D19 (JANSSEN))	Cerebral haematomas	1,671	1,176	0,874				1,266	0,942	1,266	2,165	0,613	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2,248	1,849	0,908			0.531	1,794	1,927	1,45	3,271	1,107	
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2,554	2,011	0,892			0.548	1,147	1,009	1,342	0,978		
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2,021	1,444	0,868				1,005	1,366	1,096	2,273	1,015	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3,415	2,509	0,886			0.532	2,626	2,504	0,823	4,049	1,231	
COVID19 (COV D19 (JANSSEN))	Computerized tomogram head abnormal	2,719	2,002	0,944	0.611		0.649	2,242	2,479	3,526	2,174	1,784	
COVID19 (COV D19 (JANSSEN))	Computerized tomogram head normal	1,932	1,426	1,078			0.415	1,639	1,989	1,513	2,093	1,472	
COVID19 (COV D19 (JANSSEN))	Computerized tomogram thorax abnormal	2,084	1,627	0,896			0.485	1,465	2,14	1,905	2,387	1,598	
COVID19 (COV D19 (JANSSEN))	Computerized tomogram thorax normal	2,553	1,841	0,905	0.477		0.777	2,193	2,102	3,194	3,138	1,98	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	1,649	1,469	0,866				1,621	1,841	2,64	1,849	1,533	
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	2,281	1,309	0,877	0.385		0.259	2,082	1,949	2,539	1,585	1,585	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,122	1,479	0,9	0.611		0.342	1,653	2,363	1,959	2,569	1,42	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,915	1,403	0,836			0.436	1,868	1,908	1,777	2,179	1,668	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	2,301	0,978	0,874			0.43	2,346	1,757	0,933	2,618	1,355	
COVID19 (COV D19 (JANSSEN))	Guillain-Barre syndrome	2,277	1,872	0,865			0.442	1,322	2,837	1,659	2,127	2,051	
COVID19 (COV D19 (JANSSEN))	Haemolysis decreased	1,718	1,354	0,86	0.606		0.422	1,981	2,063	1,549	2,065	1,549	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,42	3,584	0,879				3,843	4,472	5,482	6,947	2,105	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,722	3,447	0,869			0.557	5,027	5,136	0,668	7,434	1,966	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2,047	1,665	0,869			0.018	1,854	2,482	1,52	2,211	1,947	
COVID19 (COV D19 (JANSSEN))	Intensive care	1,728	1,402	0,949			0.027	1,356	1,809	1,929	2,13	1,318	
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1,748	1,255	0,861	0.746		0.413	1,588	1,867	1,223	2,104	1,228	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1,931	1,283	0,873				1,913	2,059	1,983	2,059	1,122	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,128	2,026	0,869				1,584	1,142	1,484	2,484	0,774	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1,823	1,419	0,866				1,205	2,072	1,053	1,662	1,618	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1,971	1,164	0,866				0,806	1,085	1,469	1,712	1,172	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,155	1,745	0,871	0.516		0.516	1,806	1,906	2,255	2,521	1,558	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head normal	1,9	1,35	0,861	0.611		0.47	1,333	2,108	1,214	2,107	1,15	
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1,682	1,252	0,863				1,318	2,008	2,78	2,008	1,012	
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1,515	1,296	0,862	0.61		0.223	0,95	2,048	1,731	2,287	0,972	
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1,501	1,238	0,871			0.121	1,249	1,674	1,093	2,174	0,788	
COVID19 (COV D19 (JANSSEN))	Off label use	1,577	0,267	0,867			5,817	0,37	0,982	0,545	0,982	1,4	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1,809	0,757	0,869				2,927	2,46	1,019	2,46		
COVID19 (COV D19 (JANSSEN))	Pain assessment	2,502	0,856	0,866			0.536	2,213	1,738	1,084	2,455	1,43	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3,768	1,895	0,869			0.656	1,078	2,618	2,32	0,995		
COVID19 (COV D19 (JANSSEN))	Platelet count	2,697	2,454	0,924	0.611		0.496	1,91	3,129	3,065	1,738	1,753	
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1,841	1,436	0,891	0.61		0.303	1,572	2,06	1,44	2,164	1,406	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,796	2,13	0,862			0.413	2,106	3,052	2,406	3,473	1,704	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	6,039	3,56	0,869				4,305	2,975	1,668	6,038	2,07	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1,101		0,864			0.864	3,969	2,96	5,913	4,577	3,68	
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1,829	1,48	0,877	0.744		0.274	1,473	2,261	1,272	2,328	1,291	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2,204	1,672	0,866	0.612		0.596	1,666	2,115	2,561	2,533	1,787	
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2,005	1,55	0,877				1,549	1,391	1,205	1,919	1,58	
COVID19 (COV D19 (JANSSEN))	Red blood cell count decreased	1,789	1,333	0,871	0.608		0.551	1,415	2,094	1,412	1,983	1,425	
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	1,877	1,325	0,869	0.608		0.368	1,301	2,068	1,432	2,208	1,169	
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2,222	1,145	0,872			0.547	1,396	1,794	1,277	1,844	1,755	
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	3,143	2,642	1,836			0.541	2,018	2,364	0,89	2,666	3,068	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	7,566	0,603	0,863			0.653	3,897	6,602	15,3	8,207	6,807	
COVID19 (COV D19 (JANSSEN))	Therapy partial responder	2,075		0,863				0,582	0,57	0,582	0,57	1,019	
COVID19 (COV D19 (JANSSEN))	Thrombectomy	1,602		0,877			0.531	1,337	1,515	1,416	2,108	1,28	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2,217	1,957	0,889			0.407	1,797	2,218	1,539	2,602	1,595	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,656	2,186	0,862	0.612		0.591	2,02	2,385	3,517	2,839	2,156	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,26	1,923	0,869				1,935	1,237	0,647	2,291	0,913	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,277	1,298	0,878			0.656	1,812	2,065	2,223	2,571	0,833	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,746	2,002	0,864	0.612		0.55	2,273	2,278	3,265	3,222	2,129	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2,484	1,781	0,877			0.47	2,692	1,885	1,485	2,47	1,841	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1,744	1,283	0,865				1,16	1,861	2,005	1,702	1,538	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1,98	1,171	0,871	0.61			1,373	2,174	1,771	2,104	1,298	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1,125	2,705	1,083	0.575		0.575	1,083	2,312	4,585	1,773	1,957	
COVID19 (COV D19 (JANSSEN))	Venogram	2,791	2,076	0,867				2,114	1,831	0,722	3,193	1,015	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3,365	2,534	0,863			0.617	2,907	1,862	0,704	4,132	1,195	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4,31	2,527	0,869				3,636	2,489	0,863	5,358	1,077	
COVID19 (COV D19 (MODERNA))	Exposure via breast milk	1,303	0,769	0,867	0.832			1,193	0,513	0,513	1,295	0,945	
COVID19 (COV D19 (MODERNA))	Headache	0,968	0,961	0,867	0.591		0.308	0,945	0,985	1,014	0,954	1,027	
COVID19 (COV D19 (MODERNA))	No adverse event	1,212	0,842	0,875			0.271	0,807	1,092	0,752	1,094	1,202	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2,387	0,928	0,872	1,346		0.583	0,065	0,065	0,078	2,396	2,43	
COVID19 (COV D19 (MODERNA))	Product dose omission issue	1,985	1,97	0,866			2,087	1,864	1,912	1,861	1,912	1,912	
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1,933	1,002	0,872			0.604	0,878	1,282	1,912	1,912	1,484	
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2,059	1,051	0,867			0.641	1,614	1,872	1,949	2,018	1,59	
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2,298	1,172	0,865			1,006	1,817	1,817	1,817	1,968	1,74	
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0,685	0,845	0,871	10,376								

From: (b) (6)
To: (b) (6) <(CDC)>; (b) (6) <(CDC)>
Cc: (b) (6) <(CDC)>; (b) (6) <(CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, October 26, 2021 7:13:34 AM
Attachments: [USST_20211022.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/22/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211022	US Serious EB05 20211022	US Fatal EB05 20211022	US Infant EB05 20211022	US Child EB05 20211022	US Teen EB05 20211022	US Adult1 EB05 20211022	US Adult2 EB05 20211022	US Adult3 EB05 20211022	US Female EB05 20211022	US Male EB05 20211022	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	0.96		0.86				0.402	2.61	1.62	1.71	2.16	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	2.086	1.699	0.873				1.576	2.15	1.71	2.634	1.388	
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1.86	1.257	0.93				0.478	1.209	1.62	1.135	1.418	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	0.902	0.902	0.874					0.763	0.763	2.475	1.621	
COVID19 (COV D19 (JANSSEN))	Adverse event	2.043	1.015	0.877					1.019	0.693	0.723	1.455	
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1.821	1.247	0.895					1.373	1.362	1.369	1.098	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2.957	2.191	0.885				0.503	1.859	2.102	3.367	1.383	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2.113	1.602	0.872					1.208	1.176	1.215	1.341	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	1.566	1.969	0.886					1.646	2.272	2.816	2.035	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary normal	1.914	1.695	0.885				0.373	1.298	2.453	0.996	1.319	
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	2.337	0.863	0.871					0.981	1.732	1.936	1.991	
COVID19 (COV D19 (JANSSEN))	Antibody test	2.226	1.672	0.958	0.612			0.443	1.863	2.004	2.47	1.589	
COVID19 (COV D19 (JANSSEN))	Arflexia	2.011	1.886	0.873					0.862	1.867	1.331	1.492	
COVID19 (COV D19 (JANSSEN))	Atrioagram carotid abnormal	1.81	1.155	0.872					0.899	1.175	1.369	1.136	
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1.811	1.507	0.875	0.609				1.186	2.424	1.418	1.201	
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1.655	1.478	0.873	0.608			0.3	1.26	2.211	1.247	1.153	
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1.833	1.421	0.88				0.413	1.362	2.211	1.982	2.102	
COVID19 (COV D19 (JANSSEN))	Blood chloride increased	1.936	1.491	0.891					0.467	2.292	1.653	1.292	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3.237	2.584	0.882				0.515	1.67	2.113	0.737	1.003	
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1.762	1.479	0.882				1.134	2.016	1.36	2.4	0.997	
COVID19 (COV D19 (JANSSEN))	Blood urea decreased	1.691	1.564	0.871				1.339	2.039	1.198	1.198	0.863	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2.647	2.206	0.871				0.527	1.617	2.612	1.173	2.345	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2.233	1.828	0.907				0.542	1.723	1.914	1.452	1.284	
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2.513	1.969	0.894				1.148	1.302	0.977	3.279	0.974	
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2.027	1.436	0.872					0.973	1.194	1.354	1.035	
COVID19 (COV D19 (JANSSEN))	Cerebral venous thrombosis	3.398	2.491	0.889				0.520	2.574	2.522	4.072	1.217	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2.717	1.984	0.934	0.611			0.647	2.259	2.48	2.206	1.772	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head normal	1.969	1.451	0.885				0.413	1.648	2.019	1.589	1.486	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2.076	1.599	0.894				0.477	1.452	2.15	1.893	1.994	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2.782	2.173	0.863				0.473	2.246	2.246	3.176	2.009	
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	1.765	1.462	0.87					1.298	2.286	1.373	1.169	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2.278	1.336	0.881				0.382	2.194	2.069	1.89	1.583	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	2.127	1.462	0.860	0.611			0.338	1.632	2.382	1.449	1.287	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1.964	1.007	0.872				0.433	1.968	1.968	0.769	2.206	
COVID19 (COV D19 (JANSSEN))	Galacta paly	2.321	1.009	0.88				0.423	2.341	1.79	0.989	2.591	
COVID19 (COV D19 (JANSSEN))	Gulian-Barre syndrome	2.295	1.924	0.874					1.333	2.877	2.679	1.929	
COVID19 (COV D19 (JANSSEN))	Haemolysis decreased	1.758	1.326	0.89	0.606			0.439	2.072	1.62	1.133	1.286	
COVID19 (COV D19 (JANSSEN))	Haemoglobin decreased	1.707	1.28	0.887	0.607			0.34	1.375	1.971	1.497	1.277	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.097	3.707	0.873					5.097	4.865	4.865	2.291	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.755	3.489	0.873				0.553	5.044	5.353	7.467	1.208	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2.054	1.943	0.872				0.02	1.856	2.475	1.554	1.658	
COVID19 (COV D19 (JANSSEN))	Intensive care	1.743	1.4	0.956					1.352	1.954	1.527	1.347	
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1.793	1.286	0.872	0.746			0.409	1.596	1.215	2.182	1.821	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1.901	1.238	0.878					1.359	1.944	0.907	2.036	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2.124	1.681	0.873					1.597	1.837	0.784	1.137	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1.861	1.494	0.87					1.199	2.153	1.688	1.688	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	2.047	1.825	0.878					0.902	2.361	1.175	1.786	
COVID19 (COV D19 (JANSSEN))	Lymphocyte percentage decreased	1.635	1.201	0.877				0.184	1.516	1.91	2.016	1.591	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.171	1.745	0.879				0.515	1.927	2.315	2.515	1.798	
COVID19 (COV D19 (JANSSEN))	Mean cell haemoglobin concentration decreased	1.966	1.403	0.873	0.611			0.468	1.344	2.226	1.251	1.217	
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1.717	1.227	0.872				0.357	1.423	2.275	0.863	1.017	
COVID19 (COV D19 (JANSSEN))	Mechanical ventilation	2.018	1.515	0.955				0.5	1.955	2.023	1.626	1.632	
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1.531	1.302	0.881	0.61				0.987	2.033	1.734	0.972	
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1.581	1.32	0.879				0.13	1.225	1.806	1.243	0.791	
COVID19 (COV D19 (JANSSEN))	Off label use	1.499	0.23	0.872					5.699	0.347	0.925	1.339	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1.784	0.758	0.979					2.979	1.008	2.203	1.203	
COVID19 (COV D19 (JANSSEN))	Pain assessment	2.541	0.855					0.532	1.827	2.172	1.171	2.341	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3.441	1.769	0.873					2.656	1.957	2.551	0.972	
COVID19 (COV D19 (JANSSEN))	Platelet count	2.719	2.497	0.923	0.611				1.883	3.104	1.796	1.791	
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1.842	1.419	0.894	0.609			0.299	1.549	2.033	1.469	1.413	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2.754	2.1	0.987				0.41	2.104	3.036	2.933	3.445	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	6.067	3.544	0.874					4.321	3.034	6.686	6.069	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1.151		0.863					3.986	2.903	6.155	4.56	
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1.879	1.519	0.893	0.744				0.269	1.495	2.33	1.338	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2.209	1.672	1.006	0.612				0.591	1.654	2.557	1.796	
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2.027	1.549	0.881					1.514	1.451	2.077	1.807	
COVID19 (COV D19 (JANSSEN))	Red blood cell count decreased	1.847	1.377	0.877	0.607			0.546	1.435	1.625	1.543	2.056	
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	1.971	1.403	0.88	0.609				1.308	2.186	1.546	1.211	
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2.247	1.182	0.876					0.543	1.4	1.776	1.893	
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1.56	1.237	0.872					0.553	1.033	0.825	0.668	
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	3.219	2.742	1.941					0.537	2.045	2.341	1.163	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	6.996	0.737					0.651	3.574	6.684	15.215	7.897	
COVID19 (COV D19 (JANSSEN))	Therapy partial responder	2.158								0.834	0.589	0.659	
COVID19 (COV D19 (JANSSEN))	Thrombectomy	2.097	1.676	0.885				0.527	1.413	1.582	1.405	2.083	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2.295	2.009	0.9					1.782	2.316	1.642	1.621	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2.655	2.179	0.814	0.612			0.582	2.002	2.39	3.528	2.147	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2.274	1.957	0.873					1.949	1.239	0.646	0.913	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2.332	1.365	0.884					1.851	2.14	2.654	1.66	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2.74	1.985	0.887				0.547	2.306	2.283	3.137	2.141	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2.551	1.814	0.886	0.612			0.463	2.656	1.973	1.642	1.844	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1.948	1.156	0.875					1.361	2.118	1.747	2.059	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1.182	2.797	2.377					0.563	1.15	2.337	1.834	
COVID19 (COV D19 (JANSSEN))	Vasodilation	2.003	0.881	0.868					1.506	0.972	1.773	1.912	
COVID19 (COV D19 (JANSSEN))	Venogram	2.674	2.031	1.176					1.749	3.085	0.721	0.993	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3.354	2.532					0.608	2.931	1.87	0.703	4.161	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4.164	2.444	0.873					1.685	2.181	2.181	0.851	
COVID19 (COV D19 (MODERNA))	Exposure via breast milk	1.334	0.831	1.197	7.31		0.871		0.513	0.513	1.314	0.189	
COVID19 (COV D19 (MODERNA))	Headache	0.969	0.963	0.876				0.305	0.945	0.985	1.014	0.955	
COVID19 (COV D19 (MODERNA))	No adverse event	1.197	1.844	0.917	5.803				2.025	1.197	0.762	1.205	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2.373	0.944	0.123					0.2	0.534	0.534	2.422	
COVID19 (COV D19 (MODERNA))	Product dose omission issue	2.02	1.986	0.872					2.16	1.988	1.933	1.57	
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1.931	1.049	0.876					0.602	0.876	1.469	1.469	
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2.058	1.049	0.872					1.515	1.68	1.943	1.601	
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2.298	1.711	0.965				1.013	1.735	1.799	1.952	2.058	
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0.706	0.876	0.876	11.694				0.602	0.876	1.32	1.469	
COVID19 (COV D19 (PFIZER-BIONTECH))													

From: (b) (6)
To: (b) (6)
Subject: RE: Weekly data mining
Date: Tuesday, October 26, 2021 8:03:10 AM

Appreciate it – managing ok – nothing needed now – thanks again

(b) (6)

From: (b) (6) @fda.hhs.gov>
Sent: Tuesday, October 26, 2021 7:50 AM
To: (b) (6) @fda.hhs.gov>
Subject: RE: Weekly data mining

Thanks (b) (6)

Just checking in. Is everything OK? Is there anything you need?

(b) (6)

From: (b) (6) @fda.hhs.gov>
Sent: Tuesday, October 26, 2021 7:14 AM
To: (b) (6) (CDC) (b) (6) @cdc.gov>; (b) (6) @cdc.gov>
Cc: (b) (6) @fda.hhs.gov>; (b) (6) @fda.hhs.gov>; (b) (6) @fda.hhs.gov>; (b) (6) (CDC) (b) (6) @cdc.gov>; (b) (6) (CDC) (b) (6) @cdc.gov>
Subject: RE: Weekly data mining

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/22/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: (b) (6)
To: (b) (6) (CDC); (b) (6) (CDC)
Cc: (b) (6) (CDC); (b) (6) (CDC)
Subject: RE: Weekly data mining
Date: Tuesday, November 2, 2021 12:09:29 PM
Attachments: [USST_20211029.xls](#)

Hi (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/29/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211029	US Serious EB05 20211029	US Fatal EB05 20211029	US Infant EB05 20211029	US Child EB05 20211029	US Teen EB05 20211029	US Adult1 EB05 20211029	US Adult2 EB05 20211029	US Adult3 EB05 20211029	US Female EB05 20211029	US Male EB05 20211029	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	2 153	1 861	0	0	0	0 596	1 611	1 911	1 761	2 291	1 453	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	2 203	1 784	0	0	0	0	1 639	1 639	1 625	1 625	1 453	
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1 951	1 312	0	0	0	0 467	1 25	1 793	1 763	2 201	1 536	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	3 059	2 083	0	0	0	0	0 841	1 731	1 603	2 382	1 564	
COVID19 (COV D19 (JANSSEN))	Adverse event	2 054	1 084	0	0	0	0	0 997	0 684	0 72	1 599	1 436	
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1 933	1 327	0	0	0	0	1 901	1 533	1 533	3 377	1 092	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3 034	2 206	0	0	0	0 499	2 273	2 061	2 061	4 396	1 354	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2 188	1 691	0	0	0	0	1 731	1 603	1 603	3 342	1 368	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2 544	1 949	0	0	0	0	1 713	2 5	2 5	2 781	2 056	
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	1 911	1 663	0	0	0	0	1 313	2 417	1 022	2 318	1 301	
COVID19 (COV D19 (JANSSEN))	Anion gap increased	1 911	1 663	0	0	0	0	1 313	2 417	1 022	2 318	1 301	
COVID19 (COV D19 (JANSSEN))	Arterioogram carotid abnormal	1 919	1 224	0	0	0	0	1 118	1 179	1 179	1 356	1 493	
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1 886	1 591	0	0 609	0	0	1 239	2 441	1 579	2 299	1 229	
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1 719	1 542	0	0 608	0	0	1 292	2 276	1 363	2 09	1 189	
COVID19 (COV D19 (JANSSEN))	Blood albumin decreased	1 765	1 253	0	0	0	0	1 504	1 812	1 521	2 075	1 25	
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1 919	1 486	0	0	0	0	1 43	2 254	1 728	2 244	1 466	
COVID19 (COV D19 (JANSSEN))	Blood chloride increased	1 993	1 539	0	0	0	0	1 439	2 252	1 768	2 38	1 351	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3 517	2 66	0	0	0	0	1 852	2 44	0 738	4 604	1 073	
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1 889	1 633	0	0	0	0	1 166	2 144	1 545	2 602	1 094	
COVID19 (COV D19 (JANSSEN))	Blood urea decreased	1 745	1 607	0	0	0	0	1 401	2 055	1 241	2 059	0 92	
COVID19 (COV D19 (JANSSEN))	COVID-19 pneumonia	1 915	1 326	0	0	0	0	1 338	1 762	1 762	1 676	1 676	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2 655	2 194	0	0	0	0	1 687	2 6	1 159	2 37	2 15	
COVID19 (COV D19 (JANSSEN))	Cerebral hemorrhage	2 306	1 863	0	0	0	0 523	2 049	1 915	1 443	3 456	1 098	
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2 55	1 961	0	0	0	0 538	1 291	1 268	1 268	0 995	0 971	
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2 113	1 537	0	0	0	0	1 123	1 189	1 358	2 497	1 04	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3 489	2 496	0	0	0	0	2 672	2 562	0 825	4 162	2 229	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2 749	1 987	0	0 611	0	0	2 375	2 48	2 271	3 618	1 773	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head normal	2 03	1 562	0	0	0	0	1 409	2 036	1 759	2 036	1 562	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2 144	1 636	0	0	0	0	1 494	2 172	2 063	2 473	1 64	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax normal	2 605	1 872	0	0	0	0	1 466	2 176	2 273	3 254	3 227	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2 605	1 872	0	0	0	0	1 466	2 176	2 273	3 254	3 227	
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	1 785	1 491	0	0	0	0	1 296	1 45	1 121	1 45	1 121	
COVID19 (COV D19 (JANSSEN))	Feeling cold	1 785	0 784	0	0	0	0	2 001	1 504	1 084	1 894	1 448	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2 295	1 293	0	0	0	0	3 777	2 208	2 089	1 924	2 543	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1 915	1 212	0	0 611	0	0	1 692	2 141	1 983	2 483	1 683	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1 953	0 994	0	0	0	0	1 707	1 971	1 824	2 224	1 824	
COVID19 (COV D19 (JANSSEN))	Fluoxetine present	2 356	1 038	0	0	0	0	2 288	1 79	1 136	2 621	1 448	
COVID19 (COV D19 (JANSSEN))	Guillain-Barre syndrome	1 297	1 894	0	0	0	0	1 399	2 84	1 742	2 162	1 023	
COVID19 (COV D19 (JANSSEN))	Haemoglobin decreased	1 831	1 372	0	0	0	0	1 372	2 118	1 689	2 226	1 339	
COVID19 (COV D19 (JANSSEN))	Haemoglobin increased	1 767	0 898	0	0	0	0 433	1 447	2 023	1 59	1 347	1 098	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5 66	3 695	0	0	0	0	4 027	4 858	6 152	7 14	2 473	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6 814	3 509	0	0	0	0 549	5 092	5 536	6 666	7 529	1 388	
COVID19 (COV D19 (JANSSEN))	Hypoxia	1 79	0 863	0	0	0	0	1 254	1 788	1 611	1 236	1 512	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2 073	1 941	0	0	0	0	1 874	2 479	1 654	2 217	1 667	
COVID19 (COV D19 (JANSSEN))	Intensive care	1 787	1 422	0	0	0	0	1 404	1 978	1 906	2 186	1 382	
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1 831	1 312	0	0	0 746	0	1 382	1 626	1 382	1 626	1 382	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1 905	1 225	0	0	0	0	1 367	1 945	2 038	1 904	1 205	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2 149	2 006	0	0	0	0	1 599	1 139	0 744	2 78	0 785	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1 8	1 037	0	0	0	0	1 251	1 261	1 098	1 173	1 173	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	2 039	1 797	0	0	0	0	2 342	1 987	1 173	1 497	1 785	
COVID19 (COV D19 (JANSSEN))	Lymphocyte percentage decreased	1 598	1 243	0	0	0	0	1 037	2 042	1 616	2 002	1 137	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2 186	1 738	0	0	0 611	0	1 811	1 937	1 937	2 539	1 605	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head normal	2 052	1 483	0	0	0	0	1 465	1 989	1 427	1 427	1 427	
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1 788	1 075	0	0	0	0	1 351	1 031	2 226	2 127	1 064	
COVID19 (COV D19 (JANSSEN))	Mechanical ventilation	2 055	1 533	0	0	0 61	0	1 496	2 061	1 654	1 968	1 645	
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1 596	1 586	0	0	0	0	1 324	0 864	0 864	1 022	1 022	
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1 616	1 348	0	0	0	0	1 222	1 839	1 342	0 818	1 018	
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage increased	1 645	1 267	0	0	0	0	1 138	2 011	1 594	1 899	1 256	
COVID19 (COV D19 (JANSSEN))	Off label use	1 449	0 216	0	0	0	0	5 946	0 324	0 471	0 911	1 253	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1 746	0 757	0	0	0	0	3 03	0 998	0 998	2 15	1 473	
COVID19 (COV D19 (JANSSEN))	Pain assessment	2 582	0 876	0	0	0	0 524	1 782	2 289	1 165	2 634	1 473	
COVID19 (COV D19 (JANSSEN))	Peripneumonia	3 51	1 765	0	0	0	0	0 666	1 058	2 671	2 482	0 974	
COVID19 (COV D19 (JANSSEN))	Platelet count	2 735	2 489	0	0 611	0	0	1 886	3 113	1 789	3 13	1 811	
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1 848	1 405	0	0 609	0	0	1 563	2 027	1 463	2 161	1 415	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2 762	2 085	0	0	0	0	2 095	3 1	2 302	3 484	1 7	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5 998	3 519	0	0	0	0	4 363	3 241	0 685	6 13	1 931	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1 205	1 577	0	0	0 744	0	4 019	3 183	0 153	4 622	3 771	
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1 945	1 426	0	0	0	0	1 521	2 337	1 598	2 523	1 375	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2 246	1 679	0	0 612	0	0	1 667	2 164	2 68	2 577	1 63	
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2 084	1 552	0	0	0	0	1 53	1 473	2 101	1 91	1 664	
COVID19 (COV D19 (JANSSEN))	Red blood cell count decreased	2 189	1 402	0	0	0	0 637	1 515	2 147	1 571	2 102	1 664	
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	2 021	1 434	0	0 609	0	0	1 35	2 183	1 646	2 41	1 249	
COVID19 (COV D19 (JANSSEN))	Subarachnoid hemorrhage	1 73	1 171	0	0	0	0	1 615	1 074	0 899	2 082	0 809	
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2 227	1 169	0	0	0	0	1 374	1 776	1 416	1 676	1 735	
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1 66	1 351	0	0	0	0	1 132	0 826	0 648	2 785	0 67	
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	3 245	2 722	0	0	0	0	1 807	1 99	3 229	2 73	3 154	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	7 038	0 797	0	0	0	0	3 617	6 722	15 126	7 93	5 962	
COVID19 (COV D19 (JANSSEN))	Therapy partial responder	2 207	1 491	0	0	0	0	0 634	0 577	0 577	0 569	1 025	
COVID19 (COV D19 (JANSSEN))	Thrombectomy	2 134	1 701	0	0	0	0	1 432	1 665	1 256	1 385	1 385	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2 843	2 013	0	0	0	0	1 788	2 351	1 672	2 637	1 634	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2 862	2 18	0	0 612	0	0	2 019	3 396	3 647	2 869	2 159	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2 302	1 947	0	0</								

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: RE: Weekly data mining
Date: Tuesday, November 9, 2021 8:33:48 AM
Attachments: [USST_20211105.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 11/5/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211105	US Serious EB05 20211105	US Fatal EB05 20211105	US Infant EB05 20211105	US Child EB05 20211105	US Teen EB05 20211105	US Adult1 EB05 20211105	US Adult2 EB05 20211105	US Adult3 EB05 20211105	US Female EB05 20211105	US Male EB05 20211105	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,627	1,627	0.862				0.355	1,525	1,970	1,671	2,121	3,207
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,777	1,841	0.863					1,673	2,295	2,074	2,178	4,478
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,972	1,32	0.961				0.462	1,283	1,778	1,819	2,275	1,534
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,978	0,078	0.875					0,721	2,362	0,722	1,532	1,332
COVID19 (COVID19 (JANSSEN))	Adverse event	2,052	0,992	0.876					0,945	0,745	1,633	1,633	1,888
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,896	1,312	0.903					1,495	1,346	1,512	2,345	1,085
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,05	2,202	0.89				0.498	2,245	2,062	3,44	4,433	1,362
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,202	1,672	0.897					1,779	1,822	1,192	1,336	1,332
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,534	1,931	0.888					1,714	2,492	2,764	2,059	1,085
COVID19 (COVID19 (JANSSEN))	Arion gap decreased	1,914	1,657	0.887					1,289	2,463	1,041	2,35	1,295
COVID19 (COVID19 (JANSSEN))	Arthralgia	2,36	0,872	0.888					0,888	1,738	1,863	2,108	1,085
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,238	1,656	0.888	0.612				1,869	2,011	2,522	2,855	1,628
COVID19 (COVID19 (JANSSEN))	Areflexia	2,12	1,948	0.878					0,899	1,917	1,527	1,84	1,548
COVID19 (COVID19 (JANSSEN))	Atherosclerotic carotid abnormal	1,956	1,244	0.878				1,181	1,18	1,416	2,702	0,93	1,085
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,955	1,651	0.877	0.609			0.335	1,202	2,585	1,711	2,37	1,29
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,751	1,559	0.874	0.608			0.292	1,271	2,34	1,438	2,149	1,202
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,755	1,28	0.875				0.333	1,472	1,785	1,562	2,114	1,22
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,946	1,502	0.886					1,421	2,273	1,819	2,304	1,475
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	2,02	1,565	0.897				0.452	1,439	2,271	1,963	2,438	1,36
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3,412	2,595	0.885				0.51	1,857	2,118	0,738	4,416	1,075
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,839	1,559	0.888				0.28	1,179	2,087	1,507	2,579	1,046
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,712	1,544	0.87				0.217	1,359	2,02	1,296	2,064	0,877
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1,762	1,299	0.872					1,042	1,904	1,527	2,016	1,394
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	1,938	1,334	1,067					1,322	1,818	1,812	2,028	1,692
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,708	2,215	0.872					1,673	2,737	1,162	2,403	2,212
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,328	1,867	0.918				0.521	2,143	1,869	1,492	3,32	1,108
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,364	1,86	0.893				0.537	1,256	1,23	0,997	2,863	0,959
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,106	1,527	0.873					1,124	1,201	1,362	2,471	1,041
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,402	2,432	0.899				0.523	2,534	2,455	0,822	4,118	1,193
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head abnormal	2,732	1,939	0.893	0.611			0.635	2,088	3,732	2,452	1,743	1,085
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head normal	2,026	1,492	0.896					1,692	2,018	1,768	2,245	1,516
COVID19 (COVID19 (JANSSEN))	Computerized tomogram thorax abnormal	2,116	1,605	0.907				0.462	1,502	2,125	2,056	2,437	1,63
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,814	1,891	0.866					1,001	2,278	2,814	2,937	1,085
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,817	1,505	0.871					1,268	2,363	1,516	2,133	1,212
COVID19 (COVID19 (JANSSEN))	Feeling cold	1,779	0,802	0.872				1,131	2,003	1,495	0,992	1,883	1,414
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,278	1,691	0.861					2,207	2,617	1,847	1,547	1,085
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,156	1,512	0.705	0.611			0.33	1,705	2,327	2,585	2,212	1,485
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,93	0,997	0.873					1,696	1,931	0,75	2,194	1,182
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,329	1,02	0.88					2,278	2,174	1,131	1,429	1,085
COVID19 (COVID19 (JANSSEN))	Glaucoma increased	1,857	1,382	0.843					1,373	1,514	1,499	2,014	1,219
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1,756	1,261	0.862					1,171	1,244	1,39	2,046	1,047
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2,302	1,802	0.872					1,394	1,784	2,062	2,062	1,085
COVID19 (COVID19 (JANSSEN))	Haematocrit decreased	1,833	1,366	0.896	0.606			0.426	1,37	2,108	1,72	2,238	1,345
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,755	1,303	0.897	0.607			0.327	1,423	1,98	1,595	2,088	1,336
COVID19 (COVID19 (JANSSEN))	Hepatitis-induced thrombocytopenia test	5,605	4,688	0.864					4,841	6,011	4,688	5,605	1,085
COVID19 (COVID19 (JANSSEN))	Hepatitis-induced thrombocytopenia test positive	6,836	3,516	0.874				0.547	5,116	6,065	5,553	1,389	1,085
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,803	1,234	0.89					1,312	1,798	1,612	2,08	1,405
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,074	1,631	0.875				0.019	1,872	2,504	1,651	1,881	1,085
COVID19 (COVID19 (JANSSEN))	Intensive care	1,791	1,414	1,01				0.029	1,408	1,948	1,959	2,207	1,085
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,834	1,315	0.882	0.746			0.395	1,639	1,888	1,425	2,378	1,23
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,922	1,415	0.879					1,416	1,935	0,899	1,197	1,085
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,104	1,661	0.874					1,602	1,122	0,744	2,831	0,755
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,897	1,531	0.871					1,231	2,162	1,155	1,705	1,723
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,022	1,764	0.886					0,896	2,323	1,163	1,488	1,78
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,629	1,628	0.888				0.182	1,628	1,901	1,779	1,417	1,085
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,174	1,718	0.882				0.502	1,723	1,956	1,507	2,536	1,085
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,08	1,524	0.889	0.611			0.46	1,295	2,348	2,33	2,063	1,283
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin decreased	1,977	1,541	0.894					1,541	1,304	1,024	1,913	0,895
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,773	1,289	0.877					1,26	2,207	1,077	2,072	1,123
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,04	1,495	0.935				0.494	0,935	2,025	1,671	1,927	1,663
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,617	1,377	0.863	0.61				1,172	0,965	2,13	1,617	1,085
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,596	1,317	0.878					1,221	1,823	1,313	2,337	0,809
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,682	1,295	0.883				0.241	1,106	1,962	1,712	1,962	1,276
COVID19 (COVID19 (JANSSEN))	Off label use	1,387	0,872	0.867					0,869	0,298	0,361	0,929	1,236
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,752	0,758	0.959					0,509	0,998	2,172	1,085	1,085
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,575	0,874	0.874				0.517	1,767	2,297	1,169	2,631	1,469
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,393	1,716	0.874					0,656	1,059	2,063	2,544	0,966
COVID19 (COVID19 (JANSSEN))	Platelet count	2,752	2,503	0.922	0.61			0.483	1,86	3,158	1,786	3,136	1,837
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,855	1,406	0.893	0.609			0.291	1,595	2,019	1,466	2,187	1,411
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,73	2,087	0.888					2,087	3,09	2,201	3,661	1,683
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,018	3,523	0.875					4,382	3,335	0,685	6,151	1,933
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1,227		0.866					4,034	3,298	1,651	4,62	3,842
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1,55	1,586	0.903	0.744			0.326	1,514	2,321	1,53	2,548	1,379
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,246	1,879	0.883	0.612				1,697	2,15	2,68	2,581	1,829
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2,046	1,532	0.883					1,546	1,453	1,887	2,066	1,661
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1,885	1,382	0.88				0.528	1,486	2,137	1,602	2,119	1,486
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	2,043	1,44	0.884	0.609			0.356	1,307	2,291	1,609	2,458	1,264
COVID19 (COVID19 (JANSSEN))	Subarachnoid haemorrhage	1,736	1,176	0.959					1,698	1,056	0,901	2,206	0,787
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2,262	1,2	0.879				0.538	1,486	1,78	1,377	1,957	1,749
COVID19 (COVID19 (JANSSEN))	Superior sagittal sinus thrombosis	1,655	1,369	0.875					1,132	0,827	0,847	2,857	0,67
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	3,215	2,643	1,727				0.531	1,892	2,334	1,206	2,677	3,109
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	7,077	0,797	0.875				0.647	3,642	6,746	15,322	8,003	5,996
COVID19 (COVID19 (JANSSEN))	Therapy partial responder	2,295		0.869					0,635	0,635	0,635	0,635	1,025
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2,116	1,675	0.886					1,416	1,656	2,27	1,384	1,346
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2,374	2,044	0.916				0.39	1,846	2,378	1,688	2,817	1,701
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,464	1,964	0.871	0.612				2,007	2,608	1,959	2,616	1,085
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,255	1,907	0.874					1,974	1,224	0,644	2,402	0,904
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,397	1,445	0.893				0.648	1,928	2,165	2,371	2,786	1,66
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	1,971	1,752	0.892	0.612			0.504	1,752	2,388	2,299	2,924	1,153
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,53	1,811	0.881					2,484	1,983	1,777	1,805	1,085
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,933	1,152	0.875					1,358	2,078	1,782	2,056	1,263
COVID19 (COVID19 (JANSSEN))	Urobilinogen urine increased	1,673	1,087	0.876	0.611			0.309	0,86	1,087	1,291	1,485	1,085
COVID19 (COVID19 (JANSSEN))	Vaccination failure												

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: RE: Weekly data mining
Date: Tuesday, November 16, 2021 6:48:39 AM
Attachments: [USST_20211112.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 11/12/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211112	US Serious EB05 20211112	US Fatal EB05 20211112	US Infant EB05 20211112	US Child EB05 20211112	US Teen EB05 20211112	US Adult1 EB05 20211112	US Adult2 EB05 20211112	US Adult3 EB05 20211112	US Female EB05 20211112	US Male EB05 20211112	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,159	1,604	0.895			0.592	1,192	2,063	1,558			
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	2,254	1,804	0.892				1,646	2,268	2,087		3,072	1,466
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1,976	1,314	0.962			0.458	1,303	1.8	1.81		2,273	1,549
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2,952	0,683	0.897				0,697	0,717	0,689		2,205	1,557
COVID19 (COV D19 (JANSSEN))	Adverse event	2,048	1,684	0.886				1,608	0,718	0,631		2,036	1,416
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1,89	1.3	0.904				1,468	1,378	1,495		2,328	1,078
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3,01	2,172	0.901			0.497	2,266	2,068	3,255		4,336	1,407
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	1,933	1,644	0.88				1,753	1,863	1,976		2,362	1,362
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,544	1,931	0.895				1,748	2,437	2,852		2,852	2,037
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	1,905	1,647	0.896				0.398	1,241	2,455		1,121	1,327
COVID19 (COV D19 (JANSSEN))	Antibody test	2,348	0.895	0.86				0.572	0.899	1.75		1,831	1,086
COVID19 (COV D19 (JANSSEN))	Arthrocentesis	2,218	1,633	0.898	0.612			0.432	1,858	1,998		2,466	1,619
COVID19 (COV D19 (JANSSEN))	Areflexia	2,162	1,975	0.892				0.892	2,027	1,509		1,824	1,544
COVID19 (COV D19 (JANSSEN))	Atrioagram carotid abnormal	1,976	1,292	0.893				1,295	1,164	1,423		2,559	1,081
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1,948	1,623	0.886	0.609			0.329	1,216	2,597		1,436	1,243
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1,819	1,608	0.887	0.608			0.291	1,291	2,356		1,818	1,257
COVID19 (COV D19 (JANSSEN))	Blood albumin decreased	1,755	1,271	0.884				0.333	1,478	1,773		1,578	1,237
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1,949	1,496	0.896				0.4	1,423	2,262		1,843	1,485
COVID19 (COV D19 (JANSSEN))	Blood chloride increased	2,043	1,579	0.908				0.451	1,417	2,288		1,956	1,399
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	1,939	2,891	0.894				0.509	1,863	2,817		0.83	4,888
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1,841	1,529	0.901				0.263	1,204	2.05		1,514	1,05
COVID19 (COV D19 (JANSSEN))	Blood urea decreased	1,79	1,641	0.88				0.215	1,389	2,101		1,508	1,139
COVID19 (COV D19 (JANSSEN))	Blood urea increased	1,784	1,215	0.878				1,073	1,967	1,508		2,021	1,43
COVID19 (COV D19 (JANSSEN))	COVID-19 pneumonia	1,971	1,349	1.337				1,404	1,846	1,846		2,033	1,747
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,698	2,192	0.88				1,676	2,772	1,147		2,343	2,234
COVID19 (COV D19 (JANSSEN))	CSF red blood cell count positive	2,019	1,763	0.88				1,227	1,827	1,627		1,576	1,483
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2,324	1,849	0.904			0.521	1,849	2,08	1,867		1,465	1,539
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2,636	1,988	0.916				1,326	1,228	1.11		1,326	0,96
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2,155	1,582	0.882				1,125	1.25	1,353		2,647	1,031
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	2,019	2,442	0.916			0.522	2,442	2,404	1,815		1,179	1,179
COVID19 (COV D19 (JANSSEN))	Computerized tomogram head abnormal	2,737	1,958	0.961	0.611			0.636	2,382	2,434		3,637	1,754
COVID19 (COV D19 (JANSSEN))	Computerized tomogram head normal	2,02	1,469	0.901				0.397	1,674	2,007		1,803	2,227
COVID19 (COV D19 (JANSSEN))	Computerized tomogram thorax abnormal	2,114	1,916	0.914				0.456	1,482	2,119		2,119	1,823
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,604	1,873	0.97				0.456	2,159	2,321		3,232	2,034
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	1,838	1,504	0.889				1,302	2,348	1,552		2,175	1,219
COVID19 (COV D19 (JANSSEN))	Eosinophil percentage decreased	1,985	1,868	0.89			0.301	1,868	2,041	1,964		2,161	1,295
COVID19 (COV D19 (JANSSEN))	Feeling cold	1,78	0,836	0.887	0.61			1,117	1.49	1.81		1,881	1,425
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,291	1,323	0.885				0.372	2.17	2,127		2,019	1,867
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,983	1,403	0.893	0.611			0.325	1,478	1,897		2,217	1,404
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1,964	1,021	0.881				0.425	1,731	1,961		2,19	1,253
COVID19 (COV D19 (JANSSEN))	Galactosemia	2,297	1,015	0.887				0.416	2,258	1,752		1,13	2,894
COVID19 (COV D19 (JANSSEN))	Galactose increased	1,948	0,893	0.886				0.398	1,406	1,616		1,134	1,294
COVID19 (COV D19 (JANSSEN))	Glucose urine present	1,764	1,255	0.893				1.16	1,286	1,371		2,096	1,037
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	2,289	1,872	0.879				1,478	2,869	1.75		2,129	2,995
COVID19 (COV D19 (JANSSEN))	Haemolysis decreased	1,841	1,605	0.904	0.607		0.426	1,357	1,762	2,227		1,364	1,364
COVID19 (COV D19 (JANSSEN))	Haemoglobin decreased	1,769	1,306	0.904				0.322	1,423	1,992		2,088	1,366
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,579	3,662	0.893				3,989	4,855	6,228		6,998	2,888
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,863	3,149	0.882			0.546	3,149	5,13	6,665		5,389	3,889
COVID19 (COV D19 (JANSSEN))	Hypoxia	1,836	1,248	0.9				1,357	1,817	1,817		2,172	1,396
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2,074	1,918	0.883			0.019	1,917	2,492	1,631		2,214	1,885
COVID19 (COV D19 (JANSSEN))	Intensive care	1,828	1,433	0.893			0.028	1,401	2,048	1,589		2,245	1,417
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1,855	1,322	0.894	0.746			0.397	1,625	1,941		1,433	1,22
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1,966	1,294	0.886				1,381	1,979	1,026		2,103	1,257
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,131	1,954	0.885				1,606	1,152	0,735		3,111	0,746
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1,896	1,532	0.876				1,532	1,558	1,704		1,723	1,179
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	2,005	1,731	0.887				0,887	2,317	1,167		1,515	1,753
COVID19 (COV D19 (JANSSEN))	Lymphocyte percentage decreased	1,657	1,278	0.886			0.179	1,03	2,089	1,807		2,103	1,137
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,157	1,688	0.889			0.453	1,771	2,497	1,817		2,497	1,593
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head normal	2,128	1,558	0.901	0.611			0.459	1,275	2,468		1,539	1,319
COVID19 (COV D19 (JANSSEN))	Mean cell haemoglobin decreased	1,863	1,24	0.885			0.339	1,028	2,098	1,113		1,918	0,922
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1,923	1,891	0.891			0.34	1,299	1,823	1,59		1,919	1,19
COVID19 (COV D19 (JANSSEN))	Mechanical ventilation	2,025	1,457	0.938			0.49	0.988	2,061	1.63		1,918	1,657
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1,619	1,371	0.893	0.61			0.256	0.985	1,982		2,507	1,037
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1,965	1,287	0.887			0.12	1,212	1.8	1,917		1,918	1,828
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage increased	1,711	1,307	0.891				0.24	1,133	2,057		1,749	1,881
COVID19 (COV D19 (JANSSEN))	Off label use	1,341	0,203	0.888			0.031	0,282	0,409	0,339		0,834	1,301
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1,751	0,768	0.887				0.989	3,089	2,186		1,166	1,219
COVID19 (COV D19 (JANSSEN))	Pain assessment	2,537	0,875	0.871			0.512	1,771	2,279	1,168		2,637	1,44
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3,38	1,71	0.882				0.656	1.06	2,091		2,581	0,967
COVID19 (COV D19 (JANSSEN))	Platelet count	2,768	2,804	0.912	0.61		0.483	1,864	3,159	1,941		3,155	1,841
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1,869	1,409	0.9	0.609			0.289	1,605	1,515		2,202	1,429
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,726	2,067	0.896			0.394	2,019	3,128	2,319		3,468	1,883
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	6,041	3,492	0.882				4,394	3,399	6,683		6,175	1,935
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1,259					0.869	4,014	3,383	5,896		4,534	3,831
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1,995	1,597	0.913	0.744		0.325	1,519	2,374	1,602		2,66	1,39
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2,239	1,669	0.917	0.612		0.584	1,68	2,154	2.65		2,565	1,833
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2,064	1,543	0.894				1,557	1,482	2,009		1,879	1,684
COVID19 (COV D19 (JANSSEN))	Red blood cell count decreased	1,917	1,413	0.891			0.527	1,475	2.19	1,663		2,137	1,545
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	2,082	1,469	0.899	0.609			0.355	1,321	2,321		1,701	1,319
COVID19 (COV D19 (JANSSEN))	Subarachnoid haemorrhage	1,761	1,199	0.886				0.546	1,657	0.884		2,301	0,779
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2,311	1,217	0.886				0.537	1.85	1,384		2,048	1,736
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1,583	1,242	0.881				0.546	1,132	0,827		2,	

From: (b) (6)
To: (b) (6); (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: RE: Weekly data mining
Date: Tuesday, November 23, 2021 3:14:28 PM
Attachments: [USST_20211119.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 11/19/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 2021119	US Serious EB05 2021119	US Fatal EB05 2021119	US Infant EB05 2021119	US Child EB05 2021119	US Teen EB05 2021119	US Adult EB05 2021119	US Female EB05 2021119	US Male EB05 2021119	Comment			
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time prolonged	2,244	1,555	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time shortened	2,229	1,769	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Acute respiratory failure	1,988	1,337	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Adverse drug reaction	2,869	2,085	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Adverse event	2,052	0,997	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Angiogram abnormal	1,84	1,374	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Angiogram cerebral abnormal	3,008	2,008	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Angiogram cerebral normal	1,715	0	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary abnormal	2,538	1,912	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Arterial gas decreased	1,883	597	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Antibody test	2,352	0,861	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Anticoagulant therapy	2,224	1,614	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Areflexia	1,134	0,943	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Arterogram carotid abnormal	2,021	1,299	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Basophil count decreased	1,569	1,619	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Basophil percentage decreased	1,817	1,583	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Blood albumin decreased	1,793	1,292	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Blood calcium decreased	1,995	1,498	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Blood chloride increased	2,079	1,608	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Blood fibrinogen decreased	3,39	2,633	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Blood magnesium increased	1,907	1,577	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Blood urea decreased	1,825	1,677	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Blood urea increased	1,613	1,227	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	COV D19 pneumonia	1,983	1,371	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	CSF protein increased	2,697	2,19	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	CSF total blood cell count positive	2,022	1,176	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Cerebral haemorrhage	2,333	1,855	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Cerebral mass effect	2,603	1,976	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Cerebral thrombosis	2,156	1,526	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Cerebral venous sinus thrombosis	3,302	2,318	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Computerized tomogram head abnormal	2,702	1,929	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Computerized tomogram head normal	2,022	1,603	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Computerized tomogram thorax abnormal	1,128	0,623	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Deep vein thrombosis	2,805	1,853	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Eosinophil count decreased	1,846	0,891	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Eosinophil percentage decreased	1,71	1,355	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Fasting glucose	1,778	1,183	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Fibrin D dimer	2,283	1,317	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Fibrin D dimer increased	2,182	1,502	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Fibrin D dimer normal	1,975	1,016	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Gaze palsy	1	1	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Globulins increased	1,943	1,478	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Glucose urine present	1,769	1,247	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Gullain-Barre syndrome	2,303	1,851	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Haemoptysis decreased	1,852	1,364	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Haemoglobin decreased	1,795	1,309	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Heparin-induced thrombocytopenia test	5,553	3,685	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Heparin-induced thrombocytopenia test positive	6,877	3,5	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Hypoxia	1,833	1,263	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Immunoglobulin therapy	2,077	1,906	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	International normalized ratio	1,824	1,409	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	International normalized ratio increased	1,877	1,355	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	International normalized ratio normal	2,011	1,308	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Jugular vein thrombosis	2,129	1,683	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Lumbar puncture	1,902	1,51	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Lumbar puncture abnormal	2,018	1,73	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Lymphocyte percentage decreased	1,677	1,088	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Magnetic resonance imaging head abnormal	2,176	1,706	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Magnetic resonance imaging head decreased	2,144	1,586	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin decreased	1,867	1,386	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin increased	1,842	1,354	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Mean platelet volume increased	2,048	1,501	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Mechanical ventilation	1,501	1,053	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Monocyte percentage increased	1,82	1,363	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Neutrophil percentage decreased	1,591	1,294	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Neutrophil percentage increased	1,732	1,317	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Non-specific reaction	2,181	0,723	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Off label use	1,335	0,315	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	On and off phenomenon	1,751	0,766	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Pain assessment	2,531	0,869	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Peripheral embolism	3,398	1,715	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Platelet count	2,775	2,016	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Platelet count decreased	1,874	1,407	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Platelet count normal	2,731	2,037	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Platelet factor 4	6,054	3,501	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Poor quality product administered	1,294	0	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Prothrombin time prolonged	2,028	1,619	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Pulmonary embolism	2,233	1,661	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Pulmonary thrombosis	2,071	1,574	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Red blood cell count decreased	1,182	1,409	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Red cell distribution width increased	2,076	1,454	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Subarachnoid haemorrhage	1,729	1,15	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Superficial vein thrombosis	2,418	1,354	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Superior sagittal sinus thrombosis	1,584	1,243	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Suspected COV D-19	5,322	2,571	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Therapy non-responder	7,084	0,796	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Therapy partial responder	2,351	0	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Thrombocytopenia	2,091	1,638	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Thrombocytopenia	2,351	1,973	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Thrombosis	2,674	2,137	0	0	0	0	0	0	0	0	0	0	
COVID19 (COV D19 (ANSEN))	Transverse sinus thrombosis	2,214	1,812											

From: (b) (6)
To: (b) (6) <(CDC)>; (b) (6) <(CDC)>
Cc: (b) (6) <(CDC)>; (b) (6) <(CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, November 30, 2021 6:30:27 AM
Attachments: [USST_20211126.xls](#)

Good morning (b) (6)

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 11/26/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211126	US Serious EB05 20211126	US Fatal EB05 20211126	US Infant EB05 20211126	US Child EB05 20211126	US Teen EB05 20211126	US Adult1 EB05 20211126	US Adult2 EB05 20211126	US Adults EB05 20211126	US Female EB05 20211126	US Male EB05 20211126	Comment
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time prolonged	2,222	1,922	0.903	0.891		0.394	1,591	2,228	2,032	2,331	2,454	
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time shortened	2,222	1,759	0.891				1,642	2,258	2,032	2,932	1,492	
COVID19 (COV D19) (ANSENSE)	Acute respiratory failure	2,001	1,361	0.979	0.979		0.455	1,323	1,944	1,888	2,356	1,842	
COVID19 (COV D19) (ANSENSE)	Adverse drug reaction	0.977	0.962	0.502	0.502		0.52	0.969	0.809	0.809	0.809	1,554	
COVID19 (COV D19) (ANSENSE)	Adverse event	2,052	0.985	0.885	0.767			0.965	0.767	1,625	1,625	1,471	
COVID19 (COV D19) (ANSENSE)	Angiogram abnormal	1,932	1,347	0.909				1,502	1,403	1,601	2,386	1,135	
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral abnormal	2,099	1,996	0.906	0.497			2,297	2,068	2,386	3,385	1,464	
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral normal	2,212	1,674	0.88				1,906	1,428	1,147	2,428	1,335	
COVID19 (COV D19) (ANSENSE)	Angiogram pulmonary abnormal	2,519	1,89	0.608	0.427			1,706	2,448	2,708	2,068	2,068	
COVID19 (COV D19) (ANSENSE)	Angiogram pulmonary normal	1,807	1,691	0.866				1,231	1,801	2,411	1,161	1,335	
COVID19 (COV D19) (ANSENSE)	Antibody test	2,353	0.856	0.877				0.887	1,752	1,906	2,154	1,875	
COVID19 (COV D19) (ANSENSE)	Anticoagulant therapy	2,228	1,599	0.965				1,853	1,99	2,45	2,809	1,84	
COVID19 (COV D19) (ANSENSE)	Areflexia	2,131	1,966	0.89		0.612		0.895	2,088	1,485	2,031	1,529	
COVID19 (COV D19) (ANSENSE)	Arteriogram carotid abnormal	1,976	1,275	0.879				1,204	1,17	1,05	2,94	0,945	
COVID19 (COV D19) (ANSENSE)	Basophil count decreased	1,947	1,605	0.901		0.61	0.329	1,204	2,027	1,716	2,422	1,901	
COVID19 (COV D19) (ANSENSE)	Basophil percentage decreased	1,817	1.59	0.89	0.609			1,282	2,352	1,679	2,224	1,304	
COVID19 (COV D19) (ANSENSE)	Blood albumin decreased	1,785	1,295	0.884				1,509	1,798	1,861	2,084	1,35	
COVID19 (COV D19) (ANSENSE)	Blood calcium decreased	1,994	1,496	0.904				1,459	1,399	2.27	1,807	1,544	
COVID19 (COV D19) (ANSENSE)	Blood chloride increased	2,078	1,606	0.913				1,412	2,382	2,004	2,482	1,478	
COVID19 (COV D19) (ANSENSE)	Blood fibrinogen decreased	3,564	2,618	0.852				1,865	2,615	0.813	4,599	1,133	
COVID19 (COV D19) (ANSENSE)	Blood fibrinogen increased	1,892	1,539	0.906				1,215	2,077	1,639	2,077	1,522	
COVID19 (COV D19) (ANSENSE)	Blood urea decreased	1,811	1,684	0.879	0.225			1,428	2,235	1,471	2,185	0,995	
COVID19 (COV D19) (ANSENSE)	Blood urea increased	1,817	1,233	0.884				1,059	2,012	1,56	2,022	1,487	
COVID19 (COV D19) (ANSENSE)	COV D-19 pneumonia	1,878	1,381	0.968				1,372	1,956	1,506	2,151	1,788	
COVID19 (COV D19) (ANSENSE)	CSF protein increased	2,722	2,204	0.877				1,739	2,906	1,134	2.42	2.29	
COVID19 (COV D19) (ANSENSE)	CSF red blood cell count positive	2,022	1,811	0.877				1,282	1,666	1,113	1,624	1,522	
COVID19 (COV D19) (ANSENSE)	Cerebral haemorrhage	2,336	1,845	0.929	0.519			1,906	1,931	1.54	3,606	1,008	
COVID19 (COV D19) (ANSENSE)	Cerebral mass effect	2,606	1.92	0.911	0.534			1,227	1,331	1,092	3,235	0,964	
COVID19 (COV D19) (ANSENSE)	Cerebral thrombosis	2,154	1,484	0.879				1,139	1,239	1,342	2,068	1,004	
COVID19 (COV D19) (ANSENSE)	Cerebral venous sinus thrombosis	3,306	2,299	0.916				2,245	2,335	0.82	3,906	1,175	
COVID19 (COV D19) (ANSENSE)	Computerised tomogram head abnormal	2,702	1,918	0.947	0.611			0.633	2,403	2,436	2,257	3,685	1,763
COVID19 (COV D19) (ANSENSE)	Computerised tomogram head normal	1,005	1,901	0.905				1,602	2,102	1,522	1,941	1,441	
COVID19 (COV D19) (ANSENSE)	Computerised tomogram thorax abnormal	2,121	1,591	0.921				1,481	1,921	2,147	2,147	1,876	
COVID19 (COV D19) (ANSENSE)	Computerised tomogram thorax normal	1,005	1,901	0.905				1,602	2,102	1,522	1,941	1,441	
COVID19 (COV D19) (ANSENSE)	Deep vein thrombosis	2,121	1,591	0.921				1,481	1,921	2,147	2,147	1,876	
COVID19 (COV D19) (ANSENSE)	Electrocardiogram head normal	1,851	1,488	0.885				1,456	2,244	3,241	2,017	1,761	
COVID19 (COV D19) (ANSENSE)	Eosinophil count decreased	1,851	1,488	0.885				1,284	1,895	2,326	1,65	1,268	
COVID19 (COV D19) (ANSENSE)	Eosinophil percentage decreased	1,707	1,358	0.886	0.61			1,265	2,06	1,487	2,074	1,274	
COVID19 (COV D19) (ANSENSE)	Fasting glucose	1,778	1,308	0.886				1,134	1,477	1,813	1,477	1,426	
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer	2,29	1,308	0.884				2,186	2,134	2,021	2,56	1,651	
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer increased	2,155	1.49	0.916	0.611			1,693	2,329	2,178	2,504	1,546	
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer normal	1,917	0.913	0.878				1,428	1,862	1,682	2,225	1,225	
COVID19 (COV D19) (ANSENSE)	Gaze palsy	2,276	1,019	0.884				2,281	1,723	2,525	1,121	1,434	
COVID19 (COV D19) (ANSENSE)	Glucosuria increased	1,928	1,442	0.892	0.4			1,482	1,554	1,64	2,096	1,293	
COVID19 (COV D19) (ANSENSE)	Glucose urine present	1,768	1.24	0.892	0.29			1,298	1,892	1.29	1,84	1,49	
COVID19 (COV D19) (ANSENSE)	Guillain-Barre syndrome	2,317	1,844	0.916				1,402	1,758	2,151	2,228	1,215	
COVID19 (COV D19) (ANSENSE)	Haemagglutination decreased	1,849	1,368	0.891	0.607		0.425	1,386	2,117	1,79	2,224	1,434	
COVID19 (COV D19) (ANSENSE)	Haemoglobin decreased	1,769	1,315	0.906	0.607			1,451	2,027	1,498	2,468	1,498	
COVID19 (COV D19) (ANSENSE)	Heparin-induced thrombocytopenia test	5,558	3,684	0.895				3,966	4,998	6,279	7,059	2,873	
COVID19 (COV D19) (ANSENSE)	Heparin-induced thrombocytopenia test positive	6,887	3,647	0.879	0.544			3,201	5,011	7,648	6,662	2,873	
COVID19 (COV D19) (ANSENSE)	Hypoxia	1,843	1.3	0.914				1,373	1,932	1,722	2,227	1,911	
COVID19 (COV D19) (ANSENSE)	Immunoglobulin therapy	2,09	1,912	0.88				1,939	2,567	1.61	1,726	1,726	
COVID19 (COV D19) (ANSENSE)	Intensive care	1,421	1,421	0.89				1.4	0.29	2,908	2,34	1,443	
COVID19 (COV D19) (ANSENSE)	International normalised ratio increased	1,877	1,347	0.892	0.746			1,636	2,016	1,472	2,501	1,277	
COVID19 (COV D19) (ANSENSE)	International normalised ratio normal	2,013	1,336	0.883				1,399	2,082	1,018	2,212	1,253	
COVID19 (COV D19) (ANSENSE)	Jugular vein thrombosis	1,927	1,306	0.892				1,662	1,994	2,047	2,747	1,443	
COVID19 (COV D19) (ANSENSE)	Lumbar puncture	1,902	1,489	0.875				2,166	1,705	1,12	1,735	1,732	
COVID19 (COV D19) (ANSENSE)	Lumbar puncture abnormal	2,015	1,727	0.901				0.871	2,441	1,147	1,487	1,818	
COVID19 (COV D19) (ANSENSE)	Lymphocyte percentage decreased	1,927	1,474	0.926	0.184			1,063	1,905	1,693	1.29	1,621	
COVID19 (COV D19) (ANSENSE)	Magnetic resonance imaging head abnormal	2,172	1.69	0.885	0.488			1,943	2,528	2,328	1,605	1,605	
COVID19 (COV D19) (ANSENSE)	Magnetic resonance imaging head normal	1,847	1,571	0.897	0.611			1,456	2,402	2,448	1,712	1,415	
COVID19 (COV D19) (ANSENSE)	Mean cell haemoglobin concentration decreased	1,887	1,469	0.884				1,335	1,849	2,065	1,239	0,975	
COVID19 (COV D19) (ANSENSE)	Mean cell haemoglobin increased	2,147	1,439	0.897				1,317	2,336	2,191	1,356	1,282	
COVID19 (COV D19) (ANSENSE)	Mean platelet volume increased	2,052	1,471	0.894				1,471	2,024	2,189	1,658	1,716	
COVID19 (COV D19) (ANSENSE)	Mechanical ventilation	1,859	1,354	0.892	0.61			0.86	1,984	2,434	1,08	1,08	
COVID19 (COV D19) (ANSENSE)	Monocyte percentage increased	1,609	1,318	0.886				1,196	1,812	1,493	1,871	0,894	
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage decreased	1,732	1,325	0.897				1,151	1,698	2.38	1,627	1,374	
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage increased	2,189	0.724	0.882				0.761	0.81	1,602	1,027	0,898	
COVID19 (COV D19) (ANSENSE)	Off label use	1,399	0.901	0.887	0.614			0.276	0.84	0.4	0.85	1.24	
COVID19 (COV D19) (ANSENSE)	On and off phenomenon	1,763	0.799	0.899				3,198	1,802	2.16	1,828	1,16	
COVID19 (COV D19) (ANSENSE)	Pain assessment	2,535	0.869		0.51			1,746	2,297	2,59	1,144	1,433	
COVID19 (COV D19) (ANSENSE)	Peripheral embolism	3,372	1,709	0.879				0.656	1,863	2,144	2,621	0,969	
COVID19 (COV D19) (ANSENSE)	Platelet count	2,779	2,044	0.921	0.61			1,845	3,129	3,109	3,109	1,967	
COVID19 (COV D19) (ANSENSE)	Platelet count decreased	1,886	1,414	0.901	0.609			0.292	1,574	2,101	1,543	2,202	1,483
COVID19 (COV D19) (ANSENSE)	Platelet count normal	2,707	2.03	0.894				0.39	2,004	3,142	3.43	1,689	
COVID19 (COV D19) (ANSENSE)	Platelet factor 4	3,005	0.605	0.88				4,447	0.682	6,229	1,944	1,944	
COVID19 (COV D19) (ANSENSE)	Poor quality product administered	1,303			0.958			4,016	3,414	5.92	4.57	3.94	
COVID19 (COV D19) (ANSENSE)	Profilamin time prolonged	2,037	1,617	0.914	0.746			1,562	2,488	1,614	2,681	1,461	
COVID19 (COV D19) (ANSENSE)	Pulmonary embolism	2,237	1,666	0.912	0.612			1,703	2.15	2.73	2,567	1,855	
COVID19 (COV D19) (ANSENSE)	Pulmonary thrombosis	2,069	1,563	0.894				1,588	1.53	1,939	1,945	1,724	
COVID19 (COV D19) (ANSENSE)	Red blood cell count decreased	1,902	1,402	0.895	0.606			1.48	2,181	1,684	2.12	1,578	
COVID19 (COV D19) (ANSENSE)	Red cell distribution width increased	2,061	1,456	0.904	0.61			0.352	1,319	2,276	2,478	1,362	
COVID19 (COV D19) (ANSENSE)	Subarachnoid haemorrhage	1,73	1,132	1.426				0.544	1.52	1.05	0.972	0.782	
COVID19 (COV D19) (ANSENSE)	Superficial vein thrombosis	2.42	1.36	0.935				0.935	1.678	1.522	2.34	1,753	
COVID19 (COV D19) (ANSENSE)	Superior sagittal sinus thrombosis	1,585	1,206	0.877				0.134	0.828	2,096	0.645	0.67	
COVID19 (COV D19) (ANSENSE)	Suspected COV D-19	3,231	2.56	1.617				0.529	1,898	2,835	1,196	2,835	
COVID19 (COV D19) (ANSENSE)	Therapy non-responder	7,026	0.796	0.88				0.645	3,244	0.84	6,782	1,691	
COVID19 (COV D19) (ANSENSE)	Therapy partial responder	2,375			0.89			0.514	1,413	0.635	0.568	1,026	
COVID19 (COV D19) (ANSENSE)	Thrombocytopenia	2,104	1,616	0.926				1,724	2,443	1,783	2,643	1,771	
COVID19 (COV D19) (ANSENSE)	Thrombosis	2,677	2,131	1.807	0.612			1,965	2,362	3,479	2,822	2,166	
COVID19 (COV D19) (ANSENSE)	Tamoxifen sinus thrombosis	2,216	1,912	0.879				1,776	1,219	0.642	2,121	0,907	
COVID19 (COV D19) (ANSENSE)	Ultrasound Doppler	2,434	1.47	0.899	0.646			1,903	2,185	2.5			

From: (b) (6)
To: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Cc: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, December 7, 2021 6:23:13 AM
Attachments: [USST_20211203.xls](#)

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/3/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211203	US Serious EB05 20211203	US Fatal EB05 20211203	US Infant EB05 20211203	US Child EB05 20211203	US Teen EB05 20211203	US Adult1 EB05 20211203	US Adult2 EB05 20211203	US Adult3 EB05 20211203	US Female EB05 20211203	US Male EB05 20211203	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,607	1,51		0.95		0.596	1,607	1,607	1,607	1,607	1,607	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,227	1,758		0.69			1,681	2,217	2,081	2,081	2,081	
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	2,001	1,333		0.978		0.457	1,361	1,931	1,831	1,831	1,831	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,865	2,088		0.82		0.52	0,860	1,520	1,449	1,449	1,449	
COVID19 (COVID19 (JANSSEN))	Adverse event	2,047	1,007		0.886			0,954	0,716	0,812	0,812	0,812	
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,946	1,325		0.909			1,377	1,393	1,628	1,628	1,628	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,972	2,158		0.902		0.493	2,478	2,177	2,1	3,242	4,282	1,494
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,212	1,817		0.881			1,624	1,89	1,14	1,449	1,449	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,501	1,859		0.906		0.427	1,713	2,412	2,418	2,749	2,047	
COVID19 (COVID19 (JANSSEN))	Angion gap decreased	1,816	1,486		0.898		0.371	1,192	2,322	1,155	2,17	1,305	
COVID19 (COVID19 (JANSSEN))	Antibody test	2,367	0,849		0.876			0,564	0,884	1,773	2,095	1,896	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,228	1,585		0.954	0.612	0.433	1,864	1,987	2,407	2,787	1,646	
COVID19 (COVID19 (JANSSEN))	Arrhythmia	2,117	1,94		0.887			0,897	2,063	1,461	2,013	1,52	
COVID19 (COVID19 (JANSSEN))	Arteriogram carotid abnormal	1,976	1,27		0.979			1,205	1,172	1,545	2,946	0,946	
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,919	1,551		0.891	0.61	0.332	1,206	2,547	1,672	2,375	1,298	
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,811	1,564		0.893	0.609	0.298	1,298	2,336	1,834	2,18	1,332	
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,604	1,307		0.899		0.336	1,533	1,873	1,631	2,111	1,376	
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,96	1,482		0.904		0.403	1,487	2,263	1,873	2,31	1,554	
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	2,053	1,574		0.915		0.458	1,416	2,371	1,942	2,447	1,484	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3,51	2,967		0.92		0.505	1,869	2,604	0,797	4,477	1,129	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen increased	1,818	1,583		0.886		0.333	1,051	2,102	0,954	1,669	1,323	
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,917	1,536		0.916		0.279	1,222	2,138	1,646	2,533	1,207	
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,803	1,661		0.877		0.231	1,421	2,222	1,454	2,195	0,98	
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1,815	1,232		0.889			1,109	2,027	1,564	1,993	1,544	
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	1,977	1,393		1,387			1,438	2,028	1,9	2,186	1,819	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,737	2,191		0.877			1,806	2,926	1,113	2,379	2,304	
COVID19 (COVID19 (JANSSEN))	CSF red blood cell count positive	2,04	1,768		0.876			1,364	1,67	1,113	1,691	1,507	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,333	1,829		0.923	0.52	1,94	1,923	1,932	1,532	3,557	1,114	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,606	1,916		0.911		0.534	1,228	1,333	1,09	3,281	0,964	
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,154	1,446		0.879			1,1	1,879	1,331	1,676	1,046	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,295	2,289		0.916	0.611	0.521	2,252	2,341	3,919	1,173	1,708	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,676	1,889		0.847		0.636	2,426	2,412	2,206	3,519	1,768	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head normal	2,608	1,421		0.892		0.396	1,002	2,007	1,777	2,19	1,516	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,109	1,577		0.917		0.461	1,454	2,133	2,149	2,446	1,768	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,613	1,834		1,007		0.458	2,143	2,293	3,139	3,247	2,014	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis decreased	1,839	1,454		0.886			1,274	2,34	1,607	2,15	1,372	
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1,717	1,356		0.888	0.61	0.304	1,259	2,09	1,48	1,938	1,31	
COVID19 (COVID19 (JANSSEN))	Feeling cold	1,778	0,834		0.886		1,142	2,009	1,474	1,01	1,868	1,425	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,295	1,825		0.923	0.611	0.373	1,323	2,311	2,1	1,719	1,511	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,162	1,488		0.925		0.329	1,718	2,165	2,333	1,544	1,544	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,965	1,024		0.879		0.429	1,704	1,954	0,742	1,155	1,259	
COVID19 (COVID19 (JANSSEN))	Gate delay	2,857	2,037		0.887		0.402	1,037	1,749	1,119	1,496	1,119	
COVID19 (COVID19 (JANSSEN))	Globulins increased	1,903	1,387		0.892		0.4	1,436	1,553	1,584	2,111	1,282	
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1,852	1,318		0.891			1,323	1,378	1,376	2,27	1,106	
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2,132	1,407		0.897		1,42	1,821	2,159	1,714	2,159	1,158	
COVID19 (COVID19 (JANSSEN))	Haemastrol decreased	1,857	1,914		0.429	0.607	0,429	2,113	1,807	1,789	2,22	1,456	
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,775	1,315		0.91	0.607	0.321	1,457	2,04	1,647	2,104	1,43	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,663	3,712		0.896		0.563	1,712	1,98	5,112	3,124	3,124	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,896	3,654		0.88		0.544	5,224	5,729	6,772	7,073	2,102	
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,842	1,305		0.915			1,427	1,964	1,722	2,263	1,522	
COVID19 (COVID19 (JANSSEN))	Immunoagglutination therapy	2,069	1,916		0.893		0.022	1,629	2,246	2,534	2,743	1,743	
COVID19 (COVID19 (JANSSEN))	Intensive care	1,844	1,422		1,063		0.03	1,422	2,012	2,066	2,272	1,452	
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,898	1,36		0.898	0.746	0.408	1,659	2,079	1,446	2,528	1,304	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2,013	1,329		0.884			1,402	2,087	1,017	2,209	1,296	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,113	1,896		0.896		0.394	1,694	1,98	1,729	1,874	1,744	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,899	1,469		0.876			1,232	1,818	1,101	1,707	1,718	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,046	1,776		0.88			0,855	2,544	1,138	1,557	1,89	
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,668	1,29		0.904		0.187	1,479	1,964	1,187	1,966	1,398	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,167	1,663		0.885		0.486	1,829	2,505	1,922	2,279	1,588	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,153	1,577		0.91	0.611	0.458	1,269	1,928	1,72	2,444	1,432	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration increased	1,651	1,241		0.886		0.337	1,444	2,068	1,214	1,914	1,988	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,896	1,437		0.901		0.34	1,312	2,328	1,406	2,118	1,297	
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,048	1,473		0.844		0.484	1,012	2,116	1,698	1,925	1,74	
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,598	1,322		0.893	0.61	0.265	1,093	2,06	1,933	1,377	1,377	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,598	1,327		0.884		0.15	1,248	1,782	1,475	2,286	0,91	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,736	1,322		0.902		0.244	1,151	2,099	1,827	2,002	1,384	
COVID19 (COVID19 (JANSSEN))	Non-specific reaction	2,189	1,725		0.881			1,725	0,61	1,605	1,966	1,11	
COVID19 (COVID19 (JANSSEN))	Off label use	1,339	0,239		0.88		6.71	0,275	0,394	0,324	0,842	1,265	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,753	0,758		0.887		0.511	1,322	1,003	1,142	2,17	1,424	
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,535	0,868		0.887			1,687	2,302	2,558	2,637	0,962	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,211	1,633		0.879			0,656	1,064	1,883	2,637	1,856	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,779	2,485		0,922	0.61	0.469	1,841	3,139	2,199	3,136	1,856	
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,898	1,407		0.905	0.609	0.291	1,591	2,125	1,511	2,209	1,49	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,734	2,006		0.884		0.388	2,038	3,081	2,23	3,387	1,704	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,06	3,06		0.88			4,466	3,609	6,682	6,249	1,824	
COVID19 (COVID19 (JANSSEN))	Plur quality product administered	1,304	1,304		0.964		0.964	4,059	3,449	6,226	4,576	4,014	
COVID19 (COVID19 (JANSSEN))	Protrombin time prolonged	2,056	1,624		0.923	0.745	0.331	1,587	2,485	1,629	2,696	1,497	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,234	1,561		0.886	0.612	0.586	1,706	2,137	2,712	2,55	1,859	
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2,067	1,549		0.894			1,574	1,563	1,919	1,947	1,732	
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1,902	1,398		0.901	0.608	0.53	1,479	2,18	1,69	2,111	1,955	
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	2,057	1,448		0.908		0.352	1,315	2,323	1,759	2,466	1,384	
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2,407	1,405		0.884		0.535	1,612	1,953	1,482	2,363	1,707	
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	3,206	2,569		1,094		0.529	1,869	2,979	1,19	3,688	3,046	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	7,025	0,788		0.88		0.645	3,256	6,698	15,886	6,887	6,015	
COVID19 (COVID19 (JANSSEN))	Therapy partial responder	2,376	1,687		0.893			0,635	0,752	0,568	1,025	1,025	
COVID19 (COVID19 (JANSSEN))	Thrombectomy	2,104	1,587		0.915	0.612	0.515	1,446	1,864	1,338	2,137	1,411	
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2,36	1,954		0.375	0.594	0.655	1,719	2,482	1,795	2,662	1,776	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,677	2,121		1,779	0.612	0.655	1,963	2,387	3,449	2,808	2,181	
COVID19 (COVID19 (JANSSEN))	Thrombosis with thrombocytopenia syndrome	2,294	1,296		0.884			1,665	0,766	0,766	1,865	1,865	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,216	1,806		0.879			1,779	1,208	0,641	2,084	0,908	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,437	1,484		0.899		0.648	1,912	2,193	2,484	1,726	1,726	

From: (b) (6)
To: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Cc: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Subject: Weekly data mining
Date: Tuesday, December 14, 2021 7:20:05 AM
Attachments: [20211210_USST.xls](#)

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/10/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211210	US Serious EB05 20211210	US Fatal EB05 20211210	US Infant EB05 20211210	US Child EB05 20211210	US Teen EB05 20211210	US Adult1 EB05 20211210	US Adult2 EB05 20211210	US Adult3 EB05 20211210	US Female EB05 20211210	US Male EB05 20211210	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,157	1,750	0,803			0,396	1,525	1,761	2,382	1,761	362	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,239	1,764	0,889				1,678	2,199	2,135	2,966	1,615	
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,993	1,314	0,985			0,459	1,368	1,883	1,818	2,257	1,618	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,832	2,086	0,868			0,521	1,867	2,629	2,629	2,494	1,522	
COVID19 (COVID19 (JANSSEN))	Adverse event	2,035	1,019	0,885				0,939	0,678	0,789	1,617	1,425	
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,923	1,315	0,908				1,455	1,371	1,659	2,314	1,141	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,833	2,097	0,905			0,494	2,214	2,079	2,922	4,176	1,489	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,179	1,643	0,876				1,847	1,126	1,372	1,882	1,442	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,482	1,828	0,904			0,429	1,672	2,396	2,349	2,686	2,02	
COVID19 (COVID19 (JANSSEN))	Arion gap decreased	1,795	1,471	0,897			0,373	1,205	2,281	1,126	2,174	1,279	
COVID19 (COVID19 (JANSSEN))	Antibody test	2,367	0,847	0,877			0,566	0,875	1,768	2,051	1,137	1,887	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,228	1,57	0,965	0,612		0,437	1,874	1,968	2,352	2,767	1,642	
COVID19 (COVID19 (JANSSEN))	Arterfexia	2,117	1,931	0,887				0,885	2,062	1,455	2,015	1,506	
COVID19 (COVID19 (JANSSEN))	Arteriogram carotid abnormal	1,943	1,242	0,876				1,174	1,134	1,592	2,885	1,92	
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,911	1,547	0,89	0,609		0,333	1,173	2,522	1,713	2,327	1,314	
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,806	1,557	0,89	0,609		0,3	1,276	2,307	1,675	2,151	1,341	
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,765	1,28	0,885			0,339	1,49	1,835	1,607	2,075	1,35	
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,941	1,464	0,901			0,409	1,463	2,21	1,881	2,297	1,526	
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	2,012	1,539	0,913			0,462	1,385	2,349	1,892	2,407	1,457	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3,599	2,566	0,892			0,506	1,871	2,629	0,798	4,493	1,129	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen increased	1,786	1,504	0,885			0,335	1,022	2,021	0,944	1,666	1,28	
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,864	1,469	0,916			0,278	1,228	2,059	1,585	2,411	1,186	
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,764	1,805	0,875			0,237	1,424	2,137	1,417	2,182	1,095	
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	1,968	1,404	1,328				1,557	1,989	1,989	2,526	1,797	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,737	2,205	0,877				1,838	2,931	1,111	2,383	2,319	
COVID19 (COVID19 (JANSSEN))	CSF total blood cell count positive	2,034	1,765	0,877				1,355	1,669	1,105	1,684	1,508	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,319	1,664	0,908			0,52	1,918	1,932	1,503	3,48	1,126	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,685	1,967	0,829			0,529	1,184	1,332	1,197	3,723	0,943	
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,185	1,584	0,878				1,13	1,229	1,327	2,734	1,014	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,018	3,267	0,926			0,522	2,327	2,377	0,813	3,927	1,524	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,642	1,869	0,958	0,611		0,638	2,342	2,395	2,195	3,471	1,755	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head normal	2,004	1,41	0,902			0,394	1,651	2,003	1,754	2,195	1,513	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,092	2,549	0,921			0,484	1,44	2,192	2,4	1,651	1,851	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,611	1,827	1,013			0,46	2,282	2,126	3,127	2,021	2,021	
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,789	1,386	0,894				1,246	2,226	1,569	2,082	1,244	
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1,699	1,320	0,886			0,307	1,050	2,043	1,995	2,905	1,305	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,295	1,303	0,883	0,61		0,376	2,207	2,126	2,021	2,545	1,686	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,154	1,469	0,93	0,611		0,332	1,686	2,306	2,157	2,473	1,554	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,963	1,023	0,876			0,433	1,007	2,074	1,921	2,741	1,301	
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,274	1,027	0,886			0,405	2,34	1,731	1,102	2,463	1,492	
COVID19 (COVID19 (JANSSEN))	Globulins increased	1,874	1,36	0,891			0,4	1,435	1,55	1,537	2,124	1,236	
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1,815	1,029	0,89				1,391	1,34	2,202	1,341	1,071	
COVID19 (COVID19 (JANSSEN))	Guillain-Barre syndrome	2,311	1,862	0,878				1,462	2,913	1,695	2,177	2,144	
COVID19 (COVID19 (JANSSEN))	Haemolysis decreased	1,846	1,355	0,911	0,606		0,434	1,388	2,089	1,79	2,218	1,442	
COVID19 (COVID19 (JANSSEN))	Haemolysis increased	1,713	1,306	0,908	0,607		0,327	1,45	2,018	1,845	1,428	1,508	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,664	3,714	0,895			0,434	3,994	5,116	6,752	7,146	3,167	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,584	3,57	0,879			0,544	4,684	5,734	0,771	7,693	1,778	
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,839	1,508	0,917				1,489	1,84	1,738	2,277	1,524	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,105	1,921	0,882			0,024	1,928	2,637	1,565	2,292	1,733	
COVID19 (COVID19 (JANSSEN))	Intensive care	1,854	1,43	0,997			0,031	1,443	1,996	2,065	2,288	1,462	
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,878	1,332	0,896	0,746		0,409	1,844	2,45	2,468	2,4	1,291	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2,014	1,329	0,883				1,404	2,076	1,007	2,152	2,255	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,056	1,876	0,882			0,197	1,497	1,978	2,979	1,079	0,733	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,899	1,453	0,875				1,226	2,164	1,908	1,69	1,716	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,046	1,761	0,891			0,189	1,119	1,541	2,546	1,847	1,686	
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,654	1,267	0,899			0,189	1,042	2,063	1,848	2,079	1,226	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,137	1,643	0,884			0,485	1,846	1,896	2,217	2,157	1,517	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,117	1,529	0,911	0,611		0,461	1,461	1,208	1,624	1,524	1,389	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin decreased	1,632	1,224	0,885			0,334	1,014	1,462	1,233	1,908	0,969	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,898	1,439	0,903			0,344	1,29	2,329	1,417	2,2	1,313	
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,075	1,495	0,895				1,44	1,608	2,192	1,763	1,872	
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,574	1,309	0,89	0,61		0,268	0,947	2,034	1,966	2,359	1,081	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,565	1,288	0,883			0,166	1,229	1,733	1,44	2,229	0,896	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,727	1,311	0,886			0,247	1,149	2,07	1,915	1,372	1,372	
COVID19 (COVID19 (JANSSEN))	Nonspecific reaction	2,188	0,724	0,886			0,761	0,87	0,61	1,767	1,767	0,896	
COVID19 (COVID19 (JANSSEN))	Off label use	1,34	0,232	0,88			0,708	0,757	0,629	0,421	1,051	1,564	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,752	0,738	0,876				3,134	1,003	1,003	2,17	1,025	
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,522	0,865	0,879			0,512	1,689	2,381	1,14	2,579	1,494	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,208	1,642	0,896			0,656	1,063	1,063	1,849	2,618	0,962	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,779	2,439	0,921	0,61		0,47	1,869	3,144	2,165	2,139	1,813	
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,901	1,414	0,904	0,608		0,292	1,591	2,138	1,518	2,208	1,503	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,735	2,015	0,894			0,393	2,05	3,029	2,244	3,376	1,708	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,062	3,496	0,909				4,482	3,633	0,892	6,265	1,838	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1,305		0,97			0,403	3,445	3,445	6,104	4,524	4,055	
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	2,024	1,588	0,923	0,745		0,334	1,569	2,419	1,612	2,604	1,492	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,236	1,546	0,903	0,612		0,589	1,716	2,124	2,676	2,529	1,86	
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2,067	1,521	0,891				1,559	1,562	1,866	1,938	1,723	
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1,873	1,373	0,898	0,607		0,536	1,447	2,134	1,664	2,089	1,557	
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	2,103	1,421	0,905	0,61		0,353	1,28	2,281	1,759	2,42	1,375	
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2,386	1,342	0,884			0,53	1,648	1,908	1,457	1,866	1,666	
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	3,228	2,597	1,739			0,529	1,947	2,255	1,177	2,654	3,048	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	7,026	0,79	0,879			0,645	3,266	6,704	15,851	7,895	6,016	
COVID19 (COVID19 (JANSSEN))	Therapy partial responder	2,372								0,971	0,971	1,025	
COVID19 (COVID19 (JANSSEN))	Thrombectomy	2,13	1,575	0,892			0,515	1,431	1,645	1,389	2,178	1,386	
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2,35	1,953	0,936			0,376	1,717	2,479	1,779	2,636	1,776	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,677	1,746	0,881	0,612		0,651	1,746	1,605	2,979	2,165	1,847	
COVID19 (COVID19 (JANSSEN))	Thrombosis with thrombocytopenia syndrome	2,913	1,558	0,886				0,954	0,766	1,238	0,766	1,106	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,18	1,786	0,879				1,727	1,208	0,641	2,035	0,908	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,425	1,443	0,896			0,65	1,896	1,935	2,408	1,768	1,686	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,738	1,899	0,907	0,612		0,525	2,37	2,258	2,988	3,229	2,134	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,47	1,714	0,901			0,444	2,281	1,969	1,838	2,459	1,852	
COVID19 (COVID19 (

From: (b) (6)
To: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Cc: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, December 21, 2021 10:44:00 AM
Attachments: [USST_20211217.xls](#)

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/17/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211217	US Serious EB05 20211217	US Fatal EB05 20211217	US Infant EB05 20211217	US Child EB05 20211217	US Teen EB05 20211217	US Adult1 EB05 20211217	US Adult2 EB05 20211217	US Adult3 EB05 20211217	US Female EB05 20211217	US Male EB05 20211217	Comment
COVID19 (COVID19 (JANSEN))	Activated partial thromboplastin time prolonged	1.747	1.847	0.592			0.401	1.535	1.704	2.267	2.461	3.371	
COVID19 (COVID19 (JANSEN))	Activated partial thromboplastin time shortened	2.284	1.812	0.887				1.704	2.267	2.202	3.074	1.963	
COVID19 (COVID19 (JANSEN))	Acute respiratory failure	1.987	1.319	0.984			0.461	1.35	1.893	1.821	2.229	1.839	
COVID19 (COVID19 (JANSEN))	Adverse drug reaction	2.52	0.832	0.88			0.522	0.862	1.053	0.807	2.582	1.572	
COVID19 (COVID19 (JANSEN))	Adverse event	2.028	1.029	0.875				0.961	0.785	0.872	1.597	1.516	
COVID19 (COVID19 (JANSEN))	Angiogram abnormal	1.967	1.373	0.905				1.432	1.441	1.757	2.334	1.229	
COVID19 (COVID19 (JANSEN))	Angiogram cerebral abnormal	2.823	2.104	0.909			0.496	2.224	2.056	3.072	4.149	1.513	
COVID19 (COVID19 (JANSEN))	Angiogram cerebral normal	2.177	1.622	0.977				1.925	1.953	1.953	2.347	1.427	
COVID19 (COVID19 (JANSEN))	Angiogram pulmonary abnormal	2.467	1.808	0.903			0.429	1.691	2.36	2.397	2.654	2	
COVID19 (COVID19 (JANSEN))	Angiogram pulmonary normal	1.773	1.435	0.895			0.376	1.199	2.276	2.111	1.098	2.11	1.289
COVID19 (COVID19 (JANSEN))	Antibody test	2.038	0.838	0.875			0.569	0.969	1.745	1.987	1.987	1.865	
COVID19 (COVID19 (JANSEN))	Anticoagulant therapy	2.231	1.558	0.965	0.612		0.441	1.842	1.958	2.347	2.74	1.635	
COVID19 (COVID19 (JANSEN))	Arrhythmia	2.103	1.899	0.885				0.873	2.044	1.442	1.935	1.508	
COVID19 (COVID19 (JANSEN))	Arteriogram carotid abnormal	1.929	1.221	0.876				1.159	1.134	1.552	2.734	0.914	
COVID19 (COVID19 (JANSEN))	Basophil count decreased	1.905	1.527	0.888	0.609		0.338	1.179	2.519	1.705	2.296	1.34	
COVID19 (COVID19 (JANSEN))	Basophil percentage decreased	1.776	1.521	0.888	0.609		0.305	1.238	2.285	1.67	2.125	1.324	
COVID19 (COVID19 (JANSEN))	Blood albumin decreased	1.754	1.285	0.882			0.343	1.466	1.868	1.801	2.056	1.379	
COVID19 (COVID19 (JANSEN))	Blood calcium decreased	1.923	1.449	0.898			0.413	1.438	2.214	1.853	2.261	1.538	
COVID19 (COVID19 (JANSEN))	Blood chloride increased	1.986	1.508	0.912			0.467	1.353	2.322	1.969	2.364	1.445	
COVID19 (COVID19 (JANSEN))	Blood fibrinogen decreased	3.41	2.516	0.89			0.507	1.783	2.65	0.786	4.455	1.106	
COVID19 (COVID19 (JANSEN))	Blood magnesium increased	1.836	1.431	0.914			0.28	1.187	2.046	1.587	2.349	1.194	
COVID19 (COVID19 (JANSEN))	Blood urea decreased	1.745	1.552	0.873			0.238	1.43	2.1	1.363	2.156	0.936	
COVID19 (COVID19 (JANSEN))	Blood urea increased	1.763	1.223	0.881				1.053	2.006	1.587	1.97	1.529	
COVID19 (COVID19 (JANSEN))	COVID-19 pneumonia	1.978	1.443	1.384				1.596	2.036	1.973	2.319	1.83	
COVID19 (COVID19 (JANSEN))	CSF protein increased	2.71	2.213	0.875				1.81	3.007	1.1	2.466	2.301	
COVID19 (COVID19 (JANSEN))	Cerebral haemorrhage	2.335	1.786	0.925			0.521	1.882	1.92	1.486	3.472	1.109	
COVID19 (COVID19 (JANSEN))	Cerebral mass effect	2.75	2.005	0.91				1.31	1.307	1.194	3.968	0.931	
COVID19 (COVID19 (JANSEN))	Cerebral thrombosis	2.215	1.572	0.876				1.101	1.222	1.394	2.764	1.001	
COVID19 (COVID19 (JANSEN))	Cerebral venous sinus thrombosis	3.303	2.313	0.924			0.523	2.337	2.384	0.869	3.978	1.214	
COVID19 (COVID19 (JANSEN))	Computerised tomogram head abnormal	2.858	1.858	0.909	0.611		0.362	1.616	2.395	1.616	3.421	1.74	
COVID19 (COVID19 (JANSEN))	Computerised tomogram head normal	1.999	1.401	0.9			0.392	1.657	1.966	1.783	2.184	1.516	
COVID19 (COVID19 (JANSEN))	Computerised tomogram thorax abnormal	2.094	1.525	0.919			0.488	1.413	2.087	2.082	2.377	1.843	
COVID19 (COVID19 (JANSEN))	Computerised tomogram thorax normal	2.808	1.951	0.927			0.482	1.805	2.277	1.967	3.171	2.005	
COVID19 (COVID19 (JANSEN))	Eosinophil count decreased	1.781	1.359	0.882				1.284	2.241	2.052	1.498	1.254	
COVID19 (COVID19 (JANSEN))	Eosinophil percentage decreased	1.681	1.313	0.884	0.61		0.311	1.262	2.037	1.407	1.873	1.302	
COVID19 (COVID19 (JANSEN))	Fading coil	1.933	0.833	0.883			0.129	1.129	1.471	1.897	2.002	1.427	
COVID19 (COVID19 (JANSEN))	Fibrin D dimer	2.288	1.302	0.874			0.375	2.204	2.124	1.24	1.988	1.667	
COVID19 (COVID19 (JANSEN))	Fibrin D dimer increased	2.149	1.456	0.929	0.611		0.338	1.659	2.298	2.138	2.446	1.555	
COVID19 (COVID19 (JANSEN))	Fibrin D dimer normal	1.96	1.381	0.873			0.437	1.621	2.019	2.184	2.302	1.302	
COVID19 (COVID19 (JANSEN))	Gaze palsy	2.289	1.069	0.887			0.406	2.35	1.771	1.164	2.453	1.561	
COVID19 (COVID19 (JANSEN))	Globulins increased	1.852	1.316	0.889			0.403	1.433	1.826	1.518	2.115	1.212	
COVID19 (COVID19 (JANSEN))	Glucose urine present	1.792	1.392	0.883				1.302	1.33	1.33	1.058	1.058	
COVID19 (COVID19 (JANSEN))	Gullain-Barre syndrome	2.297	1.856	0.876				1.518	2.866	1.677	2.157	1.618	
COVID19 (COVID19 (JANSEN))	Haemolysis decreased	1.837	1.344	0.909	0.606		0.344	1.368	2.111	1.759	2.191	1.452	
COVID19 (COVID19 (JANSEN))	Haemoglobin decreased	1.771	1.301	0.903	0.607		0.432	1.618	2.023	1.618	2.013	1.436	
COVID19 (COVID19 (JANSEN))	Heparin-induced thrombocytopenia test	5.64	3.65	0.894			0.405	4.092	4.092	6.197	7.101	2.89	
COVID19 (COVID19 (JANSEN))	Heparin-induced thrombocytopenia test positive	6.498	3.555	0.877			0.544	4.694	5.745	0.762	7.708	1.712	
COVID19 (COVID19 (JANSEN))	Hypoxia	1.951	1.521	0.879				1.562	1.846	1.965	2.468	1.548	
COVID19 (COVID19 (JANSEN))	Immunoglobulin therapy	2.115	1.927	0.88			0.025	1.958	2.65	1.531	2.319	1.748	
COVID19 (COVID19 (JANSEN))	Intensive care	1.856	1.44	1.113			0.032	1.433	2.029	2.074	2.268	1.502	
COVID19 (COVID19 (JANSEN))	International normalised ratio increased	1.879	1.325	0.884			0.413	1.613	2.008	1.444	2.08	1.291	
COVID19 (COVID19 (JANSEN))	International normalised ratio normal	2.029	1.342	0.881				1.39	2.089	1.995	2.149	1.279	
COVID19 (COVID19 (JANSEN))	Jugular vein thrombosis	2.056	1.863	0.878				1.459	2.925	1.197	0.724	0.733	
COVID19 (COVID19 (JANSEN))	Lumbar puncture	1.895	1.441	0.873				1.234	2.15	1.089	1.709	1.889	
COVID19 (COVID19 (JANSEN))	Lumbar puncture abnormal	2.023	1.811	0.876				0.959	1.685	1.612	1.858	1.612	
COVID19 (COVID19 (JANSEN))	Lymphocyte percentage decreased	1.683	1.279	0.897			0.192	1.043	2.113	1.836	2.091	1.244	
COVID19 (COVID19 (JANSEN))	Magnetic resonance imaging head abnormal	2.141	1.54	0.885	0.611		0.489	1.843	2.208	2.465	2.465	1.567	
COVID19 (COVID19 (JANSEN))	Mean cell haemoglobin concentration decreased	2.152	1.12	0.903			0.464	1.302	2.143	1.43	1.43	1.375	
COVID19 (COVID19 (JANSEN))	Mean cell haemoglobin decreased	1.651	1.232	0.883			0.336	1.004	2.046	1.315	1.145	0.944	
COVID19 (COVID19 (JANSEN))	Mean platelet volume increased	1.874	1.417	0.901			0.349	1.251	2.331	1.418	2.144	1.335	
COVID19 (COVID19 (JANSEN))	Mechanical ventilation	2.094	1.511	0.887				1.009	1.73	1.692	1.765	1.692	
COVID19 (COVID19 (JANSEN))	Monocyte percentage increased	1.567	1.296	0.888	0.61		0.27	0.951	2.023	1.848	2.363	1.075	
COVID19 (COVID19 (JANSEN))	Neutrophil percentage decreased	1.553	1.285	0.881			0.172	1.212	2.107	1.396	2.204	0.891	
COVID19 (COVID19 (JANSEN))	Neutrophil percentage increased	1.732	1.302	0.895			0.249	1.32	2.119	1.792	2.013	1.387	
COVID19 (COVID19 (JANSEN))	Nonspecific reaction	2.188	0.725					0.761	0.811	0.811	1.956	0.895	
COVID19 (COVID19 (JANSEN))	Off label use	1.34	0.228	0.878			7.528	1.25	1.392	1.181	1.392	1.952	
COVID19 (COVID19 (JANSEN))	On and off phenomenon	1.752	0.76	0.873				3.17	1.002	1.002	2.183	1.002	
COVID19 (COVID19 (JANSEN))	Pain assessment	2.522	0.864				0.513	1.677	2.304	1.131	1.311	1.479	
COVID19 (COVID19 (JANSEN))	Peripheral embolism	3.205	1.648	0.877				0.656	1.083	1.834	2.65	0.962	
COVID19 (COVID19 (JANSEN))	Platelet count	2.762	2.458	0.919	0.61		0.472	1.886	3.107	2.578	3.194	1.838	
COVID19 (COVID19 (JANSEN))	Platelet count decreased	1.894	1.397	0.901	0.608		0.298	1.564	2.145	1.498	2.206	1.495	
COVID19 (COVID19 (JANSEN))	Platelet count normal	2.73	1.978	0.893			0.394	2.027	2.978	2.176	3.298	1.709	
COVID19 (COVID19 (JANSEN))	Platelet factor	6.083	3.513	0.878				1.453	3.726	0.681	6.271	1.847	
COVID19 (COVID19 (JANSEN))	Poor quality product administered	1.305					0.977	4.068	3.443	6.177	4.557	4.085	
COVID19 (COVID19 (JANSEN))	Prothrombin time prolonged	2.029	1.586	0.922	0.745		0.339	1.568	2.438	1.602	2.597	1.51	
COVID19 (COVID19 (JANSEN))	Pulmonary embolism	2.23	1.634	1.542	0.612		0.592	1.691	2.094	2.698	2.519	1.842	
COVID19 (COVID19 (JANSEN))	Pulmonary thrombosis	2.056	1.557	0.894				1.603	1.905	1.923	1.957	1.781	
COVID19 (COVID19 (JANSEN))	Red blood cell count decreased	1.858	1.358	0.895	0.607			1.426	2.154	2.062	1.629	1.563	
COVID19 (COVID19 (JANSEN))	Red cell distribution width increased	2.017	1.407	0.903	0.61		0.357	1.241	2.32	1.728	2.369	1.402	
COVID19 (COVID19 (JANSEN))	Superficial vein thrombosis	2.278	1.278	0.882			0.531	1.639	1.891	1.452	2.377	1.645	
COVID19 (COVID19 (JANSEN))	Suspected COV D-19	3.227	2.533	1.676			0.53	2.026	2.237	1.169	2.644	1.924	
COVID19 (COVID19 (JANSEN))	Therapy non-responder	7.028	0.789	0.878			0.646	3.52	6.721	15.803	7.878	5.962	
COVID19 (COVID19 (JANSEN))	Therapy partial responder	2.373									0.672	0.688	
COVID19 (COVID19 (JANSEN))	Thrombectomy	2.152	1.551	0.891			0.516	1.407	1.664	2.214	1.362	1.353	
COVID19 (COVID19 (JANSEN))	Thrombocytopenia	2.34	1.947	0.94			0.379	1.695	2.49	2.669	1.809	1.787	
COVID19 (COVID19 (JANSEN))	Thrombosis	2.878	2.078	0.878	0.612		0.165	2.131	2.878	3.463	2.803	2.186	
COVID19 (COVID19 (JANSEN))	Thrombosis with thrombocytopenia syndrome	2.911	2.073	0.887				0.954	0.766	0.766	1.731	0.68	
COVID19 (COVID19 (JANSEN))	Transverse sinus thrombosis	2.18	1.772	0.877				1.732	1.207	1.207	0.638	0.908	
COVID19 (COVID19 (JANSEN))	Ultrasound Doppler	2.42	1.447	0.877			0.652	1.447	1.931	2.42	2.431	1.718	
COVID19 (COVID19 (JANSEN))	Ultrasound Doppler abnormal	2.743	1.897	0.906	0.612		0.528	2.314	2.26	2.983	3.247	2.104	
COVID19 (COVID19 (JANSEN))	Ultrasound Doppler normal	2.469	1.892	0.904	0.446		0.446	2.267	1.851	1.838	2.455	1.824	
COVID19 (COVID19 (JANSEN))	Ultrasound scan normal	1.893	1.388	0.893				1.245					

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: RE: Weekly data mining
Date: Tuesday, January 4, 2022 6:39:06 AM
Attachments: [USST_20211231.xls](#)

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/31/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211231	US Serious EB05 20211231	US Fatal EB05 20211231	US Infant EB05 20211231	US Child EB05 20211231	US Teen EB05 20211231	US Adult EB05 20211231	US Adult2 EB05 20211231	US Adults EB05 20211231	US Female EB05 20211231	US Male EB05 20211231	Comment
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time prolonged	2,12	1,14	0,907			0,405	1,59	2,14	2,15	2,14	1,415	
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time shortened	2,284	1,797	0,887				1,747	2,236	2,268	2,015	1,572	
COVID19 (COV D19 (ANSEN))	Acute respiratory failure	2,019	1,333	0,982			0,461	1,42	1,949	1,835	1,835	1,651	
COVID19 (COV D19 (ANSEN))	Adverse drug reaction	2,911	0,843	0,876			0,523	0,921	2,222	2,004	2,611	1,925	
COVID19 (COV D19 (ANSEN))	Adverse event	2,022	1,088	0,961				0,961	0,718	1,485	0,78	1,485	
COVID19 (COV D19 (ANSEN))	Angiogram abnormal	1,948	1,324	0,903				1,473	1,431	1,269	1,69	1,268	
COVID19 (COV D19 (ANSEN))	Angiogram cerebral abnormal	2,749	1,966	1,269			0,491	2,222	2,602	2,722	2,022	1,472	
COVID19 (COV D19 (ANSEN))	Angiogram cerebral normal	2,243	1,671	0,876				1,96	1,868	1,824	1,224	1,479	
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary abnormal	2,485	1,888	0,43				1,84	2,421	2,369	1,827	2,369	
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary normal	1,787	1,431	0,893			0,38	1,179	2,268	1,988	1,187	1,228	
COVID19 (COV D19 (ANSEN))	Antion cap decreased	2,359	0,822	0,872				0,858	1,692	1,923	1,923	1,8	
COVID19 (COV D19 (ANSEN))	Antibody test	2,245	1,553	0,995			0,612	1,856	1,862	2,359	1,862	1,638	
COVID19 (COV D19 (ANSEN))	Anticoagulant therapy	2,113	1,893	0,883				0,875	2,113	1,931	1,434	1,532	
COVID19 (COV D19 (ANSEN))	Arterogram carotid abnormal	1,883	1,175	0,873				1,147	1,101	1,534	2,485	0,903	
COVID19 (COV D19 (ANSEN))	Basophil count decreased	1,906	1,492	0,884	0,61		0,34	1,199	2,514	1,677	2,323	1,13	
COVID19 (COV D19 (ANSEN))	Basophil percentage decreased	1,773	1,487	0,884	0,609			1,246	2,284	1,681	2,151	1,681	
COVID19 (COV D19 (ANSEN))	Blood albumin decreased	1,775	1,294	0,886				1,473	1,85	1,683	2,119	1,373	
COVID19 (COV D19 (ANSEN))	Blood calcium decreased	1,918	1,434	0,898				1,446	2,296	1,841	2,291	1,511	
COVID19 (COV D19 (ANSEN))	Blood chloride increased	1,976	1,488	0,915				1,352	2,301	1,896	2,363	1,438	
COVID19 (COV D19 (ANSEN))	Blood fibrinogen decreased	3,368	2,525	0,888				1,928	2,47	0,785	4,425	1,101	
COVID19 (COV D19 (ANSEN))	Blood fibrinogen increased	1,851	1,427	0,916				1,245	1,897	1,912	1,912	1,912	
COVID19 (COV D19 (ANSEN))	Blood sodium increased	1,507	1,08	0,902				1,359	1,376	0,928	2,009	0,795	
COVID19 (COV D19 (ANSEN))	Blood urea decreased	1,737	1,516	0,874	0,247			1,44	2,078	1,833	2,17	0,919	
COVID19 (COV D19 (ANSEN))	Blood urea increased	1,833	1,244	0,879				1,141	2,063	1,61	2,037	1,543	
COVID19 (COV D19 (ANSEN))	COV D-19 pneumonia	1,995	1,441	1,358				1,603	2,084	1,987	2,328	1,862	
COVID19 (COV D19 (ANSEN))	CSF-immunoglobulin increased	2,034	1,77					0,953	1,453	0,868			
COVID19 (COV D19 (ANSEN))	CSF protein increased	2,761	2,202	0,873				1,825	3,05	2,519	1,086	2,312	
COVID19 (COV D19 (ANSEN))	CSF red blood cell count positive	2,004	1,724	0,873				1,305	1,751	1,081	1,742	1,46	
COVID19 (COV D19 (ANSEN))	Cerebral haemorrhage	2,357	1,729	0,92	0,518			1,876	1,881	1,49	3,436	1,087	
COVID19 (COV D19 (ANSEN))	Cerebral mass effect	3,038	2,068	0,907	0,527			1,473	1,309	1,263	0,919		
COVID19 (COV D19 (ANSEN))	Cerebral thrombosis	2,289	1,679	0,975				1,086	1,334	1,45	2,912	1,2	
COVID19 (COV D19 (ANSEN))	Cerebral venous sinus thrombosis	3,399	2,277	0,918	0,524			2,407	2,983	2,607	1,967	1,967	
COVID19 (COV D19 (ANSEN))	Computerised tomogram head abnormal	2,031	1,832	0,843	0,611			2,333	3,397	2,19	1,742	1,742	
COVID19 (COV D19 (ANSEN))	Computerised tomogram head normal	2,017	1,384	0,939				1,844	2,034	1,582	1,582	1,582	
COVID19 (COV D19 (ANSEN))	Computerised tomogram thorax abnormal	2,075	0,883	0,918				1,435	2,067	2,032	1,636	1,636	
COVID19 (COV D19 (ANSEN))	Deep vein thrombosis	2,607	1,796	0,978	0,485			2,171	2,597	3,018	3,219	2,198	
COVID19 (COV D19 (ANSEN))	Eosinophil count decreased	1,769	1,328	0,888				1,271	2,265	2,058	1,237	1,663	
COVID19 (COV D19 (ANSEN))	Eosinophil percentage decreased	1,685	1,309	0,879	0,61			1,284	2,054	1,928	1,908	1,289	
COVID19 (COV D19 (ANSEN))	Feeling cold	1,78	0,833	0,881				1,133	2,018	1,471	1,805	1,421	
COVID19 (COV D19 (ANSEN))	Fibrin D dimer	2,286	1,278	0,881				1,278	1,987	1,917	1,917	1,69	
COVID19 (COV D19 (ANSEN))	Fibrin D dimer increased	2,145	1,451	0,928	0,612			1,656	2,285	2,447	1,577	1,657	
COVID19 (COV D19 (ANSEN))	Fibrin D dimer normal	1,953	1,022	0,874	0,442			1,889	2,028	0,729	2,131	1,314	
COVID19 (COV D19 (ANSEN))	Glucose palsy	2,337	1,114	0,885	0,41			1,763	1,693	1,693	2,443	1,523	
COVID19 (COV D19 (ANSEN))	Globulins increased	1,865	1,328	0,889	0,407			1,428	1,559	1,585	1,209	1,585	
COVID19 (COV D19 (ANSEN))	Glomerular filtration rate decreased	1,775	1,161	0,886				1,014	2,03	1,36	1,965	1,36	
COVID19 (COV D19 (ANSEN))	Glucose urine present	1,845	1,845	0,866				1,511	1,303	1,379	1,303	1,379	
COVID19 (COV D19 (ANSEN))	Gullain-Barre syndrome	2,301	1,85	0,873				1,516	2,927	1,689	2,2	1,689	
COVID19 (COV D19 (ANSEN))	Haemolysis decreased	1,948	1,343	0,888	0,442			1,368	2,108	2,227	1,448	1,448	
COVID19 (COV D19 (ANSEN))	Haemoglobin decreased	1,782	1,102	0,932	0,608			1,422	2,105	1,444	2,127	1,444	
COVID19 (COV D19 (ANSEN))	Hepatin-induced thrombocytopenia test	5,616	3,658	0,892				4,036	5,197	7,239	2,96	2,96	
COVID19 (COV D19 (ANSEN))	Hepatin-induced thrombocytopenia test positive	6,499	3,567	0,875	0,545			4,723	6,788	7,144	1,713	1,713	
COVID19 (COV D19 (ANSEN))	Hypoxia	1,872	1,327	0,912				1,535	1,972	1,759	1,559	1,559	
COVID19 (COV D19 (ANSEN))	Immunoglobulin therapy	2,114	1,887	0,877	0,027			1,969	2,593	1,517	1,725	1,725	
COVID19 (COV D19 (ANSEN))	Intensiv care	1,861	1,434	0,903	0,434			1,434	2,087	2,08	1,523	1,523	
COVID19 (COV D19 (ANSEN))	International normalised ratio increased	1,911	1,366	0,891	0,747			1,646	2,048	1,522	1,348	1,522	
COVID19 (COV D19 (ANSEN))	International normalised ratio normal	2,016	1,39	0,879				1,472	2,163	0,99	2,225	1,329	
COVID19 (COV D19 (ANSEN))	Jaquelet vein thrombosis	2,045	1,456	0,878	0,47			1,979	1,959	1,72	2,887	1,72	
COVID19 (COV D19 (ANSEN))	Lumbar puncture	1,884	1,433	0,87				1,479	2,188	1,706	1,083	1,706	
COVID19 (COV D19 (ANSEN))	Lumbar puncture abnormal	2,02	1,745	0,866	0,079			0,979	1,873	2,066	1,798	1,798	
COVID19 (COV D19 (ANSEN))	Lumbar puncture decreased	1,574	1,048	0,874	0,196			1,096	1,968	1,968	2,018	1,968	
COVID19 (COV D19 (ANSEN))	Lymphocyte percentage decreased	1,688	1,275	0,896	0,216			1,055	2,059	1,847	1,234	1,234	
COVID19 (COV D19 (ANSEN))	Magnetic resonance imaging head abnormal	2,153	1,829	0,888	0,463			1,884	2,589	2,465	1,811	1,811	
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin concentration decreased	2,143	1,516	0,91	0,612			1,234	2,405	1,744	2,436	1,368	
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin decreased	1,645	1,224	0,882	0,335			1,035	2,006	1,318	1,96	0,922	
COVID19 (COV D19 (ANSEN))	Mean platelet volume increased	1,861	1,361	0,902	0,357			1,247	2,145	2,45	2,165	1,655	
COVID19 (COV D19 (ANSEN))	Mechanical ventilation	2,088	1,518	0,977	0,486			1,1	2,219	1,768	1,855	1,855	
COVID19 (COV D19 (ANSEN))	Metabolic percentage increased	1,588	1,252	0,89	0,61			0,939	2,048	1,972	2,389	1,084	
COVID19 (COV D19 (ANSEN))	Neutrophil percentage decreased	1,549	1,252	0,878	0,185			1,182	1,789	0,866	1,454	1,454	
COVID19 (COV D19 (ANSEN))	Neutrophil percentage increased	1,732	1,315	0,897	0,251			1,145	2,104	1,376	2,034	1,827	
COVID19 (COV D19 (ANSEN))	Non-specific reaction	2,191	0,725	0,872				0,782	0,611	1,965	1,069	1,069	
COVID19 (COV D19 (ANSEN))	Off label use	1,339	0,266	0,878	0,766			1,234	1,334	0,821	1,374	1,374	
COVID19 (COV D19 (ANSEN))	On and off phenomenon	1,754	0,759					3,246	1,003	2,205			
COVID19 (COV D19 (ANSEN))	Pain assessment	2,523	0,86		0,514			1,874	2,182	1,114	2,445	1,431	
COVID19 (COV D19 (ANSEN))	Peripartum embolism	3,214	1,631	0,875				0,657	1,063	1,82	2,689	1,82	
COVID19 (COV D19 (ANSEN))	Platelet count	2,772	2,352	0,921	0,611			1,848	3,003	2,61	3,163	1,793	
COVID19 (COV D19 (ANSEN))	Platelet count decreased	1,887	1,362	0,899	0,809			1,556	2,116	1,502	2,191	1,481	
COVID19 (COV D19 (ANSEN))	Platelet count normal	2,725	1,978	0,991				2,046	2,95	3,296	2,203	1,708	
COVID19 (COV D19 (ANSEN))	Platelet factor 4	6,083	3,517	0,876				4,527	3,803	0,817	6,294	2,614	
COVID19 (COV D19 (ANSEN))	Poor quality product administered	1,305		0,968				4,127	3,304	5,945	4,69	4,69	
COVID19 (COV D19 (ANSEN))	Prothrombin time prolonged	2,038	1,598	0,92	0,746			1,584	2,469	1,517	2,689	1,517	
COVID19 (COV D19 (ANSEN))	Pulmonary embolism	2,222	1,606	0,926	0,612			1,703	2,059	2,677	2,507	1,824	
COVID19 (COV D19 (ANSEN))	Pulmonary thrombosis	2,047	1,541	0,896				1,687	1,601	1,878	1,986	1,759	
COVID19 (COV D19 (ANSEN))	Red blood cell count decreased	1,881	1,387	0,897	0,608			1,432	2,143	1,556	1,696	1,556	
COVID19 (COV D19 (ANSEN))	Red cell distribution width increased	2,033	1,469	0,905	0,611			0,949	1,273	2,338	1,427	1,427	
COVID19 (COV D19 (ANSEN))	Superficial vein thrombosis	2,403	1,362	0,88				1,091	1,815	1,815	2,366	1,815	
COVID19 (COV D19 (ANSEN))	Suspected COV D-19	3,228	2,434	1,038	0,531			2,308	2,647	1,207	3,084	1,207	
COVID19 (COV D19 (ANSEN))	Therapy non-response	7,03	0,786	0,876	0,646			3,575	6,892	15,662	7,823	5,922	
COVID19 (COV D19 (ANSEN))	Therapy partial responder	3,777						0,637	0,572	0,568	1,019	0,568	
COVID19 (COV D19 (ANSEN))	Thrombectomy	1,594		0,889	0,511			1,467	1,632	1,528	2,345	1,364	
COVID19 (COV D19 (ANSEN))	Thrombocytopenia	2,338	1,904	0,941	0,382			1,691	2,488	2,488	1,776	1,776	
COVID19 (COV D19 (ANSEN))	Thrombosis	2,675	2,124	1,738	0,612			1,953	2,404	3,51	2,21	2,21	
COVID19 (COV D19 (ANSEN))	Thrombosis with thrombocytopenia syndrome	4,406	2,205	0,887				1,182	0,766	1,867	1,87	0,681	
COVID19 (COV D19 (ANSEN))	Transverse sinus thrombosis	2,296	1,831										

From: (b) (6)
To: (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>;
Cc: (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>;
Subject: RE: Weekly data mining
Date: Wednesday, January 12, 2022 5:27:15 AM

Good morning all,

Please note we are having technical difficulties accessing our data mining and I'll forward weekly output when able. Apologies for the delay.

Best,

(b) (6)

From: (b) (6)
Sent: Tuesday, January 04, 2022 6:39 AM
To: (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>;
Cc: (b) (6) <(b) (6)@fda.hhs.gov>; (b) (6) <(b) (6)@fda.hhs.gov>; (b) (6) <(b) (6)@fda.hhs.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>;
Subject: RE: Weekly data mining

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/31/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: Weekly data mining
Date: Wednesday, January 12, 2022 9:03:53 AM
Attachments: [USST_20220107.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 1/7/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20220107	US Serious EB05 20220107	US Fatal EB05 20220107	US Infant EB05 20220107	US Child EB05 20220107	US Teen EB05 20220107	US Adult1 EB05 20220107	US Adult2 EB05 20220107	US Adult3 EB05 20220107	US Female EB05 20220107	US Male EB05 20220107	Comment
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time prolonged	2,146	1,762	0,925				0,404	1,635	1,976	1,713	1,488	
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time shortened	2,254	1,774	0,984				0,404	1,735	2,222	2,202	1,545	
COVID19 (COV D19) (ANSENSE)	Acute respiratory failure	2,032	1,332	0,977				0,461	1,417	1,849	1,843	2,328	
COVID19 (COV D19) (ANSENSE)	Adverse drug reaction	2,941	2,022	1,075				0,283	0,942	1,206	0,843	1,608	
COVID19 (COV D19) (ANSENSE)	Adverse event	2,02	1,054	0,861				0,954	0,712	1,488	0,772	1,488	
COVID19 (COV D19) (ANSENSE)	Angiogram abnormal	1,954	1,134	0,901				0,491	1,502	1,423	1,684	2,25	
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral abnormal	2,142	1,242	1,007				0,491	2,206	2,012	1,466	1,466	
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral normal	2,257	1,641	0,872				0,491	1,963	1,879	1,413	1,469	
COVID19 (COV D19) (ANSENSE)	Angiogram pulmonary abnormal	2,484	1,718	1,007				0,399	0,43	1,626	2,304	2,713	
COVID19 (COV D19) (ANSENSE)	Angion cap decreased	1,789	1,422	0,889				0,378	1,232	1,232	1,332	1,132	
COVID19 (COV D19) (ANSENSE)	Anticoagulant therapy	2,359	0,823	0,869				0,568	0,854	1,088	1,925	2,088	
COVID19 (COV D19) (ANSENSE)	Arteriojugular catheter	2,144	1,544	0,925	0,612			0,435	1,84	1,868	2,379	1,688	
COVID19 (COV D19) (ANSENSE)	Arteriojugular catheter abnormal	1,878	1,185	0,873				0,34	1,146	1,146	1,425	1,528	
COVID19 (COV D19) (ANSENSE)	Basophil count decreased	1,521	1,518	0,881		0,61		0,34	1,221	2,485	1,76	2,368	
COVID19 (COV D19) (ANSENSE)	Basophil percentage decreased	1,777	1,5	0,883		0,609		0,304	1,265	2,253	1,728	1,319	
COVID19 (COV D19) (ANSENSE)	Blood albumin decreased	1,178	1,316	0,883				0,344	1,485	1,858	1,744	2,184	
COVID19 (COV D19) (ANSENSE)	Blood calcium decreased	1,501	1,446	0,896				0,415	1,458	2,188	1,988	1,522	
COVID19 (COV D19) (ANSENSE)	Blood chloride increased	1,976	1,503	0,919				0,461	1,368	2,262	1,972	2,364	
COVID19 (COV D19) (ANSENSE)	Blood fibrinogen decreased	3,371	2,505	0,886				0,505	1,897	2,477	0,785	4,377	
COVID19 (COV D19) (ANSENSE)	Blood fibrinogen increased	1,84	1,44	0,918				0,284	1,231	1,972	1,703	1,183	
COVID19 (COV D19) (ANSENSE)	Blood potassium decreased	1,676	1,125	0,899				0,548	1,237	1,481	2,031	1,874	
COVID19 (COV D19) (ANSENSE)	Blood urea decreased	1,725	1,508	0,887				0,243	1,471	2,011	1,915	1,953	
COVID19 (COV D19) (ANSENSE)	Blood urea increased	1,628	1,251	0,871				0,548	1,138	2,027	1,642	2,102	
COVID19 (COV D19) (ANSENSE)	COV D-19 pneumonia	2	1,433	1,28				1,659	2,083	2,083	1,988	2,297	
COVID19 (COV D19) (ANSENSE)	CSF immunoglobulin increased	2,037	1,701	0,869				0,863	1,431	1,431	0,545	1,585	
COVID19 (COV D19) (ANSENSE)	CSF protein increased	2,788	2,199	0,869				1,827	3,057	3,057	1,078	2,487	
COVID19 (COV D19) (ANSENSE)	Cerebral haemorrhage	2,344	1,707	0,919				0,519	1,841	1,875	1,47	3,388	
COVID19 (COV D19) (ANSENSE)	Cerebral mass effect	3,011	2,142	0,906				0,527	1,474	1,308	1,242	0,919	
COVID19 (COV D19) (ANSENSE)	Cerebral thrombosis	2,29	1,656	0,872				1,075	1,334	2,807	1,425	1,2	
COVID19 (COV D19) (ANSENSE)	Cerebral venous sinus thrombosis	3,31	2,267	0,917				0,524	2,414	2,296	0,883	3,94	
COVID19 (COV D19) (ANSENSE)	Computerized tomogram head abnormal	2,613	0,945	0,921	0,611			0,631	1,945	2,291	1,342	1,72	
COVID19 (COV D19) (ANSENSE)	Computerized tomogram head normal	2,013	1,384	0,898				0,394	2,074	2,004	1,485	1,485	
COVID19 (COV D19) (ANSENSE)	Computerized tomogram thorax abnormal	2,074	1,184	0,914				0,465	1,431	2,012	1,662	1,662	
COVID19 (COV D19) (ANSENSE)	Deep vein thrombosis	2,607	2,607	0,959				0,482	2,181	2,045	2,288	3,209	
COVID19 (COV D19) (ANSENSE)	Eosinophil count decreased	1,737	1,319	0,884				0,314	1,281	1,476	1,496	1,223	
COVID19 (COV D19) (ANSENSE)	Eosinophil percentage decreased	1,78	1,35	0,874	0,61			1,708	1,326	1,622	1,362	1,368	
COVID19 (COV D19) (ANSENSE)	Feeling cold	1,78	0,838	0,879				1,13	2,002	1,466	0,976	1,854	
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer	2,286	1,253	0,878				0,379	2,192	2,148	1,903	1,673	
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer increased	2,14	1,444	0,925		0,612		0,333	1,867	2,27	2,438	1,753	
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer normal	1,959	1,037	0,87				0,441	1,673	2,052	0,8	1,139	
COVID19 (COV D19) (ANSENSE)	Gasx palsy	2,313	1,101	0,883				0,411	2,293	1,762	1,294	2,485	
COVID19 (COV D19) (ANSENSE)	Glaucoma increased	1,878	1,366	0,845				0,465	1,415	1,656	1,215	1,248	
COVID19 (COV D19) (ANSENSE)	Glucose urine present	1,847	1,279	0,89				1,482	1,287	1,293	1,423	1,103	
COVID19 (COV D19) (ANSENSE)	Gullain-Barre syndrome	2,313	1,845	0,87				1,534	2,084	2,178	1,661	2,178	
COVID19 (COV D19) (ANSENSE)	Haemoglobin decreased	1,850	1,352	0,892	0,607			0,445	1,377	1,979	1,444	1,845	
COVID19 (COV D19) (ANSENSE)	Haemoglobin increased	1,783	1,306	0,901	0,608			0,331	1,431	2,028	1,68	1,41	
COVID19 (COV D19) (ANSENSE)	Hepatin-induced thrombocytopenia test	6,616	6,655	0,988				0,409	4,329	5,201	2,342	2,37	
COVID19 (COV D19) (ANSENSE)	Hepatin-induced thrombocytopenia test positive	6,545	6,593	0,972				0,465	4,729	5,913	2,469	2,469	
COVID19 (COV D19) (ANSENSE)	Hypoxia	1,869	1,333	0,922				1,577	1,987	1,987	1,767	1,562	
COVID19 (COV D19) (ANSENSE)	Immunoglobulin therapy	2,111	1,852	0,874				0,027	1,986	2,574	1,428	2,262	
COVID19 (COV D19) (ANSENSE)	Intensive care	1,858	1,424	0,873				1,033	1,437	2,038	2,241	1,508	
COVID19 (COV D19) (ANSENSE)	International normalised ratio increased	1,897	1,346	0,888		0,747		0,409	1,651	2,019	1,492	2,044	
COVID19 (COV D19) (ANSENSE)	International normalised ratio normal	2,017	1,395	0,876				1,472	1,928	1,928	0,99	0,237	
COVID19 (COV D19) (ANSENSE)	Jugular vein thrombosis	2,046	1,843	0,875				1,511	1,197	2,703	0,719	1,319	
COVID19 (COV D19) (ANSENSE)	Lumbar puncture	1,905	1,425	0,867				1,213	1,176	1,176	1,172	1,671	
COVID19 (COV D19) (ANSENSE)	Lumbar puncture abnormal	2,047	1,769	0,892				1,769	0,992	1,992	1,768	1,768	
COVID19 (COV D19) (ANSENSE)	Lymphocyte count decreased	1,561	1,142	0,872				0,209	1,692	2,176	2,003	1,027	
COVID19 (COV D19) (ANSENSE)	Lymphocyte percentage decreased	1,607	1,262	0,884				1,607	1,607	2,086	1,862	1,264	
COVID19 (COV D19) (ANSENSE)	Lymphocyte percentage increased	1,405	1,146	0,894	0,608			1,034	1,546	1,546	0,7	1,141	
COVID19 (COV D19) (ANSENSE)	Magnetic resonance imaging head abnormal	2,14	1,615	0,887				0,484	1,862	1,908	2,448	1,608	
COVID19 (COV D19) (ANSENSE)	Mean cell haemoglobin concentration decreased	2,135	1,52	0,862	0,612			0,462	1,221	1,663	2,448	1,379	
COVID19 (COV D19) (ANSENSE)	Mean cell haemoglobin decreased	1,616	1,215	0,879				0,334	1,028	1,909	1,262	1,959	
COVID19 (COV D19) (ANSENSE)	Mean platelet volume increased	1,882	1,451	0,902				0,349	1,29	2,302	2,202	1,354	
COVID19 (COV D19) (ANSENSE)	Mechanical ventilation	2,076	1,486	0,974				0,466	1,508	2,218	1,762	1,869	
COVID19 (COV D19) (ANSENSE)	Monocyte percentage increased	1,59	1,297	0,893	0,61			0,275	2,002	2,407	2,041	1,088	
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage decreased	1,551	1,264	0,875				0,183	1,239	1,748	1,446	2,262	
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage increased	1,724	1,374	0,896				1,316	1,416	2,083	1,443	1,807	
COVID19 (COV D19) (ANSENSE)	Non-specific reaction	2,194	0,724	0,762				0,641	0,611	1,068	1,068	1,068	
COVID19 (COV D19) (ANSENSE)	Off label use	1,34	0,324	0,875				7,692	1,229	1,133	0,821	1,372	
COVID19 (COV D19) (ANSENSE)	On and off phenomenon	1,759	0,769	0,865				3,295	1,003	1,003	2,913	1,903	
COVID19 (COV D19) (ANSENSE)	Pain assessment	2,525	0,86	0,874				0,514	1,675	2,193	1,114	2,448	
COVID19 (COV D19) (ANSENSE)	Peripheral embolism	3,668	1,367	0,892				0,657	1,083	1,083	1,688	0,865	
COVID19 (COV D19) (ANSENSE)	Platelet count	2,773	2,351	0,92	0,611			1,84	3,053	3,053	3,179	1,731	
COVID19 (COV D19) (ANSENSE)	Platelet count decreased	1,893	1,368	0,898	0,609			0,3	1,551	2,113	1,546	2,199	
COVID19 (COV D19) (ANSENSE)	Platelet count normal	2,723	2,033	0,889				0,365	2,065	2,844	2,295	3,325	
COVID19 (COV D19) (ANSENSE)	Platelet factor 4	6,063	3,504	0,972				0,983	4,529	3,85	6,295	2,64	
COVID19 (COV D19) (ANSENSE)	Poor quality product administered	1,306						0,988	4,13	3,315	5,947	4,501	
COVID19 (COV D19) (ANSENSE)	Protein total decreased	1,755	1,268	0,885	0,611			1,416	1,676	1,676	1,59	2,006	
COVID19 (COV D19) (ANSENSE)	Prothrombin time prolonged	2,025	1,687	0,918	0,746			0,339	2,438	2,438	2,84	1,647	
COVID19 (COV D19) (ANSENSE)	Pulmonary embolism	2,224	1,604	1,537	0,613			0,59	1,716	2,005	2,65	2,504	
COVID19 (COV D19) (ANSENSE)	Pulmonary thrombosis	2,647	1,824	0,895				1,711	1,983	1,983	1,851	1,851	
COVID19 (COV D19) (ANSENSE)	Red blood cell count decreased	1,883	1,374	0,896	0,608			1,451	1,732	2,114	1,563	1,227	
COVID19 (COV D19) (ANSENSE)	Red cell distribution width increased	2,027	1,426	0,904	0,611			0,348	1,286	2,378	2,089	1,453	
COVID19 (COV D19) (ANSENSE)	Superficial vein thrombosis	2,4	1,386	0,877				0,532	1,731	1,902	1,379	1,346	
COVID19 (COV D19) (ANSENSE)	Suspected COV D-19	3,229	2,389	1,145				0,531	2,35	2,419	2,682	3,094	
COVID19 (COV D19) (ANSENSE)	Therapy non-responder	7,031	0,781	0,872				0,646	6,659	6,659	16,657	7,765	
COVID19 (COV D19) (ANSENSE)	Therapy partial responder	2,388						0,611	0,637	0,637	0,572	1,068	
COVID19 (COV D19) (ANSENSE)	Thrombectomy	2,148	1,558	0,887				0,511	1,451	1,632	1,485	2,308	
COVID19 (COV D19) (ANSENSE)	Thrombocytopenia	2,333	1,892	0,937				0,38	1,675	2,495	1,815	2,589	
COVID19 (COV D19) (ANSENSE)	Thrombosis	2,673	2,104	1,174	0,612			0,656	1,956	2,399	2,851	2,214	
COVID19 (COV D19) (ANSENSE)	Thrombosis with thrombocytopenia syndrome	4,41	2,188	0,885				1,182	0,766	0,766	1,676	0,681	
COVID19 (COV D19) (ANSENSE)	Transverse sinus thrombosis	2,254	1,769	0,844				0,872	1,288	1,969	0,637	1,969	
COVID19 (COV D19) (ANSENSE)	Ultrasound Doppler	2,402	1,441	0,884				1,888	2,223				

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: RE: Weekly data mining
Date: Tuesday, January 25, 2022 6:41:14 AM
Attachments: [USST_20220121.xls](#)

Hi All,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 1/21/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 2020/21	US Serious EB05 2020/21	US Fatal EB05 2020/21	US Infant EB05 2020/21	US Child EB05 2020/21	US Teen EB05 2020/21	US Adult EB05 2020/21	US Adult2 EB05 2020/21	US Adult3 EB05 2020/21	US Female EB05 2020/21	US Male EB05 2020/21	Comment
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time prolonged	2,138	1,711	0,950				0,402	1,138	1,711	1,454	1,454	
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time shortened	2,23	1,736	0,88					1,698	2,128	2,286	2,094	1,491
COVID19 (COV D19) (ANSENSE)	Acute respiratory failure	2,024	1,327	0,999				0,457	1,423	1,986	1,809	2,312	1,641
COVID19 (COV D19) (ANSENSE)	Adverse drug reaction	2,892	2,402	0,874				0,518	1,987	2,465	2,817	2,643	1,611
COVID19 (COV D19) (ANSENSE)	Adverse event	2,022	1,07						0,926	0,763	1,516	0,765	1,755
COVID19 (COV D19) (ANSENSE)	Angiogram abnormal	1,932	1,331	0,9					1,476	1,413	1,704	2,235	1,257
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral abnormal	1,932	0,902					0,486	2,240	1,967	2,465	1,446	1,468
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral normal	2,235	1,617	0,897					1,875	1,201	1,767	1,201	1,468
COVID19 (COV D19) (ANSENSE)	Angiogram pulmonary abnormal	2,481	1,726	0,897				0,425	1,726	1,004	2,369	2,589	1,844
COVID19 (COV D19) (ANSENSE)	Angion gas decreased	1,826	1,46	0,89					1,375	2,241	1,324	1,318	1,318
COVID19 (COV D19) (ANSENSE)	Antibody test	2,36	0,817	0,869				0,563	1,843	1,647	1,866	2,054	1,791
COVID19 (COV D19) (ANSENSE)	Anticoagulant therapy	2,241	1,85	0,432		0,612			1,809	1,998	2,398	2,638	1,616
COVID19 (COV D19) (ANSENSE)	Areflexia	2,134	1,883	0,882					0,85	2,171	1,477	1,56	1,56
COVID19 (COV D19) (ANSENSE)	Arteriogram carotid abnormal	1,843	1,18	0,871				0,61	1,145	1,194	1,47	2,581	0,918
COVID19 (COV D19) (ANSENSE)	Basophil count decreased	1,923	1,481	0,881				0,332	1,226	2,468	1,762	2,393	1,311
COVID19 (COV D19) (ANSENSE)	Basophil percentage decreased	1,783	1,487	0,885		0,609			2,295	1,252	2,166	1,725	1,318
COVID19 (COV D19) (ANSENSE)	Blood albumin decreased	1,778	1,303	0,883				0,337	1,432	1,84	1,758	2,171	1,365
COVID19 (COV D19) (ANSENSE)	Blood calcium decreased	1,995	1,402	0,866				0,406	1,431	2,127	1,852	2,274	1,478
COVID19 (COV D19) (ANSENSE)	Blood chloride increased	1,953	1,464	0,924				0,451	1,356	2,203	2,322	1,641	1,441
COVID19 (COV D19) (ANSENSE)	Blood fibrinogen decreased	3,226	2,454	0,885				0,503	1,843	2,206	0,784	4,29	1,087
COVID19 (COV D19) (ANSENSE)	Blood magnesium increased	1,816	1,913	0,288				1,178	2,398	1,848	1,722	1,171	1,171
COVID19 (COV D19) (ANSENSE)	Blood potassium decreased	1,685	1,241	0,909				0,538	1,211	1,498	2,043	1,824	1,205
COVID19 (COV D19) (ANSENSE)	Blood sodium increased	1,506	1,09	0,964					1,331	1,465	0,85	2,024	0,827
COVID19 (COV D19) (ANSENSE)	Blood urea decreased	1,668	1,401	0,868				0,235	1,411	1,835	1,292	0,877	1,252
COVID19 (COV D19) (ANSENSE)	Blood urea increased	1,825	1,239	0,874					1,105	2,018	1,624	2,062	1,536
COVID19 (COV D19) (ANSENSE)	COV D-19 pneumonia	2,005	1,44	1,365					1,684	2,117	1,963	2,293	1,888
COVID19 (COV D19) (ANSENSE)	CSF protein increased	2,777	2,161	0,87					1,805	2,989	1,061	2,398	2,305
COVID19 (COV D19) (ANSENSE)	Cerebral haemorrhage	2,314	1,618	0,917				0,517	1,711	1,855	1,433	3,23	1,1
COVID19 (COV D19) (ANSENSE)	Cerebral mass effect	2,042	1,612	0,912				0,522	1,479	1,769	1,228	1,689	0,969
COVID19 (COV D19) (ANSENSE)	Cerebral thrombosis	2,29	1,635	0,87					1,305	1,733	1,24	1,733	1,24
COVID19 (COV D19) (ANSENSE)	Cerebral venous sinus thrombosis	3,246	2,193	0,907				0,519	2,209	2,299	0,878	3,926	1,191
COVID19 (COV D19) (ANSENSE)	Computerized tomogram head abnormal	2,011	1,398	0,895		0,611		0,622	2,195	2,32	2,52	1,721	1,221
COVID19 (COV D19) (ANSENSE)	Computerized tomogram head normal	2,011	1,398	0,895				0,387	1,735	2,170	2,234	1,514	2,234
COVID19 (COV D19) (ANSENSE)	Computerized tomogram thorax abnormal	2,001	1,473	0,903				0,461	1,41	2,084	2,031	2,359	1,665
COVID19 (COV D19) (ANSENSE)	Deep vein thrombosis	2,001	1,779	0,46					1,723	2,288	3,042	3,214	1,887
COVID19 (COV D19) (ANSENSE)	Embolic stroke	1,496	1,089	0,874					0,455	0,962	2,159	0,827	1,212
COVID19 (COV D19) (ANSENSE)	Eosinophil count decreased	1,742	1,368	0,897					1,253	1,253	2,12	1,253	2,043
COVID19 (COV D19) (ANSENSE)	Eosinophil percentage decreased	1,719	1,352	0,881		0,61		0,306	1,292	2,037	1,265	2,006	1,265
COVID19 (COV D19) (ANSENSE)	Feeling cold	1,78	0,84	0,877				1,117	2,007	1,453	0,974	1,852	1,405
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer	2,294	1,244	0,886				0,378	2,018	2,172	1,965	2,621	1,673
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer increased	2,146	1,448	0,937		0,612			1,647	2,259	2,175	2,402	1,59
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer normal	1,966	1,065	0,869				0,438	1,657	2,093	0,853	2,13	1,359
COVID19 (COV D19) (ANSENSE)	Gate palsy	1,296	1,077	0,869					1,428	2,278	1,62	1,62	1,62
COVID19 (COV D19) (ANSENSE)	Globulins increased	1,877	1,33	0,887				0,4	1,385	1,57	2,189	1,237	1,237
COVID19 (COV D19) (ANSENSE)	Glucose urine present	1,821	1,247	0,888					1,429	1,309	1,397	1,102	2,229
COVID19 (COV D19) (ANSENSE)	Gullain-Barre syndrome	1,919	1,319	0,872					2,922	2,922	1,29	2,42	1,29
COVID19 (COV D19) (ANSENSE)	Haematocrit decreased	1,824	1,315	0,904		0,607		0,432	1,336	2,044	1,793	2,031	1,432
COVID19 (COV D19) (ANSENSE)	Haemoglobin decreased	1,776	1,248	0,911		0,608		0,325	2,003	1,688	1,395	1,688	1,395
COVID19 (COV D19) (ANSENSE)	Heparin-induced thrombocytopenia test	5,59	3,587	0,889					5,191	5,962	7,214	2,830	2,830
COVID19 (COV D19) (ANSENSE)	Heparin-induced thrombocytopenia test positive	6,495	3,607	0,87				0,543	4,727	5,899	0,761	7,741	2,065
COVID19 (COV D19) (ANSENSE)	Hypoxia	1,872	1,313	0,909					1,872	1,509	1,911	1,565	1,565
COVID19 (COV D19) (ANSENSE)	Immunoglobulin therapy	2,092	1,837	0,993				0,625	1,871	2,514	1,713	2,237	1,713
COVID19 (COV D19) (ANSENSE)	Intensive care	1,851	1,417	1,055				0,631	1,415	2,045	2,048	2,259	1,52
COVID19 (COV D19) (ANSENSE)	International normalised ratio increased	1,896	1,306	0,866		0,747			1,896	2,063	1,598	2,443	1,598
COVID19 (COV D19) (ANSENSE)	International normalised ratio normal	2,016	1,306	0,875					1,441	2,078	1,238	1,963	1,238
COVID19 (COV D19) (ANSENSE)	Jugular vein thrombosis	1,952	1,685	0,874					1,376	1,195	0,714	2,486	0,734
COVID19 (COV D19) (ANSENSE)	Lumbar puncture	1,906	1,366	0,866					1,664	2,114	1,693	1,611	1,611
COVID19 (COV D19) (ANSENSE)	Lumbar puncture abnormal	2,049	1,736	0,998					1,998	1,693	1,747	1,747	1,747
COVID19 (COV D19) (ANSENSE)	Lumbar puncture normal	1,946	1,269	0,923					1,633	1,733	1,633	1,404	1,404
COVID19 (COV D19) (ANSENSE)	Lung opacity	1,669	1,27	0,895				0,184	1,022	2,074	1,923	2,105	2,105
COVID19 (COV D19) (ANSENSE)	Lymphocyte percentage increased	1,386	1,128	0,868		0,608			1,008	1,508	1,193	0,669	0,669
COVID19 (COV D19) (ANSENSE)	Magnetic resonance imaging head abnormal	2,114	1,581	0,899					1,82	1,897	2,114	2,384	1,623
COVID19 (COV D19) (ANSENSE)	Mean cell haemoglobin concentration decreased	2,124	1,495	0,9		0,612			1,459	1,213	2,318	1,362	1,362
COVID19 (COV D19) (ANSENSE)	Mean platelet volume increased	1,903	1,435	0,903				0,342	1,311	2,34	1,459	1,733	1,373
COVID19 (COV D19) (ANSENSE)	Mechanical ventilation	1,479	0,993	0,893					0,972	2,186	1,852	1,859	1,859
COVID19 (COV D19) (ANSENSE)	Monocyte percentage increased	1,569	1,272	0,889		0,61			0,917	1,945	2,034	2,263	1,07
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage decreased	1,512	1,223	0,872				0,152	1,12	1,672	1,472	2,283	0,843
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage increased	1,729	1,313	0,9				0,343	1,112	2,088	2,017	1,867	1,867
COVID19 (COV D19) (ANSENSE)	Nonspecific reaction	2,194	0,725						0,761	0,612	1,852	1,069	1,069
COVID19 (COV D19) (ANSENSE)	Off label use	1,34	0,414	0,875				7,887	1,246	1,105	0,801	1,381	1,918
COVID19 (COV D19) (ANSENSE)	On and off phenomenon	1,764	0,76						2,273	1,001	2,213	2,213	2,213
COVID19 (COV D19) (ANSENSE)	Pain assessment	2,515	0,857					0,513	1,61	2,139	1,095	2,284	1,403
COVID19 (COV D19) (ANSENSE)	Peripheral embolism	3,063	1,553	0,87					0,607	1,061	1,69	2,715	0,954
COVID19 (COV D19) (ANSENSE)	Platelet count	2,763	2,259	0,91		0,611			1,804	3,092	1,786	3,159	1,786
COVID19 (COV D19) (ANSENSE)	Platelet count decreased	1,874	1,317	0,896		0,609			0,297	1,483	2,077	1,513	1,442
COVID19 (COV D19) (ANSENSE)	Platelet count normal	2,723	1,935	0,888					2,023	2,834	2,175	3,231	1,667
COVID19 (COV D19) (ANSENSE)	Platelet factor 4	6,028	3,384	0,871					4,266	2,803	0,817	6,291	1,838
COVID19 (COV D19) (ANSENSE)	Poor quality product administered	1,305						0,966	4,153	3,378	5,968	4,508	4,027
COVID19 (COV D19) (ANSENSE)	Positive airway pressure therapy	1,761	1,334	0,936		0,611			0,973	1,673	1,713	2,004	1,629
COVID19 (COV D19) (ANSENSE)	Protein total decreased	1,747	1,247	0,883					1,364	1,633	1,611	1,328	2,004
COVID19 (COV D19) (ANSENSE)	Prothrombin time prolonged	2,031	1,558	0,919		0,746			1,334	2,459	1,642	2,693	1,496
COVID19 (COV D19) (ANSENSE)	Pulmonary embolism	2,215	1,577	1,013		0,613			1,704	2,021	2,662	2,483	1,812
COVID19 (COV D19) (ANSENSE)	Pulmonary thrombosis	2,048	1,46	0,873					1,563	1,996	1,563	1,796	1,796
COVID19 (COV D19) (ANSENSE)	Red blood cell count decreased	1,87	1,345	0,884		0,608			1,412	2,088	1,711	2,114	1,525
COVID19 (COV D19) (ANSENSE)	Red cell distribution width increased	2,003	1,38	0,895		0,611			0,539	1,412	2,262	2,021	1,525
COVID19 (COV D19) (ANSENSE)	Superficial vein thrombosis	2,354	1,354	0,876				0,34	1,281	2,273	1,734	2,368	1,462
COVID19 (COV D19) (ANSENSE)	Suspected COV D-19	3,225	2,33	1,062					1,717	1,865	2,403	1,443	1,631
COVID19 (COV D19) (ANSENSE)	Therapy non-responder	7,024	0,779	0,871					0,526	2,679	2,72	1,178	2,649
COVID19 (COV D19) (ANSENSE)	Therapy partial responder	2,387							3,554	6,563	15,36	7,795	5,841
COVID19 (COV D19) (ANSENSE)	Thrombectomy	2,141	1,516	0,886				0,508	1,429	1,628	0,572	0,568	1,02
COVID19 (COV D19) (ANSENSE)	Thrombocytopenia	2,313	1,838	0,939					1,745	2,561	1,749	2,562	1,749
COVID19 (COV D19) (ANSENSE)	Thrombosis	2,698	2,097	1,066		0,613							

From: (b) (6)
To: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Cc: (b) (6) <(CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, February 1, 2022 6:00:27 AM
Attachments: [USST_20220128.xls](#)

Hi All,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 1/28/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBO5 20220128	US Serious EBO5 20220128	US Fatal EBO5 20220128	US Infant EBO5 20220128	US Child EBO5 20220128	US Teen EBO5 20220128	US Adult1 EBO5 20220128	US Adult2 EBO5 20220128	US Adult3 EBO5 20220128	US Female EBO5 20220128	US Male EBO5 20220128	Comment		
COVID19 (COV D19 (ANSSEN))	Activated partial thromboplastin time prolonged	2,112	1,956	0.953			0.397	1,558	1,825	1,825	2,174	1,441	Reviewed, Regulatory Action		
COVID19 (COV D19 (ANSSEN))	Activated partial thromboplastin time shortened	2,23	1,73	0.876				1,732	2,117	2,117	2,233	3,026	1,515	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Acute respiratory failure	2,04	1,331	0.999				1,448	1,976	1,976	1,831	2,301	1,662	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Adverse drug reaction	2,865	0,867	0.87				0,518	2,864	2,864	2,864	2,867	1,453	Other	
COVID19 (COV D19 (ANSSEN))	Adverse event	2,019	1,061	0.871				0,748	0,748	0,748	1,734	1,734	1,505	Other	
COVID19 (COV D19 (ANSSEN))	Angiogram abnormal	1,948	1,379	0.898				1,463	1,428	1,428	1,813	2,24	1,322	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Angiogram cerebral abnormal	0,901	1,084	0.901			0.487	0,904	2,264	1,943	1,943	1,783	1,428	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Angiogram cerebral normal	2,229	1,653	0.874				1,937	1,851	1,851	2,476	1,322	1,476	Not an AE	
COVID19 (COV D19 (ANSSEN))	Angiogram pulmonary abnormal	2,464	1,706	0.894				1,625	1,615	1,615	2,331	2,182	1,949	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Angiogram pulmonary normal	1,628	1,487	0.89				1,211	1,211	1,211	2,223	1,316	1,316	Other	
COVID19 (COV D19 (ANSSEN))	Antibody test	2,359	0,824	0.866				0,564	1,659	1,659	1,923	2,079	1,759	Not an AE	
COVID19 (COV D19 (ANSSEN))	Anticoagulant therapy	2,244	1,539	0.87	0.612			1,807	2,015	2,015	2,329	2,805	1,622	Other	
COVID19 (COV D19 (ANSSEN))	Atreflexia	1,234	1,869	0.875				0,85	2,17	2,17	1,451	1,507	1,554	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Arteriogram carotid abnormal	1,831	1,157	0.867				1,136	1,194	1,194	1,427	2,499	0,903	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Basophil count decreased	1,929	1,477	0.878		0.81	0.329	1,233	2,415	2,415	1,736	2,397	1,315	Other	
COVID19 (COV D19 (ANSSEN))	Basophil percentage decreased	1,789	1,485	0.882		0.609		1,261	2,257	2,257	1,717	2,171	1,318	Other	
COVID19 (COV D19 (ANSSEN))	Blood albumin decreased	1,796	1,306	0.88				1,467	1,842	1,842	1,758	2,188	1,374	Other	
COVID19 (COV D19 (ANSSEN))	Blood calcium decreased	1,989	1,392	0.894				1,425	2,118	2,118	1,936	2,27	1,461	Other	
COVID19 (COV D19 (ANSSEN))	Blood chloride increased	1,965	1,486	0.931				1,383	2,192	2,192	1,98	2,334	1,439	Other	
COVID19 (COV D19 (ANSSEN))	Blood fibrinogen decreased	2,373	2,459	0.998				1,844	2,108	2,108	0,975	4,407	1,074	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Blood fibrinogen increased	1,797	1,36	0.98				1,156	1,915	1,915	1,713	2,403	1,130	Other	
COVID19 (COV D19 (ANSSEN))	Blood potassium decreased	1,698	1,243	0.911				1,209	1,514	1,514	2,033	1,882	1,197	Other	
COVID19 (COV D19 (ANSSEN))	Blood sodium increased	1,598	1,123	0.903				1,38	1,491	1,491	1,844	2,131	1,87	Other	
COVID19 (COV D19 (ANSSEN))	Blood urea decreased	1,668	1,397	0.964		0.234		1,401	1,84	1,84	0,889	1,273	0,889	Other	
COVID19 (COV D19 (ANSSEN))	Blood urea increased	1,837	1,234	0.872				1,086	2,03	2,03	1,819	2,027	1,557	Other	
COVID19 (COV D19 (ANSSEN))	COVID-19 pneumonia	2,013	1,417	1,286				1,69	2,124	2,124	1,905	2,218	1,903	Other	
COVID19 (COV D19 (ANSSEN))	CSF protein increased	2,775	2,159	0.866				1,775	2,965	2,965	1,1	2,518	2,253	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Cerebral haemorrhage	2,311	1,643	0,918			0.518	1,712	1,85	1,85	1,474	3,275	1,1	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Cerebral mass effect	2,916	1,956	0.906			0.922	1,473	1,328	1,328	1,205	1,946	1,946	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Cerebral thrombosis	2,289	1,619	0.862				1,133	1,305	1,305	2,842	1,188	1,188	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Cerebral venous sinus thrombosis	2,243	2,186	0,908			0.519	2,263	2,238	2,238	3,919	1,184	1,184	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Completed tomogram head abnormal	0,949	1,751	0.949		0.611		1,015	2,216	2,216	2,31	1,733	1,733	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Completed tomogram head normal	2,003	1,401	0.897				1,097	1,979	1,979	2,254	1,53	Not an AE		
COVID19 (COV D19 (ANSSEN))	Completed tomogram thorax abnormal	2,088	1,488	0.891				1,386	2,083	2,083	2,48	1,644	1,644	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Completed tomogram thorax normal	2,081	1,488	0.891				1,386	2,083	2,083	2,48	1,644	1,644	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Deep vein thrombosis	2,601	1,77	0.991			2,457	2,148	2,255	2,255	1,981	1,981	1,981	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Embolic stroke	1,497	1,083	0.87				0,456	0,862	0,862	2,031	1,726	0,861	Reviewed, Branch Mfg	
COVID19 (COV D19 (ANSSEN))	Eosinophil count decreased	1,769	1,323	0.865				1,287	1,527	1,527	1,527	1,079	1,24	Other	
COVID19 (COV D19 (ANSSEN))	Eosinophil percentage decreased	1,741	1,364	0.877	0.609		0.304	1,293	2,079	2,079	1,561	2,028	1,311	Other	
COVID19 (COV D19 (ANSSEN))	Feeling cold	1,78	0,838	0.874				2,007	1,458	1,458	1,852	1,407	1,407	Labeled	
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer increased	2,264	1,363	0.883				2,119	2,378	2,378	2,142	2,502	1,842	1,842	Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer normal	2,178	1,463	0.845		0.612		1,684	2,272	2,272	2,435	2,168	1,608	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer normal	1,961	1,063	0.864				1,439	2,066	2,066	0,898	2,136	1,372	Not an AE	
COVID19 (COV D19 (ANSSEN))	Face palsy	2,265	1,407	0.875				1,426	1,747	1,747	1,668	1,946	1,668	Labeled	
COVID19 (COV D19 (ANSSEN))	Globulins increased	1,88	1,329	0.881			0.401	1,388	1,615	1,615	2,206	1,778	1,235	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Glucose urine present	1,835	1,228	0.888				1,414	2,216	2,216	1,437	1,21	1,21	Other	
COVID19 (COV D19 (ANSSEN))	Gullain-Barre syndrome	2,329	1,844	0.872				1,508	2,189	2,189	2,251	2,165	2,165	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Haemafiori decreased	1,838	1,314	0.904		0.606		1,353	2,055	2,055	1,769	2,212	1,409	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Haemoglobin decreased	1,748	1,305	0.885		0.607	0.428	1,419	2,006	2,006	2,104	1,494	1,494	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Heparin-induced thrombocytopenia test	5,589	3,592	0.885				3,951	5,16	5,16	5,868	2,745	2,745	Not an AE	
COVID19 (COV D19 (ANSSEN))	Heparin-induced thrombocytopenia test positive	6,409	3,562	0.866		0.544		4,723	5,918	5,918	7,737	1,975	1,975	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Hypoxia	1,668	1,291	0.904				1,488	1,934	1,934	2,278	1,929	1,929	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Immunoglobulin therapy	2,095	1,837	0.967				1,969	2,528	2,528	1,758	2,24	1,708	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Intensive care	1,861	1,425	1,05				1,441	2,05	2,05	2,261	1,534	1,534	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	International normalised ratio increased	1,85	1,273	0.988		0.747		1,415	1,933	1,933	1,402	1,925	1,259	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	International normalised ratio normal	2,016	1,295	0.861				1,436	2,072	2,072	1,171	2,117	1,171	Not an AE	
COVID19 (COV D19 (ANSSEN))	Jugular vein thrombosis	2,949	1,628	0.87				1,376	1,179	1,179	2,468	0,724	0,724	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Lumbar puncture	1,91	1,368	0.898				1,502	1,946	1,946	1,691	1,691	1,691	Not an AE	
COVID19 (COV D19 (ANSSEN))	Lumbar puncture abnormal	1,951	1,723	0.884				1,984	2,588	2,588	1,688	1,731	1,731	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Lumbar puncture normal	1,707	1,377	0.918				1,338	1,688	1,688	1,754	1,426	1,426	Other	
COVID19 (COV D19 (ANSSEN))	Lymphocyte count decreased	1,688	1,149	0.864			0.197	1,076	1,076	1,076	1,1	1,5	1,5	Other	
COVID19 (COV D19 (ANSSEN))	Lymphocyte percentage decreased	1,689	1,274	0.892			0.197	1,074	2,082	2,082	1,217	2,117	1,277	Other	
COVID19 (COV D19 (ANSSEN))	Metabolic clearance imaging head abnormal	2,117	1,578	0.873				1,476	1,823	1,823	1,987	2,122	1,633	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Metabolic clearance imaging head normal	2,117	1,578	0.873				1,476	1,823	1,823	1,987	2,122	1,633	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Mean cell haemoglobin concentration decreased	0	1,491	0	0.612			1,212	2,33	2,33	1,817	2,423	1,378	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Mean platelet volume increased	1,89	1,413	0.899				1,318	2,307	2,307	1,457	2,127	1,364	Other	
COVID19 (COV D19 (ANSSEN))	Mechanical ventilation	2,092	1,498	0.878				1,478	1,969	1,969	2,214	1,952	1,952	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Monocyte percentage increased	1,58	1,291	0.891		0.609		1,089	1,852	1,852	2,025	2,347	1,089	Other	
COVID19 (COV D19 (ANSSEN))	Neutrophil percentage decreased	1,527	1,229	0.871				1,208	1,65	1,65	2,234	1,846	0,846	Other	
COVID19 (COV D19 (ANSSEN))	Neutrophil percentage increased	1,731	1,303	0.895			0.24	1,179	1,943	1,943	2,198	1,981	1,981	Other	
COVID19 (COV D19 (ANSSEN))	Non-specific reaction	2,192	0,783	0.871			0.876	0,781	0,612	0,612	1,961	1,068	1,068	Other	
COVID19 (COV D19 (ANSSEN))	Off label use	1,34	0,426	0.876				1,226	1,116	1,116	1,391	1,914	1,914	Not an AE	
COVID19 (COV D19 (ANSSEN))	On and off phenomenon	1,793	0,781	0.871				2,279	1,901	1,901	2,214	1,001	1,001	Other	
COVID19 (COV D19 (ANSSEN))	Pain assessment	2,514	0,859	0.873				1,584	2,11	2,11	1,077	2,28	1,372	Not an AE	
COVID19 (COV D19 (ANSSEN))	Peripheral embolism	2,931	1,492	0.866				0,657	1,06	1,06	1,584	2,455	1,954	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Platelet count	2,762	2,23												

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: Weekly data mining
Date: Tuesday, February 8, 2022 6:52:05 AM
Attachments: [USST_20220204.xls](#)

Hi All,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 2/4/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20220204	US Serious EB05 20220204	US Fatal EB05 20220204	US Infant EB05 20220204	US Child EB05 20220204	US Teen EB05 20220204	US Adult EB05 20220204	US Adult2 EB05 20220204	US Adult3 EB05 20220204	US Female EB05 20220204	US Male EB05 20220204	Comment
COVID19 (COV D19 (ANSSEN))	Activated partial thromboplastin time prolonged	1,021	1,021	0.266				0.397	1.51	1.32	1.41	1.41	1.41 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Activated partial thromboplastin time shortened	2,208	1,706	0.874				1.686	2.125	2.197	2.197	2.197	1.497 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Acute respiratory failure	2,04	1,341	1,005				0.455	1.435	2,009	1,827	2,298	1.676 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Adverse drug reaction	2,862	0.867	0.867				0.919	0.977	1,454	0.977	1,554	1.442 Other
COVID19 (COV D19 (ANSSEN))	Adverse event	2,018	1,059	0.875				0.908	0.739	1,789	1,755	1,453	1.755 Other
COVID19 (COV D19 (ANSSEN))	Angiogram abnormal	1,941	1,396	0.903				0.487	1.454	1,444	1,789	2,252	1.296 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Angiogram cerebral abnormal	2,591	1,89	0.904				0.487	2,591	2,225	1,773	1,905	1.416 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Angiogram cerebral normal	1,196	1,586	0.871				1.895	1,817	1,239	1,239	1,421	1.421 Not an AE
COVID19 (COV D19 (ANSSEN))	Angiogram pulmonary abnormal	2,426	1,607	0.886				1,550	2,309	2,180	2,501	1,962	1.962 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Angiogram pulmonary normal	1,812	1,429	0.883				1,184	1,683	1,351	1,351	1,193	1.193 Not an AE
COVID19 (COV D19 (ANSSEN))	Antibody test	2,359	0.807	0.86				0.563	0.834	1,651	1,889	2,028	1.787 Not an AE
COVID19 (COV D19 (ANSSEN))	Anticoagulant therapy	2,234	1,514	0.956	0.612			1,799	1.99	2,256	1,99	2,75	1.603 Other
COVID19 (COV D19 (ANSSEN))	Areflexia	2,133	1,835	0.876				0.819	2,234	1,434	1,655	1,572	1.572 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Arterigram carotid abnormal	1,81	1,141	0.864				1,135	1,186	1,404	2,424	2,424	0.895 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Basophil count decreased	1,905	1,437	0.876	0.61		0.329	1,228	2,348	1,713	2,354	1,263	1.263 Other
COVID19 (COV D19 (ANSSEN))	Basophil percentage decreased	1,789	1,466	0.883	0.609			1,237	2,238	2,162	2,162	1,313	1.313 Other
COVID19 (COV D19 (ANSSEN))	Blood albumin decreased	1,789	1,3	0.883				1,459	1,628	1,761	2,169	1,381	1.381 Other
COVID19 (COV D19 (ANSSEN))	Blood calcium increased	1,873	1,374	0.866				1,141	2,074	1,835	2,241	1,443	1.443 Other
COVID19 (COV D19 (ANSSEN))	Blood chloride increased	1,923	1,423	0.936				1,323	2,121	1,911	2,296	1,396	1.396 Other
COVID19 (COV D19 (ANSSEN))	Blood thrombin decreased	2,273	2,429	0.885				1,844	2,108	0.98	4,355	1,067	1.067 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Blood magnesium increased	1,935	1,386	0.867				1,173	1,932	2,482	1,558	1,558	1.558 Other
COVID19 (COV D19 (ANSSEN))	Blood potassium decreased	1,875	1,221	0.909				1,192	1,478	1,781	1,857	1,171	1.171 Other
COVID19 (COV D19 (ANSSEN))	Blood sodium increased	1,584	1,12	0.862				1,426	1,45	1,656	2,146	1,46	0.87 Other
COVID19 (COV D19 (ANSSEN))	Blood urea decreased	1,654	1,36	0.861				1,377	1,926	1,251	0.872	0.872 Other	
COVID19 (COV D19 (ANSSEN))	Blood urea increased	1,828	1,233	0.874				1,066	2,013	1,634	2,032	1,548	1.548 Other
COVID19 (COV D19 (ANSSEN))	COVID-19 pneumonia	2,003	1,413	1,157				1,65	2,111	1,603	2,211	1,888	1.888 Other
COVID19 (COV D19 (ANSSEN))	CSF protein increased	2,779	2,146	0.863				1,815	2,937	1,083	2,43	2,267	2.267 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Cerebral haemorrhage	2,307	1,616	0.917				1,711	1,823	1,459	3,214	1,088	1.088 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Cerebral mass effect	2,283	1,966	0.912				1,445	1,387	1,203	3,881	1,002	1.002 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Cerebral thrombosis	2,289	0.86	0.86				1,129	1,304	2,945	1,235	2,945	1.235 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Cerebral venous sinus thrombosis	3,243	2,176	0.905				0.518	2,265	2,236	3,857	1,183	1.183 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Computed tomogram head abnormal	2,586	1,726	0.816				1,726	2,149	1,312	1,232	1,126	1.126 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Computed tomogram head normal	1,987	0.381	0.888	0.611			1,707	1,969	1,817	2,25	1,517	1.517 Not an AE
COVID19 (COV D19 (ANSSEN))	Computed tomogram thorax abnormal	2,074	1,422	0.821				0.458	1,976	2,049	2,289	1,618	1.618 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Deep vein thrombosis	2,563	1,77	0.859				1,019	2,248	3,049	1,977	1,977	1.977 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Endotracheal intubation	1,925	1,396	1,216				0.478	1,324	1,075	1,52	1,528	1.528 Other
COVID19 (COV D19 (ANSSEN))	Eosinophil count decreased	1,761	1,381	0.861				1,761	1,287	1,243	2,043	1,243	1.243 Other
COVID19 (COV D19 (ANSSEN))	Eosinophil percentage decreased	1,755	1,307	0.876	0.609			1,295	2,081	1,81	2,024	1,81	1.81 Other
COVID19 (COV D19 (ANSSEN))	Feeling cold	1,78	0.836	0.871				1,109	2,012	1,452	0.988	1,848	1.415 Labeled
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer normal	2,324	0.881	0.881				2,157	1,124	1,477	1,477	1,477	1.477 Other
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer increased	2,164	1,445	0.95	0.612			0.319	1,656	2,258	1,585	2,429	1.585 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer normal	1,961	1,078	0.866				0.438	1,642	2,049	0.986	2,121	1.356 Not an AE
COVID19 (COV D19 (ANSSEN))	Gain policy	2,409	1,629	0.829				1,921	1,772	1,388	1,625	1,625	1.625 Labeled
COVID19 (COV D19 (ANSSEN))	Gilberts increased	1,862	1,328	0.861				0.401	1,683	1,647	1,242	2,228	1,242 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Glucose urine present	1,811	1,227	0.886				1,369	1,306	1,403	2,184	1,102	1.102 Other
COVID19 (COV D19 (ANSSEN))	Gullain-Barre syndrome	1,636	0.87	0.87				0.531	1,24	2,24	2,162	2,162	2.162 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Haematuria decreased	1,822	1,295	0.901				1,333	2,023	2,193	2,196	1,384	1.384 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Haemoglobin decreased	1,803	0.869	0.869	0.607			0.426	1,77	1,965	2,094	1,381	1.381 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Heparin-induced thrombocytopenia test	5,565	3,156	0.863				3,871	5,208	5,208	1,103	2,85	2.85 Not an AE
COVID19 (COV D19 (ANSSEN))	Heparin-induced thrombocytopenia test positive	6,409	3,492	0.864				4,723	6,581	0.753	7,738	1,803	1.803 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Hypoxia	1,862	1,266	0.922				1,498	1,941	2,498	2,044	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Immunoglobulin therapy	2,08	0.812	0.864				0.544	1,918	1,457	2,236	1,685	1.685 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Intensive care	1,849	1,43	1,049				0.433	2,047	2,048	2,289	1,538	1.538 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	International normalised ratio increased	1,863	0.863	0.863	0.747			1,095	1,454	1,381	1,381	1,381	1.381 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	International normalised ratio normal	2,016	0.267	0.868				1,435	2,047	2,047	2,153	2,047	2.153 Not an AE
COVID19 (COV D19 (ANSSEN))	Jugular vein thrombosis	1,951	1,626	0.868				1,375	1,778	2,173	2,463	0.726 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Lumbar puncture	1,909	0.857	0.857				0.857	1,122	1,698	1,698	1,698	1.698 Not an AE
COVID19 (COV D19 (ANSSEN))	Lumbar puncture abnormal	2,049	1,691	0.877				0.977	1,054	1,718	1,665	1,665	1.665 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Lung opacity	1,345	0.826	0.884				1,311	1,872	1,010	2,113	1,458	1.458 Other
COVID19 (COV D19 (ANSSEN))	Lymphocyte percentage decreased	1,691	1,273	0.861			0.179	1,279	1,041	1,05	2,08	1,05	1.05 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Magnetic resonance imaging head abnormal	2,103	1,554	0.895				0.476	1,81	1,876	2,35	1,62	1.62 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Mean cell haemoglobin concentration decreased	2,028	1,452	0.862				1,488	1,884	2,31	1,965	1,965	1.965 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Mean platelet volume increased	1,806	1,375	0.866				1,279	2,264	2,24	1,444	1,331	1.331 Other
COVID19 (COV D19 (ANSSEN))	Mechanical ventilation	2,079	1,531	0.878				0.957	1,828	2,248	1,881	1,881	1.881 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Monocyte percentage increased	1,867	1,364	0.887				1,581	1,936	1,936	1,325	1,325	1.325 Other
COVID19 (COV D19 (ANSSEN))	Neutrophil percentage decreased	1,526	1,136	0.868				1,191	1,543	1,64	0.833	2,231	0.833 Other
COVID19 (COV D19 (ANSSEN))	Neutrophil percentage increased	1,733	1,302	0.896				1,229	1,896	2,069	1,833	1,399	1.399 Other
COVID19 (COV D19 (ANSSEN))	Nonspecific reaction	2,191	0.792	0.861				0.791	0.912	1,861	0.912	2,237	1.861 Other
COVID19 (COV D19 (ANSSEN))	Off label use	1,34	0.491	0.875			7.877	1,229	1.13	0.827	1,392	1,899	1.899 Not an AE
COVID19 (COV D19 (ANSSEN))	On and off phenomenon	1,753	0.762	0.868				3,286	1,13	0.827	2,212	2,212	2,212 Other
COVID19 (COV D19 (ANSSEN))	Packed red blood cell transfusion	1,724	1,307	0.885				1,134	1,226	1,196	2,037	0.898	0.898 Other
COVID19 (COV D19 (ANSSEN))	Pain assessment	2,518	0.858	0.858				0.514	1,582	2,202	2,321	1,41	1.41 Not an AE
COVID19 (COV D19 (ANSSEN))	Peripheral embolism	2,628	0.863	0.863				0.657	1,38	1,587	2,448	0.953 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Platelet count	2,773	1,908	0.876	0.611			1,776	3,095	2,593	3,145	1,768	1.768 Not an AE
COVID19 (COV D19 (ANSSEN))	Platelet count decreased	1,865	1,295	0.887	0.609			0.292	1,477	2,059	1,499	1,429	1.429 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Platelet count normal	2,722	1,843	0.883				0.388	2,722	2,007	2,748	1,991	1,991 Not an AE
COVID19 (COV D19 (ANSSEN))	Platelet factor 4	6,028	3,382	0.865				0.388	4,274	2,592	6,288	1,842	1.842 Not an AE
COVID19 (COV D19 (ANSSEN))	Poor quality product administered	1,306						4,151	3,371	5,811	4,528	4,528	4,528 Not an AE
COVID19 (COV D19 (ANSSEN))	Prolonged labour	1,098	1,068					3,193	1,174				
COVID19 (COV D19 (ANSSEN))	Prothrombin time												

From: (b) (6)
To: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Cc: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, February 15, 2022 7:01:40 AM
Attachments: [USST_20220211.xls](#)

Hi All,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 2/11/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBO6 20220211	US Serious EBO6 20220211	US Fatal EBO6 20220211	US Infant EBO6 20220211	US Child EBO6 20220211	US Teen EBO6 20220211	US Adult EBO6 20220211	US Adult2 EBO6 20220211	US Adult3 EBO6 20220211	US Female EBO6 20220211	US Male EBO6 20220211	Comment
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time prolonged	2,591	1,663	0.91				0.397	1,505	1,941	2,564	2,915	1,472 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time shortened	2,194	1,686	0.872				1.692	2,098	2,098	2,162	2,915	1,499 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Acute respiratory failure	2,058	1,334	1,012				1.4	1,993	1,845	2,262	1,845	1,694 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Adverse drug reaction	2,871	0,861	0,865				0,918	0,977	0,861	0,867	0,861	1,474 Other
COVID19 (COV D19 (ANSEN))	Adverse event	2,018	1,055	0,872				0,905	0,738	0,738	1,507	0,733	1,507 Other
COVID19 (COV D19 (ANSEN))	Angiogram abnormal	1,904	1,366	0,902				1,443	1,463	1,463	2,192	1,786	1,320 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Angiogram cerebral abnormal	2,574	1,891	1,891				2,181	2,181	2,181	2,181	2,181	1,444 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Angiogram cerebral normal	1,542	1,542	0,869				0,485	1,884	1,823	1,073	1,273	1,407 Not an AE
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary abnormal	2,445	1,706	0,897				1,685	2,309	2,309	2,546	2,546	1,196 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary normal	1,818	1,427	0,89				1,161	2,231	1,944	1,293	1,558	1,293 Other
COVID19 (COV D19 (ANSEN))	Anticoagulant therapy	2,359	0,703	0,858				0,368	0,823	1,658	1,867	2,016	1,761 Not an AE
COVID19 (COV D19 (ANSEN))	Anticoagulant therapy	2,228	1,518	0,857		0.613		1,428	1,833	1,99	2,24	2,763	1,607 Other
COVID19 (COV D19 (ANSEN))	Arterial hypotension	2,121	1,833	0,874				0,862	2,219	1,428	1,906	1,518	1,518 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Arterogram carotid abnormal	1,795	1,128	0,862				1,135	1,178	1,386	2,344	2,344	0,891 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Arterogram carotid normal	1,698	1,436	0,88		0.61		0,326	1,222	2,32	1,773	2,344	1,621 Other
COVID19 (COV D19 (ANSEN))	Basophil count decreased	1,789	1,468	0,892		0.609		0,286	1,215	2,239	1,774	2,166	1,327 Other
COVID19 (COV D19 (ANSEN))	Blood albumin decreased	1,785	1,297	0,888				0,33	1,469	1,812	1,767	2,135	1,403 Other
COVID19 (COV D19 (ANSEN))	Blood calcium decreased	1,862	1,381	0,905				0,397	1,4	2,085	1,862	2,23	1,472 Other
COVID19 (COV D19 (ANSEN))	Blood chloride increased	1,907	1,41	0,944				0,444	1,306	2,096	1,988	2,278	1,391 Other
COVID19 (COV D19 (ANSEN))	Blood fibrinogen decreased	3,22	2,384	0,883				0,504	1,797	2,024	2,024	2,86	1,059 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Blood magnesium increased	1,838	1,383	0,923				0,264	1,157	1,893	2,413	1,386	1,186 Other
COVID19 (COV D19 (ANSEN))	Blood potassium decreased	1,682	1,231	0,911				0,529	1,197	1,489	1,853	2,044	1,213 Other
COVID19 (COV D19 (ANSEN))	Blood sodium increased	1,618	1,069	0,860				1,506	1,421	1,609	1,819	1,115	1,219 Other
COVID19 (COV D19 (ANSEN))	Blood urea decreased	1,655	1,354	0,858				0,227	1,389	1,837	1,223	1,874	0,874 Other
COVID19 (COV D19 (ANSEN))	Blood urea increased	1,832	1,246	0,878				1,075	2,002	2,002	1,681	2,029	1,584 Other
COVID19 (COV D19 (ANSEN))	COV D-19 pneumonia	2,028	1.4	1.1				1.67	2.126	1.99	2.24	2.191	1,885 Other
COVID19 (COV D19 (ANSEN))	CSF protein increased	2,752	2,118	0,861				1,773	2,104	2,21	1,083	2,485	2,21 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Cerebral haemorrhage	2,307	1,612	0,918				0,514	1,702	1,826	1,454	3.2	1,089 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Cerebral mass effect	2,862	1,197	0,922				1,446	1,39	1,304	3,902	1,024	1,024 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Cerebral thrombosis	2,278	1,635	0,857				1.12	1,305	1,99	1,522	2.99	1,211 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Cerebral venous sinus thrombosis	2,462	2.18	0.904				0.518	2.267	2.238	3.863	1.185	1,185 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Computerised tomogram head abnormal	1,904	1,704	0,956		0.612		0,816	1,497	2,177	1,828	1,973	1,233 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Computerised tomogram head normal	1,992	1,371	0,899				0,585	1,885	1,965	2,234	1,823	1.52 Not an AE
COVID19 (COV D19 (ANSEN))	Computerised tomogram thorax abnormal	2,085	1,443	0,908				0,458	1,408	2,043	2,287	2,006	1,654 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Computerised tomogram thorax normal	2,665	1,787	1,014				0,457	2,141	2,043	2,246	3.02	1,984 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Deep vein thrombosis	1,927	1,307	0,872				1,174	1,297	2,062	1,723	1,889	1,811 Labeled
COVID19 (COV D19 (ANSEN))	Endotracheal intubation	1,863	1,176	0,862				1,783	1,298	1,862	2,078	1,994	1,298 Other
COVID19 (COV D19 (ANSEN))	Eosinophil count decreased	1,772	1,395	0,885		0.609		0,302	1,303	1,683	2,025	1,39	1,39 Other
COVID19 (COV D19 (ANSEN))	Feeling cold	1,779	0,843	0,869				1,106	2,01	1,455	0,964	1,844	1,414 Labeled
COVID19 (COV D19 (ANSEN))	Fibrin D dimer	2,384	1,241	0,879				0,441	2,175	2,132	2,48	1,911	1,979 Other
COVID19 (COV D19 (ANSEN))	Fibrin D dimer increased	1,986	1,453	0,866		0.612		0,316	1,669	2,192	2,434	1.59	1,59 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Fibrin D dimer normal	1,968	1,092	0,863				0,435	1,831	2,038	1.03	2,118	1,281 Not an AE
COVID19 (COV D19 (ANSEN))	Gain weight	2,308	1,084	0,808				0,408	0,877	1,754	1,94	2,04	1,94 Labeled
COVID19 (COV D19 (ANSEN))	Globulins increased	1,873	1,303	0,877				0.4	1,345	1,627	2,188	1,877	1,231 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Glucose urine present	1,771	1.21	0.889				1.349	1.289	1.429	1.429	1.087	1.087 Other
COVID19 (COV D19 (ANSEN))	Gullain-Barre syndrome	2,331	1,836	0,87				1,606	1,606	1,606	2,143	1,606	2,143 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Haematuria decreased	1,823	1,291	0,906		0.606		0.425	1,947	2,006	1,751	1,935	1,395 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Haemoglobin decreased	1,767	1,207	0.9		0.607		0.319	1,861	2,077	1,628	1,386	1,386 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Heparin-induced thrombocytopenia test	5.57	5.57	0.882				4.083	5.207	5.207	7.205	5.207	2,099 Not an AE
COVID19 (COV D19 (ANSEN))	Heparin-induced thrombocytopenia test positive	6,408	3,498	0,861				0,544	4,722	5.62	6.732	7.733	1,821 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Hypoxia	1.88	1.3	0.924				1.469	1.58	1,749	2,248	1,949	1,973 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Immunoglobulin therapy	2,095	1,797	0,861				0,522	1,91	2,515	1,457	1,665	1,665 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Intensive care	1,845	1,425	1,043				0,029	1,479	2,055	2,023	2,289	1.54 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	International normalised ratio increased	1,862	1,287	0,865		0.747		0,396	1,617	1,947	1,471	2.34	1,622 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	International normalised ratio normal	2,016	1,246	0,866				1,432	2,045	2,129	2,045	1,247	1,247 Not an AE
COVID19 (COV D19 (ANSEN))	Jugular vein thrombosis	1,961	1,627	0,885				1,374	1.17	1,374	2,393	1,714	0,727 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Lumbar puncture	1,911	1,358	0,853				1,223	1,506	1,506	2.15	2,004	1,686 Not an AE
COVID19 (COV D19 (ANSEN))	Lumbar puncture abnormal	2,069	1,722	0,865				1,402	1,599	1,701	1,566	1,701	1,701 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Lumbar puncture normal	1,712	1,276	0,854				1,405	1,706	1,866	2,179	1,486	1,486 Other
COVID19 (COV D19 (ANSEN))	Lymphocyte percentage decreased	2,002	1,704	0,902				1,034	2,105	1,981	1,984	1,984	1,984 Other
COVID19 (COV D19 (ANSEN))	Magnetic resonance imaging head abnormal	2,09	1,536	0,884				1,792	2,328	1,878	2,108	1,815	1,615 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Magnetic resonance imaging head normal	2,098	1,476	0,861		0.612		1,211	1,511	2,111	2,387	1,852	1,428 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Mean platelet volume increased	1,863	1,372	0,895				0,337	1,266	2,272	1,426	1,332	1,332 Other
COVID19 (COV D19 (ANSEN))	Mechanical ventilation	2,098	1,529	1,023				0,478	0,999	2,254	1,842	1,903	1,976 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Mechanical ventilation	1,588	1,263	0,889		0.609		0,257	0,931	1,463	1,603	1,603	1,112 Other
COVID19 (COV D19 (ANSEN))	Neutrophil percentage decreased	1,506	1,202	0,869				0.13	1,179	1,642	1,519	2,199	0,841 Other
COVID19 (COV D19 (ANSEN))	Neutrophil percentage increased	1,752	1,302	0,902				0,235	1,132	2,092	1,879	2,016	1,423 Other
COVID19 (COV D19 (ANSEN))	Non-specific reaction	2,917	1,791	0,878				0,748	0,612	0,612	1,247	1,388	1,049 Other
COVID19 (COV D19 (ANSEN))	Off label use	1.34	0.496	0.873				7.951	2.19	1.143	1.388	0.85	1.914 Not an AE
COVID19 (COV D19 (ANSEN))	On and off phenomenon	1,753	0,781	0,882				3.285	1.54	1.54	2.214	2.11	1.078 Other
COVID19 (COV D19 (ANSEN))	Packed red blood cell transfusion	1,746	1,283	0,872				1,214	1,193	1,175	1,175	0.879	0,879 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Pain assessment	2,556	0,878	0,861				0,513	1,586	2.23	1.06	2.261	1,442 Not an AE
COVID19 (COV D19 (ANSEN))	Peripheral embolism	2,627	1,486	0,861				0,637	1,609	1,609	1,56	0,953	0,953 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Platelet count	2,772	2,246	0,906		0.611		0,472	1,769	3,092	2,572	2,408	1,779 Not an AE
COVID19 (COV D19 (ANSEN))	Platelet count decreased	1,871	1,301	0,891		0.609		0.29	1,492	2,067	1,496	2,174	1,428 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSEN))	Platelet count normal	2,728	1,829	0,881				0,388	2,011	2,716	3,101	1,617	1,627 Not an AE
COVID19 (COV D19 (ANSEN))	Platelet factor 4	6,027	3,391	0,862				4,285	2,593	0,814	6,284	1,849	1,849 Not an AE
COVID19 (COV D19 (ANSEN))	Poor quality product administered	1,306	0,867	0,867				4,151	3,402	5,755	4,506	4,039	4,039 Not an AE
COVID19 (COV D19 (ANSEN))	Prolonged labour	1,088	1,065	0,868				3,333	3,333	1,			

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: RE: Weekly data mining
Date: Tuesday, February 22, 2022 5:29:33 AM
Attachments: [USST_20220218.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 2/18/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20220218	US Serious EB05 20220218	US Fatal EB05 20220218	US Infant EB05 20220218	US Child EB05 20220218	US Teen EB05 20220218	US Adult1 EB05 20220218	US Adult2 EB05 20220218	US Adult3 EB05 20220218	US Female EB05 20220218	US Male EB05 20220218	Comment
COVID19 (COV D19 (ANSSEN))	Activated partial thromboplastin time prolonged	2,267	1,671	0.929				0.397	1,214	2,353	1,771	2,381	1,471 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Activated partial thromboplastin time shortened	2,186	1,687	0.873				1,683	2,144	2,918	1,711	2,918	1,504 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Acute respiratory failure	2,062	1,342	1.02				0.452	1,431	2,024	1,886	2,321	1,7 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Adverse drug reaction	0,987	0,918	0.807				0,918	0,972	0,807	1,448	1,448	1,448 Other
COVID19 (COV D19 (ANSSEN))	Adverse event	2,018	1,055	0.874				0.9	0,769	1,786	1,509	1,786	1,509 Other
COVID19 (COV D19 (ANSSEN))	Angiogram abnormal	1,524	1,363	0.803					1,444	1,457	1,789	2,18	1,328 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Angiogram cerebral abnormal	0,903	0,903	0.903				0.485	1,179	2,013	1,703	2,170	1,444 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Angiogram cerebral normal	2,157	1,505	0.871					1,878	2,383	1,749	2,383	1,378 Not an AE
COVID19 (COV D19 (ANSSEN))	Angiogram pulmonary abnormal	2,454	1,702	0.901				0.425	1,666	2,331	1,666	2,565	1,962 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Angiogram pulmonary normal	1,805	1,407	0.869					1,171	1,806	1,283	1,714	1,283 Other
COVID19 (COV D19 (ANSSEN))	Anticoagulant therapy	2,359	0,818	0.859				0.368	1,077	1,522	1,392	2,044	1,765 Not an AE
COVID19 (COV D19 (ANSSEN))	Antipsychotic therapy	2,237	1,519	0.962					1,845	2,014	2,238	2,161	1,629 Other
COVID19 (COV D19 (ANSSEN))	Areflexia	2,131	1,831	0.875				0.612	0,859	2,257	1,413	1,899	1,527 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Arterigram carotid abnormal	1,795	1,126	0.863					1,135	1,179	1,381	2,328	0,862 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Basophil count decreased	1,852	1,444	0.886				0.326	1,389	2,112	1,647	2,233	1,639 Other
COVID19 (COV D19 (ANSSEN))	Basophil percentage decreased	1,788	1,479	1.21				0.608	0,286	1,26	1,801	1,318	1,318 Other
COVID19 (COV D19 (ANSSEN))	Blood albumin decreased	1,792	1,309	0.896					0,327	1,467	1,767	2,17	1,429 Other
COVID19 (COV D19 (ANSSEN))	Blood calcium decreased	1.88	1,381	0.929					1,389	2,112	1,647	2,233	1,473 Other
COVID19 (COV D19 (ANSSEN))	Blood chloride increase	1,906	1,441	0.884					1,296	1,948	1,384	2,283	1,384 Other
COVID19 (COV D19 (ANSSEN))	Blood fibrinogen decreased	1,223	2,345	0.84					1,798	1,928	1,856	4,249	1,048 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Blood lactate dehydrogenase increased	1,604	1,253	0.878				0.612	1,056	2,003	1,153	1,597	1,389 Not an AE
COVID19 (COV D19 (ANSSEN))	Blood magnesium increased	1,818	1,384	0.925					1.14	1,935	1,818	1,818	1,187 Other
COVID19 (COV D19 (ANSSEN))	Blood potassium decreased	1,872	1,224	0.914				0.527	1,119	1,483	1,652	2,038	1,201 Other
COVID19 (COV D19 (ANSSEN))	Blood sodium decreased	1,821	1,529	0.878				0.609	1,342	2,017	1,605	1,904	1,586 Not an AE
COVID19 (COV D19 (ANSSEN))	Blood sodium increased	1,634	1,157	0.912					1,491	1,509	1,112	2,206	0,945 Other
COVID19 (COV D19 (ANSSEN))	Blood urea decreased	1,673	1,359	0.863				0.224	1,403	1,939	1,214	2,106	0,871 Other
COVID19 (COV D19 (ANSSEN))	Blood urea increased	1,842	1,257	0.881					2,052	2,068	1,682	1.59	1.59 Other
COVID19 (COV D19 (ANSSEN))	COV D-19 pneumonia	2,031	1,405	1.106					1,698	2,166	1,888	2.26	1,882 Other
COVID19 (COV D19 (ANSSEN))	CSF protein increased	2,731	2,123	0.862					1,774	2,93	1,084	2,486	2,215 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Cerebral hemorrhage	2.32	1,602	0.921				0.514	1,678	1.45	3.164	3.164	1,112 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Cerebral mass effect	2,883	1,943	0.913					1,445	1,381	1,197	3,789	1,004 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Cerebral thrombosis	2,279	1,859	0.862					1,824	1.12	2,821	2,821	2,005 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Cerebral venous sinus thrombosis	3,243	2,174	0.905					2,518	2,223	3,852	3,852	1,187 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Chest X-ray abnormal	1,771	1,201	0.93					1,349	1,669	1,719	2,019	1,537 Confounded/indication
COVID19 (COV D19 (ANSSEN))	Computed tomogram head abnormal	2,877	1,704	0.865				0.611	0,817	2,124	2,048	2,647	2,068 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Computed tomogram head normal	1,988	1,362	0.901					1,385	1,663	1.96	2,616	1,509 Not an AE
COVID19 (COV D19 (ANSSEN))	Computed tomogram thorax abnormal	2,078	1,428	0.858					1,428	2,037	2,037	2,28	1,448 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Deep vein thrombosis	2,588	1,78	1,043					2,162	2,287	3,028	3,533	1,978 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Endotracheal intubation	1,935	1,375	1.213					1,296	2,082	2,082	1,924	1,807 Labeled
COVID19 (COV D19 (ANSSEN))	Eosinophil count decreased	1,755	1,359	0.861					1,318	1,955	1,618	2,045	1,158 Other
COVID19 (COV D19 (ANSSEN))	Eosinophil percentage decreased	1,771	1,406	0.897				0.609	1,309	2,104	1,698	2,078	1,373 Other
COVID19 (COV D19 (ANSSEN))	Feeling cold	1.78	0,837	1.206					2,013	1,457	1,886	1.85	1,418 Labeled
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer	2,246	1,346	0.863					2,364	2,143	2,084	2,486	1,688 Other
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer increased	2,166	1,443	0.965				0.612	1,664	2.23	2,175	2.42	1,581 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer normal	1,958	1,107	0.886					1,63	2,109	1,103	2,139	1,382 Not an AE
COVID19 (COV D19 (ANSSEN))	Gaze palsy	2,305	1.99	0.405					1,875	2,257	1,76	1,763	1,615 Labeled
COVID19 (COV D19 (ANSSEN))	Glaucoma present	1,871	1,315	0.882					0.4	1,329	1.65	1,656	1,213 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Glucose urine increased	1,784	2,462	0.88					1.33	1,362	2,315	1,813	1,081 Other
COVID19 (COV D19 (ANSSEN))	Gullain-Barre syndrome	2,337	1,848	0.911					1,977	2,199	1,959	2,315	1,199 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Haematuria decreased	1,825	1,295	0.909				0.606	0.425	1,339	2,038	1,746	1,399 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Haemoglobin decreased	1,768	1,294	0.919				0.607	1,298	1,409	1,917	2,086	1,389 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Heparin-induced thrombocytopenia test	5.57	3,623	0.868					4,086	5,207	5,341	7,209	3,008 Not an AE
COVID19 (COV D19 (ANSSEN))	Heparin-induced thrombocytopenia test positive	6,409	3,503	0.863				0.544	4,723	5,631	6,763	7,729	1,825 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Hypoxia	1,863	1,311	0.824					1,472	1,974	1,974	2,283	1,533 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Immunoglobulin therapy	2,108	1,804	0.863					1,927	2,517	1,447	2,252	1,674 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Intensive care	1,837	1,42	1.057					1,468	2,084	2,022	2,303	1,533 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	International normalised ratio increased	1,856	1,286	0.895				0.747	1,605	1.98	1,85	2,135	1,621 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	International normalised ratio normal	2,016	1,243	0.888					2,042	2,042	2.12	1.25	1.25 Not an AE
COVID19 (COV D19 (ANSSEN))	Jugular vein thrombosis	1,951	1,627	0.867					1,374	1,174	1,416	2,408	0,727 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Lumbar puncture	1,812	1,344	0.855					1,219	1,855	2,149	1,009	1,662 Not an AE
COVID19 (COV D19 (ANSSEN))	Lumbar puncture abnormal	2,096	1,728	0.89					1,012	2,606	1,059	1,703	1,743 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Lung aspirate	1,714	1,274	0.836					1,607	1,726	1,186	1,815	1,459 Other
COVID19 (COV D19 (ANSSEN))	Lymphocyte percentage decreased	1,902	1,289	0.891					1,028	1,111	1,958	1,129	1,306 Other
COVID19 (COV D19 (ANSSEN))	Magnetic resonance imaging head abnormal	2,087	1,532	0.893					1,794	1,873	2,12	2,327	1,618 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Mean cell haemoglobin concentration decreased	2,098	1,474	0.869				0.612	1,474	1,227	2,332	2,004	1,427 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Mean platelet volume increased	1,866	1,392	0.897					1,237	1,403	2.186	1,332	1,332 Other
COVID19 (COV D19 (ANSSEN))	Mechanical ventilation	2,104	1,555	0.895					0,995	2,285	1,888	1,974	1,981 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Monocyte percentage increased	1,561	1,296	0.889				0.609	1,563	1,943	1,943	2,065	1,405 Other
COVID19 (COV D19 (ANSSEN))	Neutrophil percentage decreased	1,498	1,204	0.87					1,174	1,857	1.51	2,221	0,834 Other
COVID19 (COV D19 (ANSSEN))	Neutrophil percentage increased	1.75	1,327	0.911					1,125	2,128	1,878	2,054	1,413 Other
COVID19 (COV D19 (ANSSEN))	Non-specific reaction	2,162	1,734	0.876					1,407	0,812	0,812	1,05	1,05 Other
COVID19 (COV D19 (ANSSEN))	Off label use	1.34	0.569	0.874				8.015	1,208	1.176	0.85	1.41	1,922 Not an AE
COVID19 (COV D19 (ANSSEN))	On and off phenomenon	1,763	0,762	0.863					3,288	2.143	1,498	2,221	1,528 Other
COVID19 (COV D19 (ANSSEN))	Packed red blood cell transfusion	1,741	1,238	0.883					1,214	1,183	1,157	2,049	0,871 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Pain assessment	2,552	0,876	0.867				0.513	1,569	2,224	1,051	2,241	1,429 Not an AE
COVID19 (COV D19 (ANSSEN))	Peripheral embolism	2,163	1,487	0.863					0,657	1,059	1,582	2,469	0,953 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Platelet count	2,773	2,243	0.908				0.611	0,472	1,805	3.05	3,122	1,781 Not an AE
COVID19 (COV D19 (ANSSEN))	Platelet count decreased	1,868	1,298	0.896				0.609	0,289	1,484	2,078	2,185	1,418 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Platelet count normal	2,726	1,941	0.902					0,388	2,716	1,984	3,118	1,641 Not an AE
COVID19 (COV D19 (ANSSEN))	Platelet factor 4	6,027	3,397	0.864					4,294	2.8	0,814	1,855	1,855 Not an AE
COVID19 (COV D19 (ANSSEN))	Poor quality product administered	1,306						0.965	3,807	2,948	4,607	4,236	3,729 Not an AE
COVID19 (COV D19 (ANSSEN))	Prolonged intuse												

From: (b) (6)
To: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Cc: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, March 1, 2022 5:57:24 AM
Attachments: [USST_20220225.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 2/25/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBOS 2020/2021	US Serious EBOS 2020/2021	US Fatal EBOS 2020/2021	US Infant EBOS 2020/2021	US Child EBOS 2020/2021	US Teen EBOS 2020/2021	US Adult EBOS 2020/2021	US Adult EBOS 2020/2021	US Adult EBOS 2020/2021	US Female EBOS 2020/2021	US Male EBOS 2020/2021	Comment
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,515	1,515	0	0	0	0	1,515	1,515	1,515	1,515	1,515	1.45 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time shortened	2,174	1,672	0,873	0	0	0	1,676	2,111	2,112	2,112	2,112	1.5 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory failure	2,888	1,241	0,452	0	0	0	1,452	2,034	2,034	2,034	2,034	1.72 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Adverse drug reaction	2,871	0,961	0,37	0	0	0	0,518	0,805	0,689	0,689	0,689	1.603 Other
COVID-19 (COVID-19 (JANSSEN))	Adverse event	2,018	1,064	0,877	0	0	0	0,925	0,765	0,765	0,765	0,765	1.51 Other
COVID-19 (COVID-19 (JANSSEN))	Angiogram abnormal	0,135	0,135	0	0	0	0	0,135	0,135	0,135	0,135	0,135	1.326 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral abnormal	2,556	1,881	0,902	0	0	0,485	2,134	2,015	2,015	2,015	2,015	1.437 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral normal	2,154	1,522	0,873	0	0	0	1,874	1,811	1,842	1,842	1,842	1.407 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Angiogram pulmonary abnormal	1,443	1,088	0,425	0	0	0	1,088	1,237	1,237	1,237	1,237	1.903 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram pulmonary normal	1,812	1,421	0,803	0	0	0	1,168	2,216	2,216	2,216	2,216	1.308 Other
COVID-19 (COVID-19 (JANSSEN))	Antibody test	0,359	0,317	0,163	0	0	0	0,163	0,117	0,117	0,117	0,117	1.744 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Anticoagulant therapy	2,229	1,516	0,96	0,612	0	0	0,427	0,811	0,775	0,775	0,775	2.246 Other
COVID-19 (COVID-19 (JANSSEN))	Areflexia	2,118	1,809	0,806	0	0	0	0,86	2,258	2,258	2,258	2,258	1.519 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Aterogram carotid abnormal	1,78	1,112	0,376	0	0	0	1,109	1,178	1,386	1,386	1,386	0.883 Other
COVID-19 (COVID-19 (JANSSEN))	Basophil count decreased	1,891	1,431	0,886	0	0,61	0	0,325	1,21	2,339	1,785	1,785	1.314 Other
COVID-19 (COVID-19 (JANSSEN))	Basophil percentage decreased	1,797	1,477	0,906	0	0,008	0	0,286	1,206	2,251	1,83	1,83	2.203 Other
COVID-19 (COVID-19 (JANSSEN))	Blood albumin decreased	1,791	1,306	0,9	0	0	0	0,327	1,456	1,873	1,873	1,873	1.419 Other
COVID-19 (COVID-19 (JANSSEN))	Blood calcium decreased	1,878	1,38	0,912	0	0	0	0,394	1,378	2,113	1,86	1,86	2.224 Other
COVID-19 (COVID-19 (JANSSEN))	Blood chloride increased	1,997	1,384	0,842	0	0	0	0,442	1,202	2,113	1,84	1,84	2.265 Other
COVID-19 (COVID-19 (JANSSEN))	Blood fibrinogen decreased	3,124	2,342	0,886	0	0	0	0,504	1,803	1,926	0,987	0,987	4.253 Other
COVID-19 (COVID-19 (JANSSEN))	Blood magnesium increased	1,896	1,391	0,863	0	0	0	0,263	1,14	1,961	1,812	1,812	2.462 Other
COVID-19 (COVID-19 (JANSSEN))	Blood potassium decreased	1,681	1,236	0,92	0	0	0	0,527	1,192	1,5	2,011	1,865	1.235 Other
COVID-19 (COVID-19 (JANSSEN))	Blood sodium decreased	1,819	1,324	0,881	0,609	0	0	1,331	2,019	1,665	1,665	1,665	1.597 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Blood sodium increased	1,652	1,162	0,912	0	0	0	1,476	1,932	1,135	1,135	1,135	2.148 Other
COVID-19 (COVID-19 (JANSSEN))	Blood urea decreased	1,675	1,365	0,885	0	0	0,225	1,286	1,36	1,983	1,983	1,983	0.991 Other
COVID-19 (COVID-19 (JANSSEN))	Blood urea increased	1,854	1,257	0,89	0	0	0	1,008	2,044	1,711	1,711	1,711	2.087 Other
COVID-19 (COVID-19 (JANSSEN))	COVID-19 pneumonia	2,04	1,416	1,122	0	0	0	1,731	2,186	1,923	1,923	1,923	1.912 Other
COVID-19 (COVID-19 (JANSSEN))	CFP protein increased	2,716	2,108	0,866	0	0	0	1,762	2,037	1,077	2,482	2,482	2.2 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Central haemorrhage	2,32	1,823	0,912	0,514	0	0	1,681	1,883	1,448	3,158	3,158	1.145 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Central mass effect	2,887	1,885	0,912	0,522	0	0	1,409	1,383	1,174	3,703	3,703	0.993 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Central thrombosis	2,279	1,609	0,862	0,512	0	0	1,12	1,617	1,617	1,617	1,617	1.205 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Central venous sinus thrombosis	3,243	2,168	0,907	0,517	0	0	2,257	2,226	2,226	3,847	3,847	1.189 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Chest X-ray abnormal	1,779	1,27	0,929	0,348	0	0	1,329	1,876	1,791	2,023	2,023	1.564 Confounded-indication
COVID-19 (COVID-19 (JANSSEN))	Completed tomogram head abnormal	2,566	1,956	0,965	0,511	0	0	1,684	2,327	2,028	3,028	3,028	1.741 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Completed tomogram head normal	1,991	1,383	0,802	0,391	0	0	1,067	1,804	1,967	2,233	2,233	1.516 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Completed tomogram thorax abnormal	2,073	0,914	0,314	0,485	0	0	0,438	2,031	1,829	2,283	2,283	1.974 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Deep vein thrombosis	2,885	1,77	0,57	0,457	0	0	2,155	2,263	1,938	3,248	3,248	1.974 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Endotracheal intubation	1,384	1,376	1,183	0,375	0	0	1,348	2,094	1,734	2,094	2,094	1.816 Labeled
COVID-19 (COVID-19 (JANSSEN))	Eosinophil count decreased	1,792	1,392	0,89	0,512	0	0	1,205	1,89	1,612	2,057	2,057	1.417 Other
COVID-19 (COVID-19 (JANSSEN))	Eosinophil percentage decreased	1,773	1,408	0,902	0,301	0	0,609	1,301	2,088	1,734	2,077	2,077	1.384 Other
COVID-19 (COVID-19 (JANSSEN))	Fasting creatinine	1,779	1,325	0,872	0,295	0	0	1,293	1,615	0,967	1,85	1,85	1.85 Labeled
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer	2,305	1,241	0,886	0,44	0	0	2,184	2,15	1,816	2,494	2,494	1.693 Other
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer increased	2,161	1,443	0,964	0,314	0	0	1,683	2,241	2,182	2,462	2,462	1.602 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer normal	1,963	1,452	0,913	0,452	0	0	1,1	2,065	1,024	2,139	2,139	1.372 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Gaze palsy	2,305	1,09	0,881	0,405	0	0	0,881	2,26	1,752	1,302	2,343	1.608 Labeled
COVID-19 (COVID-19 (JANSSEN))	Glycolysis increased	1,877	0,4	0,163	0,4	0	0	0,163	1,828	1,698	2,287	2,287	2.208 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Glucose urine present	1,799	1,236	0,895	0,31	0	0	1,37	1,87	1,465	2,344	2,344	1.068 Other
COVID-19 (COVID-19 (JANSSEN))	Gullström-Barro syndrome	2,338	1,846	0,871	0,421	0,006	0	1,579	2,078	1,633	2,344	2,344	1.712 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin decreased	1,832	1,399	0,919	0,424	0,007	0	1,209	2,037	1,775	2,179	2,179	1.411 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin increased	1,771	1,257	0,909	0,317	0,007	0	1,166	1,641	1,641	2,078	2,078	1.397 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Hepatitis-induced thrombocytopenia test	6,408	4,518	2,312	0,548	0,006	0,006	4,018	5,207	5,34	7,214	7,214	1.507 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Hepatitis-induced thrombocytopenia test positive	6,408	3,449	0,866	0,543	0,006	0,006	4,721	5,662	5,746	7,507	7,507	1.837 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Hypoxia	1,885	1,299	0,931	0,31	0	0	1,468	1,977	1,776	2,119	2,119	1.581 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Immunoagglutination therapy	2,104	1,606	0,905	0,422	0	0	1,405	2,24	1,44	2,44	2,44	1.602 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Intensive care	1,843	1,055	0,629	0,209	0	0	1,46	2,08	1,773	2,32	2,32	1.513 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	International normalised ratio increased	0,853	0,884	0,768	0,394	0,147	0	0,88	1,071	1,463	2,339	2,339	1.318 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	International normalised ratio normal	2,016	1,237	0,619	0,201	0	0	1,43	2,045	0,922	2,114	2,114	1.252 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Jugular vein thrombosis	1,817	1,317	0,869	0,312	0	0	1,522	1,105	1,069	2,414	2,414	0.714 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture	1,906	1,341	0,858	0,341	0	0	1,216	1,613	1,1	1,678	1,678	1.074 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture abnormal	2,096	1,733	0,919	0,312	0	0	1,054	2,815	1,959	1,618	1,618	1.782 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lung opacity	1,172	0,969	0,512	0,31	0	0	0,969	1,295	1,824	1,901	1,901	1.501 Other
COVID-19 (COVID-19 (JANSSEN))	Lymphocyte percentage decreased	1,699	1,283	0,93	0,173	0,101	0	1,02	2,1	1,964	2,104	2,104	1.161 Other
COVID-19 (COVID-19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,39	1,624	0,886	0,422	0	0	1,324	0,88	2,127	2,387	2,387	2.318 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Magnetic resonance imaging head normal	1,479	0,921	0,511	0,449	0,182	0	1,248	2,317	1,842	2,387	2,387	1.444 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mean platelet volume increased	1,936	1,391	0,88	0,336	0	0	1,285	2,345	1,445	2,231	2,231	1.338 Other
COVID-19 (COVID-19 (JANSSEN))	Mechanical ventilation	2,097	1,524	0,818	0,475	0,004	0	1,024	1,264	1,991	1,991	1,991	1.978 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Monocyte percentage increased	1,58	1,255	0,892	0,301	0,609	0	0,911	1,936	2,008	1,104	1,104	1.104 Other
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage decreased	1,499	1,202	0,872	0,129	0	0	1,186	1,646	1,501	2,209	2,209	0.844 Other
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage increased	1,746	1,293	0,811	0,231	0	0	1,011	1,884	2,117	1,84	1,84	1.417 Other
COVID-19 (COVID-19 (JANSSEN))	Nonspecific reaction	2,193	0,793	0,317	0,749	0	0	0,612	0,612	1,824	2,303	2,303	1.05 Other
COVID-19 (COVID-19 (JANSSEN))	Off-label use	1,134	0,166	0,077	0,193	0	0	1,193	1,175	0,851	1,405	1,405	1.931 Not an AE
COVID-19 (COVID-19 (JANSSEN))	On and off phenomenon	1,754	0,762	0,397	0,762	0	0	3,297	1	1	2,218	2,218	Other
COVID-19 (COVID-19 (JANSSEN))	Packed red blood cell transfusion	1,73	1,217	0,884	0,113	0	0	1,213	1,178	1,148	2,028	2,028	0.865 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Pain assessment	2,192	1,595	0,876	0,513	0	0	1,55	2,206	1,644	2,22	2,22	1.428 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Peripneumonia	2,932	1,487	0,866	0,608</								

From: (b) (6)
To: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Cc: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, March 8, 2022 5:23:58 AM
Attachments: [USST_20220304.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 3/4/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: (b) (6)
To: (b) (6) (CDC); (b) (6) (CDC); (b) (6) (CDC)
Cc: (b) (6) (CDC); (b) (6) (CDC); (b) (6) (CDC);
Subject: RE: Weekly data mining
Date: Tuesday, March 15, 2022 6:22:15 AM
Attachments: [USST_20220311.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 3/11/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, March 22, 2022 7:24:24 AM
Attachments: [USST_20220318.xls](#)

Good morning,

I am providing the data mining alerts this week as (b) (6) is on leave. Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 3/18/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

Drug	Event	US EBUS 2020/2019	US Serious EBUS 2020/2019	US Fatal EBUS 2020/2019	US Infant EBUS 2020/2019	US Child EBUS 2020/2019	US Teen EBUS 2020/2019	US Adult EBUS 2020/2019	US Female EBUS 2020/2019	US Male EBUS 2020/2019	Comment				
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,171	1,622	0.878				1,642	2,117	2,033	2,171	1,622	1,458	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,139	1,622	0.878				1,642	2,117	2,033	2,139	1,622	1,474	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,207	1,207	0.648				1,486	2,068	1,989	1,207	1,207	1,198	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,854	1,953	0.851				0,972	0,754	0,687	2,854	1,953	1,627	Other	
COVID19 (COVID19 (JANSSEN))	Adverse event	2,016	1,097	0.887				0,764	0,764	0,733	2,016	1,097	1,520	Other	
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,323	1,323	0.963				1,465	1,426	1,443	1,323	1,323	1,338	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,509	1,839	0.484				2,01	2,01	2,069	2,509	1,839	1,667	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,157	1,522	0.884				1,846	1,818	1,337	2,157	1,522	1,46	Not an AE	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,468	1,683	0.462				2,313	2,313	2,265	2,468	1,683	2,172	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary normal	1,783	1,392	0.905				1,155	2,205	1,423	1,783	1,392	1,31	Other	
COVID19 (COVID19 (JANSSEN))	Antibody test	2,371	1,838	0.876				1,638	1,638	1,638	2,371	1,838	2,024	1,71	Not an AE
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,226	1,563	0.96	0.613			1,835	2,27	2,777	2,226	1,563	1,662	Other	
COVID19 (COVID19 (JANSSEN))	Antrax	2,069	1,809	0.891				2,374	1,319	1,319	2,069	1,809	1,488	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Antigen carotid abnormal	1,765	1,311	0.862				1,112	1,31	1,337	1,765	1,311	2,184	Other	
COVID19 (COVID19 (JANSSEN))	Basophi count decreased	1,897	1,462	0.904	0.61			0,369	0,219	1,803	1,897	1,462	2,309	Other	
COVID19 (COVID19 (JANSSEN))	Basophi percentage decreased	1,799	1,461	0.919	0.608			1,19	2,291	1,834	1,799	1,461	1,345	Other	
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,794	1,366	0.921				1,834	1,827	1,827	1,794	1,366	1,435	Other	
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,891	1,39	0.936				1,401	2,195	1,926	1,891	1,39	1,516	Other	
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1,852	1,363	0.953				1,263	2,066	1,971	1,852	1,363	1,355	Other	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,915	2,269	0.894				1,724	1,922	0,843	2,915	2,269	1,941	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,827	1,376	0.928				1,145	1,928	1,843	1,827	1,376	2,447	Other	
COVID19 (COVID19 (JANSSEN))	Blood potassium decreased	1,684	1,241	0.937				1,489	2,119	1,856	1,684	1,241	1,279	Other	
COVID19 (COVID19 (JANSSEN))	Blood sodium decreased	1,817	1,32	0.894	0.609			1,341	2,025	1,655	1,817	1,32	1,612	Not an AE	
COVID19 (COVID19 (JANSSEN))	Blood sodium increased	1,595	1,141	0.916				1,427	1,49	1,185	1,595	1,141	1,01	Other	
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,683	1,38	0.886			0.217	1,416	2,019	1,52	1,683	1,38	0,92	Other	
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1,859	1,275	0.913				1,903	2,045	1,752	1,859	1,275	1,643	Other	
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	2,051	1,417	1,137				1,795	2,227	1,984	2,051	1,417	2,34	Other	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,667	2,091	0.878				1,901	2,949	1,063	2,667	2,091	2,234	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,332	1,660	0.931			0.512	1,373	1,687	1,489	2,332	1,660	1,166	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,865	1,962	0.93			0.52	1,355	1,645	1,181	2,865	1,962	1,101	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,297	1,613	0.877				1,122	1,263	1,605	2,297	1,613	1,204	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,233	2,142	0.913				2,224	2,884	0,874	3,233	2,142	1,322	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Chen X-ray abnormal	1,774	1,272	0.936				1,309	1,807	1,837	1,774	1,272	1,606	Corbunded-indication	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	1,774	1,272	0.936				1,309	1,807	1,837	1,774	1,272	1,738	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head normal	1,999	1,367	0.896	0.611			1,977	1,977	1,848	1,999	1,367	1,831	Not an AE	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,425	1,043	0.875				1,043	2,054	2,054	1,425	1,043	1,066	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax normal	1,554	1,172	0.86				1,149	1,589	1,528	1,554	1,172	1,516	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,58	1,778	0.867				2,168	2,291	3,024	2,58	1,778	1,997	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Endotracheal intubation	1,845	1,405	0.933				1,383	1,933	2,187	1,845	1,405	1,856	Labeled	
COVID19 (COVID19 (JANSSEN))	Eosinophi count decreased	1,773	1,324	0.904				1,247	2,162	1,56	1,773	1,324	1,365	Other	
COVID19 (COVID19 (JANSSEN))	Eosinophi percentage decreased	1,799	1,369	0.897	0.609			1,268	2,127	1,62	1,799	1,369	1,417	Other	
COVID19 (COVID19 (JANSSEN))	Fatigue	1,778	1,266	0.885				1,455	0,976	1,848	1,778	1,266	1,421	Labeled	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,296	1,262	0.895			0.612	2,217	2,198	1,328	2,296	1,262	1,73	Other	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,169	1,468	0.869				2,116	2,475	2,475	2,169	1,468	1,626	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,94	1,096	0.846				2,088	1,022	1,262	1,94	1,096	1,35	Not an AE	
COVID19 (COVID19 (JANSSEN))	Gate palsy	2,903	1,893	0.902				2,402	2,269	1,269	2,903	1,893	1,268	Labeled	
COVID19 (COVID19 (JANSSEN))	Globose increased	1,874	1,287	0.895				1,27	1,699	1,679	1,874	1,287	1,266	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Glomerular filtration rate decreased	1,756	1,148	0.827				1,024	1,903	2,001	1,756	1,148	1,362	Other	
COVID19 (COVID19 (JANSSEN))	Glycosuria present	1,765	1,249	0.896				1,296	1,45	1,449	1,765	1,249	1,415	Other	
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2,329	1,859	0.885			0.432	1,638	2,953	1,629	2,329	1,859	2,168	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Haemorrhoid increased	1,386	1,041	0.864	0.605			1,041	1,384	1,224	1,386	1,041	1,433	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,768	1,262	0.934	0.606			1,143	1,609	1,697	1,768	1,262	1,1	1,41	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Heart-induced thrombocytopenia test	3,522	3,522	0.894				4,447	5,434	4,766	3,522	3,522	3,268	Not an AE	
COVID19 (COVID19 (JANSSEN))	Heart-induced thrombocytopenia test positive	1,738	1,346	0.872			0.542	6,173	6,434	0,741	1,738	1,346	1,738	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,892	1,295	0.897				1,204	1,816	1,629	1,892	1,295	1,824	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,099	1,78	0.876				1,969	2,051	1,409	2,099	1,78	1,731	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Intensive care	1,837	1,409	1,008	0.746			1,452	2,04	2,045	1,837	1,409	1,564	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,842	1,386	0.882				1,397	1,479	1,479	1,842	1,386	1,318	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2,015	1,416	0.862				2,065	0,926	2,018	2,015	1,416	1,275	Not an AE	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1,916	1,489	0.881				1,361	1,158	2,367	1,916	1,489	0,715	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,824	1,324	0.871				1,265	2,157	1,937	1,824	1,324	1,708	Not an AE	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,105	1,735	1,008				2,749	1,047	1,367	2,105	1,735	1,838	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Lung opacity	1,735	1,274	0.937				1,786	1,786	1,699	1,735	1,274	1,542	Other	
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,829	1,315	0.915			0.235	1,075	2,081	1,006	1,829	1,315	2,319	Other	
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage increased	1,409	1,141	0.904	0.607			1,085	1,522	1,278	1,409	1,141	0,876	Other	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,084	1,516	0.891				1,865	1,865	2,123	2,084	1,516	1,644	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,106	1,502	0.937	0.612			1,281	2,278	1,972	2,106	1,502	1,468	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,591	1,415	0.917				1,286	2,394	1,563	1,591	1,415	1,422	Other	
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,195	1,520	0.913				1,913	2,271	2,013	2,195	1,520	1,903	Reviewed, Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,563	1,25	0.909	0.609			1,197	2,019	2,265	1,563	1,25	1,12	Other	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,51	1,223	0.868				1,164	1,817	1,616	1,51	1,223	0,838	Other	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,73	1,295	0.916				2,102	1,858	2,011	1,73	1,295	1,433	Other	
COVID19 (COVID19 (JANSSEN))	Nospecific reaction	2,192	0,794	0.888				1,763	0,612	0,743	2,192	0,794	1,052	Other	
COVID19 (COVID19 (JANSSEN))	Of label use	1,23	1,23	0.864				1,195	1,195	1,211	1,23	1,23	1,903	Not an AE	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,753	1,362	0.932				3,224	1,001	2,243	1,753	1,362	2,711	Other	
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,933	1,864	0.933			0.509	1,533	2,168	1					

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: RE: Weekly data mining
Date: Tuesday, March 29, 2022 6:11:20 AM
Attachments: [USST_20220325.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 3/25/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: RE: Weekly data mining
Date: Tuesday, April 5, 2022 6:42:16 AM
Attachments: [USST_20220401.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/1/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB04 20220401	US Barbus EB05 20220401	US Falmi EB04 20220401	US Inhami EB05 20220401	US CNH1 EB04 20220401	US Team EB05 20220401	US Aduri EB05 20220401	US Aduro EB05 20220401	US Aduro EB05 20220401	US Femur EB05 20220401	US Male EB05 20220401	Comment		
COVID-19 (COVID-19 (JANSEN))	Activated partial thromboplastin time prolonged	2.11	1.52	1.57	1.57	1.57	1.57	1.57	1.57	1.57	1.57	1.57	1.57	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Activated partial thromboplastin time shortened	2.13	1.58	0.73	0.73	0.73	0.73	1.60	2.07	1.93	2.76	2.46	1.45	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Acute respiratory failure	2.08	1.58	0.44	0.44	0.44	0.44	1.49	1.49	1.49	1.49	1.49	1.49	1.49	Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Adverse drug reaction	2.81	0.99	0.87	0.87	0.87	0.87	0.91	0.78	0.87	0.87	0.87	0.87	0.87	Other
COVID-19 (COVID-19 (JANSEN))	Allergic event	2.09	1.80	0.80	0.80	0.80	0.80	0.91	0.83	0.72	2.02	1.51	1.51	Other	
COVID-19 (COVID-19 (JANSEN))	Angiogram abnormal	1.51	1.51	0.31	0.31	0.31	0.31	1.47	1.47	1.47	1.47	1.47	1.47	1.47	Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Angiogram cerebral abnormal	2.47	1.81	0.03	0.03	0.03	0.03	1.28	2.03	2.03	3.52	3.52	1.45	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Angiogram cerebral normal	2.14	1.67	0.84	0.84	0.84	0.84	1.83	1.84	1.84	1.84	1.84	1.84	1.84	Not an AE
COVID-19 (COVID-19 (JANSEN))	Angiogram pulmonary abnormal	2.41	1.61	0.03	0.03	0.03	0.03	1.26	2.03	2.02	2.72	2.72	1.97	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Arion eye abnormal	1.71	1.34	0.03	0.03	0.03	0.03	1.13	2.02	2.02	2.02	2.02	1.95	Other	
COVID-19 (COVID-19 (JANSEN))	Arthralgia	2.38	0.83	0.07	0.07	0.07	0.07	0.84	1.01	1.78	1.96	1.96	1.62	Not an AE	
COVID-19 (COVID-19 (JANSEN))	Anticoagulant therapy	1.42	0.82	0.03	0.03	0.03	0.03	1.09	1.09	1.09	1.09	1.09	1.09	1.09	Other
COVID-19 (COVID-19 (JANSEN))	Arteritis	2.05	1.74	0.88	0.88	0.88	0.88	0.87	2.05	2.05	2.05	2.05	2.05	1.82	Not an AE
COVID-19 (COVID-19 (JANSEN))	Arteriosclerosis abnormal	1.73	1.16	0.77	0.77	0.77	0.77	1.11	1.11	1.11	1.11	1.11	1.11	1.11	Other
COVID-19 (COVID-19 (JANSEN))	Basophil count decreased	1.80	1.45	0.61	0.61	0.61	0.61	1.02	2.41	1.81	2.12	2.12	0.93	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Basophil count increased	1.80	1.45	0.61	0.61	0.61	0.61	1.02	2.41	1.81	2.12	2.12	0.93	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Bleeding time increased	1.76	1.28	0.26	0.26	0.26	0.26	1.45	1.79	1.79	2.47	2.47	1.48	Other	
COVID-19 (COVID-19 (JANSEN))	Blood calcium decreased	1.87	1.32	0.42	0.42	0.42	0.42	1.31	2.11	1.91	2.28	2.28	1.55	Other	
COVID-19 (COVID-19 (JANSEN))	Blood chloride decreased	1.96	1.25	0.16	0.16	0.16	0.16	1.07	1.07	1.07	1.07	1.07	1.41	Other	
COVID-19 (COVID-19 (JANSEN))	Blood chloride increased	1.84	1.43	0.53	0.53	0.53	0.53	1.21	2.69	1.92	2.12	2.12	1.37	Other	
COVID-19 (COVID-19 (JANSEN))	Blood creatinine decreased	1.84	1.43	0.53	0.53	0.53	0.53	1.21	2.69	1.92	2.12	2.12	1.37	Other	
COVID-19 (COVID-19 (JANSEN))	Blood creatinine increased	1.84	1.43	0.53	0.53	0.53	0.53	1.21	2.69	1.92	2.12	2.12	1.37	Other	
COVID-19 (COVID-19 (JANSEN))	Blood magnesium increased	1.81	1.32	0.24	0.24	0.24	0.24	1.19	1.91	1.82	2.47	2.47	1.92	Other	
COVID-19 (COVID-19 (JANSEN))	Blood potassium decreased	1.87	1.28	0.34	0.34	0.34	0.34	1.21	1.49	2.01	1.89	1.89	1.51	Other	
COVID-19 (COVID-19 (JANSEN))	Blood sodium decreased	1.87	1.32	0.30	0.30	0.30	0.30	1.30	2.08	1.73	1.84	1.84	1.63	Not an AE	
COVID-19 (COVID-19 (JANSEN))	Blood urea decreased	1.83	1.34	0.81	0.81	0.81	0.81	1.38	1.96	1.28	2.56	2.56	0.89	Other	
COVID-19 (COVID-19 (JANSEN))	Blood urea increased	1.81	1.27	0.17	0.17	0.17	0.17	1.06	2.63	1.71	1.63	1.63	1.63	Other	
COVID-19 (COVID-19 (JANSEN))	Brain oedema	1.58	1.32	0.92	0.92	0.92	0.92	1.22	1.55	0.88	2.06	2.06	0.75	Other	
COVID-19 (COVID-19 (JANSEN))	COVID-19 pneumonia	2.07	1.39	1.07	1.07	1.07	1.07	1.35	1.68	1.68	2.85	2.85	1.47	Other	
COVID-19 (COVID-19 (JANSEN))	CSF protein increased	2.68	2.09	0.73	0.73	0.73	0.73	1.84	2.96	1.09	2.32	2.32	1.48	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	CSF red blood cell count positive	1.84	1.33	0.73	0.73	0.73	0.73	1.09	1.09	1.09	1.09	1.09	1.09	1.09	Other
COVID-19 (COVID-19 (JANSEN))	Cerebral ischaemia	1.38	1.68	0.98	0.98	0.98	0.98	0.51	1.48	1.78	1.48	1.48	1.15	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Cerebral mass effect	2.38	1.95	0.25	0.25	0.25	0.25	0.19	1.61	1.75	3.94	3.94	1.09	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Cerebral thrombosis	2.30	1.62	0.76	0.76	0.76	0.76	1.15	2.29	1.65	3.19	3.19	1.65	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Cerebral venous sinus thrombosis	1.96	1.96	0.25	0.25	0.25	0.25	0.51	2.27	0.74	3.84	3.84	1.09	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Chest X-ray abnormal	1.72	1.34	0.84	0.84	0.84	0.84	1.34	1.34	1.34	1.64	1.64	1.62	Other	
COVID-19 (COVID-19 (JANSEN))	Computed tomogram head abnormal	2.38	1.64	0.94	0.94	0.94	0.94	1.17	2.32	1.96	3.23	3.23	1.73	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Computed tomogram head normal	1.91	1.39	0.94	0.94	0.94	0.94	1.39	1.39	1.39	2.84	2.84	1.54	Other	
COVID-19 (COVID-19 (JANSEN))	Computed tomogram thorax abnormal	2.03	1.49	0.45	0.45	0.45	0.45	1.41	2.04	2.04	2.04	2.04	1.62	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Death	1.91	1.39	0.94	0.94	0.94	0.94	1.39	1.39	1.39	2.84	2.84	1.54	Other	
COVID-19 (COVID-19 (JANSEN))	Deep vein thrombosis	2.07	1.72	0.92	0.92	0.92	0.92	1.17	2.01	1.81	2.58	2.58	1.91	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Endotracheal intubation	1.92	1.34	1.45	1.45	1.45	1.45	1.39	1.39	1.39	1.39	1.39	1.39	1.39	Labelled
COVID-19 (COVID-19 (JANSEN))	Eosinophil count decreased	1.75	1.50	0.24	0.24	0.24	0.24	1.30	1.42	1.67	2.11	2.11	1.34	Labelled	
COVID-19 (COVID-19 (JANSEN))	Eosinophil percentage decreased	1.73	1.37	0.25	0.25	0.25	0.25	1.20	2.10	1.74	2.04	2.04	1.41	Other	
COVID-19 (COVID-19 (JANSEN))	Eosinophil percentage increased	1.78	1.46	0.92	0.92	0.92	0.92	1.07	2.03	1.64	1.64	1.64	1.64	1.64	Other
COVID-19 (COVID-19 (JANSEN))	Fabry D dimer	2.3	1.25	0.82	0.82	0.82	0.82	2.12	2.18	1.80	2.54	2.54	1.78	Other	
COVID-19 (COVID-19 (JANSEN))	Fabry D normal	2.12	1.67	0.82	0.82	0.82	0.82	2.04	2.04	2.04	2.04	2.04	2.04	2.04	Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Fabry D normal	1.94	1.28	0.75	0.75	0.75	0.75	1.63	2.10	1.01	2.16	2.16	1.34	Not an AE	
COVID-19 (COVID-19 (JANSEN))	Gasx pain	2.86	1.09	0.88	0.88	0.88	0.88	2.29	1.47	1.45	2.81	2.81	1.57	Labelled	
COVID-19 (COVID-19 (JANSEN))	Glaucosuria increased	1.83	1.83	1.29	1.29	1.29	1.29	1.72	1.72	1.72	1.72	1.72	1.58	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Glomerular filtration rate decreased	1.76	1.52	0.91	0.91	0.91	0.91	0.99	1.28	1.56	2.11	2.11	1.39	Other	
COVID-19 (COVID-19 (JANSEN))	Glomerular filtration rate increased	1.85	1.23	0.31	0.31	0.31	0.31	1.04	1.04	1.04	1.04	1.04	1.04	1.04	Other
COVID-19 (COVID-19 (JANSEN))	Gullain-Barre syndrome	2.83	1.83	0.43	0.43	0.43	0.43	1.64	2.07	1.65	2.49	2.49	2.16	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Haemoglobin decreased	1.85	1.64	0.68	0.68	0.68	0.68	1.48	2.08	1.68	2.82	2.82	1.68	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Haemoglobin increased	1.77	1.25	0.98	0.98	0.98	0.98	1.05	1.93	1.63	2.12	2.12	1.48	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Heparin-induced thrombocytopenia test	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	Not an AE
COVID-19 (COVID-19 (JANSEN))	Heparin-induced thrombocytopenia test positive	1.07	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	Not an AE
COVID-19 (COVID-19 (JANSEN))	Hypoxia	1.80	1.37	0.94	0.94	0.94	0.94	1.42	2.06	1.83	2.54	2.54	1.88	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Immunoassay therapy	1.07	1.07	0.94	0.94	0.94	0.94	1.07	1.07	1.07	1.07	1.07	1.07	1.07	Other
COVID-19 (COVID-19 (JANSEN))	Intensive care	1.80	1.45	1.08	1.08	1.08	1.08	1.28	2.18	2.18	2.18	2.18	2.18	1.96	Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	International normalised ratio increased	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	International normalised ratio normal	2.01	1.24	0.78	0.78	0.78	0.78	1.39	2.04	0.94	2.87	2.87	1.53	Not an AE	
COVID-19 (COVID-19 (JANSEN))	Jugular vein thrombosis	1.80	1.80	0.87	0.87	0.87	0.87	1.48	1.71	1.48	2.11	2.11	1.48	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Lumbar puncture	1.91	1.36	0.85	0.85	0.85	0.85	1.28	2.17	1.07	1.68	1.68	1.71	Not an AE	
COVID-19 (COVID-19 (JANSEN))	Lumbar puncture abnormal	1.80	1.80	0.85	0.85	0.85	0.85	1.28	2.17	1.07	1.68	1.68	1.71	Not an AE	
COVID-19 (COVID-19 (JANSEN))	Lung capacity	1.78	1.22	0.93	0.93	0.93	0.93	1.41	1.75	1.86	2.18	2.18	1.51	Other	
COVID-19 (COVID-19 (JANSEN))	Lymphocyte percentage decreased	1.80	1.22	0.21	0.21	0.21	0.21	1.04	2.02	1.82	2.07	2.07	1.34	Other	
COVID-19 (COVID-19 (JANSEN))	Lymphocyte percentage increased	1.78	1.19	0.93	0.93	0.93	0.93	1.11	1.49	1.52	2.03	2.03	1.67	Other	
COVID-19 (COVID-19 (JANSEN))	Magnetic resonance imaging head abnormal	2.01	1.43	0.88	0.88	0.88	0.88	1.19	1.81	2.12	2.39	2.39	1.84	Reviewed, Regulatory Action	
COVID-19 (COVID-19 (JANSEN))	Magnetic resonance imaging head normal	1.85	1.45	0.84	0.84	0.84	0.84	1.26	2.21	1.45	2.42	2.42	1.62	Other	
COVID-19 (COVID-19 (JANSEN))	Mean cell haemoglobin decreased	1.81	1.45	0.98	0.98	0.98	0.98	1.77	1.91	1.51	2.01	2.01	0.85	Other	
COVID-19 (COVID-19 (JANSEN))	Mean platelet volume increased	1.84	1.41	0.25	0.25	0.25	0.25	1.45	2.05	2.05</					

From: (b) (6)
To: (b) (6) (CDC); (b) (6) (CDC); (b) (6) (CDC)
Cc: (b) (6) (CDC); (b) (6) (CDC); (b) (6) (CDC);
Subject: RE: Weekly data mining
Date: Tuesday, April 12, 2022 5:44:45 AM
Attachments: [USST_20220408.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/8/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBIS 20220409	US Serious EBIS 20220409	US Fatal EBIS 20220409	US Infant EBIS 20220409	US Child EBIS 20220409	US Teen EBIS 20220409	US Adult EBIS 20220409	US Adult2 EBIS 20220409	US Adult3 EBIS 20220409	US Female EBIS 20220409	US Male EBIS 20220409	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,015	1,591	0.876				1,015	1,591	0.876			1,015 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,125	1,591	0.876				2,125	1,591	0.876			2,125 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	2,064	1,337	1,016				2,064	1,337	1,016			2,064 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	0,855	0,877	0,877				0,855	0,877	0,877			0,855 Other
COVID19 (COVID19 (JANSSEN))	Adverse event	2,016	1,094	0,883				2,016	1,094	0,883			2,016 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,905	0,877	0,877				1,905	0,877	0,877			1,905 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,473	1,834	0,903				2,473	1,834	0,903			2,473 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,159	1,496	0,879				2,159	1,496	0,879			2,159 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,421	1,601	0,899				2,421	1,601	0,899			2,421 Not an AE
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary normal	1,794	1,307	0,906				1,794	1,307	0,906			1,794 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Anion gap decreased	2,302	0,877	0,877				2,302	0,877	0,877			2,302 Not an AE
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,212	1,064	0,612				2,212	1,064	0,612			2,212 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Areflexia	1,730	1,722	0,881				1,730	1,722	0,881			1,730 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Atrioventricular conduction abnormal	1,899	1,444	0,904		0,61		1,899	1,444	0,904			1,899 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,792	1,432	0,926				1,792	1,432	0,926			1,792 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,759	1,017	0,917				1,759	1,017	0,917			1,759 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,876	1,365	0,939				1,876	1,365	0,939			1,876 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood chloride decreased	1,843	1,251	0,914				1,843	1,251	0,914			1,843 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1,836	1,333	0,948				1,836	1,333	0,948			1,836 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood flow through decreased	2,922	1,929	1,402				2,922	1,929	1,402			2,922 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,801	1,31	0,921				1,801	1,31	0,921			1,801 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood potassium decreased	1,699	1,219	0,932				1,699	1,219	0,932			1,699 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood sodium decreased	1,815	1,317	0,9		0,609		1,815	1,317	0,9			1,815 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,548	1,334	0,88			0,201	1,548	1,334	0,88			1,548 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Brain edema	1,545	1,269	0,92				1,545	1,269	0,92			1,545 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	2,096	1,402	1,082				2,096	1,402	1,082			2,096 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	CHF protein increased	2,703	2,084	1,598				2,703	2,084	1,598			2,703 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	CHF red blood cell count positive	2,054	1,743	0,873				2,054	1,743	0,873			2,054 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,305	1,603	1,028			0,511	2,305	1,603	1,028			2,305 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,834	1,922	1,381			0,519	2,834	1,922	1,381			2,834 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,301	1,626	0,876				2,301	1,626	0,876			2,301 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,052	1,521	1,025			0,335	2,052	1,521	1,025			2,052 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Chest X-ray abnormal	1,707	1,017	0,937				1,707	1,017	0,937			1,707 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Computed tomography head abnormal	2,916	2,058	1,498			0,611	2,916	2,058	1,498			2,916 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Computed tomography head normal	1,991	1,355	0,91				1,991	1,355	0,91			1,991 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Computed tomography thorax abnormal	2,096	1,405	0,919				2,096	1,405	0,919			2,096 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Death	1,591	1,064	0,612				1,591	1,064	0,612			1,591 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,584	1,774	0,979				2,584	1,774	0,979			2,584 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Endotracheal intubation	1,926	1,39	0,92				1,926	1,39	0,92			1,926 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,759	1,297	0,902				1,759	1,297	0,902			1,759 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1,788	1,137	0,82		0,61		1,788	1,137	0,82			1,788 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Fatigue	1,772	1,362	0,862				1,772	1,362	0,862			1,772 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,292	1,29	0,891				2,292	1,29	0,891			2,292 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,145	1,299	0,89			0,612	2,145	1,299	0,89			2,145 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,93	1,089	0,875				1,93	1,089	0,875			1,93 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,281	1,063	0,888				2,281	1,063	0,888			2,281 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Globulins increased	1,876	1,275	0,864				1,876	1,275	0,864			1,876 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1,71	1,224	0,907				1,71	1,224	0,907			1,71 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Guttal-Barré syndrome	2,388	1,685	1,066			0,606	2,388	1,685	1,066			2,388 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Haematocrit decreased	1,814	1,289	0,942				1,814	1,289	0,942			1,814 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,757	1,252	0,929			0,606	1,757	1,252	0,929			1,757 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	3,029	2,081	1,491			0,501	3,029	2,081	1,491			3,029 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,177	3,473	2,413				6,177	3,473	2,413			6,177 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,902	1,316	0,944				1,902	1,316	0,944			1,902 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,088	1,751	0,869				2,088	1,751	0,869			2,088 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Intensive care	1,396	1,396	0,89			0,746	1,396	1,396	0,89			1,396 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	International normalized ratio increased	1,845	1,245	0,885				1,845	1,245	0,885			1,845 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	International normalized ratio normal	2,015	1,227	0,878				2,015	1,227	0,878			2,015 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1,987	1,462	0,915				1,987	1,462	0,915			1,987 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,931	1,355	0,866				1,931	1,355	0,866			1,931 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,095	1,692	1,078				2,095	1,692	1,078			2,095 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lung capacity	1,723	1,257	0,928				1,723	1,257	0,928			1,723 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,668	1,14	0,914			0,607	1,668	1,14	0,914			1,668 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage increased	1,962	1,365	0,909				1,962	1,365	0,909			1,962 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,075	1,496	0,908				2,075	1,496	0,908			2,075 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,075	1,463	0,939		0,612		2,075	1,463	0,939			2,075 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,898	1,396	0,92				1,898	1,396	0,92			1,898 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,127	1,537	1,022			0,61	2,127	1,537	1,022			2,127 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,543	1,028	0,88				1,543	1,028	0,88			1,543 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,497	1,202	0,888				1,497	1,202	0,888			1,497 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,713	1,271	0,912				1,713	1,271	0,912			1,713 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Non-specific reaction	2,274	1,697	1,076				2,274	1,697	1,076			2,274 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	OT label use	1,33	0,607	0,884				1,33	0,607	0,884			1,33 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,792	1,309	0,89				1,792	1,309	0,89			1,792 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,529	0,865	0,503				2,529	0,865	0,503			2,529 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Peripneumonia	2,919	1,415	0,873			0,611	2,919	1,415	0,873			2,919 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Platelet count	2,764	1,229	0,917				2,764	1,229	0,917			2,764 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,857	1,3	0,908			0,607	1,857	1,3	0,908			1,857 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,723	1,863	1,022				2,723	1,863	1,022			2,723 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,024	3,426	0,874				6,024	3,426	0,874			6,024 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Positive airway pressure therapy	1,791	1,265	0,941			0,72	1,791	1,265	0,941			1,791 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Product administered to patient of inappropriate age	1,991	0,842	0,874				1,991	0,842	0,874			1,991 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Prolonged labour	1,098	1,066	0,86				1,098	1,066	0,86			1,098 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1,943	1,451	0,924			0,746	1,943	1,451	0,924			1,943 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,229	1,57	0,613				2,229	1,57	0,613			2,229 Reviewed Regulatory Action
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2,057	1,463	0,901				2					

From: (b) (6)
To: (b) (6) [.CDC](#); (b) (6) [.CDC](#); (b) (6) [.CDC](#)
Cc: (b) (6) [.CDC](#); (b) (6) [.CDC](#); (b) (6) [.CDC](#)
Subject: RE: Weekly data mining
Date: Tuesday, April 19, 2022 6:42:57 AM
Attachments: [USST_20220415.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/15/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBOS 2020/2015	US Serious EBOS 2020/2015	US Fatal EBOS 2020/2015	US Infant EBOS 2020/2015	US Child EBOS 2020/2015	US Teen EBOS 2020/2015	US Adult EBOS 2020/2015	US Adult EBOS 2020/2015	US Adult EBOS 2020/2015	US Female EBOS 2020/2015	US Male EBOS 2020/2015	Comment
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,015	1,957					1,957	2,015				2,015 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time shortened	2,118	1,571	0,881				1,612	2,044				2,118 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory failure	2,083	1,234	0,914				1,44	1,44				2,083 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Adverse drug reaction	2,852	0,968	0,854				0,972	0,715				2,852 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Adverse event	2,016	1,091	0,89				0,907	0,85				2,016 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram abnormal	1,934	1,3	0,906				1,3	1,3				1,934 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral normal	2,487	1,831	0,909				2,136	2,012				2,487 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral abnormal	2,148	1,458	0,885				1,991	1,732				2,148 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram pulmonary abnormal	2,42	0,631	0,912				0,912	2,202				2,42 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Anion gap decreased	1,784	1,309	0,939				1,112	2,197				1,784 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Antibody test	2,371	0,823	0,879				0,599	1,084				2,371 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Anticoagulant therapy	2,211	1,474	0,971	0,619			1,812	2,047				2,211 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Areflexia	2,03	1,099	0,802				1,113	2,021				2,03 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Atrioventricular conduction abnormal	1,722	1,125	0,863				1,133	1,255				1,722 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Basophil count decreased	1,871	1,411	0,887		0,616		0,366	1,184				1,871 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Basophil percentage decreased	1,784	1,408	0,927		0,615		1,144	2,295				1,784 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood albumin decreased	1,756	1,267	0,92				1,415	1,851				1,756 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood calcium decreased	1,875	1,338	0,941				1,236	2,113				1,875 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood chloride decreased	1,844	1,249	0,943				1,043	1,541				1,844 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood chloride increased	1,813	1,312	0,948				1,201	2,033				1,813 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood fibrinogen decreased	2,24	2,165	0,955				1,743	1,933				2,24 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood magnesium increased	1,807	1,31	0,925				1,074	1,929				1,807 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood potassium decreased	1,679	1,226	0,938				1,2	1,51				1,679 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood sodium decreased	1,816	1,316	0,903	0,616			1,328	1,732				1,816 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood urea decreased	1,638	1,32	0,887				1,352	1,988				1,638 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood urea increased	1,654	1,257	0,911				1,023	2,007				1,654 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Brain edema	1,535	1,263	0,926				1,196	1,591				1,535 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	COVID-19 pneumonia	2,018	1,402	0,882				1,761	2,027				2,018 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	CHF protein increased	2,624	2,019	1,247				2,078	2,177				2,624 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Cerebral haemorrhage	2,325	1,588	0,934				1,708	1,902				2,325 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Cerebral mass effect	2,863	1,933	0,927				1,381	1,601				2,863 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Cerebral thrombosis	2,322	1,719	0,882				1,278	1,326				2,322 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Cerebral sinus thrombosis	3,229	2,191	0,916				2,529	2,506				3,229 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Chest X-ray abnormal	1,708	1,27	0,915				2,411	2,887				1,708 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram head abnormal	2,524	1,663	0,961	0,617			2,199	2,209				2,524 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram head normal	1,985	1,349	0,911				1,349	1,71				1,985 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram thorax abnormal	2,057	1,403	0,925				1,393	2,049				2,057 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Death	1,589	1,165	0,961				1,169	1,608				1,589 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Deep vein thrombosis	2,588	1,781	0,998				1,951	2,272				2,588 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Endotracheal intubation	1,914	1,395	1,189				1,388	2,108				1,914 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Eosinophil count decreased	1,755	1,298	0,925				1,048	1,612				1,755 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Eosinophil percentage decreased	1,763	1,357	0,92	0,616			1,254	2,114				1,763 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fatigue	1,78	0,843	0,889				1,102	1,461				1,78 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer	2,284	1,561	0,93				2,048	2,192				2,284 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer increased	1,91	1,457	0,968	0,618			1,709	2,298				1,91 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer normal	1,917	1,091	0,439				1,466	2,244				1,917 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Gaze palsy	2,288	1,06	0,884				2,209	1,242				2,288 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Gilvins increased	1,844	1,254	0,898				1,243	1,706				1,844 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Glucose urine present	1,691	1,211	0,877				1,223	1,427				1,691 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Guttain-Barré syndrome	2,335	1,842	0,93				1,642	3,075				2,335 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin decreased	1,811	1,262	0,941	0,612			1,505	2,049				1,811 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin increased	1,753	1,245	0,936	0,613			1,366	1,98				1,753 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,527	3,709	0,997				4,18	5,604				5,527 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	1,901	1,388	0,866				1,056	1,486				1,901 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Hypoxia	1,901	1,388	0,967				1,483	2,054				1,901 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Immunoglobulin therapy	2,08	0,911	0,873				1,371	1,564				2,08 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Intensive care	1,827	1,392	1,063				1,405	2,09				1,827 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	International normalized ratio increased	1,818	1,387	1,031	0,754			1,521	1,436				1,818 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	International normalized ratio normal	2,12	1,387	0,884				1,387	2,029				2,12 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Jugular vein thrombosis	1,92	1,465	0,883				1,384	1,123				1,92 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture	1,837	1,362	0,973				1,075	2,174				1,837 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture abnormal	2,053	1,635	1,029				2,737	1,629				2,053 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lung opacity	1,733	1,265	0,943				1,174	1,883				1,733 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lymphocyte percentage decreased	1,675	1,239	0,914				1,096	1,874				1,675 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lymphocyte percentage increased	1,345	1,095	0,868	0,613			0,998	1,488				1,345 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,065	1,492	0,913				1,913	2,198				2,065 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,066	1,426	0,94	0,619			1,234	2,283				2,066 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin increased	1,689	1,227	0,913				1,093	1,981				1,689 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mean platelet volume increased	1,882	1,324	0,914				1,174	1,926				1,882 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mechanical ventilation	2,118	1,516	1,023				1,106	2,252				2,118 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Monocyte percentage increased	1,542	1,224	0,915	0,616			1,224	1,917				1,542 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage decreased	1,479	1,185	1,103				1,616	1,62				1,479 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage increased	1,718	1,27	0,915				1,097	2,103				1,718 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Non-specific reaction	2,303	0,784	0,811				0,744	0,812				2,303 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	OT label use	1,33	0,623	0,919				1,213	1,207				1,33 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	On and off phenomenon	1,781	0,763	0,883				3,431	0,883				1,781 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Pain assessment	2,546	0,872	0,939				1,539	2,209				2,546 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Peripartum embolism	3,204	1,389	0,879				0,656	1,034				3,204 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Platelet count	2,796	2,024	0,92	0,617			1,761	2,938				2,796 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Platelet count decreased	1,884	1,3	0,911	0,613			1,442	2,08				1,884 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Platelet count normal	2,711	1,851	0,908				2,077	2,15				2,711 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Platelet factor 4	6,014	3,463	0,881				4,296	4,57				6,014 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Positive airway pressure therapy	1,781	1,27	0,948				1,072	1,996				1,781 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Product administered to patient of inappropriate age	1,616	0,81	0,88		0,72		2,053	1,002				1,616 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Prolonged labour	1,1	1,048	0,919				4,078	3,328				1,1 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Prothrombin time prolonged	1,842	1,427	0,926	0,753			1,431	2,328				1,842 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Pulmonary embolism	2,226	1,067	0,958	0,619			1,752	2,04				2,226 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Pulmonary thrombosis	2,048	1,438	0,907									

From: (b) (6)
To: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Cc: (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#); (b) (6) [\(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, May 3, 2022 6:23:48 AM
Attachments: [USST_20220429.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/29/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBDS 2022Q429	US Serious EBDS 2022Q429	US Fatal EBDS 2022Q429	US Infant EBDS 2022Q429	US Child EBDS 2022Q429	US Teen EBDS 2022Q429	US Adult EBDS 2022Q429	US Adult2 EBDS 2022Q429	US Adult3 EBDS 2022Q429	US Female EBDS 2022Q429	US Male EBDS 2022Q429	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,175	1,558	0.875	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,106	1,558	0.875	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	2,089	1,558	0.875	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,849	1,558	0.88	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Adverse event	2,016	1,592	0.887	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,899	1,592	0.887	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,459	1,812	0.908	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,129	1,411	0.881	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,405 Not an AE
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,417	1,411	0.881	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary normal	2,417	1,411	0.881	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Anion gap decreased	1,78	1,383	0.909	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,339 Other
COVID19 (COVID19 (JANSSEN))	Antibody test	2,371	1,873	0.973	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Not an AE
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,21	1,475	0.863	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,603 Other
COVID19 (COVID19 (JANSSEN))	Areflexia	2,036	1,717	0.884	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,434 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Arteriogram carotid abnormal	1,713	1,332	0.879	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,384 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Arteriogram carotid decreased	1,854	1,388	0.913	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1.3 Other
COVID19 (COVID19 (JANSSEN))	Asaphot count decreased	1,79	1,405	0.933	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,755	1,363	0.921	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,383 Other
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,869	1,349	0.945	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1.48 Other
COVID19 (COVID19 (JANSSEN))	Blood chloride decreased	1,836	1,266	0.92	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,541 Other
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1,809	1,31	0.955	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,889 Other
COVID19 (COVID19 (JANSSEN))	Blood glucose decreased	2,31	2,381	0.992	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	0.999
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,813	1,299	0.925	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,786 Other
COVID19 (COVID19 (JANSSEN))	Blood potassium decreased	1,669	1,212	0.933	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,879 Other
COVID19 (COVID19 (JANSSEN))	Blood sodium decreased	1,817	1,313	0.905	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,607 Not an AE
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1,859	1,293	0.909	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,609 Other
COVID19 (COVID19 (JANSSEN))	Brain oedema	1,523	1,249	0.925	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	0.77 Other
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	2,067	1,412	0.906	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Other
COVID19 (COVID19 (JANSSEN))	CYP protein increased	2,607	2,003	0.875	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,157 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,317	1,981	0.935	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,337 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	3,067	1,976	0.928	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,143 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,402	1,725	0.879	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,227 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,219	2,165	0.915	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,225 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Chest X-ray abnormal	1,769	1,277	0.913	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,507 Confirmed Indicator
COVID19 (COVID19 (JANSSEN))	Computed tomography head abnormal	2,32	1,455	0.932	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,172 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Computed tomography head normal	1,983	1,345	0.903	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,534 Not an AE
COVID19 (COVID19 (JANSSEN))	Computed tomography thorax abnormal	2,405	1,415	0.862	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,062 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Death	1,593	1,167	0.963	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,509 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,591	1,779	0.904	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,021 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Diastolic blood pressure decreased	1,913	1,913	1.0	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,121 Labeled
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,763	1,293	0.913	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,297 Other
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1,728	1,293	0.913	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,272 Other
COVID19 (COVID19 (JANSSEN))	Feeling cold	1,783	0,859	0.889	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,483 Labeled
COVID19 (COVID19 (JANSSEN))	Flavin D dimer	2,283	1,296	0.899	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,712 Other
COVID19 (COVID19 (JANSSEN))	Flavin D dimer increased	1,911	1,085	0.987	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,489 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Flavin D dimer normal	1,083	0,878	0.903	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,333 Not an AE
COVID19 (COVID19 (JANSSEN))	Fatty palms	2,262	1,092	0.922	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,060 Labeled
COVID19 (COVID19 (JANSSEN))	Gibulins increased	1,834	1,237	0.897	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,193 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Glomerular filtration rate decreased	1,766	1,139	0.935	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,256 Other
COVID19 (COVID19 (JANSSEN))	Glucone urine present	1,693	1,175	0.917	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,281 Other
COVID19 (COVID19 (JANSSEN))	Gutta-Sera syndrome	2,336	1,836	0.887	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,166 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,811	1,225	0.898	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,195 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Haemoglobin increased	1,75	1,238	0.936	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,401 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Hepatitis B surface antigenemia test	5,568	3,636	0.896	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	3,389 Not an AE
COVID19 (COVID19 (JANSSEN))	Hepatitis-induced thrombocytopenia test positive	6,109	3,695	0.895	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,712 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,912	1,223	0.848	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,649 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Immune globulin therapy	2,98	1,221	0.87	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,889 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Intensive care	1,832	1,394	0.922	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,264 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,823	1,222	0.884	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,559 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2,021	1,222	0.881	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,776 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1,948	1,474	0.88	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,011 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,938	1,068	0.868	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,712 Not an AE
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,081	1,657	0.905	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,778 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lung opacity	1,752	1,281	0.946	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,518 Other
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,679	1,076	0.921	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,538 Not an AE
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage increased	1,327	1,093	0.986	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	2,062 Other
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,065	1,451	0.877	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head normal	2,063	1,417	0.948	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,422 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	1,678	1,269	0.94	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,992 Other
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin increased	1,617	1,032	0.877	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Other
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,813	1,278	0.912	1,446	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941 Other
COVID19 (COVID19 (JANSSEN													

From: (b) (6)
To: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Cc: (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>; (b) (6) <(b) (6)@CDC>
Subject: RE: Weekly data mining
Date: Tuesday, May 10, 2022 5:46:09 AM
Attachments: [USST_20220506.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/6/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBDS 2020Q06	US Serious EBDS 2020Q06	US Fatal EBDS 2020Q06	US Infant EBDS 2020Q06	US Child EBDS 2020Q06	US Teen EBDS 2020Q06	US Adult EBDS 2020Q06	US Female EBDS 2020Q06	US Male EBDS 2020Q06	Comment			
COVID-19 (COVID-19 (JANSEN))	Activated partial thromboplastin time prolonged	2,155	0.92	0.01				0.31						1,545 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Activated partial thromboplastin time shortened	2,092	1,562	0.891				1,609	2,056	2			2,763	1,428 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Acute respiratory distress syndrome	2,081	1,24	0.881				0.79	1,807	1,807			1,807	1,807 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Acute respiratory failure	2,099	1,323	1,017				1,43	2,023	1,979			2,445	1,72 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Adverse drug reaction	3,336	0.98	0.884				0.529	1,015	0,717			2,622	1,515 Other
COVID-19 (COVID-19 (JANSEN))	Adverse event	2,005	1,685	1,085					1,607	2,294			2,623	1,878 Other
COVID-19 (COVID-19 (JANSEN))	Albumin CSE increased	2,304	1,969	1,403					1,444	1,444			0,907	1,671
COVID-19 (COVID-19 (JANSEN))	Angiogram abnormal	1,918	1,293	0.907					1,566	1,444			1,681	1,318 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Angiogram cerebral abnormal	2,037	1,811	1,912			0.489		2,119	1,955			2,141	1,493 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Angiogram cerebral normal	2,115	1,428	0.885					1,844	1,787			2,209	1,448 Not an AE
COVID-19 (COVID-19 (JANSEN))	Angiogram pulmonary abnormal	2,304	1,635	1,007				0.415	1,607	2,304			2,436	2,162 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Anion gap decreased	1,809	1,368	0.91					1,103	2,229			2,083	1,368 Other
COVID-19 (COVID-19 (JANSEN))	Antiobesity therapy	2,109	0.823	0.877					0.795	1,081			1,862	1,56 Not an AE
COVID-19 (COVID-19 (JANSEN))	Anticoagulant therapy	2,117	0.974	0.974			0.619		1,471	2,047			2,753	2,027 Other
COVID-19 (COVID-19 (JANSEN))	Arthritis	1,719	1,719	0.29					0,905	2,482			2,256	1,458 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Arteriovenous carotid abnormal	1,876	1,166	0.865					1,303	1,231			1,427	1,028 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Basophil count decreased	1,392	0.922	0.616					1,175	2,324			1,781	2,363
COVID-19 (COVID-19 (JANSEN))	Basophil percentage decreased	1,788	1,41	0.636			0.615		1,148	2,325			1,756	1,328 Other
COVID-19 (COVID-19 (JANSEN))	Blood albumin decreased	1,926	1,296	0.925					1,456	1,746			2,169	1,386 Other
COVID-19 (COVID-19 (JANSEN))	Blood calcium decreased	1,864	1,349	0.948					1,349	2,109			1,868	2,2
COVID-19 (COVID-19 (JANSEN))	Blood chloride increased	1,923	1,309	0.957					1,227	2,026			1,426	1,469 Other
COVID-19 (COVID-19 (JANSEN))	Blood fibrinogen decreased	2,809	2,197	0.894					1,747	2,171			0,885	4,054
COVID-19 (COVID-19 (JANSEN))	Blood magnesium increased	1,81	1,312	0.926					1,138	1,872			1,771	2,417
COVID-19 (COVID-19 (JANSEN))	Blood potassium decreased	1,693	1,214	0.938					1,21	1,52			2,027	1,881
COVID-19 (COVID-19 (JANSEN))	Blood sodium decreased	1,827	1,31	0.903			0.616		2,02	1,74			1,841	1,604 Not an AE
COVID-19 (COVID-19 (JANSEN))	Blood urea increased	1,991	1,267	0.909					1,029	2,865			1,764	1,605 Other
COVID-19 (COVID-19 (JANSEN))	Brain edema	1,558	1,246	0.926					1,196	1,555			0,602	2,011
COVID-19 (COVID-19 (JANSEN))	COVID-19 pneumonia	2,204	1,409	1,092					1,807	2,221			2,202	1,962 Other
COVID-19 (COVID-19 (JANSEN))	CSF protein increased	2,071	1,792	1,092					1,792	2,092			1,021	2,159 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Cerebral haemorrhage	2,218	1,583	0.935				0.526	1,711	1,899			1,471	1,136 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Cerebral mass effect	2,182	1,188	0.824					1,384	1,716			1,117	1,322
COVID-19 (COVID-19 (JANSEN))	Cerebral thrombosis	1,741	0.882	0.882					1,364	1,365			1,626	1,268 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Cerebral venous sinus thrombosis	3,292	2,147	0.917				0.929	2,48	2,342			3,879	1,226 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Chest X-ray abnormal	1,867	1,363	0.933					1,185	2,017			1,651	1,927 Confirmed indication
COVID-19 (COVID-19 (JANSEN))	Computed tomogram head abnormal	1,657	0.968	0.968			0.618		0,613	2,206			2,041	3,039
COVID-19 (COVID-19 (JANSEN))	Computed tomogram head normal	2,005	1,465	0.933					1,744	2,463			1,943	1,602 Not an AE
COVID-19 (COVID-19 (JANSEN))	Computed tomogram thorax abnormal	2,017	1,407	0.928				0.463	1,386	2,062			2,026	1,686 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Creatinine renal clearance decreased	2,022	1,287	0.886					1,097	0,886			1,968	1,039
COVID-19 (COVID-19 (JANSEN))	Death	1,832	1,185	0.892					1,199	1,526			1,026	1,312 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Deep vein thrombosis	2,601	1,784	1,024				0.465	2,194	2,28			3,097	2,022 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Endotracheal intubation	2,963	1,144	0.865					1,415	2,365			2,118	1,925 Labeled
COVID-19 (COVID-19 (JANSEN))	Eosinophil count decreased	1,733	1,292	0.822					1,238	2,086			1,665	2,086
COVID-19 (COVID-19 (JANSEN))	Eosinophil percentage decreased	1,778	1,362	0.933			0.616		2,075	2,116			1,708	1,395 Other
COVID-19 (COVID-19 (JANSEN))	Fatigue	0.892	1,186	0.872					1,186	2,017			1,651	1,651 Labeled
COVID-19 (COVID-19 (JANSEN))	Fibrin D dimer	1,294	0.446	0.897					1,294	2,461			1,974	2,644
COVID-19 (COVID-19 (JANSEN))	Fibrin D monomer	2,147	1,447	0.881			0.619		2,119	2,298			2,469	2,149 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Fibrin D dimer normal	1,968	1,082	0.882					1,656	2,041			1,229	1,328 Not an AE
COVID-19 (COVID-19 (JANSEN))	Foetal exposure during pregnancy	2,088	1,412	0.924			0.756		0,604	1,72			1,435	1,732
COVID-19 (COVID-19 (JANSEN))	Glass opacity	2,007	1,043	0.84				0.406	1,207	1,7			2,023	1,927 Labeled
COVID-19 (COVID-19 (JANSEN))	Globulins increased	1,816	1,242	0.904				0.401	1,231	1,701			1,599	2,181
COVID-19 (COVID-19 (JANSEN))	Glucose urine present	1,706	1,164	0.84					1,216	1,369			1,236	1,084 Other
COVID-19 (COVID-19 (JANSEN))	Gutta-Serre syndrome	2,462	1,838	0.99				0.44	1,639	3,107			1,646	2,439
COVID-19 (COVID-19 (JANSEN))	Haematocrit decreased	1,844	1,276	0.941			0.612		1,508	2,04			1,778	2,188
COVID-19 (COVID-19 (JANSEN))	Haemoglobin decreased	1,756	1,396	0.933					1,372	1,665			2,11	1,416 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Hepatin-induced thrombocytopenia test	3,628	0.998	0.888					4,917	5,517			4,787	3,364 Not an AE
COVID-19 (COVID-19 (JANSEN))	Hepatin-induced thrombocytopenia test positive	6,466	4,466	3,665				0.555	4,665	5,717			6,269	3,073 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Hypoxia	2,056	1,322	0.923					1,511	2,085			2,436	1,66 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Immunoglobulin therapy	2,068	1,172	0.873					1,485	2,349			1,896	1,686 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Intervene care	1,109	1,107	0.873				0.022	1,108	2,11			2,068	1,686 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	International normalised ratio increased	1,739	1,225	0.89			0.754		1,549	1,943			2,317	1,279 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	International normalised ratio normal	1,929	1,305	0.925					1,209	1,965			2,032	1,923 Not an AE
COVID-19 (COVID-19 (JANSEN))	Intra-aortic thrombus	1,767	0.909	0.809					1,408	1,996			1,734	1,594
COVID-19 (COVID-19 (JANSEN))	Jugular vein thrombosis	1,631	1,452	0.884					1,125	2,078			2,333	0,711 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Lumbar puncture	1,976	1,378	0.916					1,186	1,976			2,023	1,018 Not an AE
COVID-19 (COVID-19 (JANSEN))	Lumbar puncture abnormal	2,148	1,707	1,028					2,43	2,83			1,785	1,814 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Lung opacity	1,985	1,364	0.945					1,384	1,923			2,027	1,957 Other
COVID-19 (COVID-19 (JANSEN))	Lymphocyte percentage decreased	1,881	1,234	0.924				0.19	1,002	2,094			1,824	2,065
COVID-19 (COVID-19 (JANSEN))	Magnetic resonance imaging head abnormal	2,065	1,477	0.912					1,768	1,877			2,139	2,323
COVID-19 (COVID-19 (JANSEN))	Mean cell haemoglobin concentration decreased	1,945	1,346	0.946			0.619		1,465	2,16			2,173	1,612 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Mean cell haemoglobin decreased	1,713	1,268	0.926					1,123	1,945			2,053	0,997 Other
COVID-19 (COVID-19 (JANSEN))	Mean platelet volume increased	1,87	1,319	0.914					1,174	1,611			1,913	1,964 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Mechanical ventilation	2,282	1,027	0.888					1,164	2,291			1,993	2,126
COVID-19 (COVID-19 (JANSEN))	Monocyte percentage increased	1,628	1,122	0.917			0.616		0,839	1,905			1,109	1,109 Other
COVID-19 (COVID-19 (JANSEN))	Neutrophil percentage decreased	1,919	1,324	0.904					1,204	1,659			2,184	0,843 Other
COVID-19 (COVID-19 (JANSEN))	Neutrophil percentage increased	1,726	1,266	0.952					2,104	1,763			1,989	1,089
COVID-19 (COVID-19 (JANSEN))	Non-specific reaction	4,048	2,744	1,744					3,045	4,015			3,057	2,175 Other
COVID-19 (COVID-19 (JANSEN))	Off label use	0,602	0.892	0.892					1,182	1,305			0,932	1,467
COVID-19 (COVID-19 (JANSEN))	On and off phenomenon	1,783	0,754	0.857					3,445	0,963			2,289	0,789 Other
COVID-19 (COVID-19 (JANSEN))	Pain assessment	2,226	0,866	0.866					1,096	2,116			1,107	1,444 Not an AE
COVID-19 (COVID-19 (JANSEN))	Pulmonary embolism	3,17	1,394	0.88					0,656	1,034			1,593	0,95 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSEN))	Platelet count	2,071	2,166	1,102			0.618		1,788	2,095			3,029	1,822 Not an AE
COVID-19 (COVID-19 (JANSEN))	Platelet count decreased	1,867	1,315	0.918					1,424	2,1				

From: (b) (6)
To: (b) (6) <(b) (6) <(CDC); (b) (6) <(CDC); (b) (6) <(CDC)>>>
Cc: (b) (6) <(CDC); (b) (6) <(CDC); (b) (6) <(CDC)>>>
Subject: Weekly data mining
Date: Tuesday, May 17, 2022 6:18:18 AM
Attachments: [USST_20220513.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/13/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 2020(91)	US Serious EB05 2020(91)	US Fatal EB05 2020(91)	US Infant EB05 2020(91)	US Child EB05 2020(91)	US Teen EB05 2020(91)	US Adult EB05 2020(91)	US Adult2 EB05 2020(91)	US Adult3 EB05 2020(91)	US Female EB05 2020(91)	US Male EB05 2020(91)
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	7.56	1.54					0.32	1.54	1.55	2.46	1.37
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2.04	1.54	0.883				1.59	2.07	2.14	1.46	1.46
COVID19 (COVID19 (JANSSEN))	Acute respiratory distress syndrome	2.86	1.33	0.008				0.79	1.67	1.61	1.82	1.82
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	2.02	1.32	0.144				1.42	2.03	1.98	1.78	1.78
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	3.43	0.975	0.888				0.973	0.718	0.881	2.622	1.485
COVID19 (COVID19 (JANSSEN))	Adverse event	1.964	1.062	0.971				0.964	0.851	0.864	1.964	1.484
COVID19 (COVID19 (JANSSEN))	Albumin CSF increased	2.226	1.907					1.304	0.906	1.41	2.006	1.624
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1.907	1.262	0.900				1.403	1.427	1.677	2.099	1.303
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2.935	0.914	0.806	0.49			1.922	1.11	1.566	1.464	1.464
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2.081	1.402	0.888				1.801	1.758	1.287	2.254	1.406
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2.289	1.621	0.929				1.621	1.598	2.281	2.198	1.503
COVID19 (COVID19 (JANSSEN))	Arion gap decreased	1.808	1.365	0.91				1.103	2.091	1.478	2.091	1.303
COVID19 (COVID19 (JANSSEN))	Artbody test	2.114	0.822	0.882				0.792	1.874	1.886	2.022	1.652
COVID19 (COVID19 (JANSSEN))	Arthroclavicular therapy	2.172	1.466	0.971		0.619		1.827	2.029	2.758	1.669	1.669
COVID19 (COVID19 (JANSSEN))	Application site pain	2.001	1.734	0.902				0.635	1.006	1.032	0.678	0.764
COVID19 (COVID19 (JANSSEN))	Arteriovenous fistula	2.147	1.466	0.971				0.907	2.413	2.312	1.449	1.449
COVID19 (COVID19 (JANSSEN))	Arteriovenous fistula abnormal	1.845	1.164	0.889				1.123	2.232	1.417	1.886	0.983
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1.873	1.383	0.928		0.616		1.212	2.28	1.806	2.319	1.328
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1.79	1.458	0.944		0.616		1.463	1.903	1.794	2.307	1.342
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1.81	1.263	0.929				1.447	1.844	1.751	2.16	1.39
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1.828	1.342	0.951				1.348	2.087	1.585	2.087	1.491
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1.812	1.302	0.949				1.214	2.022	1.499	1.86	1.346
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2.814	2.199	0.897				1.749	2.173	0.888	4.053	1.039
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1.925	1.303	0.928				0.317	1.077	1.981	1.795	1.254
COVID19 (COVID19 (JANSSEN))	Blood potassium decreased	1.699	1.216	0.938		0.616		1.512	1.889	1.204	1.889	1.104
COVID19 (COVID19 (JANSSEN))	Blood sodium decreased	1.623	1.306	0.904				1.33	2.016	1.736	1.958	1.587
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1.888	1.251	0.933				1.022	2.048	1.773	2.048	1.602
COVID19 (COVID19 (JANSSEN))	Brain edema	1.58	1.269	0.910				1.196	1.507	0.603	2.118	0.806
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	2.212	1.41	1.003				2.238	2.207	1.41	2.028	1.978
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2.589	2.018	0.882				1.847	2.985	1.005	2.517	2.16
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2.229	1.998	0.939				1.712	1.878	1.508	3.333	1.191
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2.828	1.962	0.934				1.384	3.923	1.117	1.144	1.144
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2.653	1.738	0.886				1.364	1.629	3.528	1.269	1.269
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3.31	1.963	0.916				2.156	2.344	2.872	3.078	1.255
COVID19 (COVID19 (JANSSEN))	Chest X-ray abnormal	1.963	1.28	0.957				1.902	1.989	1.902	1.904	1.904
COVID19 (COVID19 (JANSSEN))	Computed tomogram head abnormal	2.438	1.965	0.946		0.618		2.466	2.296	2.033	2.296	1.904
COVID19 (COVID19 (JANSSEN))	Computed tomogram head normal	1.999	1.338	0.916				0.381	1.711	1.983	2.275	1.841
COVID19 (COVID19 (JANSSEN))	Computed tomogram thorax abnormal	2.001	1.398	0.926				1.376	2.046	2.009	2.248	1.673
COVID19 (COVID19 (JANSSEN))	Computed tomogram thorax normal	2.001	1.398	0.926				1.376	2.046	2.009	2.248	1.673
COVID19 (COVID19 (JANSSEN))	Death	1.833	1.164	0.963				1.187	1.621	1.526	2.059	1.508
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2.61	1.705	0.946				2.295	2.261	1.705	2.261	2.055
COVID19 (COVID19 (JANSSEN))	Endotracheal intubation	2.055	1.147	0.987				2.096	1.874	2.285	1.832	1.832
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1.771	1.288	0.927				1.232	2.054	1.696	2.067	1.325
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1.771	1.288	0.927		0.616		1.232	2.054	1.696	2.067	1.325
COVID19 (COVID19 (JANSSEN))	Feeling cold	1.753	0.857	0.895				1.186	0.988	1.848	1.422	1.429
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2.273	1.299	0.945				1.299	1.898	1.292	1.898	1.292
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2.128	1.441	0.886		0.619		1.713	2.276	2.201	2.494	1.615
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1.934	1.081	0.886				1.036	1.979	1.927	2.168	1.289
COVID19 (COVID19 (JANSSEN))	Fetal exposure during pregnancy	2.085	1.432	0.886		0.756		1.636	1.878	1.527	1.432	1.432
COVID19 (COVID19 (JANSSEN))	Flare up	2.23	1.036	0.897				0.406	2.273	1.7	1.228	2.243
COVID19 (COVID19 (JANSSEN))	Flu-like illness increased	1.83	1.293	0.923				1.293	1.609	1.609	1.609	1.609
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1.696	1.147	0.907				1.216	1.342	1.342	1.014	1.014
COVID19 (COVID19 (JANSSEN))	Gullström syndrome	2.473	1.842	0.884				1.842	3.113	2.432	1.626	1.626
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1.8	1.272	0.944		0.612		1.381	1.712	2.028	1.778	1.434
COVID19 (COVID19 (JANSSEN))	Haemoglobin increased	1.756	1.238	0.934		0.613		1.373	1.967	1.688	2.096	1.403
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	2.766	1.819	0.916				1.819	2.266	2.266	2.266	2.266
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.457	3.472	0.884				5.719	4.664	4.739	7.264	3.079
COVID19 (COVID19 (JANSSEN))	Hypoxia	2.076	1.332	0.984				1.511	2.095	1.922	2.448	1.685
COVID19 (COVID19 (JANSSEN))	Immuno-globulin therapy	2.069	1.997	0.911				1.719	2.645	1.397	1.704	1.704
COVID19 (COVID19 (JANSSEN))	Intensive care	1.937	1.396	0.921		0.754		1.425	2.108	2.071	2.331	1.581
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1.778	1.22	0.923				1.927	1.927	1.434	1.927	1.299
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1.897	1.198	0.889				1.384	2.032	2.031	1.248	1.248
COVID19 (COVID19 (JANSSEN))	Intra-aortic thrombolysis	2.628	1.759	0.871				0.84	1.402	1.992	1.677	1.595
COVID19 (COVID19 (JANSSEN))	Isolated vein thrombosis	1.83	1.33	0.917				1.213	1.714	1.714	1.714	1.714
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1.875	1.36	0.877				1.195	1.749	1.614	1.749	1.614
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2.147	1.466	0.971				1.125	2.834	1.023	1.834	1.023
COVID19 (COVID19 (JANSSEN))	Lung opacity	1.976	1.281	0.945				1.377	1.977	1.977	2.318	1.52
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1.681	1.223	0.93		0.614		0.188	1.839	2.068	1.839	1.3
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage increased	1.414	1.097	0.917				0.109	1.421	1.621	1.621	1.621
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.056	1.468	0.914				1.764	1.866	2.132	2.329	1.592
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head normal	1.843	1.243	0.943		0.619		1.243	2.043	2.107	2.043	1.854
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	1.701	1.258	0.923				1.117	1.939	2.04	1.496	0.991
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration increased	1.866	1.318	0.917				0.319	2.316	1.876	2.107	1.394
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2.493	1.919	0.919				1.919	2.278	1.919	2.278	2.015
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1.521	1.214	0.918		0.616		0.845	1.213	1.915	1.958	1.105
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1.533	1.298	0.925				1.298	1.645	1.645	1.645	0.985
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1.722	1.262	0.929				1.101	1.981	2.088	1.775	1.4
COVID19 (COVID19 (JANSSEN))	Non-specific reaction	4.051	0.787	0.895				0.744	0.812	0.961	2.981	1.076
COVID19 (COVID19 (JANSSEN))	Off-label use	2.029	0.699	0.895				1.195	1.339	1.473	1.339	1.975
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1.794	0.795	0.886				3.446	0.982	0.982	2.288	0.982
COVID19 (COVID19 (JANSSEN))	Pain assessment	2.227	1.807	0.917				1.506	2.219	1.104	2.219	1.445
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3.087	1.362	0.884				0.656	2.246	1.034	1.54	0.951
COVID19 (COVID19 (JANSSEN))	Platelet count	2.66	2.187	0.918		0.618		1.84	2.864	2.725	3.025	1.862
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1.872	1.317	0.922				1.446	1.646	2.146	1.646	1.646
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2.562	1.82	0.901				2.099	2.767	2.134	1.591	1.689
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5.782	3.288	0.926				4.296	4.645	4.645	5.733	2.291
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1.3						0.88	1.957	1.993	2.029	2.022
COVID19 (COVID19 (JANSSEN))	Portal vein thrombosis	2.072	1.425	0.886				0.859	1.646	1.626	2.024	1.268
COVID19 (COVID19 (JANSSEN))	Positive airway pressure therapy	2.045	0.953	0.923				1.014	2.083	1.664	2.083	1.613
COVID19 (COVID19 (JANSSEN))	Product administered to patient of inappropriate age	1.772	0.832	0.885			0.72	0.041	0.002	0.514	1.671	1.832
COVID19 (COVID19 (JANSSEN))	Prolonged labour	5.177	1.345	0.915				1.345	5.05	5.149	5.149	5.149
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1.925	1.389	0.941		0.754		2.283	1.657	2.448	1.657	1.454
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2.237	1.584	0.917				1.773	2.066	2.618	2.618	1.942
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2.286	1.482	0.909				1.726	1.631	1.913	2.161	1.878
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1.806	1.276	0.932		0.619		1.36	2.024	1.67	2.028	1.501
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	1.959	1.319	0.933				1.286	1.933	2.118	1.789	1.425
COVID19 (COVID19 (JANSSEN))	Russell's viper venom time abnormal	1.368	1.004	0.889				2.691	0.505	1.08	1.08	0.73
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2.562	1.648	0.889				1.774	1.986</			

From: (b) (6)
To: (b) (6) <(b) (6) <(CDC); (b) (6) <(CDC); (b) (6) <(CDC)>>>
Cc: (b) (6) <(CDC); (b) (6) <(CDC); (b) (6) <(CDC)>>>
Subject: RE: Weekly data mining
Date: Tuesday, May 24, 2022 6:43:28 AM
Attachments: [USST_20220520.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/20/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB06 20220520	US Serious EB06 20220520	US Fatal EB06 20220520	US Infant EB06 20220520	US Child EB06 20220520	US Teen EB06 20220520	US Adult EB06 20220520	US Adult EB06 20220520	US Adult EB06 20220520	US Female EB06 20220520	US Male EB06 20220520
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,174	1,371					2,375	1,952	2,044	2,277	1,411
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time shortened	2,107	1,538	0,883				1,583	2,044	1,883	2,727	1,411
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory distress syndrome	2,887	1,338	1,039				1,249	1,679	1,829	1,811	1,747
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory failure	2,107	1,386	1,017				1,458	2,046	1,991	2,465	1,478
COVID-19 (COVID-19 (JANSSEN))	Adverse drug reaction	3,339	0,974	0,889			0,527	0,969	0,716	0,679	2,619	1,478
COVID-19 (COVID-19 (JANSSEN))	Adverse event	2,169	1,964	1,084				1,992	2,044	1,883	1,877	1,688
COVID-19 (COVID-19 (JANSSEN))	Albumin CBF increased	2,232	1,904					1,405	1,411		0,907	1,625
COVID-19 (COVID-19 (JANSSEN))	Angiogram abnormal	1,152	1,201	0,908				1,432	1,469	1,669	2,149	1,296
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral abnormal	2,658	1,896	1,914		0,488		2,482	1,914	1,948	2,082	3,438
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral normal	2,066	1,383	0,889				1,779	1,75	1,283	2,218	1,405
COVID-19 (COVID-19 (JANSSEN))	Angiogram pulmonary abnormal	2,359	1,916	1,016			0,614	1,631	1,631	2,225	2,471	1,973
COVID-19 (COVID-19 (JANSSEN))	Anion gap decreased	1,813	1,137	0,911				1,117	2,234	1,464	1,128	1,339
COVID-19 (COVID-19 (JANSSEN))	Antibody test	2,118	0,823	0,883				0,969	1,58	1,905	2,003	1,658
COVID-19 (COVID-19 (JANSSEN))	Anticoagulant therapy	2,177	1,463	0,973		0,619		0,847	2,039	2,296	2,752	1,657
COVID-19 (COVID-19 (JANSSEN))	Application site pain	2,104		0,901				0,79	0,636	1,036	0,778	1,433
COVID-19 (COVID-19 (JANSSEN))	Arrhythmia	2,128	1,709	0,881				0,847	2,418	1,338	2,315	1,433
COVID-19 (COVID-19 (JANSSEN))	Arterogram carotid abnormal	1,847	1,163	0,89				1,213	1,231	1,419	2,236	0,983
COVID-19 (COVID-19 (JANSSEN))	Asplough count decreased	1,884	1,391	0,931		0,616		1,179	2,251	1,858	2,325	1,348
COVID-19 (COVID-19 (JANSSEN))	Asplough count increased	1,796	1,413	0,947				1,325	2,313	1,977	2,187	1,353
COVID-19 (COVID-19 (JANSSEN))	Blood albumin decreased	1,821	1,288	0,83				1,395	1,485	1,847	1,755	2,168
COVID-19 (COVID-19 (JANSSEN))	Blood calcium decreased	1,975	1,352	0,954				1,374	1,261	2,103	1,893	2,19
COVID-19 (COVID-19 (JANSSEN))	Blood chloride increased	1,823	1,309	0,963				1,232	2,027	1,872	1,872	1,359
COVID-19 (COVID-19 (JANSSEN))	Blood fibrinogen decreased	2,801	2,196	0,897				0,922	1,75	2,176	0,881	4,054
COVID-19 (COVID-19 (JANSSEN))	Blood magnesium increased	1,854	1,18	0,929				1,077	1,976	1,751	2,357	1,221
COVID-19 (COVID-19 (JANSSEN))	Blood potassium decreased	1,704	1,217	0,938				0,513	1,524	1,522	2,025	1,888
COVID-19 (COVID-19 (JANSSEN))	Blood sodium increased	1,824	1,305	0,905		0,616		1,35	2,005	1,795	1,951	1,594
COVID-19 (COVID-19 (JANSSEN))	Blood urea increased	1,648	1,315	0,895			0,085	1,36	1,938	1,216	2,008	0,889
COVID-19 (COVID-19 (JANSSEN))	Blood urea decreased	1,898	1,256	0,914				1,041	2,659	1,78	2,127	1,62
COVID-19 (COVID-19 (JANSSEN))	Brain edema	1,578	1,099	0,883				1,599	1,59	0,902	2,006	1,804
COVID-19 (COVID-19 (JANSSEN))	COVID-19 pneumonia	2,224	1,411	1,083				1,803	2,232	2,042	2,409	1,985
COVID-19 (COVID-19 (JANSSEN))	CRP protein increased	2,389	2,014	0,983				1,844	2,199	1,003	2,588	2,169
COVID-19 (COVID-19 (JANSSEN))	Cerebral haemorrhage	2,215	1,576	0,938			0,524	1,713	1,855	1,507	3,311	1,155
COVID-19 (COVID-19 (JANSSEN))	Cerebral mass effect	2,819	1,972	0,929			0,532	1,385	1,721	1,165	3,835	1,141
COVID-19 (COVID-19 (JANSSEN))	Cerebral oedema	2,696	1,736	0,887				1,476	1,887	1,633	3,409	1,263
COVID-19 (COVID-19 (JANSSEN))	Cerebral sinus thrombosis	3,304	2,149	0,919				2,504	2,348	0,879	1,879	1,226
COVID-19 (COVID-19 (JANSSEN))	Chest X-ray abnormal	1,973	1,393	0,937				1,331	1,985	1,935	2,111	1,588
COVID-19 (COVID-19 (JANSSEN))	Computed tomogram head abnormal	2,444	1,666	0,964		0,618		1,388	2,313	2,036	3,073	1,727
COVID-19 (COVID-19 (JANSSEN))	Computed tomogram head normal	1,894	1,333	0,918				1,724	1,987	1,835	2,323	1,519
COVID-19 (COVID-19 (JANSSEN))	Computed tomogram thorax abnormal	2,051	1,365	0,927				1,365	1,927	1,521	2,584	1,297
COVID-19 (COVID-19 (JANSSEN))	Creatinine renal clearance decreased	2,049	1,289	0,89				0,498	0,897	0,203	1,091	1,656
COVID-19 (COVID-19 (JANSSEN))	Death	1,849	1,117	0,865				1,117	1,527	1,445	2,075	1,503
COVID-19 (COVID-19 (JANSSEN))	Deep vein thrombosis	2,618	1,798	1,035				2,233	2,385	3,14	3,298	2,044
COVID-19 (COVID-19 (JANSSEN))	Endotracheal intubation	2,807	1,375	1,139				1,395	1,423	2,097	1,899	1,863
COVID-19 (COVID-19 (JANSSEN))	Eosinophil count decreased	1,791	1,093	0,81				1,303	1,943	1,637	2,069	1,299
COVID-19 (COVID-19 (JANSSEN))	Eosinophil percentage decreased	1,803	1,271	0,94		0,616		0,271	2,083	1,776	2,017	1,412
COVID-19 (COVID-19 (JANSSEN))	Fatigue	1,754	1,239	0,937				1,189	1,665	1,847	1,947	1,656
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer	2,266	1,278	0,961				0,442	2,152	1,964	1,684	1,684
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer increased	2,139	1,453	0,985		0,619		0,295	1,726	2,389	2,21	2,163
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer normal	1,933	1,198	0,877				0,437	1,973	1,703	2,162	1,29
COVID-19 (COVID-19 (JANSSEN))	Foetal exposure during pregnancy	2,089	1,438	0,914				0,654	1,442	1,12	1,419	1,727
COVID-19 (COVID-19 (JANSSEN))	Glass opacity	2,224	1,303	0,887				2,224	1,7	1,216	2,14	2,24
COVID-19 (COVID-19 (JANSSEN))	Globulins increased	1,845	1,299	0,907			0,405	1,407	1,73	1,585	2,237	1,2
COVID-19 (COVID-19 (JANSSEN))	Glucose urine present	1,711	1,155	0,81				1,215	1,425	1,341	2,115	1,038
COVID-19 (COVID-19 (JANSSEN))	Guttain-Baire syndrome	2,483	1,843	0,984				0,438	1,843	2,037	2,333	1,623
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin decreased	1,802	1,214	0,926		0,612		1,314	2,026	1,783	2,171	1,425
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin increased	1,761	1,239	0,937		0,613		1,239	1,987	1,674	2,092	1,503
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,709	3,612	0,901				4,482	5,521	4,283	7,268	3,477
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,144	3,303	0,884			0,554	4,216	5,727	4,739	7,655	2,339
COVID-19 (COVID-19 (JANSSEN))	Hypoxia	2,082	1,331	0,911				2,082	2,007	1,933	2,494	1,688
COVID-19 (COVID-19 (JANSSEN))	Immunoglobulin therapy	2,077	1,725	0,883				0,011	1,927	2,557	1,397	2,241
COVID-19 (COVID-19 (JANSSEN))	Intensive care	1,937	1,067	0,803				0,022	1,393	2,042	2,342	1,713
COVID-19 (COVID-19 (JANSSEN))	International normalised ratio increased	1,767	1,209	0,892		0,754		0,384	1,192	1,417	2,295	1,258
COVID-19 (COVID-19 (JANSSEN))	International normalised ratio normal	1,916	1,216	0,889				1,584	2,088	1,939	2,089	1,246
COVID-19 (COVID-19 (JANSSEN))	Intracranial thrombus	2,624	1,478	0,911				0,84	1,403	0,993	1,708	1,597
COVID-19 (COVID-19 (JANSSEN))	Jugular vein thrombosis	1,831	1,248	0,888				1,373	1,125	0,711	2,346	0,712
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture	1,862	1,182	0,895				1,122	1,952	1,616	1,611	1,588
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture abnormal	2,149	1,705					1,122	2,841	1,028	1,777	1,822
COVID-19 (COVID-19 (JANSSEN))	Lung opacity	1,983	1,087	0,849			0,191	1,407	1,933	1,991	2,359	1,521
COVID-19 (COVID-19 (JANSSEN))	Lymphocyte percentage decreased	1,685	1,211	0,911				1,211	2,074	1,859	2,059	1,608
COVID-19 (COVID-19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,061	1,47	0,917				1,177	1,877	2,127	2,341	1,592
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,023	1,386	0,887		0,619		1,441	1,938	1,647	2,336	1,592
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin decreased	1,697	1,255	0,924				1,135	1,192	1,492	2,054	0,976
COVID-19 (COVID-19 (JANSSEN))	Mean platelet volume increased	1,874	1,226	0,916				1,154	2,319	1,61	2,063	1,421
COVID-19 (COVID-19 (JANSSEN))	Mechanical ventilation	2,283	1,513	0,923				1,261	1,444	2	2,117	2,035
COVID-19 (COVID-19 (JANSSEN))	Monocyte percentage increased	1,533	1,033	0,821		0,616		0,846	1,932	1,985	2,193	1,128
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage decreased	1,52	1,186	0,888				1,186	1,454	1,616	2,173	0,848
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage increased	1,729	1,265	0,932				0,249	2,032	1,805	1,401	1,411
COVID-19 (COVID-19 (JANSSEN))	Nonspecific reaction	4,027	0,787	0,895				0,745	0,612	0,612	2,867	1,076
COVID-19 (COVID-19 (JANSSEN))	Oral use	2,041	1,092	0,892				1,193	1,932	0,961	1,468	2,024
COVID-19 (COVID-19 (JANSSEN))	On and off phenomenon	1,785	0,755	0,892				3,449	0,983		2,298	
COVID-19 (COVID-19 (JANSSEN))	Pain assessment	2,223	0,861					1,506	2,222	1,106	2,17	1,441
COVID-19 (COVID-19 (JANSSEN))	Peripheral embolism	3,096	1,359	0,885				0,647	1,034	1,541	2,283	0,951
COVID-19 (COVID-19 (JANSSEN))	Platelet count	2,665	2,176	0,918		0,618		1,841	2,869	2,75	3,047	1,796
COVID-19 (COVID-19 (JANSSEN))	Platelet count decreased	1,569	1,31	0,921				1,261	1,444	1,131	1,655	2,375
COVID-19 (COVID-19 (JANSSEN))	Platelet count normal	2,554	1,812	0,902				0,45	2,085	1,791	2,13	3,139
COVID-19 (COVID-19 (JANSSEN))	Platelet factor 4	5,750	3,367	0,866				4,862	4,962	4,862	5,752	2,267
COVID-19 (COVID-19 (JANSSEN))	Poor quality product administered	1,326						0,879	1,98	1,357	1,452	2,05
COVID-19 (COVID-19 (JANSSEN))	Portal vein thrombosis	2,075	1,427	0,887				0,889	1,447	1,027	2,027	1,208
COVID-19 (COVID-19 (JANSSEN))	Positive airway pressure therapy	2,06	1,207	0,865				1,013	1,911	1,677	2,253	1,621
COVID-19 (COVID-19 (JANSSEN))	Product administered to patient of inappropriate age	1,767	0,833	0,886		0,719		0,299	0,44	0,002	0,515	1,666
COVID-19 (COVID-19 (JANSSEN))	Prolonged labour	5,178	1,336					0,544	2,315	1,933	5,15	1,828
COVID-19 (COVID-19 (JANSSEN))	Prothrombin time prolonged	1,932	1,394	0,94		0,754		2,297	2,413	1,663	2,466	1,455
COVID-19 (COVID-19 (JANSSEN))	Pulmonary embolism	2,244	1,296	0,906		0,619		1,78	2,068	2,027	2,018	1,911
COVID-19 (COVID-19 (JANSSEN))	Pulmonary thrombosis	2,295	1,477	0,909				1,756	1,63	1,919	2,16	1,993
COVID-19 (COVID-19 (JANSSEN))	Red blood cell count decreased	1,805	1,324	0,929		0,613		1,348	2,034	1,669	2,034	1,505
COVID-19 (COVID-19 (JANSSEN))	Red cell distribution width increased	1,949	1,309	0,932				1,289	2,113	1,793	2,279	1,418

From: (b) (6)
To: (b) (6) <(b) (6) <(CDC); (b) (6) <(CDC); (b) (6) <(CDC)>>>
Cc: (b) (6) <(CDC); (b) (6) <(CDC); (b) (6) <(CDC)>>>
Subject: RE: Weekly data mining
Date: Wednesday, June 1, 2022 6:12:15 AM
Attachments: [USST_20220530.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/30/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: (b) (6)
To: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Cc: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, June 7, 2022 6:00:24 AM
Attachments: [USST_20220603.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/3/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBRS 20220603	US Serious EBRS 20220603	US Fatal EBRS 20220603	US Infant EBRS 20220603	US Child EBRS 20220603	US Teen EBRS 20220603	US Adult EBRS 20220603	US Adult EBRS 20220603	US Adult EBRS 20220603	US Female EBRS 20220603	US Male EBRS 20220603
COVID-19 (COVID-19) (ANSSEN)	Activated partial thromboplastin time prolonged	2.23	1.51	0.879				1.57	2.04	1.93	2.678	1.396
COVID-19 (COVID-19) (ANSSEN)	Activated partial thromboplastin time shortened	2.04	1.499	0.879				1.57	2.04	1.93	2.678	1.396
COVID-19 (COVID-19) (ANSSEN)	Acute respiratory distress syndrome	0.989	1.303	0.737				1.07	1.379	1.289	1.509	1.009
COVID-19 (COVID-19) (ANSSEN)	Acute respiratory failure	2.117	1.322	0.817				1.49	2.04	1.96	2.465	1.781
COVID-19 (COVID-19) (ANSSEN)	Adverse drug reaction	3.35	0.689	0.108				0.59	0.713	0.671	0.871	1.454
COVID-19 (COVID-19) (ANSSEN)	Adverse event	2.615	0.883	0.137				0.81	1.407	1.21	1.682	1.728
COVID-19 (COVID-19) (ANSSEN)	Albumin CDF increased	2.146	1.698		0.91			1.239	1.412	1.702	0.884	1.623
COVID-19 (COVID-19) (ANSSEN)	Angiogram cerebral abnormal	1.938						1.407	1.933	2.077	3.387	1.505
COVID-19 (COVID-19) (ANSSEN)	Angiogram cerebral normal	2.536	1.785	0.913	0.488			1.366	1.742	1.94	2.184	1.312
COVID-19 (COVID-19) (ANSSEN)	Angiogram pulmonary abnormal	2.3	1.813	0.911				1.62	2.269	2.207	2.471	1.942
COVID-19 (COVID-19) (ANSSEN)	Angiogram pulmonary normal	0.814	0.361	0.14				0.361	0.814	0.764	2.174	1.549
COVID-19 (COVID-19) (ANSSEN)	Antibody test	2.137	0.881	0.625				0.825	1.574	1.905	2.009	1.696
COVID-19 (COVID-19) (ANSSEN)	Anticoagulant therapy	1.456	0.972	0.415	0.619			0.845	2.033	2.048	2.783	1.968
COVID-19 (COVID-19) (ANSSEN)	Application site pain	2.062	1.166	0.9				1.029	1.271	1.325	2.169	1.415
COVID-19 (COVID-19) (ANSSEN)	Arthralgia	1.854	0.888	0.584				1.271	2.221	2.415	2.977	1.974
COVID-19 (COVID-19) (ANSSEN)	Arthralgia cervical abnormal	2.062	1.166	0.9				1.029	1.271	1.325	2.169	1.415
COVID-19 (COVID-19) (ANSSEN)	Arthralgia thorax abnormal	1.854	0.888	0.584				1.271	2.221	2.415	2.977	1.974
COVID-19 (COVID-19) (ANSSEN)	Basophil count decreased	1.872	1.373	0.933	0.616			1.157	2.295	1.886	2.329	1.328
COVID-19 (COVID-19) (ANSSEN)	Basophil percentage decreased	1.777	1.391	0.944	0.615			1.105	2.298	1.922	2.198	1.32
COVID-19 (COVID-19) (ANSSEN)	Blood albumin decreased	1.835	1.275	0.93				1.157	1.85	1.775	2.201	1.413
COVID-19 (COVID-19) (ANSSEN)	Blood albumin increased	1.348	0.955	0.372				1.372	2.098	1.922	2.196	1.519
COVID-19 (COVID-19) (ANSSEN)	Blood chloride increased	1.817	1.302	0.952				1.244	2.009	1.863	2.15	1.354
COVID-19 (COVID-19) (ANSSEN)	Blood ferritin	1.852	1.198	0.878				0.929	2.01	0.588	1.609	1.107
COVID-19 (COVID-19) (ANSSEN)	Blood ferritin decreased	2.756	1.256	0.752				1.725	2.103	0.929	1.929	1.03
COVID-19 (COVID-19) (ANSSEN)	Blood magnesium increased	1.788	1.281	0.927				1.081	1.935	1.744	2.342	1.211
COVID-19 (COVID-19) (ANSSEN)	Blood sodium decreased	1.858	1.301	0.902	0.616			1.301	2.011	1.733	1.659	1.628
COVID-19 (COVID-19) (ANSSEN)	Blood urea decreased	1.645	1.314	0.863				1.358	1.943	1.208	2.032	1.211
COVID-19 (COVID-19) (ANSSEN)	Blood urea increased	1.9	1.251	0.915				1.068	2.051	1.734	2.113	1.654
COVID-19 (COVID-19) (ANSSEN)	COVID-19 pneumonia	2.241	1.08	0.82				1.91	2.252	2.057	2.419	2.009
COVID-19 (COVID-19) (ANSSEN)	CRP protein increased	2.012	1.408	0.982				1.878	2.062	1.657	2.362	1.143
COVID-19 (COVID-19) (ANSSEN)	Central venous catheter	2.532	1.532	0.938	0.525			1.713	1.85	1.31	3.417	1.728
COVID-19 (COVID-19) (ANSSEN)	Central vein occlusion	2.856	1.59	0.927				1.86	1.263	3.612	3.912	1.199
COVID-19 (COVID-19) (ANSSEN)	Central vein thrombosis	2.704	2.134	0.886				2.058	1.938	1.617	3.012	1.617
COVID-19 (COVID-19) (ANSSEN)	Chest X-ray abnormal	2.038	2.171	0.919	0.528			2.358	2.444	0.88	3.01	1.276
COVID-19 (COVID-19) (ANSSEN)	Computerized tomogram head abnormal	1.878	0.913	0.39	0.19			1.398	2.444	0.88	3.01	1.276
COVID-19 (COVID-19) (ANSSEN)	Computerized tomogram head normal	2.444	1.633	0.945	0.618			2.132	2.202	2.067	3.041	1.737
COVID-19 (COVID-19) (ANSSEN)	Computerized tomogram thorax abnormal	1.825	0.918	0.388	0.19			1.718	2.202	2.067	3.041	1.737
COVID-19 (COVID-19) (ANSSEN)	Computerized tomogram thorax normal	2	1.381	0.818	0.488			2.048	2.022	2.048	2.722	1.495
COVID-19 (COVID-19) (ANSSEN)	Conjunctive renal clearance decreased	1.191	0.888	0.499				1.191	1.888	1.928	1.928	1.191
COVID-19 (COVID-19) (ANSSEN)	Death	1.169	0.862	0.223				1.023	1.682	1.528	1.528	1.528
COVID-19 (COVID-19) (ANSSEN)	Deep vein thrombosis	2.637	1.607	1.108	0.464			2.268	2.289	3.172	3.322	2.059
COVID-19 (COVID-19) (ANSSEN)	Encephalopathy	2.058	1.36	0.863	0.363			1.41	2.088	1.653	2.11	1.38
COVID-19 (COVID-19) (ANSSEN)	Encephalopathy decreased	1.79	1.206	0.93	0.04			1.244	2.018	1.774	2.093	1.337
COVID-19 (COVID-19) (ANSSEN)	Encephalopathy normal	1.766	1.407	0.965	0.416			1.265	1.457	2.077	2.077	1.337
COVID-19 (COVID-19) (ANSSEN)	Fatigue	1.757	1.027	0.895	0.181			1.084	1.457	0.978	1.852	1.428
COVID-19 (COVID-19) (ANSSEN)	Fatigue decreased	2.272	1.454	0.984	0.619			2.179	2.524	2.524	2.729	2.524
COVID-19 (COVID-19) (ANSSEN)	Fatigue increased	2.147	1.454	0.984	0.619			2.171	2.312	2.018	2.53	1.625
COVID-19 (COVID-19) (ANSSEN)	Fatigue normal	1.937	1.075	0.888	0.438			1.628	2.011	1.625	2.172	1.288
COVID-19 (COVID-19) (ANSSEN)	Fetal exposure during pregnancy	2.201	1.021	0.756				1.816	2.181	1.628	2.172	1.288
COVID-19 (COVID-19) (ANSSEN)	Glaze injury	2.21	1.021	0.885	0.465			2.274	1.882	1.213	2.224	1.578
COVID-19 (COVID-19) (ANSSEN)	Glucose increased	1.848	0.968	0.588	0.368			1.258	1.759	2.324	2.324	1.578
COVID-19 (COVID-19) (ANSSEN)	Glucose urea present	1.712	1.156	0.811	0.437			1.402	1.973	1.373	2.182	1.068
COVID-19 (COVID-19) (ANSSEN)	Guttal-Barré syndrome	2.488	1.584	0.984	0.488			1.628	2.329	2.438	2.438	1.068
COVID-19 (COVID-19) (ANSSEN)	Haematocrit decreased	1.806	1.271	0.941	0.613			1.335	2.02	1.874	2.181	1.43
COVID-19 (COVID-19) (ANSSEN)	Haemoglobin decreased	1.806	1.271	0.941	0.613			1.335	2.02	1.874	2.181	1.43
COVID-19 (COVID-19) (ANSSEN)	Heparin-induced thrombocytopenia test	0.39	0.835	0.267				0.39	0.835	0.267	2.041	1.419
COVID-19 (COVID-19) (ANSSEN)	Heparin-induced thrombocytopenia test positive	1.712	0.917	0.613	0.363			1.162	1.521	1.42	1.767	1.373
COVID-19 (COVID-19) (ANSSEN)	Hypoxia	2.049	3.207	0.883	0.554			4.206	2.734	0.74	7.654	2.479
COVID-19 (COVID-19) (ANSSEN)	Immunglobulin therapy	1.678	1.082	0.752	0.416			1.022	1.482	1.08	2.468	1.08
COVID-19 (COVID-19) (ANSSEN)	Intensive care	1.713	0.881	0.811	0.011			2.046	2.546	1.374	2.227	1.711
COVID-19 (COVID-19) (ANSSEN)	International normalized ratio increased	1.945	1.489	0.984	0.588			1.454	2.046	2.046	2.344	1.617
COVID-19 (COVID-19) (ANSSEN)	International normalized ratio normal	1.76	1.202	0.889	0.382			1.528	1.891	1.433	2.202	1.258
COVID-19 (COVID-19) (ANSSEN)	Intracardiac thrombosis	2.97	1.774	0.911	0.588			1.393	1.891	0.887	2.087	1.258
COVID-19 (COVID-19) (ANSSEN)	Jugular vein thrombosis	1.84	1.389	0.897	0.488			1.422	0.994	1.171	1.622	1.028
COVID-19 (COVID-19) (ANSSEN)	Lumbar puncture	2.058	1.075	0.752	0.416			1.178	1.718	1.178	2.288	1.718
COVID-19 (COVID-19) (ANSSEN)	Lumbar puncture abnormal	1.243	1.69	0.89	0.613			1.122	2.801	1.031	1.774	1.816
COVID-19 (COVID-19) (ANSSEN)	Lung infection	1.938	1.16	0.811	0.363			1.122	1.82	1.068	2.002	1.401
COVID-19 (COVID-19) (ANSSEN)	Lung opacity	2.024	1.282	0.949	0.488			1.425	1.73	2.013	2.38	1.523
COVID-19 (COVID-19) (ANSSEN)	Lymphocyte percentage decreased	1.976	1.025	0.616	0.363			1.096	1.675	1.603	1.903	0.849
COVID-19 (COVID-19) (ANSSEN)	Magnetic resonance imaging head abnormal	2.08	1.485	0.916	0.182			1.872	2.142	2.338	2.338	1.595
COVID-19 (COVID-19) (ANSSEN)	Magnetic resonance imaging head normal	1.372	0.823	0.588	0.267			1.202	1.823	1.603	2.383	1.595
COVID-19 (COVID-19) (ANSSEN)	Mean cell haemoglobin concentration decreased	1.702	1.251	0.922	0.619			1.17	1.918	1.475	2.073	0.974
COVID-19 (COVID-19) (ANSSEN)	Mean platelet volume increased	1.846	1.298	0.91	0.314			1.147	2.274	1.579	2.074	1.395
COVID-19 (COVID-19) (ANSSEN)	Mechanical ventilation	2.92	1.32	0.878	0.478			1.268	2.066	1.628	2.138	1.214
COVID-19 (COVID-19) (ANSSEN)	Monocyte percentage increased	1.533	1.223	0.918	0.207			0.855	1.931	1.981	2.102	1.118
COVID-19 (COVID-19) (ANSSEN)	Neutrophil percentage decreased	1.522	1.024	0.616	0.319			1.132	1.607	1.607	2.107	0.849
COVID-19 (COVID-19) (ANSSEN)	Neutrophil percentage increased	1.722	1.259	0.929	0.209			2.068	1.808	1.983	1.983	1.405
COVID-19 (COVID-19) (ANSSEN)	Non-specific reaction	4.088	0.788	0.488	0.182			0.745	0.613	0.588	2.888	1.075
COVID-19 (COVID-19) (ANSSEN)	Off label use	2.072	0.996	0.885	0.345			1.219	1.387	0.985	1.489	2.085
COVID-19 (COVID-19) (ANSSEN)	On and off phenomenon	1.767	0.751	0.368	0.182			3.408	0.985	2.249	2.249	1.767
COVID-19 (COVID-19) (ANSSEN)	Pain assessment	2.209	0.861	0.588	0.515			1.506	2.506	1.11	2.173	1.447
COVID-19 (COVID-19) (ANSSEN)	Pregnant abortion	3.089	1.355	0.883	0.687			1.038	1.561	2.668	2.668	0.951
COVID-19 (COVID-19) (ANSSEN)	Platelet count	2.817	1.148	0.768	0.832			1.821	2.1	2.791	2.791	1.762
COVID-19 (COVID-19) (ANSSEN)	Platelet count decreased	1.87	1.303	0.92	0.478			1.832	2.1	1.864	2.041	1.469
COVID-19 (COVID-19) (ANSSEN)	Platelet count normal	3.051	1.808	0.951	0.687			2.069	2.74	2.172	3.12	1.603
COVID-19 (COVID-19) (ANSSEN)	Platelet factor 4	5.8	3.284	0.885	0.421			4.888	0.807	5.733	2.27	2.27
COVID-19 (COVID-19) (ANSSEN)	Primal vein thrombosis	2.254	1.655	0.885	0.687			1.584	1.62	2.387	1.334	1.334
COVID-19 (COVID-19) (ANSSEN)	Positive airway pressure therapy	2.088	1.304	0.959	1.004			2.105	1.732	2.218	1.684	1.684
COVID-19 (COVID-19) (ANSSEN)	Positive airway pressure therapy inappropriate age	0.833	0.833	0.833	0.833			0.833	0.833	0.833	1.621	1.621
COVID-19 (COVID-19) (ANSSEN)	Prevalence	1.767	1.33	0.885	0.719	0.719		0.802	0.512	0.512	5.154	1.826
COVID-19 (COVID-19) (ANSSEN)	Protein total decreased	1.94	1.227	0.928	0.616			1.439	1.629	1.738	2.915	1.421
COVID-19 (COVID-19) (ANSSEN)	Prothrombin time prolonged	1.38	0.95	0.754	0.293			1.434	2.293	1.668	2.468	1.448
COVID-19 (COVID-19) (ANSSEN)	Pulmonary embolism	2.252	1.588	1.083	0.619			1.808	2.088	2.833	2.528	1.917
COVID-19 (COVID-19) (ANSSEN)	Pulmonary embolism	1.325	1.465	0.909	0.488			1.765	1.67	1.923	2.223	1.989
COVID-19 (COVID-19) (ANSSEN)	Red blood cell count decreased	1.8	1.207	0.929	0.558	0.614		1.304	2.005	1.872	2.044	1.491

From: (b) (6)
To: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Cc: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, June 14, 2022 6:37:03 AM
Attachments: [USST_20220610.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/10/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBRS 2022/26	US Sarinax EBRS 2022/26	US Fami EBRS 2022/26	US Infant EBRS 2022/26	US Child EBRS 2022/26	US Teen EBRS 2022/26	US Adult EBRS 2022/26										
COVID19 (COVID19 (ANSSEN))	Activated partial thromboplastin time prolonged	2102						1.47										2.83
COVID19 (COVID19 (ANSSEN))	Activated partial thromboplastin time shortened	2022	1.487		0.862			1.55	1.991					1.945				2.649
COVID19 (COVID19 (ANSSEN))	Acute respiratory distress syndrome	2366	1.967		0.77			1.677	1.777					1.603				1.837
COVID19 (COVID19 (ANSSEN))	Acute respiratory failure	2118	1.52		1.015			1.472	2.062					1.998				1.768
COVID19 (COVID19 (ANSSEN))	Adverse drug reaction	3341	0.824		0.624			0.766	0.766					0.676				2.649
COVID19 (COVID19 (ANSSEN))	Adverse event	2622	1.086		0.887			1.065	0.91					1.063				1.725
COVID19 (COVID19 (ANSSEN))	Albumin CSF increased	2349				0.911		1.238	1.412					0.84				1.626
COVID19 (COVID19 (ANSSEN))	Albumin decreased	1633	1.079		0.911			1.463	1.463					1.463				1.323
COVID19 (COVID19 (ANSSEN))	Angiogram cerebral abnormal	2515	1.768		0.487			2.29	1.91					2.044				1.498
COVID19 (COVID19 (ANSSEN))	Angiogram cerebral normal	2048	1.681		0.911			1.785	1.785					1.719				1.252
COVID19 (COVID19 (ANSSEN))	Angiogram pulmonary abnormal	2288	1.602		0.911			1.647	2.256					2.483				1.948
COVID19 (COVID19 (ANSSEN))	Angiogram pulmonary normal	1814	1.346		0.956			1.36	1.36					2.164				1.385
COVID19 (COVID19 (ANSSEN))	Antibody test	2148	0.828		0.588			0.828	1.569					2.031				1.09
COVID19 (COVID19 (ANSSEN))	Anticoagulant therapy	2181	0.968		0.968			0.968	2.032					2.774				1.69
COVID19 (COVID19 (ANSSEN))	Application site pain	2054						0.61	0.68					1.028				0.764
COVID19 (COVID19 (ANSSEN))	Atrial fibrillation	2049	1.446		0.903			0.904	2.247					1.325				1.498
COVID19 (COVID19 (ANSSEN))	Atrial septal aneurysm	1815	1.14		0.969			1.204	1.208					1.41				0.981
COVID19 (COVID19 (ANSSEN))	Basophil count decreased	1863	1.367		0.934		0.617	0.937	1.14					1.872				1.317
COVID19 (COVID19 (ANSSEN))	Basophil percentage decreased	1771	1.383		0.963		0.615	0.963	1.114					1.606				2.201
COVID19 (COVID19 (ANSSEN))	Blood albumin decreased	1828	1.302		0.93			1.511	1.855					1.754				1.420
COVID19 (COVID19 (ANSSEN))	Blood lactate decreased	1874	1.346		0.956			1.364	1.364					2.188				1.252
COVID19 (COVID19 (ANSSEN))	Blood chloride increased	1814	1.461		1.34			1.244	2.001					1.883				2.159
COVID19 (COVID19 (ANSSEN))	Blood ferritin	1854	1.2		0.883			0.928	0.929					0.569				1.351
COVID19 (COVID19 (ANSSEN))	Blood folic acid decreased	2891	2.12		0.959			1.749	2.025					3.024				1.527
COVID19 (COVID19 (ANSSEN))	Blood magnesium increased	1774	1.289		0.926			0.971	1.307					1.732				2.309
COVID19 (COVID19 (ANSSEN))	Blood potassium decreased	1687	1.203		0.968			1.254	1.628					2.002				1.886
COVID19 (COVID19 (ANSSEN))	Blood sodium decreased	1828	1.301		0.965		0.618	1.367	1.917					1.731				1.597
COVID19 (COVID19 (ANSSEN))	Blood sodium increased	1812	1.075		0.92			1.051	1.378					1.162				2.017
COVID19 (COVID19 (ANSSEN))	Blood urea decreased	1645	1.313		0.897		0.886	1.361	1.962					1.205				2.038
COVID19 (COVID19 (ANSSEN))	Blood urea increased	1886	1.249		0.911			1.001	1.981					1.76				1.62
COVID19 (COVID19 (ANSSEN))	COVID-19 pneumonia	2242	1.404		1.073			1.068	2.254					2.056				2.412
COVID19 (COVID19 (ANSSEN))	CFP protein increased	2581	2.001		0.887			2.26	2.26					1.005				2.130
COVID19 (COVID19 (ANSSEN))	Central haemorrhage	2228	1.678		0.908			1.872	1.842					1.944				1.344
COVID19 (COVID19 (ANSSEN))	Central mass effect	2879	1.984		0.927			1.84	1.862					2.288				1.28
COVID19 (COVID19 (ANSSEN))	Central venous sinus thrombosis	2171	1.688		0.927			1.688	1.471					1.368				3.625
COVID19 (COVID19 (ANSSEN))	Choi-Krup abnormal	3363	2.17		0.921			0.921	2.447					0.872				3.33
COVID19 (COVID19 (ANSSEN))	Choi-Krup normal	1811	1.313		0.921			0.921	1.368					2.087				1.288
COVID19 (COVID19 (ANSSEN))	Computed tomography head abnormal	2433	1.642		0.928		0.618	1.29	2.13					2.055				3.028
COVID19 (COVID19 (ANSSEN))	Computed tomography head normal	1788	1.325		0.979			1.724	1.428					1.288				1.908
COVID19 (COVID19 (ANSSEN))	Computed tomography thorax abnormal	1593	1.075		0.926			0.926	2.043					1.988				2.249
COVID19 (COVID19 (ANSSEN))	Creatinine renal clearance decreased	2064	1.299		0.893			0.893	0.893					2.149				1.892
COVID19 (COVID19 (ANSSEN))	Death	1868	1.688		0.911			1.622	1.622					1.292				1.675
COVID19 (COVID19 (ANSSEN))	Deep vein thrombosis	2646	1.803		1.044			2.253	2.298					3.192				2.087
COVID19 (COVID19 (ANSSEN))	Electrocardiogram	2047	1.483		0.963			1.483	2.066					2.066				2.288
COVID19 (COVID19 (ANSSEN))	Endosight count decreased	1789	1.293		0.951			1.298	2.044					1.75				2.302
COVID19 (COVID19 (ANSSEN))	Endosight percentage decreased	1729	1.288		0.927		0.618	1.288	2.029					1.75				2.029
COVID19 (COVID19 (ANSSEN))	Fatigue	1758	0.854		0.888			1.021	1.459					0.976				1.424
COVID19 (COVID19 (ANSSEN))	Ferritin D dimer	227	1.274		0.903			0.904	2.175					1.958				2.534
COVID19 (COVID19 (ANSSEN))	Ferritin D dimer increased	2143	1.489		0.977		0.619	1.489	2.302					2.917				1.708
COVID19 (COVID19 (ANSSEN))	Ferritin D dimer normal	1954	1.507		0.89			1.507	2.044					1.621				1.621
COVID19 (COVID19 (ANSSEN))	Fetal exposure during pregnancy	2273	0.927		0.927		0.757	0.927	1.683					1.029				2.221
COVID19 (COVID19 (ANSSEN))	Glaze palsy	2211	1.02		0.898			0.447	1.841					2.228				1.277
COVID19 (COVID19 (ANSSEN))	Glycemia increased	1888	1.888		0.937			1.753	1.753					2.248				2.248
COVID19 (COVID19 (ANSSEN))	Glomerular filtration rate decreased	1766	1.138		0.911			1.052	1.687					2.001				1.385
COVID19 (COVID19 (ANSSEN))	Glycemia urine present	1714	1.137		0.917			1.23	1.349					1.941				1.81
COVID19 (COVID19 (ANSSEN))	Kidney failure syndrome	2482	1.835		0.863			1.116	1.624					2.43				1.423
COVID19 (COVID19 (ANSSEN))	Haemoglobin decreased	1803	1.268		0.943		0.613	1.328	2.076					1.782				1.423
COVID19 (COVID19 (ANSSEN))	Haemoglobin increased	1731	1.231		0.909			1.307	1.947					2.067				1.947
COVID19 (COVID19 (ANSSEN))	Hepatic-induced thrombocytopenia test	5716	3.605		0.903			4.283	5.523					4.348				2.785
COVID19 (COVID19 (ANSSEN))	Hepatic-induced thrombocytopenia test positive	6165	3.064		0.864			3.296	3.759					4.74				3.778
COVID19 (COVID19 (ANSSEN))	Hypoxia	2108	1.318		0.958			1.491	2.059					1.932				1.889
COVID19 (COVID19 (ANSSEN))	Intensive care	2882	1.715		0.958			1.911	2.592					2.232				2.232
COVID19 (COVID19 (ANSSEN))	Intensive care	1948	1.588		0.922			1.458	2.151					2.348				1.689
COVID19 (COVID19 (ANSSEN))	International normalized ratio increased	1789	1.391		0.981			1.391	1.959					1.421				1.588
COVID19 (COVID19 (ANSSEN))	International normalized ratio normal	1528	1.232		0.896		0.755	1.232	2.076					2.689				1.421
COVID19 (COVID19 (ANSSEN))	Interatrial septum	2877	1.779		0.973			0.84	1.423					0.994				1.625
COVID19 (COVID19 (ANSSEN))	Interatrial septum	1865	1.874		0.974			1.974	1.192					1.372				1.874
COVID19 (COVID19 (ANSSEN))	Lumbar puncture	1873	1.359		0.881			1.275	2.188					1.011				1.764
COVID19 (COVID19 (ANSSEN))	Lumbar puncture abnormal	2136	1.48		0.889			1.152	2.726					2.052				1.625
COVID19 (COVID19 (ANSSEN))	Lung opacity	1988	1.048		0.949			1.417	1.729					2.679				1.754
COVID19 (COVID19 (ANSSEN))	Lymphocyte count decreased	1858	1.368		0.901			1.368	2.058					1.851				2.058
COVID19 (COVID19 (ANSSEN))	Lymphocyte percentage decreased	1684	1.243		0.931			1.065	2.065					1.885				1.885
COVID19 (COVID19 (ANSSEN))	Magnetic resonance imaging head abnormal	2058	1.465		0.977			1.777	2.033					2.331				1.398
COVID19 (COVID19 (ANSSEN))	Magnetic resonance imaging head normal	2011	0.428		0.878			1.073	2.191					1.824				1.504
COVID19 (COVID19 (ANSSEN))	Mean cell haemoglobin concentration decreased	171	1.254		0.921			1.163	1.926					2.052				0.968
COVID19 (COVID19 (ANSSEN))	Mean cell haemoglobin concentration increased	1852	1.852		0.915			1.852	1.198					2.254				1.584
COVID19 (COVID19 (ANSSEN))	Mechanical ventilation	2278	1.507		0.907			2.249	2.026					2.026				2.026
COVID19 (COVID19 (ANSSEN))	Mechanical ventilation	1828	1.218		0.888		0.618	1.218	2.028					2.188				1.928
COVID19 (COVID19 (ANSSEN))	Neutrophil dysplasia	2369	0.983		0.92			0.92	1.683					0.878				1.119
COVID19 (COVID19 (ANSSEN))	Neutrophil percentage decreased	1822	1.2		0.888			1.108	1.057					2.178				1.887
COVID19 (COVID19 (ANSSEN))	Neutrophil percentage increased	1733	1.265		0.932			1.208	2.08					1.815				1.666
COVID19 (COVID19 (ANSSEN))	Non-specific reaction	4078	0.789		0.789			0.744	0.813					0.984				1.076
COVID19 (COVID19 (ANSSEN))	Off-label use	2079	0.929		0.899			0.929	1.299					2.063				2.063
COVID19 (COVID19 (ANSSEN))	On and off phenomenon	1769	0.951		0.856			0.963	2.053					3.013				1.769
COVID19 (COVID19 (ANSSEN))	Pain assessment	2226	0.858		0.858			0.858	2.293					2.17				1.448
COVID19 (COVID19 (ANSSEN))	Peripheral embolism	3068	1.358		0.888			1.055	1.588					2.284				0.951
COVID19 (COVID19 (ANSSEN))	Plakal coat	2447																

From: (b) (6)
To: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Cc: (b) (6) <(CDC)>; (b) (6) <(CDC)>; (b) (6) <(CDC)>
Subject: RE: Weekly data mining
Date: Tuesday, June 21, 2022 7:15:05 AM
Attachments: [USST_20220617.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/17/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBOS 20220617	US Barouss EBOS 20220617	US Fadal EBOS 20220617	US Infant EBOS 20220617	US Child EBOS 20220617	US Teen EBOS 20220617	US Adult EBOS 20220617	US Adult EBOS 20220617	US Adult EBOS 20220617	US Female EBOS 20220617	US Male EBOS 20220617
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time prolonged	1.94					1.37	1.45				1.34
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time shortened	2.011	1.477	0.877			1.54	1.85	1.929	2.623		1.382
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory distress syndrome	2.094	1.279	0.974			0.779	1.023	1.781	1.602		1.481
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory failure	2.111	1.317	1.016			0.522	0.759	1.994	2.439		1.754
COVID-19 (COVID-19 (JANSSEN))	Adverse drug reaction	3.375	0.966	0.886			0.779	2.031	0.977	2.626		1.448
COVID-19 (COVID-19 (JANSSEN))	Adverse event	1.085					2.342	0.869	0.779	1.892		1.177
COVID-19 (COVID-19 (JANSSEN))	Albumin CSF increased	2.05	1.805				1.382			0.894		1.561
COVID-19 (COVID-19 (JANSSEN))	Angiogram abnormal	1.924	1.273	0.908			1.48	1.406	1.676	2.126		1.322
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral abnormal	2.602	1.911	1.011		0.487	1.744	2.032	1.907	2.007		1.325
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral normal	2.063	1.361	0.887			1.782	1.753	1.247	2.162		1.456
COVID-19 (COVID-19 (JANSSEN))	Angiogram pulmonary abnormal	2.281	1.609	0.947			1.672	2.228	2.044	2.173		2.448
COVID-19 (COVID-19 (JANSSEN))	Anion gap decreased	1.788	1.336	0.911			0.359	1.139	1.448	2.117		1.317
COVID-19 (COVID-19 (JANSSEN))	Antibody test	2.164	0.824	0.862			0.968	0.867	1.563	2.113	2.091	1.688
COVID-19 (COVID-19 (JANSSEN))	Anticoagulant therapy	2.173	1.403	0.947	0.62		0.414	1.843	2.018	2.844	2.75	1.661
COVID-19 (COVID-19 (JANSSEN))	Application site pain	2.004					0.561	0.636	1.078	1.037		0.704
COVID-19 (COVID-19 (JANSSEN))	Arteriosclerosis	2.055	1.657	0.902			0.97	2.225	1.315	2.19		1.425
COVID-19 (COVID-19 (JANSSEN))	Arteriogram carotid abnormal	1.811	1.139	0.888			1.203	1.207	1.406	2.193		0.966
COVID-19 (COVID-19 (JANSSEN))	Basophil count decreased	1.84	1.348	0.93	0.617		0.354	1.127	2.189	1.87	2.288	1.314
COVID-19 (COVID-19 (JANSSEN))	Basophil percentage decreased	1.753	1.308	0.938	0.616		0.251	1.108	2.238	1.807	2.173	1.307
COVID-19 (COVID-19 (JANSSEN))	Blood albumin decreased	1.81	1.257	0.925			0.299	1.511	1.833	1.734	2.165	1.398
COVID-19 (COVID-19 (JANSSEN))	Blood calcium decreased	1.854	1.332	0.949			0.369	1.354	2.076	1.869	2.173	1.502
COVID-19 (COVID-19 (JANSSEN))	Blood chloride increased	1.788	1.288	0.954			0.459	1.249	1.971	1.84	2.141	1.333
COVID-19 (COVID-19 (JANSSEN))	Blood fibrinogen	1.852	1.197	0.879			0.978	0.929	2.008	0.959	1.698	1.156
COVID-19 (COVID-19 (JANSSEN))	Blood fibrinogen decreased	2.696	2.12	0.986			0.25	1.744	2.032	0.87	3.832	1.026
COVID-19 (COVID-19 (JANSSEN))	Blood magnesium increased	1.757	1.257	0.922			0.166	1.097	1.732	2.286	2.026	1.388
COVID-19 (COVID-19 (JANSSEN))	Blood uric acid decreased	1.639	1.307	0.993			0.079	1.353	1.949	1.198	2.016	0.975
COVID-19 (COVID-19 (JANSSEN))	Blood urea increased	1.887	1.444	0.912			1.093	2.028	1.772	2.09	2.621	1.631
COVID-19 (COVID-19 (JANSSEN))	COVID-19 pneumonia	2.266	1.462	1.071			1.886	2.225	2.06	2.42	1.999	1.382
COVID-19 (COVID-19 (JANSSEN))	CHF protein increased	2.061	1.684	0.982			1.896	2.463	0.991	2.335		2.133
COVID-19 (COVID-19 (JANSSEN))	Cerebral haemorrhage	2.232	1.586	0.939			0.523	1.776	1.831	1.503	3.332	1.172
COVID-19 (COVID-19 (JANSSEN))	Cerebral mass effect	2.789	1.95	1.024			1.031	1.627	1.298	3.794	1.19	1.949
COVID-19 (COVID-19 (JANSSEN))	Cerebral thrombosis	1.737	1.086	0.886			1.452	1.356	1.628	3.625	2.369	1.561
COVID-19 (COVID-19 (JANSSEN))	Cerebral venous sinus thrombosis	1.358	2.171	0.919			0.827	2.085	2.443	0.872	3.007	1.271
COVID-19 (COVID-19 (JANSSEN))	Chest X-ray abnormal	1.867	1.367	0.928			0.6	1.224	2.067	2.045	3.074	1.281
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram head abnormal	2.42	1.636	0.961	0.618		0.6	2.124	2.267	2.045	3.004	1.722
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram head normal	1.968	1.368	0.916			1.368	1.711	1.933	1.854	2.249	1.61
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram thorax abnormal	1.986	1.373	0.926			1.397	2.033	1.966	2.241	1.661	1.661
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram thorax normal	2.036	1.281	0.889			0.495	0.889	2.088	2.089	1.056	1.783
COVID-19 (COVID-19 (JANSSEN))	Death	1.873	1.171	0.832			1.171	1.632	1.684	2.689	2.089	1.684
COVID-19 (COVID-19 (JANSSEN))	Deep vein thrombosis	2.643	1.801	1.06			0.483	2.271	2.297	3.159	3.323	2.069
COVID-19 (COVID-19 (JANSSEN))	Endotracheal intubation	2.04	1.147	0.812			2.04	1.847	2.065	2.065	2.065	1.61
COVID-19 (COVID-19 (JANSSEN))	Eosinophil count decreased	1.725	1.273	0.926	0.616		0.041	1.217	1.937	2.073	2.073	1.317
COVID-19 (COVID-19 (JANSSEN))	Eosinophil percentage decreased	1.755	1.316	0.934			0.265	1.223	2.032	1.748	2.053	1.327
COVID-19 (COVID-19 (JANSSEN))	Feeling cold	1.755	1.316	0.934			1.755	1.452	1.452	1.82	1.85	1.85
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer	2.267	1.675	0.899			0.504	2.275	2.152	1.946	2.522	1.702
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer increased	1.927	1.297	0.899	0.619		2.269	2.269	2.269	2.269	2.269	2.269
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer normal	1.942	1.062	0.886			0.437	0.63	2.036	1.208	2.198	1.276
COVID-19 (COVID-19 (JANSSEN))	Fetal exposure during pregnancy	2.323	1.418	0.916	0.757		0.676	1.873	1.873	1.873	1.873	1.873
COVID-19 (COVID-19 (JANSSEN))	Glaze patch	2.219	1.633	0.897			0.403	1.633	1.633	1.633	2.224	1.224
COVID-19 (COVID-19 (JANSSEN))	Globulins increased	1.855	1.263	0.913			0.397	1.277	1.738	1.6	2.219	1.239
COVID-19 (COVID-19 (JANSSEN))	Gout-like syndrome	1.695	1.147	0.812			1.695	1.427	1.427	2.138	2.138	1.61
COVID-19 (COVID-19 (JANSSEN))	Guttain-Barre syndrome	2.458	1.824	0.984			0.436	1.623	3.075	1.632	2.413	2.174
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin decreased	1.793	1.263	0.941	0.613		1.329	1.999	1.999	1.777	2.166	1.422
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin increased	1.743	1.243	0.912			1.743	1.237	1.631	1.631	2.073	1.477
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.71	3.604	0.93	0.613		0.51	5.516	2.162	2.162	3.317	1.702
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.444	3.289	0.883			0.552	6.444	5.722	0.739	7.05	2.069
COVID-19 (COVID-19 (JANSSEN))	Hypoxia	2.073	1.313	0.957			1.488	2.08	1.936	2.45	1.684	1.684
COVID-19 (COVID-19 (JANSSEN))	Immunglobulin therapy	2.09	1.722	0.924			0.011	1.843	2.346	1.863	2.213	1.741
COVID-19 (COVID-19 (JANSSEN))	Interosseous catheter	1.84	1.384	0.927			1.463	2.097	2.097	2.085	2.337	1.585
COVID-19 (COVID-19 (JANSSEN))	International normalized ratio increased	1.73	1.187	0.886	0.755		0.381	1.508	1.852	1.407	2.257	1.237
COVID-19 (COVID-19 (JANSSEN))	International normalized ratio normal	1.929	1.307	0.929			1.929	2.072	0.969	2.052	2.052	1.684
COVID-19 (COVID-19 (JANSSEN))	Intracardiac thrombus	2.699	1.814	0.924			1.814	1.42	0.994	1.771	1.622	1.622
COVID-19 (COVID-19 (JANSSEN))	Jugular vein thrombosis	1.867	1.337	0.887			1.867	1.371	1.115	0.712	2.089	1.677
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture	1.865	1.352	0.876			1.865	1.211	2.18	1.006	1.652	1.758
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture abnormal	2.141	1.685	0.946			1.156	1.815	1.074	2.024	1.752	1.837
COVID-19 (COVID-19 (JANSSEN))	Lung opacity	1.989	1.444	0.923			1.989	1.44	1.709	1.969	2.923	1.61
COVID-19 (COVID-19 (JANSSEN))	Lymphocyte percentage decreased	1.689	1.22	0.924			0.183	2.036	1.885	2.05	1.297	1.297
COVID-19 (COVID-19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.057	1.466	0.915			0.467	1.769	1.879	2.117	2.323	1.603
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2.006	1.35	0.931	0.619		1.288	2.456	1.818	1.818	2.354	1.477
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin increased	1.7	1.249	0.918			0.233	1.171	1.909	1.483	2.065	0.979
COVID-19 (COVID-19 (JANSSEN))	Mean platelet volume increased	1.813	1.307	0.927			1.813	2.207	2.207	1.533	2.036	1.61
COVID-19 (COVID-19 (JANSSEN))	Mechanical ventilation	2.279	1.507	0.916	0.616		0.477	1.156	2.249	2.053	2.111	2.038
COVID-19 (COVID-19 (JANSSEN))	Monocyte percentage increased	1.919	1.264	0.919			0.205	0.836	1.989	1.927	2.107	1.099
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage decreased	2.361	0.981	0.881			1.315	1.581	1.581	1.667	2.135	1.099
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage increased	1.552	1.187	0.894			0.315	1.187	1.899	1.927	2.107	0.85
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage normal	1.716	1.305	0.928			0.265	1.163	2.049	1.805	1.875	1.875
COVID-19 (COVID-19 (JANSSEN))	Nonspecific reaction	4.081	0.789				0.745	0.613				1.076
COVID-19 (COVID-19 (JANSSEN))	Oral label use	2.101	0.6	0.895			4.846	1.236	1.46	1.944	3.017	2.136
COVID-19 (COVID-19 (JANSSEN))	Oral and/or phenothiazone	1.768	1.372	0.927			1.768	2.427	0.982	1.805	2.246	1.44
COVID-19 (COVID-19 (JANSSEN))	Pain assessment	2.204	0.858				0.514	1.495	2.232	1.036	2.133	1.444
COVID-19 (COVID-19 (JANSSEN))	Peripneumonia	3.085	1.36	0.894			0.657	1.034	1.965	2.309	0.951	1.702
COVID-19 (COVID-19 (JANSSEN))	Platelet count	2.653	1.514	0.917	0.618		0.477	1.864	2.883	2.619	3.01	1.809
COVID-19 (COVID-19 (JANSSEN))	Platelet count decreased	1.856	1.297	0.896	0.614		0.256	1.453	2.085	1.649	2.24	1.468
COVID-19 (COVID-19 (JANSSEN))	Platelet count normal	2.645	1.606	0.93			0.445	2.092	2.725	1.969	3.088	1.17
COVID-19 (COVID-19 (JANSSEN))	Platelet factor 4	5.802	3.271	0.889			1.428	4.288	0.873	5.732	2.273	1.468
COVID-19 (COVID-19 (JANSSEN))	Pulial vein thrombosis	2.253	1.671	0.985			0.993	1.853	1.853	1.03	2.368	1.334
COVID-19 (COVID-19 (JANSSEN))	Positive airway pressure therapy	2.084	1.298	0.956			1.003	2.102	1.709	2.243	1.651	1.651
COVID-19 (COVID-19 (JANSSEN))	Product administered to patient of inappropriate age	1.751	0.834	0.885		0.705	2.06	1.038	2.002	0.511	1.617	1.816
COVID-19 (COVID-19 (JANSSEN))	Proposed label	1.184	1.332				0.554	1.332				1.157
COVID-19 (COVID-19 (JANSSEN))	Protein test decreased	1.765	1.208	0.924	0.617		0.326	1.418	1.597	1.7	2.006	1.383
COVID-19 (COVID-19 (JANSSEN))	Prothrombin time prolonged	1.9	1.365	0.934	0.754		0.293	1.444	2.26	1.627	2.424	1.44
COVID-19 (COVID-19 (JANSSEN))	Pulmonary embolism	2.248	1.582	1.048	0.62		0.587	1.806	2.064	2.613	2.528	1.91
COVID-19 (COVID-19 (JANSSEN))	Pulmonary thrombosis	2.312	1.482	0.91			1.676	1.69	1.52	2.223	2.223	1.871
COVID-19 (COVID-19 (JANSSEN))	Red blood cell count decreased											

From: (b) (6)
To: (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>;
Cc: (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>;
Subject: RE: Weekly data mining
Date: Tuesday, June 28, 2022 6:49:02 AM
Attachments: [USST_20220624.xls](#)

Sorry – forgot attachment

From: (b) (6)
Sent: Tuesday, June 28, 2022 6:48 AM
To: (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>;
Cc: (b) (6) <(b) (6)@fda.hhs.gov>; (b) (6) <(b) (6)@fda.hhs.gov>; (b) (6) <(b) (6)@fda.hhs.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>; (b) (6) <(b) (6)@cdc.gov>;
Subject: Weekly data mining

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/24/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBR3 20220424	US Biosim EBR3 20220424	US Famlar EBR3 20220424	US Infamir EBR3 20220424	US Cimiv EBR3 20220424	US Tiam EBR3 20220424	US Adult EBR3 20220424	US Adult2 EBR3 20220424	US Adult3 EBR3 20220424	US Famlar EBR3 20220424	US Min EBR3 20220424
COVID-19 (COVID-19) (ANSENSE)	Activated partial thromboplastin time prolonged	1,954	1,954	1,954	1,954	1,954	1,954	1,954	1,954	1,954	1,954	1,954
COVID-19 (COVID-19) (ANSENSE)	Activated partial thromboplastin time shortened	2,019	1,488	1,972	0.00	0.00	0.00	1,539	1,975	1,975	2,064	1,375
COVID-19 (COVID-19) (ANSENSE)	Acute respiratory distress syndrome	1,023	1,023	1,023	1,023	1,023	1,023	1,023	1,023	1,023	1,023	1,023
COVID-19 (COVID-19) (ANSENSE)	Acute respiratory failure	1,117	1,318	1,021	0.00	0.00	0.00	1,522	2,033	1,996	2,437	1,773
COVID-19 (COVID-19) (ANSENSE)	Adverse drug reaction	3,385	3,385	3,385	3,385	3,385	3,385	3,385	3,385	3,385	3,385	3,385
COVID-19 (COVID-19) (ANSENSE)	Allergic event	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
COVID-19 (COVID-19) (ANSENSE)	Albumin CDF increased	2,027	1,751	1,906	0.00	0.00	0.00	1,234	1,368	1,368	3,087	1,515
COVID-19 (COVID-19) (ANSENSE)	Albumin CDF normal	1,905	1,28	1,28	0.00	0.00	0.00	1,421	1,441	1,673	2,003	1,319
COVID-19 (COVID-19) (ANSENSE)	Angiogram cerebral abnormal	2,507	1,763	1,909	0.00	0.00	0.00	2,324	1,904	2,054	3,028	1,581
COVID-19 (COVID-19) (ANSENSE)	Angiogram cerebral normal	2,967	2,967	2,967	2,967	2,967	2,967	2,967	2,967	2,967	2,967	2,967
COVID-19 (COVID-19) (ANSENSE)	Angiogram pulmonary abnormal	2,23	1,605	1,908	0.00	0.00	0.00	1,894	2,239	2,181	2,411	1,862
COVID-19 (COVID-19) (ANSENSE)	Angiogram pulmonary normal	1,783	1,783	1,783	1,783	1,783	1,783	1,783	1,783	1,783	1,783	1,783
COVID-19 (COVID-19) (ANSENSE)	Antibody titer	2,162	2,162	2,162	2,162	2,162	2,162	2,162	2,162	2,162	2,162	2,162
COVID-19 (COVID-19) (ANSENSE)	Anticoagulant therapy	2,18	1,457	1,97	0.00	0.00	0.00	1,412	2,053	2,028	2,747	1,873
COVID-19 (COVID-19) (ANSENSE)	Application site pain	2,049	1,647	1,97	0.00	0.00	0.00	1,647	2,028	1,309	2,139	1,423
COVID-19 (COVID-19) (ANSENSE)	Arterial blood gas abnormal	1,132	1,132	1,132	1,132	1,132	1,132	1,132	1,132	1,132	1,132	1,132
COVID-19 (COVID-19) (ANSENSE)	Blepharitis decreased	1,831	1,342	1,928	0.00	0.00	0.00	1,351	1,12	1,182	2,273	1,311
COVID-19 (COVID-19) (ANSENSE)	Blepharitis percentage decreased	1,750	1,941	1,909	0.00	0.00	0.00	1,099	2,224	1,792	2,151	1,938
COVID-19 (COVID-19) (ANSENSE)	Blepharitis percentage increased	1,822	1,284	1,928	0.00	0.00	0.00	1,562	2,018	1,749	2,173	1,41
COVID-19 (COVID-19) (ANSENSE)	Blood lactate decreased	1,36	1,354	1,948	0.00	0.00	0.00	1,364	1,364	1,877	2,176	1,508
COVID-19 (COVID-19) (ANSENSE)	Blood lactate increased	1,854	1,293	1,917	0.00	0.00	0.00	1,118	2	1,58	1,908	1,587
COVID-19 (COVID-19) (ANSENSE)	Blood chloride increased	1,739	1,283	1,952	0.00	0.00	0.00	1,242	1,963	1,183	2,125	1,332
COVID-19 (COVID-19) (ANSENSE)	Blood chloride normal	1,961	1,946	1,976	1,961	1,961	1,961	1,976	2,127	1,968	2,121	1,968
COVID-19 (COVID-19) (ANSENSE)	Blood chloride decreased	2,886	2,122	1,936	0.00	0.00	0.00	1,741	2,031	1,837	3,927	1,928
COVID-19 (COVID-19) (ANSENSE)	Blood magnesium increased	1,762	1,274	1,933	0.00	0.00	0.00	1,178	1,904	1,743	2,316	1,223
COVID-19 (COVID-19) (ANSENSE)	Blood potassium decreased	1,886	1,205	1,936	0.00	0.00	0.00	1,246	1,483	2,122	1,888	1,228
COVID-19 (COVID-19) (ANSENSE)	Blood potassium increased	1,928	1,351	1,956	0.00	0.00	0.00	1,372	2,053	1,738	1,955	1,603
COVID-19 (COVID-19) (ANSENSE)	Blood sodium decreased	1,822	1,088	1,923	0.00	0.00	0.00	1,307	1,335	2,025	2,025	1,01
COVID-19 (COVID-19) (ANSENSE)	Blood sodium increased	1,328	1,328	1,328	1,328	1,328	1,328	1,328	1,328	1,328	1,328	1,328
COVID-19 (COVID-19) (ANSENSE)	Blood urea increased	1,961	1,252	1,913	0.00	0.00	0.00	1,088	2,055	1,775	2,081	1,654
COVID-19 (COVID-19) (ANSENSE)	COVID-19 pneumonia	2,228	1,401	1,074	0.00	0.00	0.00	1,885	2,245	2,057	2,422	2,071
COVID-19 (COVID-19) (ANSENSE)	CHF worse increased	1,987	1,987	1,979	1,987	1,987	1,987	1,979	1,979	1,984	2,152	1,149
COVID-19 (COVID-19) (ANSENSE)	Cerebral haemorrhage	2,235	1,987	1,934	0.00	0.00	0.00	1,774	1,828	1,949	3,34	2,003
COVID-19 (COVID-19) (ANSENSE)	Cerebral haemorrhage normal	1,763	1,763	1,763	1,763	1,763	1,763	1,763	1,763	1,763	1,763	1,763
COVID-19 (COVID-19) (ANSENSE)	Cerebral ischaemia	2,718	1,738	1,884	0.00	0.00	0.00	1,468	1,337	1,83	3,626	1,727
COVID-19 (COVID-19) (ANSENSE)	Cerebral ischaemia normal	2,357	2,357	2,357	2,357	2,357	2,357	2,357	2,357	2,357	2,357	2,357
COVID-19 (COVID-19) (ANSENSE)	Chest X-ray abnormal	1,868	1,381	1,975	0.00	0.00	0.00	1,354	1,875	1,19	2,078	1,622
COVID-19 (COVID-19) (ANSENSE)	Computed tomography head abnormal	2,411	1,623	1,959	0.00	0.00	0.00	1,255	2,021	1,93	2,999	1,714
COVID-19 (COVID-19) (ANSENSE)	Computed tomography head normal	1,977	1,923	1,912	0.00	0.00	0.00	1,717	1,945	1,798	2,255	1,511
COVID-19 (COVID-19) (ANSENSE)	Computed tomography thorax abnormal	2,022	1,381	1,925	0.00	0.00	0.00	1,408	2,044	1,198	2,243	1,883
COVID-19 (COVID-19) (ANSENSE)	Computed tomography thorax normal	1,976	1,976	1,985	1,976	1,976	1,976	1,985	1,985	1,976	1,947	1,947
COVID-19 (COVID-19) (ANSENSE)	Death	1,873	1,17	1,963	0.00	0.00	0.00	1,463	1,633	1,582	2,085	1,851
COVID-19 (COVID-19) (ANSENSE)	Deep vein thrombosis	2,95	1,963	1,963	0.00	0.00	0.00	2,392	2,392	3,107	3,107	1,873
COVID-19 (COVID-19) (ANSENSE)	Endotracheal intubation	2,034	1,342	1,934	0.00	0.00	0.00	1,459	2,088	1,859	2,079	1,821
COVID-19 (COVID-19) (ANSENSE)	Eosinophil count decreased	1,778	1,778	1,778	1,778	1,778	1,778	1,778	2,028	1,754	2,125	1,981
COVID-19 (COVID-19) (ANSENSE)	Eosinophil percentage decreased	1,78	1,318	1,931	0.00	0.00	0.00	1,213	2,031	1,748	2,047	1,371
COVID-19 (COVID-19) (ANSENSE)	Fatigue cold	1,758	1,841	1,889	0.00	0.00	0.00	1,181	2,021	1,454	1,972	1,651
COVID-19 (COVID-19) (ANSENSE)	Fibrin D dimer	1,272	1,272	1,272	1,272	1,272	1,272	1,272	1,272	1,272	1,272	1,272
COVID-19 (COVID-19) (ANSENSE)	Fibrin D dimer increased	2,138	1,443	1,978	0.00	0.00	0.00	1,205	2,265	2,218	2,515	1,623
COVID-19 (COVID-19) (ANSENSE)	Fibrin D dimer normal	1,908	1,908	1,908	1,908	1,908	1,908	1,908	2,086	1,007	2,197	1,907
COVID-19 (COVID-19) (ANSENSE)	Foetal exposure during pregnancy	2,33	1,443	1,978	0.00	0.00	0.00	1,075	1,665	1,213	1,64	1,845
COVID-19 (COVID-19) (ANSENSE)	Galacturia	2,241	1,965	1,965	1,965	1,965	1,965	1,965	1,965	1,965	1,965	1,965
COVID-19 (COVID-19) (ANSENSE)	Globulins increased	1,84	1,27	1,91	0.00	0.00	0.00	1,272	1,721	1,619	2,227	1,249
COVID-19 (COVID-19) (ANSENSE)	Glycose urine present	1,138	1,138	1,138	1,138	1,138	1,138	1,138	1,138	1,138	1,138	1,138
COVID-19 (COVID-19) (ANSENSE)	Glycose urine absent	3,453	3,453	3,453	3,453	3,453	3,453	3,453	3,453	3,453	3,453	3,453
COVID-19 (COVID-19) (ANSENSE)	Haemoglobin decreased	1,265	1,265	1,265	0.00	0.00	0.00	1,265	2,002	1,774	2,196	1,432
COVID-19 (COVID-19) (ANSENSE)	Haemoglobin increased	1,751	1,751	1,751	1,751	1,751	1,751	1,751	1,751	1,751	1,751	1,751
COVID-19 (COVID-19) (ANSENSE)	Hepatic-induced thrombocytopenia test	3,707	3,707	3,707	3,707	3,707	3,707	3,707	3,707	3,707	3,707	3,707
COVID-19 (COVID-19) (ANSENSE)	Hepatic-induced thrombocytopenia test positive	3,143	3,143	3,143	3,143	3,143	3,143	3,143	3,143	3,143	3,143	3,143
COVID-19 (COVID-19) (ANSENSE)	Hypoxia	2,078	1,313	1,958	0.00	0.00	0.00	1,488	2,035	1,932	2,448	1,89
COVID-19 (COVID-19) (ANSENSE)	Immunoglobulin therapy	1,957	1,957	1,957	1,957	1,957	1,957	1,957	1,957	1,957	1,957	1,957
COVID-19 (COVID-19) (ANSENSE)	Intensive care	1,954	1,954	1,954	1,954	1,954	1,954	1,954	1,954	1,954	1,954	1,954
COVID-19 (COVID-19) (ANSENSE)	International normalized ratio increased	1,749	1,749	1,749	1,749	1,749	1,749	1,749	1,749	1,749	1,749	1,749
COVID-19 (COVID-19) (ANSENSE)	International normalized ratio normal	1,249	1,249	1,249	1,249	1,249	1,249	1,249	1,249	1,249	1,249	1,249
COVID-19 (COVID-19) (ANSENSE)	Ischaemic thorax	2,873	1,778	1,931	0.00	0.00	0.00	1,84	1,421	1,994	1,17	1,623
COVID-19 (COVID-19) (ANSENSE)	Jaundice	1,892	1,892	1,892	1,892	1,892	1,892	1,892	1,892	1,892	1,892	1,892
COVID-19 (COVID-19) (ANSENSE)	Lumbar puncture	1,883	1,347	1,947	0.00	0.00	0.00	1,269	2,176	1,904	1,848	1,737
COVID-19 (COVID-19) (ANSENSE)	Lumbar puncture abnormal	1,746	1,746	1,746	1,746	1,746	1,746	1,746	1,746	1,746	1,746	1,746
COVID-19 (COVID-19) (ANSENSE)	Lung infiltration	1,83	1,83	1,83	1,83	1,83	1,83	1,83	1,83	1,83	1,83	1,83
COVID-19 (COVID-19) (ANSENSE)	Lung opacity	1,984	1,984	1,984	1,984	1,984	1,984	1,984	1,984	1,984	1,984	1,984
COVID-19 (COVID-19) (ANSENSE)	Lymphocyte percentage decreased	1,879	1,225	1,924	0.00	0.00	0.00	1,097	2,045	1,864	2,106	1,308
COVID-19 (COVID-19) (ANSENSE)	Magnetic resonance imaging head abnormal	2,016	1,467	1,924	0.00	0.00	0.00	1,768	1,896	2,102	2,312	1,919
COVID-19 (COVID-19) (ANSENSE)	Magnetic resonance imaging head normal	2,016	2,016	2,016	2,016	2,016	2,016	2,016	2,016	2,016	2,016	2,016
COVID-19 (COVID-19) (ANSENSE)	Mean cell haemoglobin concentration decreased	1,719	1,268	1,919	0.00	0.00	0.00	1,168	1,913	1,523	2,077	1,338
COVID-19 (COVID-19) (ANSENSE)	Mean cell haemoglobin increased	1,874	1,874	1,874	1,874	1,874	1,874	1,874	1,874	1,874	1,874	1,874
COVID-19 (COVID-19) (ANSENSE)	Mechanical ventilation	2,268	1,444	1,909	0.00	0.00	0.00	1,155	2,238	2,041	2,001	2,005
COVID-19 (COVID-19) (ANSENSE)	Monocyte percentage increased	1,917	1,917	1,917	1,917	1,917	1,917	1,917	1,917	1,917	1,917	1,917
COVID-19 (COVID-19) (ANSENSE)	Neonatal dyspnea	2,382	1,9									

From: (b) (6)
To: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Cc: (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>; (b) (6) <(b) (6) (CDC)>
Subject: Weekly data mining
Date: Tuesday, July 5, 2022 7:41:46 AM
Attachments: [USST_20220701.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/1/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

(b) (6)

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB02 2022/07/01	US Serious EB02 2022/07/01	US Fatal EB02 2022/07/01	US Infant EB02 2022/07/01	US Child EB02 2022/07/01	US Teen EB02 2022/07/01	US Adult EB02 2022/07/01	US Adult EB02 2022/07/01	US Adult EB02 2022/07/01	US Female EB02 2022/07/01	US Male EB02 2022/07/01
COVID-19 (COVID19 (ANSSENS))	Activated partial thromboplastin time prolonged	1.45	1.45					1.47	1.45	1.56	1.56	1.42
COVID-19 (COVID19 (ANSSENS))	Activated partial thromboplastin time shortened	2.019	1.454	0.899				1.536	1.967	1.989	2.886	1.366
COVID-19 (COVID19 (ANSSENS))	Acute respiratory distress syndrome	2.045	1.983	0.283				1.743	1.743	1.989	2.044	1.611
COVID-19 (COVID19 (ANSSENS))	Acute respiratory failure	1.126	1.322	1.028				1.033	2.071	1.986	2.425	1.794
COVID-19 (COVID19 (ANSSENS))	Adverse drug reaction	3.995	0.695	0.695			0.62	1.529	0.707	0.736	2.654	1.443
COVID-19 (COVID19 (ANSSENS))	Adverse event	2.44	0.886	0.886				1.068	0.906	0.833	1.634	1.714
COVID-19 (COVID19 (ANSSENS))	Angiogram abnormal	1.9	1.252	0.903				1.486	1.434	1.672	2.004	1.309
COVID-19 (COVID19 (ANSSENS))	Angiogram cerebral abnormal	2.806	1.764	1.065				2.386	1.998	2.044	2.044	1.611
COVID-19 (COVID19 (ANSSENS))	Angiogram cerebral normal	2.091	1.362	0.801				1.781	1.828	1.228	2.145	1.522
COVID-19 (COVID19 (ANSSENS))	Angiogram coronary abnormal	2.997	1.607	0.907	0.619	0.485		2.057	1.828	2.205	2.205	1.611
COVID-19 (COVID19 (ANSSENS))	Arhin gap decreased	1.756	1.346	0.91				1.142	2.144	1.424	2.149	1.311
COVID-19 (COVID19 (ANSSENS))	Arthralgia	0.866	0.866	0.866				1.068	1.068	1.068	1.068	1.068
COVID-19 (COVID19 (ANSSENS))	Anticoagulant therapy	2.176	1.45	0.619				1.844	2.026	2.25	2.733	1.674
COVID-19 (COVID19 (ANSSENS))	Application site pain	2.047	1.642	0.966				0.827	2.027	1.307	1.027	1.42
COVID-19 (COVID19 (ANSSENS))	Arterogram carotid abnormal	1.707	1.131	0.86				1.203	1.2	1.307	2.158	0.962
COVID-19 (COVID19 (ANSSENS))	Arterogram carotid decreased	1.833	1.341	0.904	0.617	0.351		1.132	0.786	1.833	2.246	1.714
COVID-19 (COVID19 (ANSSENS))	Basophil percentage decreased	1.748	1.357	0.941				1.091	2.225	1.732	2.135	1.326
COVID-19 (COVID19 (ANSSENS))	Blood alkaline decreased	1.944	1.276	0.937				1.064	1.944	1.777	2.19	1.435
COVID-19 (COVID19 (ANSSENS))	Blood calcium decreased	1.871	1.343	0.958				1.363	2.077	1.907	2.138	1.52
COVID-19 (COVID19 (ANSSENS))	Blood chloride decreased	1.976	1.252	0.824				1.111	2.032	1.603	1.944	1.586
COVID-19 (COVID19 (ANSSENS))	Blood chloride increased	1.702	1.284	0.961				1.237	1.548	1.185	2.122	1.322
COVID-19 (COVID19 (ANSSENS))	Blood folate increased	1.965	1.152	0.869				0.929	2.157	0.655	1.625	1.211
COVID-19 (COVID19 (ANSSENS))	Blood folate decreased	2.795	1.766	1.045				1.741	2.031	0.958	0.958	1.027
COVID-19 (COVID19 (ANSSENS))	Blood lactate dehydrogenase increased	1.707	1.244	0.895	0.619	0.351		1.186	2.025	1.309	1.763	1.416
COVID-19 (COVID19 (ANSSENS))	Blood magnesium increased	1.772	1.27	0.92				1.102	1.693	1.763	1.763	1.217
COVID-19 (COVID19 (ANSSENS))	Blood potassium decreased	1.7	1.218	0.94				1.256	1.487	2.058	1.897	1.245
COVID-19 (COVID19 (ANSSENS))	Blood sodium decreased	1.941	1.306	0.901	0.616	0.351		1.075	2.016	1.744	1.975	1.51
COVID-19 (COVID19 (ANSSENS))	Blood sodium increased	1.697	1.098	0.727				1.359	1.309	2.019	2.019	1.054
COVID-19 (COVID19 (ANSSENS))	Blood urea decreased	1.933	1.267	0.889				1.389	1.389	1.204	0.936	0.936
COVID-19 (COVID19 (ANSSENS))	Blood urea increased	1.911	1.269	0.819				1.097	2.064	1.788	2.111	1.658
COVID-19 (COVID19 (ANSSENS))	COVID-19 pneumonia	2.253	1.407	0.862				1.966	2.264	2.059	2.439	2.018
COVID-19 (COVID19 (ANSSENS))	CHF worse increased	2.865	1.993	1.073				1.81	3.066	3.066	3.073	2.14
COVID-19 (COVID19 (ANSSENS))	Catheter dislodged thrombolysis	1.075	0.735	0.486				0.456	1.736	0.806	0.806	0.611
COVID-19 (COVID19 (ANSSENS))	Central venous catheter thrombosis	2.23	1.168	0.627				1.766	1.962	1.5	3.131	1.919
COVID-19 (COVID19 (ANSSENS))	Central vein occlusion	2.755	1.928	1.02				1.638	1.618	1.254	3.899	1.192
COVID-19 (COVID19 (ANSSENS))	Central venous sinus thrombosis	2.71	1.866	0.938				1.734	1.866	1.584	1.271	1.027
COVID-19 (COVID19 (ANSSENS))	Chest X-ray abnormal	3.357	2.172	1.279				2.579	2.441	0.873	1.924	1.192
COVID-19 (COVID19 (ANSSENS))	Chest X-ray abnormal	0.924	0.624	0.324				1.369	0.984	1.003	1.636	0.826
COVID-19 (COVID19 (ANSSENS))	Completed bronchus head abnormal	2.4	1.4	0.659	0.618	0.351		2.055	2.055	2.017	2.066	1.714
COVID-19 (COVID19 (ANSSENS))	Completed bronchus head normal	1.988	1.332	0.916				1.734	1.962	1.18	2.258	1.531
COVID-19 (COVID19 (ANSSENS))	Completed bronchus thorax abnormal	2.008	1.364	0.827				1.406	2.064	1.874	2.064	1.531
COVID-19 (COVID19 (ANSSENS))	Coagulation renal clearance decreased	1.841	1.241	0.845				0.495	0.959	2.007	1.043	1.707
COVID-19 (COVID19 (ANSSENS))	Death	1.871	1.171	0.644				1.071	1.644	1.064	1.974	1.416
COVID-19 (COVID19 (ANSSENS))	Deep vein thrombosis	2.951	1.862	1.046				2.27	2.266	3.199	3.306	2.087
COVID-19 (COVID19 (ANSSENS))	Endotracheal intubation	0.265	0.265	0.265				0.265	0.265	0.265	0.265	0.265
COVID-19 (COVID19 (ANSSENS))	Endotracheal intubation decreased	1.797	1.285	0.932				1.214	2.04	1.737	2.38	1.388
COVID-19 (COVID19 (ANSSENS))	Endotracheal intubation increased	1.761	1.209	0.827	0.616	0.351		1.218	2.06	1.777	2.072	1.389
COVID-19 (COVID19 (ANSSENS))	Feeding oral	1.727	0.84	0.484				1.181	2.023	1.452	0.862	0.862
COVID-19 (COVID19 (ANSSENS))	Film D dimer	2.274	1.281	0.893				2.179	2.147	1.965	2.532	1.706
COVID-19 (COVID19 (ANSSENS))	Film D dimer normal	2.152	1.289	0.793	0.619	0.351		1.459	2.209	2.209	2.209	1.531
COVID-19 (COVID19 (ANSSENS))	Film D dimer raised	1.945	1.099	0.685				1.654	2.017	1.104	2.184	1.294
COVID-19 (COVID19 (ANSSENS))	Fetal exposure during pregnancy	2.239	1.462	0.842				1.642	1.642	1.642	1.642	1.642
COVID-19 (COVID19 (ANSSENS))	Gait palsy	1.031	0.89	0.62				1.031	1.696	1.215	1.604	1.604
COVID-19 (COVID19 (ANSSENS))	Gidolium increased	2.947	1.798	1.066				1.31	1.798	1.686	2.274	1.276
COVID-19 (COVID19 (ANSSENS))	Gidolium urea present	1.741	1.012	0.612				1.191	1.307	1.191	1.191	1.191
COVID-19 (COVID19 (ANSSENS))	Gullström-Bare syndrome	2.448	1.818	0.887				1.617	3.042	1.622	2.393	1.269
COVID-19 (COVID19 (ANSSENS))	Haematuria decreased	1.804	1.027	0.612				1.329	0.107	1.789	2.127	1.489
COVID-19 (COVID19 (ANSSENS))	Haemoglobin decreased	1.78	1.234	0.845	0.613	0.421		1.942	1.942	1.678	2.081	1.289
COVID-19 (COVID19 (ANSSENS))	Heparin-induced thrombocytopenia test	0.706	0.805	0.605				0.706	4.146	4.146	4.146	4.146
COVID-19 (COVID19 (ANSSENS))	Heparin-induced thrombocytopenia test positive	6.145	3.251	1.875				1.99	2.727	0.74	7.043	2.491
COVID-19 (COVID19 (ANSSENS))	Hypoxia	0.293	0.293	0.293				0.293	0.293	0.293	0.293	0.293
COVID-19 (COVID19 (ANSSENS))	Immunoassay	2.103	1.723	1.073				1.572	1.936	1.77	2.2	1.77
COVID-19 (COVID19 (ANSSENS))	Intensive care	0.265	0.265	0.265				0.265	2.13	2.13	2.13	2.13
COVID-19 (COVID19 (ANSSENS))	International normalised ratio increased	1.758	1.168	0.822	0.755	0.377		1.89	1.429	1.429	1.521	1.251
COVID-19 (COVID19 (ANSSENS))	International normalised ratio normal	1.951	1.239	0.885				1.396	2.057	1.005	2.102	1.602
COVID-19 (COVID19 (ANSSENS))	International normalised ratio normal	0.874	0.778	0.484				1.178	1.422	0.895	1.622	1.065
COVID-19 (COVID19 (ANSSENS))	Jugular vein thrombosis	1.803	1.377	0.979				1.369	1.116	0.712	2.297	1.807
COVID-19 (COVID19 (ANSSENS))	Lumbar puncture	1.945	1.345	0.945				1.345	1.945	1.945	1.945	1.945
COVID-19 (COVID19 (ANSSENS))	Lumbar puncture abnormal	2.134	1.666	1.026				1.118	2.852	1.753	1.827	1.827
COVID-19 (COVID19 (ANSSENS))	Lung opacity	1.985	1.465	0.985				1.465	1.715	1.257	1.985	1.513
COVID-19 (COVID19 (ANSSENS))	Lymphocyte percentage decreased	1.887	1.229	0.933				0.927	2.04	1.87	2.04	1.304
COVID-19 (COVID19 (ANSSENS))	Magnetic resonance imaging head abnormal	2.059	1.466	0.946				1.758	1.897	2.086	2.297	1.691
COVID-19 (COVID19 (ANSSENS))	Magnetic resonance imaging head normal	2.017	1.354	0.844	0.619	0.351		1.354	2.157	1.608	1.608	1.608
COVID-19 (COVID19 (ANSSENS))	Mean cell haemoglobin concentration decreased	1.272	1.27	0.857				1.181	1.884	1.59	2.1	0.992
COVID-19 (COVID19 (ANSSENS))	Mean cell haemoglobin increased	1.826	1.326	0.926				1.326	1.975	1.556	2.156	1.611
COVID-19 (COVID19 (ANSSENS))	Mechanical ventilation	2.284	1.503	0.92				2.284	2.048	2.048	2.048	2.048
COVID-19 (COVID19 (ANSSENS))	Monocyte percentage increased	1.574	1.093	0.743	0.616	0.351		1.093	1.893	1.796	2.175	1.622
COVID-19 (COVID19 (ANSSENS))	Neonatal dyspnea	2.377	0.985	0.685	0.62	0.311		1.107	1.59	1.69	0.876	1.117
COVID-19 (COVID19 (ANSSENS))	Neutrophil percentage decreased	1.516	1.305	0.886				1.104	2.089	1.803	1.803	1.803
COVID-19 (COVID19 (ANSSENS))	Neutrophil percentage increased	1.726	1.258	0.932				1.104	2.089	1.803	1.972	1.426
COVID-19 (COVID19 (ANSSENS))	Non-specific reaction	4.088	0.789	0.489				0.813	1.485	1.04	3.028	1.076
COVID-19 (COVID19 (ANSSENS))	Off test use	2.113	0.601	0.388				0.982	0.982	0.982	2.244	1.443
COVID-19 (COVID19 (ANSSENS))	On and off phenomenon	1.767	0.751	0.451				0.982	0.982	0.982	2.244	1.443
COVID-19 (COVID19 (ANSSENS))	Pain assessment	2.206	1.607	0.907				1.607	1.039	1.039	1.716	1.039
COVID-19 (COVID19 (ANSSENS))	Peripheral embolism	3.052	1.38	0.875				0.875	1.572	1.572	2.268	0.951
COVID-19 (COVID19 (ANSSENS))	Platelet count	2.17	0.914	0.614	0.618	0.351		0.823	2.915	2.713	3.14	1.253
COVID-19 (COVID19 (ANSSENS))	Platelet count decreased	1.889	1.306	0.915				1.488	2.102	1.664	2.265	1.491
COVID-19 (COVID19 (ANSSENS))	Platelet count normal	2.555	1.708	0.994				1.201	2.692	2.719	3.14	1.708
COVID-19 (COVID19 (ANSSENS))	Platelet factor 4	0.78	0.681	0.481				0.681	1.663	1.663	1.663	1.663
COVID-19 (COVID19 (ANSSENS))	Portal vein thrombosis	2.244	1.652	0.877				0.858	1.889	1.032	2.137	1.335
COVID-19 (COVID19 (ANSSENS))	Positive airway pressure therapy	2.086	1.293	0.826				2.123	1.796	1.796	2.175	1.622
COVID-19 (COVID19 (ANSSENS))	Product administered to patient of inappropriate age	1.78	0.835	0.535	0.693	0.346		0.835	0.002	0.506	1.67	1.812
COVID-19 (COVID19 (ANSSENS))	Proctogram	1.54	1.336	0.936				0.936	0.936	0.936	1.54	1.07
COVID-19 (COVID19 (ANSSENS))	Protein total decreased	1.809	1.227	0.877	0.616	0.309		1.466	1.646	1.744	2.036	1.604
COVID-19 (COVID19 (ANSSENS))	Prothrombin time prolonged	1.917	1.274	0.827				0.261	2.227	1.664	2.474	1.489
COVID-19 (COVID19 (ANSSENS))	Pulmonary embolism	2.261	1.588	0.985				1.819	2.071	2.632	2.529	1.625
COVID-19 (COVID19 (ANSSENS))	Pulmonary embolism	2.341	1.514	0.905				1.721	1.727			